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Project	  I:	  Chd7	  Deficiency	  does	  not	  affect	  N1-­‐driven	  T-­‐ALL	  Induction	  and	  Maintenance	  nor	  
impair	  Hematopoiesis	  Notch1	  has	  been	  shown	  to	  be	  a	  key	  driver	   in	  pediatric	  T-­‐cell	  acute	   lymphobastic	   leukemia	  (T-­‐ALL),	  and	  over-­‐expression	  of	  the	  intracellular	  domain	  of	  Notch1	  (NICD)	  in	  murine	  bone	  marrow	  (BM)	  progenitors	  induces	  T-­‐ALL.	  Previous	  work	  in	  the	  lab	  identified	  the	  chromatin-­‐remodeling	  enzyme	  Chd7	  to	  be	  highly	  over-­‐expressed	  in	  aggressive	  versus	  pre-­‐malignant	  disease.	  	  The	  aim	  of	  this	  project	  was	  to	  study	  if	  Chd7	  is	  required	  during	  T-­‐ALL	  initiation	  and	  disease	  maintenance	  as	  well	   as	   to	   characterize	   its	   role	   in	   the	   hematopoietic	   system	  under	   physiological	   and	   stress	  conditions.	  Therefore,	  Chd7	  conditional	  knock	  out	  (cKO)	  animals	  were	  crossed	  with	  the	  MxCre	  deleter	  to	  ablate	  Chd7	  specifically	   in	  BM	  progenitors.	  Chd7	  deficiency	  did	  not	   induce	  any	  overt	  phenotype	  in	  the	  hematopoietic	  system,	  when	  studied	  under	  “steady”	  state	  or	  stress	  conditions	  in	  competitive	  BM	  chimeras,	  upon	  serial	  transplantation	   or	   due	   to	   5-­‐FU-­‐mediated	  hematopoietic	   stem	  cell	   (HSC)	  mobilization.	   In	  addition,	  Chd7	  was	  studied	   in	   (i)	   the	   retroviral	  MigR1-­‐NICD	  and	  (ii)	  in	  the	  genetic	  RNIC	  murine	  T-­‐ALL	  induction	  models.	  In	  both	  models	  MxCre,	  targeting	   BM	   progenitors,	   and	   CD4Cre	   transgenic	   mice,	   targeting	   thymic	   progenitors	   at	   the	  DN3b-­‐DN4	  stage	  of	  maturation,	  were	  used	  to	  inactivate	  Chd7.	  Chd7	  proved	  to	  be	  dispensable	  in	  the	  initiation	  and	  maintenance	  of	  murine	  Notch1-­‐driven	  T-­‐ALL.	  Similarly,	  knock	  down	  of	  CHD7	  in	  human	  T-­‐ALL	  did	  not	  impact	  on	  survival	  or	  proliferation	  of	  T-­‐ALL	  cell	  lines.	  Therefore,	  we	  can	  rule	  out	  a	  role	  of	  Chd7	  during	  late-­‐stage	  leukemogenesis	  in	  Notch1-­‐induced	  murine	  and	  human	  T-­‐ALL.	  	  
Project	  II:	  Serca2,	  a	  putative	  drug	  target	  to	  fight	  Notch1-­‐driven	  T	  cell	  acute	  lymphoblastic	  
leukemia,	  and	  its	  role	  in	  Hematopoiesis	   	  Aberrant	  activation	  of	  Notch	  signalling	  has	  been	  implicated	  in	  many	  different	  aspects	  of	  human	  cancer	   such	   as	   hyperproliferation,	   invasiveness	   and	   angiogenesis.	   Therefore,	   the	   Notch	  signalling	  pathway	  represents	  a	  bona	  fide	  drug	  target.	  We	  and	  Roti	  et	  al.	  performed	  a	  chemical	  compound	   screen	   and	   identified	   Cyclopiazonic	   acid	   (CPA)	   to	   be	   a	   potent	   Notch	   inhibitor.	  Biological	  target	  of	  this	  compound	  is	  the	  Sarco/Endoplasmic	  Reticulum	  ATPase2	  (Serca2)	  that	  is	  involved	   in	   calcium	  homeostasis	  within	   the	   cell.	   Recently,	   it	  was	   shown	   that	   Serca2	   regulates	  Notch1	  (N1)	  receptor	  maturation	  and	  inhibition	  of	  Serca	  ATPases,	  using	  thapsigargin,	  blocks	  T-­‐ALL	  progression	  in	  xenografts	  (Roti	  et	  al.,	  2013).	  The	  putative	  global	  effects	  of	  Serca2	  inhibition	  on	  hematopoiesis	  have,	  however,	  not	  been	  addressed	  in	  this	  study.	  	  Aim	   of	   this	   study	   was	   to	   characterize	   the	   function	   of	   Serca2	   in	   the	   hematopoietic	   system.	  Therefore,	  we	  crossed	  Serca2	  conditional	  knock	  out	  (cKO)	  with	  MxCre	  recombinase	  Tg	  mice	  to	  ablate	   Serca2	   function	   in	   BM	   progenitors.	   Serca2	   haploinsufficiency	   did	   not	   lead	   to	   any	   overt	  phenotype	   under	   physiological	   or	   competitive	   conditions	   studied	   upon	   5-­‐FU	   administration,	  serial	   transplantation	  and	   in	  mixed	  BM	  chimeras.	   In	  contrast,	  Serca2ΔMxCre	   chimeras	  showed	  (i)	  impaired	  long-­‐term	  reconstitution	  capacity	  upon	  transplantation,	  (ii)	  a	  severe	  reduction	  of	  total	  BM,	   splenic	  and	   thymic	  cellularity	  and	   (iii)	  an	  enrichment	  of	  Lineage–CD117+Sca1+	   (KLS)	  cells,	  
	   	  	   II	  the	  cell	  pool	  that	  contains	  HSCs.	  Mature	  lineages	  were	  highly	  apoptotic,	  while	  KLS	  cells	  were	  not	  majorly	   affected	   by	   apoptosis.	   These	   cells	   resided	   predominantly	   in	   G0	   phase	   of	   the	   cell	   cycle	  (Hoechst-­‐Ki-­‐67	   staining)	   and	   exhibited	   significantly	   slower	   cycling	   kinetics	   (CFSE	   division	  tracking).	   In	   addition,	   Serca2ΔMxCre	   KLS	   cells	   were	   functionally	   impaired	   as	   they	   formed	  significantly	   less	   and	   smaller	   colony	   forming	   units	   (CFUs)	   in	   vitro.	   Deregulated	   intracellular	  calcium	  levels	  can	  lead	  to	  an	  accumulation	  of	  unfolded	  proteins	  in	  the	  ER,	  a	  phenomenon	  called	  ER	  stress.	  In	  order	  to	  resolve	  ER	  stress,	  the	  cell	  activates	  the	  unfolded	  protein	  response	  (UPR),	  thereby	   inducing	   chaperones	   to	   counter-­‐balance	   the	   impaired	   folding	   capacity.	   In	   case	   of	  unresolved	   ER	   stress,	   however,	   the	   cell	   undergoes	   apoptosis.	   We	   demonstrate	   that	   mature	  hematopoietic	  lineages	  up-­‐regulate	  UPR-­‐associated	  and	  pro-­‐apoptotic	  genes,	  while	  KLS	  cells,	  in	  contrast,	   show	   unperturbed	   expression	   of	   these	   genes.	   In	   addition,	   we	   performed	   in	   vitro	  experiments,	   inhibiting	   Serca	   function	   in	   MACS	   enriched	   Lin-­‐	   BM	   cells	   via	   thapsigargin	   (TH)	  treatment.	   Upon	   prolonged	   treatment,	   TH	   induced	   severe	   apoptosis	   in	   the	   overall	   cell	  population,	  while	  KLS	  accumulated	  and	  were	  blocked	   in	   the	  G0	  phase	  of	   the	   cell	   cycle,	   closely	  mimicking	  Serca2	  LOF	  in	  vivo.	  	  Therefore,	  we	  showed	  for	  the	  first	  time,	  that	  targeting	  Serca2	  in	  the	  BM	  leads	  to	  (i)	  induction	  of	  apoptosis	  in	  mature	  lineages	  through	  activation	  of	  UPR,	  while	  (ii)	  KLS	  are,	  to	  some	  extent,	  more	  resistant	   to	   ER	   stress	   and	   undergo	   cell	   cycle	   arrest.	   We	   therefore	   question	   the	   therapeutic	  approach	   of	   targeting	   Serca2	   in	   Notch1-­‐driven	   T-­‐ALL	   due	   to	   severe	   side	   effects	   induced	   by	  
Serca2	  inactivation	  in	  the	  BM.	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  Zusammenfassung	  
Projekt	  I:	  Chd7	  Inaktivierung	  beeinflusst	  weder	  die	  Entstehung	  noch	  Erhaltung	  Akuter	  T-­‐
Zell	  Lymphoblastischer	  Leukämie	  oder	  Hämatopoiese	  Akute	  T-­‐Zell	  Lymphoblastische	  Leukämie	  (T-­‐ALL)	  betrifft	  hauptsächlich	  Kinder	  und	  Jugendliche	  und	   liegt	   in	   mehr	   als	   50%	   der	   Fälle	   einer	   Überaktivierung	   des	   Notch	   Signalwegs	   zu	   Grunde.	  Experimentell	  wurde	  in	  Mäusen	  gezeigt,	  dass	  Expression	  der	  intrazellulären	  Domäne	  des	  Notch1	  Rezeptors	   (NICD)	   nach	   Transplantation	   zu	   T-­‐ALL	   Entwicklung	   führt.	   In	   einer	   früheren	   Studie	  wurden	   solche	  murinen	  T-­‐ALL	  Modelle	   verglichen,	   um	  Kandidaten-­‐Moleküle	   zu	   identifizieren,	  die	   potenziell	   mit	   Notch	   in	   der	   Entwicklung	   von	   T-­‐ALL	   kooperieren.	   Chd7,	   ein	   Chromatin	  remodellierendes	   Enzym,	   wurde	   dabei	   in	   aggressiver	   (RNIC+/ΔLckCre)	   im	   Vergleich	   zu	   milder	  Vorläufer	  (RNIC+/ΔMxCre)	  T-­‐ALL	  identifiziert.	  	  	  Ziel	  dieser	  Doktorarbeit	  war	  es	  die	  Funktion	  von	  Chd7	  in	  T-­‐ALL	  aber	  auch	  im	  hemätopoietischen	  System	  generell	  zu	  studieren.	  Transgene	  konditionelle	  knock	  out	  (cKO)	  Mäuse	  für	  Chd7	  wurden	  mit	  MxCre	  gekreuzt,	  um	  Chd7	  spezifisch	  im	  Knochemark	  zu	  deletieren.	  Chd7	  spielte	  keine	  Rolle	  in	   der	   Regulierung	   von	   Hämatopoiese	   unter	   physiologischen	   oder	   „Stress“	   Bedingungen,	   wie	  serielle	  Transplantation	  oder	  5-­‐FU	  Injektionen	  gezeigt	  haben.	  Chd7	  wurde	  ebenfalls	  in	  den	  zwei	  unterschiedlichen	   (i)	   Retroviralen	   MigR1-­‐NICD	   und	   (ii)	   Genetischen	   RNIC	   T-­‐ALL	  Initiationsmodellen	   studiert.	  Weder	   die	   Inaktivierung	   von	   Chd7	   in	   BM	   Progenitoren	   (MxCre),	  noch	  die	  Deletion	   in	  Progenitoren	   im	  Thymus	   (CD4Cre)	  haben	  eine	  Rolle	  bei	  der	  Entwicklung	  von	  T-­‐ALL	   in	  diesen	  Modellsystemen	  gespielt.	  Ebenso	  hatte	  die	   Inaktivierung	  von	  Chd7	  weder	  Konsequenzen	   für	   T-­‐ALL	   im	   genetischen	   RNIC	   Modell,	   noch	   in	   etablierten	   humanen	   T-­‐ALL	  Zelllinien.	   Somit	   zeigen	  unsere	  Studien,	  dass	  Chd7	  keine	  bedeutende	  Rolle	   in	  der	  Entwicklung	  von	  T-­‐ALL	  spielt.	  	  	  
Projekt	  II:	  Die	  Rolle	  von	  Serca2,	  einem	  potenziellen	  Zielmolekül	  zur	  Therapie	  von	  Notch1-­‐
induzierter	  Akuter	  T-­‐Zell	  Lymphoblastischer	  Leukämie,	  in	  Hämatopoiese	  In	   vielen	   Krebsarten	   ist	   die	   Notch	   Signalkaskade	   überaktiviert,	   was	   auf	   das	   Wachstum,	   die	  Metastasierung	  und	  den	  Metabolismus	  einer	  Krebszelle	  unterstützend	  wirkt.	  Deshalb	  stellt	  der	  Notchrezeptor	  ein	  prominentes	  Zielmolekül	  auf	  der	  Suche	  nach	  neuen	  Therapiemöglichkeiten	  in	  der	  Krebsforschung	  dar.	   In	  unserer	  Forschungsgruppe	  wurde	  ein	   initialer	  Arzneimittel	   Screen	  durchgeführt,	   um	   neue	   chemische	   Moleküle,	   die	   Notch-­‐inhibierende	   Wirkung	   haben,	   zu	  identifizieren.	  Zeitgleich	  folgten	  Roti	  et	  al.	  unserem	  Beispiel	  und	  führten	  einen	  ähnlichen	  Screen	  durch,	  um	  Inhibitoren	  für	  Notch	  aber	  auch	  Gen-­‐Kandidaten	  zu	  finden,	  die	  mit	  onkogenem	  Notch	  interagieren.	   Interessanter	  Weise	   haben	   beide	   Ansätze	   zur	   Identifikation	   derselben	   Moleküle	  geführt,	   der	   cyclopiazonic	   acid	   (CPA)	   und	   Thapsigargin	   (TH),	   die	   die	   Funktion	   von	   Kalzium	  ATPasen	   des	   Sarko/Endoplasmatischen	   Retikulums	   (Sercas)	   hemmen.	   Als	   Notch	  Interaktionsparter	   wurde	   Serca2	   aus	   der	   Famile	   der	   Sercas	   als	   potenzielles	   intermediäres	  Zielmolekul	  identifiziert,	  um	  Notch	  in	  akuter	  T-­‐Zell	  Leukämie	  (T-­‐ALL)	  zu	  inhibieren	  (Roti	  et	  al.).	  
	   IV	  
Diese	  Studien	  zeigten	  zwar,	  dass	  Serca2	  in	  der	  Tat	  den	  Notch1	  Rezeptor	  strukturell	  reguliert	  und	  sich	   Serca2	   Inhibierung	   positiv	   auf	   T-­‐ALL	   Fortschreitung	   auswirkt,	   allerdings	   wurde	   nicht	  geklärt,	   welche	   potenziellen	   globalen	   Nebenwirkungen	   eine	   Inhibierung	   von	   Serca2	   auf	   das	  blutbildende	  System	  haben	  kann.	  	  Daher	  war	  es	  Ziel	  dieser	  Doktorarbeit,	  die	  Funktion	  von	  Serca2	  im	  hämatopoietischen	  System	  zu	  untersuchen.	  	  Mit	  Hilfe	  von	  transgenenen	  Mäusen,	  die	  es	  erlauben	  das	  Serca2	  Gen	  spezifisch	  im	  Knochenmark	   zu	  deletieren,	   haben	  wir	   die	  Rolle	   von	   Serca2	  unter	  normalen	  homeostatischen	  Bedingungen	  aber	  auch	  unter	  hämatologischem	  Stress	  studiert.	  Deletion	  von	  einem	  Serca2	  Allele	  führte	  dabei	  zu	  keinem	  merklichen	  Phänotyp	  im	  hämatopoietischen	  System;	  ebenso	  nicht	  unter	  kompetitiven	   Bedingungen	   wie	   zum	   Beispiel	   nach	   5-­‐FU	   Injektionen	   oder	   serieller	  Transplantation.	   	   In	   Kontrast	   dazu,	   führt	   der	   Verlust	   von	   beiden	   Serca2	   Allelen	   zu	   einem	  drastischen	   Phänotyp:	   (i)	   Serca2-­‐defiziente	   Knockenmarkszellen	   sind	   nicht	   nachhaltig	  transplantierbar;	  (ii)	   lymphoide	  Organe	  wie	  der	  Thymus,	  die	  Milz	  aber	  auch	  das	  Knochenmark	  weisen	  verringerte	  Zellzahlen	  auf	  während	   (iii)	  hämatopoietische	  Stammzellen	   (HSC)	  anormal	  hoch	   sind	   in	   ihrer	  Anzahl.	   	  Nähere	  Analysen	   zeigten,	   dass	   ausdifferenzierte	  Effektorzellen	  des	  Immunsystems	  stark	  apoptotisch	  waren,	  während	  die	  vorwiegend	  in	  der	  Phase	  G0	  des	  Zellzyklus	  vorzufinden	  waren	  (Ki-­‐67-­‐Höchst	  Färbung)	  oder	   in	  vitro	  vergleichend	  langsamer	  proliferierten	  (CFSE	  Färbung).	  	  Ein	  unbalanzierter	  Kalziumgehalt	   im	   Inneren	  der	  Zelle	  kann	  dazu	   führen,	  dass	  Proteine	   im	  ER	  nicht	   mehr	   effizient	   ihre	   dreidimensionale	   Struktur	   einnehmen	   können.	   Es	   kommt	   zur	  fehlerhaften	  Faltung	  der	  Proteine,	  was	  der	  Zelle	  eine	  “Stress”-­‐Meldung	  sendet.	  Daraufhin,	  wird	  der	   Signalweg	   der	   Unfolded	   Protein	   response	   (UPR)	   aktiviert,	   um	   der	   fehlerhaften	  Proteinfaltung	  entgegen	  zu	  wirken.	  Ist	  dies	  allerdings	  ohne	  Erfolg,	  entscheidet	  sich	  die	  Zelle	  für	  den	  programmierten	  Zelltod	  (Apoptose).	  Gen	  Expressions	  Analysen	  zeigten,	  dass	  differenzierte	  hämatopoietische	   Zellen	   sensitiver	   auf	   Serca2	   Inaktivierung	   reagieren	   und	   apoptotisch	  waren	  im	   Gegensatz	   zu	   HSCs,	   die	   im	   Zellzyklus	   in	   der	   Phase	   G0	   “blockiert”	   sind.	   Komplementäre	  Studien	  in	  vitro	  demonstrierten,	  dass	  das	  potenzielle	  Krebsmedikament	  TH	  ähnliche	  Effekte	  auf	  wild-­‐typ	   (WT)	   Knochenmarkszellen	   hat.	   Somit	   zeigen	   wir	   in	   dieser	   Arbeit,	   dass	   Serca2	   ein	  bedenkliches	  neues	  Zielmolekühl	   in	  der	  Krebstherapie	  darstellt,	   da	   Inhibierung	  von	  Serca2	   im	  hämatopoietischen	  System	  zu	  starken	  Nebenwirkungen	  führt.	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  1 Introduction	  
1.1 Hematopoiesis	  and	  the	  Immune	  System	  Hematopoiesis	   is	   the	   process	   by	   which	   all	   cell	   types	   of	   the	   blood	   and	   immune	   system	   are	  generated.	   The	   hematopoietic	   system	   consists	   of	  more	   than	   10	   different	   cell	   types,	  with	   each	  fulfilling	   specialized	   functions.	   Blood	   cells	   can	   be	   broadly	   divided	   into	   red	   blood	   cells	  (erythrocytes),	   important	   for	  oxygen	  transport;	  platelets,	  which	  function	   in	  blood	  clotting;	  and	  white	  blood	  cells	  (leukocytes),	  which	  comprise	  innate	  and	  adaptive	  immunity.	  Although	  diverse,	  all	  different	  cell	  types	  within	  the	  hematopoietic	  system	  arise	  from	  a	  single	  pluripotent	  cell,	   the	  hematopoietic	  stem	  cell	  (HSC).	  	  During	  mammalian	  development,	  the	  first	  and	  primitive	  form	  of	  hematopoiesis	  (from	  embryonic	  day	   7.5;	   E	   7.5)	   takes	   place	   in	   the	   extra-­‐embryonic	   yolk	   sac	   and	   later	   in	   intra-­‐embryonic	   sites	  such	   as	   the	   allantois	   and	   placenta.	   Primitive	   hematopoiesis	   functions	   to	   rapidly	   produce	  erythroid	  progenitors	   in	   order	   to	   guarantee	   sufficient	   oxygen	   supply	   for	   the	  developing	   fetus.	  HSCs	  begin	   to	  arise	  only	  during	   the	  second	  or	  definitive	  wave	  of	  hematopoiesis	   (E	  8.5),	  which	  takes	  place	  in	  the	  aorta-­‐	  gonad-­‐mesonephros	  (AGM)	  region	  (Muller	  et	  al.,	  1994).	  Once	  starting	  to	  circulate	   in	   the	  blood	  stream,	  HSCs	  migrate	   from	  the	  AGM	  into	  the	   fetal	   liver	  at	  E10	  (Ema	  and	  Nakauchi,	   2000),	   which	   represents	   the	   major	   site	   for	   HSC	   expansion	   during	   embryonic	  development.	  Shortly	  after,	  HSCs	  start	   to	  populate	   the	   thymus	   (E11.5)	  and	  spleen	   (E12.5)	  and	  shortly	  before	  birth	   the	  bone	  marrow	  (BM),	  which	   is	   the	  primary	  site	  of	  hematopoiesis	   in	   the	  adult	  (Wang	  and	  Wagers,	  2011).	  	  In	  the	  adult,	  the	  long-­‐term	  (LT)	  repopulating	  HSC	  is	  unique	  in	  its	  ability	  to	  undergo	  self-­‐renewal	  and	   to	   continuously	  give	   rise	   tom	   immature	  progenitor	   cells	   (Figure	  1).	  During	  hematopoietic	  differentiation,	   LT-­‐HSCs	  give	   rise	   to	  multipotent	  progenitors	   (MPPs)	  with	   limited	   self-­‐renewal	  and	   transient	  but	  multilineage	  reconstitution	  potential.	  These	  MPPs	  subsequently	  differentiate	  into	   oligo-­‐potent	   progenitors,	   such	   as	   the	   common	   myeloid	   progenitor	   (CMP);	  megakaryocyte/erythroid	   progenitor	   (MEP);	   granulocyte/macrophage	   progenitor	   (GMP)	   and	  common	   lymphoid	   progenitor	   (CLP).	   CLPs	   have	   the	   potential	   to	   give	   rise	   to	   mature	   effector	  dendritic	  cells	  (DCs),	  T	  cells,	  natural	  killer	  (NK)	  cells	  and	  B	  cells.	  CMPs	  are	  hierarchically	  above	  MEPs	   and	   GMPs	   but	   can	   also	   immediately	   give	   rise	   to	   DCs.	  MEPs	   differentiate	   into	   erythroid	  progenitors	   (Ep)	   and	  mekaryocyte	   progenitors	   (MkP)	   to	   give	   rise	   to	  mature	   erythrocytes	   and	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platelets,	  respectively.	  GMPs	  differentiate	  into	  mature	  myeloid	  lineages	  such	  as	  granulocytes	  and	  macrophages.	  	  Flow	  cytometric	  analysis	  is	  frequently	  used	  for	  the	  identification	  and	  classification	  of	  the	  distinct	  HSC,	  progenitor	  and	  mature	  hematopoietic	  lineages	  (Figure	  1	  left).	  Each	  of	  the	  above	  mentioned	  cell	   types	   express	   specific	   cell	   surface	   antigens,	   which	   can	   be	   used	   during	   flow	   cytometry	   as	  “markers”	  to	  identify	  even	  small	  and	  rare	  populations,	  which	  are	  frequently	  characterized	  by	  the	  expression	   of	   multiple	   markers.	   Upon	   flow	   cytometric	   analysis,	   fluorochrome-­‐coupled	  antibodies	   against	   these	   cell	   surface	   markers	   are	   passing	   through	   a	   laser	   stream,	   thereby	  exciting	   the	   fluorochrome	   and	   emitted	   a	   signal	   at	   a	   discrete	  wavelength.	   Cell	   populations	   can	  thereby	  not	  only	  be	  identified	  but	  also	  collected	  (Fluoresence	  activated	  cell	  sorting;	  FACS).	  The	  system	  applied	  for	  identifying	  cell	  surface	  markers	  thereby	  allowing	  the	  immunophenotyping	  of	  HSCs	  and	  hematopoietic	  cells	  is	  called	  cluster	  of	  differentiation	  (CD).	  	  	  	  
	  
Figure	   1: Model	   of	   the	   hematopoietic	   developmental	   hierarchy.	   At	   the	   top	   of	   the	   hematopoietic	  developmental	   hierarchy	   stands	   the	   rare	   and	   unique	   long-­‐term	   (LT-­‐)	   HSC,	   which	   can	   through	   asymmetric	  division	  self-­‐renew	  but	  also	  give	  rise	  to	  multipotent	  progenitors	  (MPPs).	  These	  cells	  have	  limited	  self-­‐renewal	  capacity	  and	  but	  differentiate	  into	  all	  short-­‐lived	  mature	  blood	  cells.	  Therefore,	  MPPs	  give	  rise	  to	  oligo-­‐potent	  progenitors,	   such	   as	   the	   common	   myeloid	   progenitor	   (CMP),	   megakaryocyte/erythroid	   progenitor	   (MEP)	  granulocyte/macrophage	  progenitor	  (GMP)	  and	  common	  lymphoid	  progenitor	  (CLP).	  CLPs	  first	  differentiate	  to	  give	  rise	  to	  mature	  effector	  dendritic	  cells	  (DCs),	  T	  cells,	  natural	  killer	  (NK)	  cells	  and	  B	  cells.	  MEPs	  differentiate	  into	   erythroid	   progenitors	   (Ep)	   and	  mekaryocyte	   progenitors	   (MkP)	   to	   give	   rise	   to	  mature	   erythrocytes	   and	  platelets.	   	   GMPs	   differentiate	   into	  mature	  myeloid	   lineages	   like	   granulocytes	   and	  macrophages.	   Cell	   surface	  markers	  used	   for	   isolation	  are	   indicated	  on	   the	   left	   for	  human	  (top)	  and	  mouse	  (bottom)	   for	  each	  stem	  and	  progenitor	  cell.	  Adapted	  from	  (Bryder	  et	  al.,	  2006).	  
Introduction	   3	  
	  Mature	  oxygen-­‐transporting	  erythrocytes	  express	  markers	  such	  as	  Ter119	  and	  CD71,	  with	  early	  erythroblasts	   being	   Ter119+CD71+	   and	   mature	   erythrocytes	   Ter119+CD71-­‐.	   Myeloid-­‐derived	  granulocytes	   (CD11b+Gr1+)	   include	   monocytes,	   neutrophils	   and	   eosinophiles;	   phagocytic	   cell	  types	   specialized	   in	   defending	   the	   system	   from	   infection	   in	   a	   non-­‐specific	   manner	   in	   innate	  immunity.	  The	  cytotoxic	  lymphoid-­‐derived	  NK	  cells	  cooperate	  with	  myeloid	  cells	  by	  destroying	  compromised	  host	  cells	   that	  have	  been	   infected	  with	  a	  virus	  or	  have	  been	  transformed	  during	  tumorigenesis.	  In	  contrast,	  mature	  T	  (CD4+	  and	  CD8+	  single	  positive;	  SP)	  and	  B	  (B220+IgM+)	  cells	  are	  effectors	  of	  the	  adaptive	  immune	  system.	  	  B	  cells	  are	  specialized	  in	  antigen	  recognition	  and	  differentiate	   into	  plasma	  cells,	  which	  produce	  and	   secrete	   antibodies	   specific	   to	   the	  activating	  antigen.	  T	  cells,	  however,	  recognize	  antigens	  presented	  by	  the	  major	  histocompatibility	  complex	  (MHC)	  on	  the	  surface	  of	  infected	  cells	  through	  their	  T	  cell	  receptor	  (TCR).	  	  Antigens	  of	  the	  MHC	  class	   I	   (all	   nucleated	   cells)	   are	   recognized	   by	   the	   CD8	   co-­‐receptor	   of	   cytotoxic	   T	   cells,	   which	  consequently	  target	  the	  infected	  cell	  to	  undergo	  apoptosis.	  In	  contrast,	  antigens	  of	  the	  MHC	  class	  II	   are	   recognized	   by	   the	   CD4	   co-­‐receptor,	   expressed	   by	   helper	   T	   cells,	  which	   in	   turn	   produce	  cytokines	  in	  order	  to	  activate	  CD8	  “killer”	  T	  cells	  and	  macrophages	  for	  uptake	  of	  cellular	  debris.	  
1.2 HSCs	  in	  the	  Adult	  Hematopoietic	  System	  Within	  the	  BM,	  HSCs	  reside	  in	  a	  specialized	  microenvironment	  composed	  of	  different	  cell	  types,	  extracellular	   elements	   and	   contains	   secreted	   factors	   adapted	   to	   the	   needs	   of	   this	   rare	   cell	  population,	  which	  is	  called	  the	  stem	  cell	  niche.	  The	  stem	  cell	  niche	  guarantees	  all	  necessary	  cues	  for	   the	  HSC	   to	  maintain	  self-­‐renewal	  and	  differentiation	  potential.	  The	  crucial	   role	  of	   the	  stem	  cell	  niche	  for	  HSC	  function	  has	  long	  been	  recognized.	  For	  instance,	  studies	  in	  steel-­‐Dickie	  mice,	  harbouring	   a	   mutated	   form	   of	   the	   membrane-­‐bound	   stem	   cell	   factor	   (SCF),	   showed	   that	   in	  absence	  of	  SCF	  within	  the	  niche,	  HSC	  maintenance	  in	  vivo	  is	  severely	  impaired	  (McCulloch	  et	  al.,	  1965).	   	  Due	  to	  the	  observation	  that	  mainly	  two	  cell	  types,	  osteoblasts	  and	  endothelial	  cells,	  are	  crucial	   components	   of	   the	   BM	   niche,	   it	   is	   hypothesized	   that	   the	   niche	   contains	   two	  compartments:	   The	   endosteal	   and	   the	   perivascular	   niche.	   In	   the	   endosteal	   niche,	   rare	   and	  dormant	   LT-­‐repopulating	   HSCs	   are	   in	   close	   physical	   contact	   with	   osteoblasts	   that	   line	   the	  endosteal	   surface	   of	   the	   bone,	  while	  more	   differentiated	  HSCs	   and	   hematopoietic	   progenitors	  are	  predominantly	  residing	  in	  the	  central	  and	  more	  vascularized	  regions	  of	  the	  BM.	  Within	  the	  vascular	   HSC	   niche,	   a	   large	   pool	   of	   CD150+	   self-­‐renewing	   HSCs	   resides	   in	   close	   proximity	   to	  endothelial	   cells	   of	   sinusoids.	   These	   HSCs	   are	   believed	   to	   more	   actively	   replenish	   the	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hematopoietic	   system	   via	   intermediate	   multi-­‐potent	   progenitors,	   in	   particular	   in	   response	   to	  inury	  (Wilson	  and	  Trumpp,	  2006).	  	  Phenotypically	  HSCs	  have	  been	  well	  defined	  based	  on	   the	  expression	  of	  particular	  cell	   surface	  antigens	  and	  can	  be	  classified	  by	  flow	  cytometry.	  HSCs	  reside	  in	  the	  immature	  lineage	  negative	  (Lin-­‐),	   not	   yet	   committed	   or	   differentiated,	   fraction	   of	   cells	   within	   the	   BM	   and	   express	   high	  levels	  of	  stem	  cell	  antigen	  1	  (Sca1)	  and	  stem	  cell	  factor	  (SCF)	  receptor,	  c-­‐kit	  (CD117)	  (Bryder	  et	  al.,	  2006;	  Uchida	  and	  Weissman,	  1992).	  Given	  these	  expression	  characteristics,	  the	  overall	  HSC	  compartment	  is	  therefore	  often	  referred	  to	  as	  LSK	  (Lin-­‐Sca1+c-­‐kit+)	  fraction;	  in	  this	  work	  termed	  “KLS”.	   Consisting	   of	   rare	   hematopoietic	   cell	   types,	   the	   KLS	   population	   only	   accounts	   for	  approximately	  0.5%	  of	  total	  BM	  cells	  (Morrison	  and	  Weissman,	  1995).	  However,	  within	  the	  KLS	  fraction,	  only	  a	  small	  population	  of	  cells	  harbors	  true	  stem	  cell	  potential,	  e.g.	  the	  LT-­‐HSCs.	  This	  population	   is	   defined	   as	   CD34-­‐,	   while	   all	   MPP	   subsets	   are	   CD34+.	   The	   signalling	   lymphocyte	  activation	  molecule	  (SLAM)	  markers	  CD150	  and	  CD48	  and	  also	  CD135	  (Fms-­‐like	  tyrosine	  kinase	  3;	   Flt3	   receptor)	   allow	   further	   enrichment	   for	   pure	   HSCs	   (Kiel	   et	   al.,	   2005).	   Based	   on	   a	  combination	  of	  these	  markers	  and	  their	  cell	  cycle	  behavior,	  KLS	  can	  be	  further	  sub-­‐fractionated	  into	   LT-­‐HSCs	   (CD150+CD48-­‐CD34-­‐CD135-­‐),	   which	   differentiate	   into	   MPP1	   cells	   (CD150+CD48-­‐CD34+CD135-­‐),	   giving	   rise	   to	   MPP2	   cells	   (CD150+CD48+CD34+CD135-­‐),	   which	   consequently	  differentiate	   into	  MPP3	   cells	   (CD150-­‐CD48+CD34+CD135-­‐)	   and	   up-­‐regulation	   of	   CD135	   defines	  the	   last	   MPP	   population	   (MPP4;	   CD150-­‐CD48+CD34+CD135-­‐)	   (Figure	   2)	   (Wilson	   et	   al.,	   2008).	  Upon	  cell	  cycle	  analysis,	  LT-­‐HSCs	  were	  demonstrated	  to	  primarily	  reside	  in	  G0	  phase	  of	  the	  cell	  cycle	   (>70%),	   which	   accounts	   for	   their	   quiescent	   state,	   whereas	   less	   than	   10%	   of	   more	  differentiated	  MPPs	  (KLSCD34+)	  are	  found	  quiescent.	  
	  
Figure	   2: The	   five	  major	   KLS	   subpopulations.	  Differential	   expression	   of	   CD34,	   the	   signalling	   lymphocyte	  activation	  molecules	  (SLAM)	  CD48	  and	  CD150,	  and	  CD135	  (Flt3	  receptor)	  allows	  the	  phenotypic	  classification	  of	   5	   major	   subsets	   within	   the	   KLS	   compartment.	   The	   most	   quiescent	   KLS	   subset	   is	   the	   CD34−CD48−CD150+CD135−	   population,	   which	   accounts	   for	   only	   0.0013%	   of	   cells	   within	   the	   BM.	   Based	   on	   cell	   surface	  expression,	  relative	  cell	  cycle	  status	  and	  their	  abundance	  the	  five	  subsets	  HSC	  to	  MPP4	  are	  put	  in	  hierarchical	  order.	  Adapted	  from	  (Wilson	  et	  al.,	  2008).	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Furthermore,	  HSC	  were	   functionally	   subcategorized	  by	   efflux	   studies	   using	   rhodamine	  123	  or	  with	   Hoechst	   33342	   dye,	   which	   demonstrated	   that	   only	   the	   rare	   LT-­‐HSC	   posses	   multi-­‐drug	  resistant	   pumps,	   such	   as	   MDR1	   or	   ABC	   transporter	   G	   family	   member	   2	   (ABCG2).	   Therefore,	  these	  HSCs	  fall	   into	  the	  side	  population,	  which	  is	  able	  to	  efficiently	  efflux	  dyes	  such	  as	  Hoechst	  3334	   via	   these	   transporters.	   This	   is	   also	   of	   importance	   in	   the	   context	   of	   hematologic	  malignancies,	   as	   leukemic	   stem	   cells	   are	   resistant	   to	   conventional	   chemotherapy	   due	   to	   the	  action	  of	  these	  multi-­‐drug	  resistant	  pumps.	  Functional	  existence	  of	  LT-­‐HSCs	  was	  proven	  by	  studies	  demonstrating	  that	  a	  single	  transplanted	  HSC	   could	   fully	   reconstitute	   the	   hematopoietic	   system	   of	   lethally	   irradiated	  mice	   (Ema	   et	   al.,	  2005;	  Matsuzaki	  et	  al.,	  2004;	  Osawa	  et	  al.,	  1996;	  Trumpp	  et	  al.,	  2010;	  Wilson	  et	  al.,	  2008).	  The	  Long-­‐term	   reconstitution	   (LTR)	   capacity	   of	   HSCs	   can	   be	   further	   assessed	   using	   serial	  transplantation	   assays,	   in	   which	   transplanted	   LT-­‐HSCs	   are	   forced	   to	   replenish	   the	   entire	  hematopoietic	  system	  in	  sequentially	  transplanted	  recipient	  mice.	  True	  LT-­‐HSCs	  are	  capable	  of	  self-­‐renewal	   and	  multi-­‐lineage	   differentiation	   for	   up	   to	   three	   rounds	   of	   serial	   transplantation	  (Domen	  and	  Weissman,	  1999).	  However,	  under	  homeostatic	  conditions,	  up	  to	  70%	  of	  LT-­‐HSCs	  are	  dormant.	  These	   cells	   reside	  preferentially	   in	   the	  G0	  phase	  of	   the	   cell	   cycle	  and	  divide	  only	  five	  times	  per	  life	  time	  as	  shown	  in	  BrdU	  label	  retaining	  studies	  (Wilson	  et	  al.,	  2008).	  However,	  dormant	   HSCs	   can	   be	   successfully	   activated	   and	   “pushed”	   into	   cycle	   by	   BM	   injury	   or	  extracellular	  cues,	  such	  as	  granulocyte	  colony-­‐stimulating	  factor	  (G-­‐CSF),	  interferon-­‐α	  (INFα)	  or	  5-­‐fluorouracil	   (5-­‐FU).	  For	   instance,	   stimulation	  of	  HSCs	  and	  progenitor	  cells	  with	  recombinant	  G-­‐CSF	  leads	  to	  HSC	  mobilization	  without	  negatively	  affecting	  the	  HSC	  pool	  even	  upon	  repeated	  administration	  (de	  Kruijf	  et	  al.,	  2007).	  A	  study	  by	  Esser	  et	  al.	  demonstrated	  that	  upon	  treatment	  with	   INFα,	  dormant	  HSCs	  exit	  G0	  phase	  and	  enter	   the	   cell	   cycle	   (Essers	  et	   al.,	   2009).	  This	  was	  shown	  to	  be	  dependant	  on	  increased	  phosphorylation	  of	  STAT1	  and	  AKT1,	  up-­‐regulation	  of	  INFα	  and	  increased	  expression	  of	  Sca1.	  Reciprocal	  experiments	  in	  HSCs	  derived	  from	  INFαR	  KO	  mice,	  which	  lack	  the	  INFαβ	  receptor,	  STAT1	  cKO	  mice	  and	  Sca1	  cKO	  mice	  proved	  insensitive	  to	  INFα-­‐mediated	   mobilization	   and	   hence	   STAT1	   and	   Sca1	   are	   essential	   during	   this	   process.	  Furthermore,	   (i)	  combinatorial	   treatment	  with	   INFα	  to	  prime	  HSC	  mobilization	   followed	  by	  5-­‐FU,	   a	   chemotherapeutic	   agent,	   administration	   and	   (ii)	   chronic	   INFα	   exposure	   were	  demonstrated	  to	  lead	  to	  HSC	  loss.	  Another	  means	  to	  challenge	  and	  mobilize	  quiescent	  is	  via	  5-­‐FU	  administration.	  5-­‐FU	  is	  a	  pyrimidine	  analogue	  that	  is	  frequently	  used	  in	  the	  treatment	  of	  cancer	  as	   it	   (i)	   inhibits	   thymidylate	   synthase,	   thereby	   blocking	   thymidine	   synthesis	   and	   (ii)	  incorporates	  into	  newly	  synthesized	  DNA	  leading	  to	  cell	  cycle	  arrest	  and	  apoptosis	  (Lerner	  and	  Harrison,	  1990).	  By	  targeting	  proliferating	  cells,	  mature	  lineages	  of	  myeloid	  and	  lymphoid	  origin	  are	  rapidly	  reduced,	  resulting	  in	  the	  mobilization	  of	  the	  HSC	  compartment.	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1.3 T	  cell	  Development	  in	  the	  Thymus	  During	  T	  cell	  development,	  early	  thymic	  progenitors	  (ETPs),	  which	  arise	  from	  HSCs	  within	  the	  BM,	  migrate	  into	  the	  thymus	  whereby	  they	  progress	  through	  different	  stages	  T	  cell	  maturation	  to	  become	  mature	  CD4+	  or	  CD8+	  single	  positive	  (SP)	  T	  cells.	  The	  earliest	  thymic	  progenitors	  are	  negative	  for	  CD4	  and	  CD8,	  therefore	  referred	  to	  as	  double	  negative	  (CD4-­‐CD8-­‐,	  DN)	  thymocytes.	  DN	   thyocytes	   can	  be	   further	   subdivided	  by	   the	  differential	   expression	  of	  CD25	  and	  CD44	   into	  DN1	   (CD44+CD25-­‐CD117hi),	   DN2	   (CD44+C25+),	   DN3	   (CD44-­‐CD25+)	   and	   DN4	   (CD44-­‐CD25-­‐)	  immature	  T	  cells,	  whereby	  cells	  progress	  from	  DN1	  to	  DN4.	  At	  the	  DN2	  stage,	  T	  cell	  progenitors	  up-­‐regulate	  genes	  important	  during	  T	  cell	  maturation	  and	  selection,	  such	  as	  the	  recombination	  activating	   genes	   1	   and	   2	   (RAG1	   and	  RAG2)	   required	   for	   the	   rearrangement	   of	   	   	   cell	   receptor	  (TCR)	  genes	  and	   the	  CD3	  chain	  as	  part	  of	   the	  TCR	  complex.	  Only	  a	  small	   subset	  activates	  TCR	  rearrangement	  of	   the	  γ	  and	  δ	   loci	   to	  become	  TCRγδ	  (2%).	  This	   transition	  phase	  between	  DN2	  and	  DN3	   is	   called	   the	  TCRβ	  selection	  checkpoint	  at	  which	  progenitors	  are	  committed	   to	   the	  T	  cell	   lineage	   and	   can	   no	   longer	   differentiate	   into	   any	   other	   lineage.	   Upon	   down-­‐regulation	   of	  CD25,	  DN3	  cells	  progress	  to	  the	  DN4	  stage,	   followed	  by	  an	   immature	  single	  positive	  CD8	  (CD8	  iSP)	   stage,	   at	   which	   cells	   express	   low	   levels	   of	   surface	   TCRβ	   and	   CD8	   (CD8+	   SP).	   Extensive	  proliferation	  and	  expression	  of	  CD4	  leads	  to	  the	  CD4+CD8+	  double	  positive	  (DP)	  stage,	  at	  which	  T	  cell	   progenitors	   express	   intermediate	   levels	   of	   TCRβ	   and	   account	   for	   approximately	   80%	   of	  immature	   T	   cells.	   DP	   cells	   undergo	   TCRα	   rearrangement	   and	   then	   these	   progenitors	   undergo	  final	  maturation	  through	  positive	  and	  negative	  selection.	  During	  negative	  selection,	  self-­‐reactive	  thymocytes,	   which	   express	   their	   TCRs	   that	   recognize	   “self”-­‐peptides	   presented	   by	   MHC	  molecules	   in	   the	   thymic	   epithelium,	   undergo	   apoptosis	   and	   are	   thereby	   eliminated	   from	   the	  thymus.	  During	  positive	  selection,	  functional	  T	  cells,	  which	  are	  able	  to	  interact	  with	  molecules	  of	  the	   major	   histocompatibility	   complex	   (MHC)	   presented	   by	   thymic	   epithelial	   cells,	   survive	   to	  become	  either	  mature	  CD4+	  SP	  helper	  T	  cells	  (MHC	  class	  II)	  or	  CD8+	  SP	  cytotoxic	  T	  cells	  (MHC	  class	  I).	  
1.4 The	  Canonical	  Notch	  Signalling	  Pathway	  The	   Notch	   pathway	   is	   evolutionary	   conserved	   and	   regulates	   key	   cellular	   processes	   such	   as	  proliferation,	  differentiation	  and	  cell	  fate	  specification	  within	  self-­‐renewing	  organs	  including	  the	  hematopoietic	  system,	  the	  gut	  and	  the	  skin.	  In	  1917,	  Thomas	  Hunt	  Morgan	  described	  a	  strain	  of	  the	  fruit	  fly	  Drosophila	  melanogaster	  that	  exhibited	  notches	  at	  the	  margins	  of	  their	  wing	  blades	  (Morgan,	  1917).	  These	  notches	  were	  the	  phenotypic	  outcome	  of	  a	  partial	  loss	  in	  a	  gene	  cloned	  in	  the	  mid	  1980´s	  and	  named	  Notch	  (Kidd	  and	  Young,	  1986;	  Wharton	  et	  al.,	  1985).	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Notch	  signalling	  is	  a	  cell-­‐to-­‐cell	  communication	  pathway,	  which	  relies	  on	  the	  physical	  interaction	  between	   a	   signal-­‐sending	   cell,	   expressing	   a	   Notch	   ligand	   at	   the	   cell	   surface,	   and	   a	   signal-­‐receiving	  cell,	  which	  expresses	  the	  transmembrane	  bound	  Notch	  receptor.	  There	  exists	  only	  one	  transmembrane	  Notch	  receptor	   in	  Drosophila,	  which	  can	  be	  activated	  via	   interaction	  with	   two	  different	  membrane-­‐bound	   ligands	  called	  Delta	  and	  Serrate	   (Figure	  3	   top).	   In	  mammals,	   there	  are	  four	  Notch	  receptors,	  Notch	  (N)	  1	  to	  4,	  that	  are	  bound	  by	  five	  different	  ligands	  called	  Jagged	  1	   and	   2	   (homologs	   of	   Serrate)	   and	  Delta-­‐like	   (Dll)	   1,	   3	   and	   4,	  which	   are	   homologs	   of	   Serrate	  (Figure	  3	  bottom).	  	  
	  
Figure	  3:	  Notch	   receptors	   and	   their	   ligands.	   In	  Drosophila	   there	   exists	   only	   one	  Notch	   receptor	   (dNotch),	  which	   is	   bound	   by	   two	   transmembrane	   ligands	   Serrate	   and	   Delta.	   In	   mammals,	   there	   exist	   the	   four	   Notch	  receptors	  Notch1-­‐4	  that	  can	  be	  bound	  by	  the	  five	  different	  ligands	  Jagged	  1	  and	  2	  (homologues	  of	  Serrate)	  and	  Delta-­‐like	  (Dll)	  1,	  3	  and	  4,	  which	  are	  homologues	  of	  Delta.	  Left,	  Notch	  receptors	  are	  expressed	  at	  the	  cell	  surface	  as	   heterodimeric	   proteins,	   whose	   extracellular	   portion	   contains	   29-­‐36	   epidermal	   growth	   factor	   (EGF)-­‐like	  repeats,	   being	   important	   for	   ligand	   binding	   and	   ligand	   specificity.	   These	   are	   followed	   by	   3	   cystein-­‐rich	   LIN-­‐repeats,	  preventing	  signalling	  in	  absence	  of	  a	   ligand,	  and	  a	  heterodimerization	  domain	  (HD).	  The	  intracellular	  Notch	  domain	  is	  composed	  of	  the	  RAM	  domain	  (R)	  and	  six	  ankyrin	  repeats	  (ANK),	  both	  important	  for	  protein	  interaction,	  followed	  by	  2	  nuclear	  localization	  signals	  (NLS),	  a	  transactivation	  domain	  (TAD,	  absent	  in	  N3	  and	  N4)	  and	  a	  PEST	  sequence	  (P).	  Right,	  Similarly,	  Notch	  ligands	  are	  also	  expressed	  as	  membrane-­‐bound	  proteins.	  All	   ligands	   harbor	   an	   amino-­‐terminal	   DSL	   domain	   (Delta,	   Serrate	   and	   Lag2)	   followed	   by	   EGF-­‐like	   repeats.	  Serrate	  and	  Jagged	  ligands	  possess	  a	  cysteine-­‐rich	  (CR)	  domain	  adjacent	  to	  the	  EGF-­‐like	  repeats.	  Both	  receptors	  and	  ligands	  span	  the	  plasma	  membrane.	  Adapted	  from	  (Radtke	  et	  al.,	  2005).	  	  Notch	  receptors	  are	  expressed	  at	  the	  cell	  surface	  as	  heterodimeric	  proteins,	  whose	  extracellular	  portion	  contains	  29-­‐36	  epidermal	  growth	  factor	  (EGF)-­‐like	  repeats.	  These	  repeats	  are	  important	  for	   ligand	  binding	  and	   ligand	  specificity.	  These	  are	  structurally	   followed	  by	  3	  cystein-­‐rich	  LIN-­‐repeats,	  preventing	  signalling	  in	  absence	  of	  a	  ligand,	  and	  a	  heterodimerization	  domain	  (HD).	  The	  intracellular	  Notch	  domain	  is	  composed	  of	  the	  RBP-­‐associated	  molecule	  (RAM)	  domain	  (R)	  and	  six	   ankyrin	   repeats	   (ANK),	   both	   important	   for	   protein	   interactions,	   followed	   by	   2	   nuclear	  localization	  signals	   (NLS),	  a	   transactivation	  domain	  (TAD,	  absent	   in	  N3	  and	  N4)	  and	  a	  peptide	  sequence,	  rich	  in	  proline,	  glutamic	  acid,	  serine	  and	  threonine	  (PEST;P).	  Similarly,	  Notch	  ligands	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are	   also	   expressed	   as	  membrane-­‐bound	   proteins	   spanning	   the	   plasma	  membrane.	   All	   ligands	  share	   an	   amino-­‐terminal	   DSL	   domain	   (Delta,	   Serrate	   and	   Lag2)	   followed	   by	   EGF-­‐like	   repeats.	  Serrate	  and	  Jagged	  ligands	  possess	  a	  cysteine-­‐rich	  (CR)	  domain	  adjacent	  to	  the	  EGF-­‐like	  repeats.	  	  Newly	  synthesized	  Notch	  receptor	  proteins	  are	  proteolytically	  cleaved	  in	  the	  Golgi	  apparatus	  by	  a	   furin-­‐like	   convertase	   at	   cleavage	   site	   S1	  before	  being	   trafficked	   towards	   the	   cell	  membrane,	  where	   they	   form	   heterodimers	   (Figure	   4).	   Upon	   ligand	   receptor	   interaction,	   two	   sequential	  proteolytic	  cleavages	  are	  carried	  out	  by	  metalloproteases	  of	   the	  ADAM	  family	   (tumor	  necrosis	  factor-­‐α-­‐converting	  enzyme;	  TACE)	  at	  S2	  in	  the	  extracellular	  part	  of	  the	  receptor	  and	  by	  a	  multi-­‐protein	   complex	   exhibiting	   a	   proteolytic	   γ-­‐scretase	   activity	   at	   S3	   in	   the	   intracellular	   part.	  Consequently,	   the	  Notch	   intracellular	  domain	   (NICD)	   is	   released	  and	   shuttles	   into	   the	  nucleus	  where	   it	   binds	   to	   the	   transcription	   factor	  CSL,	   also	  known	  as	  CBF-­‐1	   in	  humans,	   suppressor	  of	  hairless	   in	   Drosophila	   and	   RBPJκ	   in	   the	   mouse.	   Further	   recruitment	   of	   co-­‐activators	   of	   the	  mastermind-­‐like	   family	   (MAML1-­‐3)	   results	   in	   the	   formation	   of	   an	   activated	   transcriptional	  complex	  and	  expression	  of	  Notch	  target	  genes	  is	  launched.	  Among	  Notch	  target	  genes,	  members	  of	   the	  Hairy	   enhancer	  of	   split	   (Hes)	   or	  Hairy	   related	   (Hey	   or	  Hrt)	   gene	   families	   of	   basic-­‐helix-­‐loop-­‐helix	   (bHLH)	   transcriptional	   repressors	   are	   best	   characterized	   (Jarriault	   et	   al.,	   1995;	  Jarriault	  et	  al.,	  1998;	  Wendorff	  et	  al.,	  2010).	  Additional	  Notch	  target	  genes	  include	  the	  cell	  cycle	  regulator,	   cyclin	   dependent	   kinase	   1	   inhibitor	  CdknIα	   (p21)	   (Rangarajan	   et	   al.,	   2001),	  Deltex1	  (Matsuno	  et	  al.,	  1995)	  and	  c-­‐myc	  (Palomero	  et	  al.,	  2006).	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Figure	   4:	   Notch	   signalling.	   Notch	   precursor	   receptors	   are	   cleaved	   in	   the	   Golgi	   apparatus	   by	   a	   furin-­‐like	  convertase	  before	  trafficking	  towards	  the	  cell	  membrane,	  where	  they	  form	  heterodimers.	  Glycosyltransferases	  of	  the	  Fringe	  family	  mediate	  glycolysation	  of	  the	  EGF	  repeats	  of	  the	  receptor,	  thereby	  regulating	  receptor-­‐ligand	  specificity.	  Upon	  receptor-­‐ligand	  interaction,	  two	  proteolytic	  cleavages	  take	  place,	  (i)	  the	  metalloprotease	  TACE	  (tumor	  necrosis	  factor	  α-­‐converting	  enzyme)	  cleaves	  within	  the	  extracelluar	  domain,	  followed	  by	  (ii)	  cleavage	  within	  the	  transmembrane	  domain	  mediated	  by	  the	  γ-­‐secretase	  complex,	  which	  is	  composed	  of	  presenilins	  such	  as	  Nicastrin,	  APH-­‐1	  and	  PEN-­‐2.	  This	   results	   in	   release	  of	   the	   intracellular	  domain	   (NICD),	  which	   translocates	  into	  the	  nucleus	  to	  form	  a	  transcriptional	  complex	  with	  CSL,	  master-­‐mind	  like	  proteins	  (MAML1)	  and	  other	  co-­‐activators	  (CoA),	  thereby	  replacing	  transcriptional	  co-­‐repressors	  (CoR).	  As	  a	  result	  expression	  of	  Notch	  target	  genes	  is	  launched.	  Adapted	  from	  (Radtke	  et	  al.,	  2005).	  	  
1.4.1 Notch	  Signalling	  in	  Hematopoietic	  Stem	  Cells	  Notch	   receptors	   and	   ligands	   are	  widely	   expressed	   in	   HSCs	   and	   in	   cells	  within	   the	   HSC	   niche.	  Therefore,	  Notch	  signalling	  was	  proposed	   to	   regulate	  hematopoiesis.	   	  While	  N1	  signalling	  was	  shown	   to	   be	   dispensable	   in	   primitive	   hematopoiesis	   within	   the	   yolk	   sac,	   germline	   mutant	  embryos	  deficient	  for	  N1	  or	  RBPJκ	  failed	  to	  generate	  intraembryonic	  HSCs	  (Robert-­‐Moreno	  et	  al.,	  2008).	   However,	   the	   impaired	   development	   of	   definitive	   hematopoiesis	   in	   these	  mice	  may	   be	  due	   to	   a	   cell-­‐autonomous	   effect	   or	   as	   a	   secondary	   effect	   due	   to	   perturbed	   vasculogenesis.	  Further	  studies	  in	  conventional	  KO	  mice	  for	  Jagged1	  demonstrated	  that	  expression	  of	  this	  ligand	  is	   essential	   for	   HSC	   numbers	   in	   the	   AGM,	   without,	   however,	   perturbing	   the	   integrity	   of	   the	  arterial	  system	  (Robert-­‐Moreno	  et	  al.,	  2008).	  In	   contrast,	  whether	  Notch1	  plays	  a	  physiological	   role	   in	   the	  maintenance	  and	   self-­‐renewal	  of	  HSCs	  is	  still	  a	  matter	  of	  debate.	  Jagged	  1	  was	  proposed	  to	  be	  important	  in	  the	  HSC	  stem	  cell	  niche	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since	   parathyroid	   hormone-­‐related	   protein-­‐receptor	   (PTHPR)	   expression	   by	   osteoblasts	  resulted	   in	   increased	  numbers	  of	   Jagged1-­‐expressing	  osteoblasts.	  This	   in	   turn	   correlated	  with	  higher	   numbers	   of	   HSCs,	   suggesting	   that	   Jagged1	  may	   support	   HSC	   self-­‐renewal	   (Calvi	   et	   al.,	  2003).	  However,	  Jagged1-­‐mediated	  Notch	  signalling	  was	  demonstrated	  to	  be	  dispensable	  for	  the	  maintenance	   of	   HSCs	   using	   a	   conditional	   gene	   targeting	   approach	   in	   BM	   and	   HSC	   niche	   cells	  (Mancini	   et	   al.,	   2005).	   Since	   Jagged2	  was	   reported	   to	   be	   also	   expressed	   in	   the	   HSC	   stem	   cell	  niche,	  Jagged2	  may	  compensate	  for	  loss	  of	  Jagged1	  function.	  In	  addition,	  a	  study	  demonstrated	  differential	   Jagged2	  expression	   in	  hematopoietic	  and	  endothelial	  cells	  (Tsai	  et	  al.,	  2000).	  Over-­‐expression	  of	  Jagged2	  promoted	  HSC	  proliferation	  and	  survival	  in	  vitro	  in	  the	  absence	  of	  growth	  factors.	  Therefore,	  Tsai	  et	  al	  propose	  Jagged2	  to	  be	  a	  regulator	  of	  hematopoiesis.	  	  In	  addition,	  Maillard	  et	  al.	  demonstrated	  that	   impairment	  of	  canonical	  Notch	  signalling	  using	  a	  dominant-­‐negative	  (dn)	  of	  MAML	  as	  well	  as	  the	  conditional	  inactivation	  of	  RBPJκ	  does	  not	  result	  in	   a	   block	   of	   HSC	   maintenance	   (Maillard	   et	   al.,	   2008).	   This	   suggests	   that	   Notch	   signalling	   is	  dispensable	   for	   HSC	   maintenance.	   Hence,	   the	   controversial	   outcome	   of	   these	   studies	   still	  questions	  whether	  Notch	  signalling	  plays	  a	  role	  in	  definitive	  hematopoiesis.	  	  
1.4.2 Notch	  Signalling	  in	  T	  Cell	  and	  MZB	  Cell	  Development	  Notch	  signalling	  in	  the	  hematopoietic	  system	  has	  been	  best	  characterized	  in	  the	  context	  of	  T	  cell	  development	   in	   the	   thymus.	   Fiorini	   et	   al.	   demonstrated	   that	   developing	   thymocytes	   express	  Notch1	   and	   Notch2	   receptors	   (Fiorini	   et	   al.,	   2009),	   while	   thymic	   epithelial	   cells	   express	   the	  ligands	  Dll1,	  Dll4	  and	  Jagged	  2	  (Felli	  et	  al.,	  1999).	  	  In	  1999,	  the	  Notch1	  conditional	  knock	  out	  (cKO)	  mouse	  was	  generated	  and	  crossed	  with	  the	  INF	  type	   I-­‐responsive	  MxCre	  recombinase	   in	  order	   to	  study	  the	  role	  of	  Notch	   in	   the	  hematopoietic	  system	   (Radtke	   et	   al.,	   1999).	   Upon	   ablation	   of	   N1	   in	   BM	   progenitors,	   the	   majority	   of	  hematopoietic	   lineages	   remained	   unaffected.	   	   T	   cell	   development	   however,	   was	   severely	  impaired	  in	  N1	  cKO	  mice	  as	  immature	  T	  cells	  were	  blocked	  at	  the	  DN1	  stage	  (Lin-­‐CD4-­‐CD8-­‐CD25-­‐CD44+),	   which	   was	   accompanied	   by	   an	   accumulation	   of	   immature	   B	   cells	   (IgM-­‐B220+CD19+)	  within	  the	  thymus.	  Therefore,	  this	  study	  demonstrated,	  for	  the	  first	  time	  that	  Notch	  is	  important	  for	  regulating	  T	  versus	  B	  lineage	  commitment	  decisions	  in	  hematopoietic	  progenitors.	  	  	  Although	  three	  different	  Notch	  ligands	  are	  expressed	  by	  the	  thymic	  epithelium,	   in	  vitro	  culture	  experiments	  suggested	  that	  Dll1	  may	  be	  physiological	  ligand	  for	  N1	  in	  the	  thymus	  (Schmitt	  et	  al.,	  2004).	  Only	  later,	  Koch	  et	  al.	  studied	  the	  conditional	  ablation	  of	  Dll1	  and	  Dll4	  in	  thymic	  epithelial	  cells	  (TECs)	  in	  order	  to	  identify	  the	  physiological	  ligand	  for	  N1	  in	  the	  thymus.	  Upon	  ablation	  of	  Dll4	   but	   not	   Dll1,	   thymocytes	   were	   blocked	   at	   the	   DN1	   stage	   of	   T	   cell	   development	   and	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immature	  B	  cells	  accumulated	  in	  the	  thymus.	  These	  results	  were	  confirmative	  of	  the	  phenotype	  observed	   in	   BM-­‐specific	  N1	   cKO	   mice,	   also	   leading	   to	   ectopic	   B	   cell	   at	   the	   expense	   of	   T	   cell	  development	   in	   the	   thymus.	   Therefore,	   Dll4	   is	   the	   essential	   Notch	   ligand	   to	   induce	   Notch	  signalling	  upon	  interaction	  with	  thymic	  progenitors	  that	  express	  N1	  (Koch	  et	  al.,	  2008).	  	  The	   second	  well	   characterized	   role	   for	   Notch	   signalling	   in	   the	   hematopoietic	   system	   involves	  mature	  B	  cell	  differentiation.	  Marginal	  zone	  B	  cells	  (MZB)	  are	  rapidly	  recruited	  in	  early	  adaptive	  immune	   responses	  against	  blood-­‐borne	  antigens	   in	   a	  T	   cell-­‐independent	  manner.	  Thereby	   the	  production	  of	  antibodies	  is	  mounted	  in	  order	  to	  defend	  the	  body	  from	  pathogens.	  First	  studies	  in	  
RBPJκ	  cKO	  mice	  crossed	  with	  the	  B	  cell	  specific	  CD19	  Cre	  revealed	  impaired	  development	  of	  MZB	  cells	   (B220+IgM+CD21hiCD23lo)	   with	   a	   concomitant	   increase	   in	   follicular	   zone	   B	   cells	  (B220+IgM+CD21intCD23hi)	   in	   the	   spleen	   (Tanigaki	   et	   al.,	   2002).	   Similarly,	   upon	   conditional	  ablation	  of	  N2	  or	  Dll1,	  MZB	  cells	  were	  negatively	  affected.	  This	  study	  hence	  provided	  evidence	  that	  N2	  and	  Dll1	  are	   the	  physiological	  Notch	  receptor	   ligand	  pair,	   responsible	   for	  MZB	   lineage	  specification	   (Hozumi	   et	   al.,	   2004;	   Saito	   et	   al.,	   2003).	   Furthermore,	   downstream	   of	   N2-­‐Dll1	  signalling,	  members	  of	  the	  MAML	  family	  of	  transcriptional	  co-­‐activators	  have	  been	  studied	  in	  the	  context	   of	   MZB	   cell	   specification.	   Chimeric	   MAML1	   KO	   mice	   exhibited	   a	   block	   in	   MZB	  development,	  while	  the	  thymic	  compartment	  remained	  mainly	  unaffected.	  This	  suggested,	  that	  a	  sole	  member	  of	  transcriptional	  co-­‐activators,	  MAML1,	  regulates	  MZB	  specification	  in	  the	  spleen,	  while	  in	  the	  thymus	  other	  members	  may	  compensate	  for	  MAML1	  deficiency	  (Wu	  et	  al.,	  2007).	  
1.4.3 Notch	  Signalling	  in	  T	  cell	  Acute	  Lymphoblastic	  Leukemia	  (T-­‐ALL)	  The	  first	   link	  between	  the	  Notch	  pathway	  and	  cancer	  was	  established	  in	  1987,	  when	  Reynolds	  and	  colleagues	  discovered	   the	  chromosomal	   translocation	   t(7;9)	   (q34;q34.3)	   in	  a	   small	   subset	  (<1%)	  of	  patients	  suffering	   from	  T-­‐cell	  acute	   lymphoblastic	   leukemia	  (T-­‐ALL)	   (Reynolds	  et	  al.,	  1987).	   This	   translocation	   leads	   to	   the	   expression	   of	   a	   dominant	   active	   form	   of	   N1	   since	   the	  intracellular	   domain	   of	   the	  Notch	   receptor	   (NICD)	   is	   juxtaposed	   to	   the	   enhancer	   of	   the	   T	   cell	  receptor	  β	   (TCRβ).	  As	  a	   result,	  developing	  T	  cells	   constitutively	  express	  NICD	  and	  are	   thereby	  transformed	   to	   become	   leukemic	   (Ellisen	   et	   al.,	   1991).	   Experimentally,	   work	   by	   Pear	   et	   al.	  demonstrated	   that	   retroviral	   overexpression	   of	   NICD	   in	   isolated	   BM	   progenitors	   leads	   to	   the	  development	   of	   T-­‐ALL	   upon	   transplantation	   in	   lethally	   irradiated	   recipient	   mice	   (Pear	   et	   al.,	  1996a).	   Leukemic	   cells	   generated	   in	   this	   retroviral	   T-­‐ALL	   induction	   model	   phenotypically	  resemble	  human	  T-­‐ALL	  due	   to	   their	   clonal	  origin	  of	   immature	   transformed	  T	  cells.	  Hence	   this	  study	   provided	   first	   experimental	   proof	   that	   aberrant	   N1	   signalling	   is	   causative	   for	   T-­‐ALL.	  Therefore,	   the	  retroviral	   induction	  model	   is	   frequently	  used	  as	  a	  means	  to	  study	  T-­‐ALL	   in	  vivo	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(Pear	  et	  al.,	  1996a).	  The	  aberrant	  expression	  of	  Notch1	  in	  T-­‐ALL	  gained	  more	  importance	  with	  the	  land	  marking	  study	  by	  Weng	  et	  al.	  (Weng	  et	  al.,	  2004).	  They	  sequenced	  96	  primary	  human	  T-­‐ALL	  samples	  and	  T-­‐ALL	  cell	  lines	  and	  identified	  activating	  mutations	  in	  the	  heterodimerization	  (HD)	  and	  PEST	  domains	  of	  the	  Notch1	  receptor	  in	  more	  than	  50%	  of	  the	  cases	  (Figure	  5).	  	  	  
	  
Figure	   5:	   Notch1	   mutations	   in	   the	   HD	   and	   PEST	   domains	   identified	   in	   human	   T-­‐ALL.	   Schematic	  representation	   of	   the	   Notch1	   receptor	   with	   its	   extracellular	   domain	   (NEC),	   harbouring	   EGF-­‐like	   repeats,	  LIN/Notch	  repeats	  and	  parts	  of	   the	  heterodimerization	  domain	  (HD).	  The	  transmembrane	  portion	  of	  N1	  with	  the	   C-­‐terminal	  HD	  domain,	   transmembrane	   domain	   (TM),	   ankyrin	   repeats,	   transactivation	   domain	   and	  PEST	  domain.	  The	  by	  DNA	  sequencing	  identified	  mutations	  affect	  the	  extracellular	  HD	  domain	  at	  the	  N-­‐	  (HDN)	  or	  C-­‐terminal	  (HDC)	  part,	  the	  transmembrane	  PEST	  domain	  or	  both	  HD	  and	  PEST	  at	  the	  same	  time.	  These	  mutations	  lead	  to	  aberrant	  Notch	  pathway	  activation	  due	  to	  ligand-­‐independent	  signalling	  (HD	  domain)	  or	  delayed	  NICD	  degradation	  (PEST	  domain).	  Adapted	  from	  (Weng	  et	  al.,	  2004).	  	  	  Mutations	  affecting	  the	  HD	  domain	  lead	  to	  ligand-­‐independent	  Notch	  pathway	  activation.	  This	  is	  due	  to	  the	  altered	  conformation	  of	  the	  negative	  regulatory	  region	  (NRR),	  which	  in	  turn	  exposes	  the	  S2	  site	   for	  cleavage	  even	  in	  absence	  of	  Notch	  receptor-­‐ligand	  interaction.	  Mutations	  within	  the	  PEST	  domain	   in	  contrast,	  negatively	  affect	   the	  degradation	  of	  NICD	  mediated	  by	  FBW7	  E3	  ligase,	  thereby	  leading	  to	  prolonged	  availability	  for	  signalling.	  In	  addition,	  it	  was	  demonstrated	  that	   the	  occurrence	  of	  mutations	  affecting	  both	   the	  HD	  and	   the	  PEST	  domain,	   further	  enhance	  Notch	   pathway	   activation	   as	   shown	   by	   a	   luciferase	   Notch	   reporter	   assay.	   Consequently,	   this	  work	  also	  proposed	  targeting	  the	  Notch	  signalling	  pathway	  as	  therapeutic	  approach	  to	  treat	  T-­‐ALL	  in	  patients	  (Weng	  et	  al.,	  2004).	  
1.5 Chromatin	  Remodellers	  as	  Regulators	  of	  Gene	  Expression	  In	   eukaryotic	   cells,	   the	   genetic	   information	   containing	  DNA	   is	   compacted	   into	   chromatin.	   The	  fundamental	  subunit	  of	  chromatin	  is	  the	  nucleosome,	  which	  consists	  of	  146	  bp	  of	  DNA	  wrapped	  around	   an	   octamer	   of	   four	   core	   histones,	   in	   general	   a	   H3/H4	   tetramer	   and	   two	   H2A/H2B	  dimers,	   forming	   a	   beads-­‐on-­‐a-­‐string-­‐structure	   (Strahl	   and	   Allis,	   2000).	   The	   nucleosomal	   units	  are	  then	  folded	  into	  higher-­‐order	  chromatin	  fibres	  (Luger	  and	  Richmond,	  1998).	  Once	  thought	  of	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as	  static,	  non-­‐participating	  structural	  elements,	   it	   is	  now	  evident	  that	  histones	  are	  integral	  and	  dynamic	  components	  of	  the	  gene	  transcription	  machinery	  (Strahl	  and	  Allis,	  2000)	  (Figure	  6).	  	  	  
Figure	   6:	   Epigenetic	   regulation	   of	   gene	  
expression.	   In	   eukaryoctes	   the	   genetic	  information,	  encoded	  by	  the	  DNA,	  is	  compacted	  into	   chromatin.	   Chromatin	   fibers	   consist	   of	  DNA	   wrapped	   around	   an	   octamer	   of	   core	  histones	   (nucleosome),	   thereby	   building	   a	  “beads-­‐on-­‐a-­‐string-­‐structure”.	   Histone	   tails	  produce	  out	  from	  the	  nucleosome	  and	  serve	  as	  docking	   sites	   for	  epigenetic	  marks.	  These	   tails	  are	   also	   recognized	   by	   chromatin-­‐binding	  proteins,	   which	   physically	   slide	   nucleosomes	  along	  the	  DNA,	  thereby	  opening	  (euchromatin)	  or	   closing	   (heterochromatin)	   the	   chromatin	  structure.	   In	   addition,	   the	   DNA	   can	   be	  methylated	  thereby	  regulating	  accessibility	  for	  the	   transcriptional	   machinery.	   Adapted	   from	  CNS	  Spectr.	  2010;15(4):220-­‐230.	  	  	  Histone	   tails	   protrude	   out	   of	   the	  nucleosome	  and	  are	  subjected	  to	  diverse	  covalent	   post-­‐translational	  modifications.	  These	  include	  acetylation,	  phosphorylation,	   methylation,	  ubiquitination,	   sumoylation	   and	   ADP-­‐ribosylation	   (Luger	   and	   Richmond,	  1998).	   These	   histone	   modifications	   act	  sequentially	   or	   in	   combination	   to	   form	  the	   “histone	   code”.	   Histone	  modifications	   directly	   influence	   chromatin	   structure,	   thereby	   regulating	   access	   to	   the	  DNA.	   In	  addition,	  specific	  histone	  modifications	  or	  combinations	  thereof	  serve	  as	  recognition	  motifs	  for	  chromatin	  binding	  proteins	  to	  bring	  about	  distinct	  downstream	  events	  (Strahl	  and	  Allis,	  2000).	  Thereby,	   the	   information	   content	   of	   the	   genome	   is	   extended	   beyond	   the	   DNA	   sequence	  (Jenuwein	   and	   Allis,	   2001).	   In	   general,	   histone	   acetylation	   favors	   gene	   activation.	   Histone	  methylation	   has	   different	   effects,	   depending	   on	   the	   site	   of	   the	  methylated	   residue,	   e.g.	   H3K4	  promotes	  transcriptional	  activation,	  while	  H3K27	  represses	  transcription.	  	  Therefore,	  it	  is	  not	  solely	  the	  DNA	  sequence	  that	  determines	  gene	  expression	  but	  also	  epigenetic	  modifications.	  Per	  definition,	  epigenetic	  regulators	  alter	   the	  activities	  and	  the	  abilities	  of	  a	  cell	  without	  affecting	  and	  mutating	  the	  sequence	  of	  the	  DNA	  (Lund	  and	  van	  Lohuizen,	  2004).	  These	  epigenetic	  alterations	  include	  (i)	  DNA	  methylation,	  (ii)	  histone	  modifications	  and	  (iii)	  chromatin	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remodelling,	  which	   are	   stable	   over	   rounds	   of	   cell	   division	   and	   get	   hence	   inherited	   (Mai	   et	   al.,	  2005).	   DNA	   methylation,	   mediated	   by	   DNA	   methyltransferases	   (DNMTs),	   is	   the	   best-­‐characterised	  epigenetic	  mark	  and	  occurs	  on	  cytosines	  directly	  located	  5´	  to	  a	  guanosine,	  which	  are	   called	   CpG	   dinucleotides	   or	   CpG	   islands.	   These	   DNMTs	   can	   be	   over-­‐expressed	   due	   to	  activating	   mutations	   in	   human	   cancer	   cells	   (Szyf	   and	   Detich,	   2001).	   As	   a	   result,	   CpG-­‐rich	  promoters	  are	  hypermethylated,	  leading	  to	  transcriptional	  inactivation	  of	  the	  respective	  genes,	  as	   binding	   of	   the	   transcription	   machinery	   is	   impaired.	   In	   contrast,	   in	   some	   cases	   proto-­‐oncogenes	   can	   become	   over-­‐expressed	   due	   to	   DNA	   hypomethylation.	   Furthermore	   and	   most	  importantly	   for	   this	   work,	   DNA	   methylation	   is	   associated	   with	   chromatin	   remodelling	   that	  promotes	  the	  formation	  of	  a	  condensed	  chromatin	  structure,	  the	  heterochromatin.	  For	  instance,	  promoter	   hypermethylation	   is	   associated	   with	   particular	   combinations	   of	   histone	   marks	  including	   (i)	   deacetylation	   of	   the	   histone	   H3	   and	   H4,	   	   (ii)	   loss	   of	   H3	   lysine	   K4	   (H3K4)	  trimethylation,	  (iii)	  H3K9	  methylation	  and	  (iv)	  H3K27	  trimethylation.	  Hence,	  DNA	  methylation	  works	   in	   concert	  with	   another	   epigenetic	   key	  mechanism,	   the	   chromatin	   remodelling.	   During	  chromatin	   remodelling	   (i)	   covalent	   post-­‐translational	   modifications	   of	   histones	   and	   (ii)	   ATP-­‐dependent	   chromatin	   remodelling	   complexes,	   which	   either	   move,	   eject	   or	   restructure	  nucleosomes,	   regulate	   the	   accessibility	   of	   the	  underlying	  DNA.	  This	   accessibility	   can	   either	   be	  enhanced,	  leading	  to	  an	  open	  chromatin	  structure	  (euchromatin)	  or	  it	  can	  be	  blocked,	  resulting	  in	  a	   closed	  chromatin	  environment	   (heterochromatin).	  Through	   the	  modulated	  accessibility	  of	  the	  DNA,	  certain	  genes	  get	  silenced	  or	  activated.	  	  Histone	  modifications	  act	  as	  docking	  sites	  for	  ATP-­‐dependant	  chromatin	  remodelling	  complexes.	  These	  are	  multi-­‐subunit	  complexes,	  which	  physically	  slide	  nucleosomes	  along	   the	  DNA	  strand,	  thereby	   regulating	   the	   accessibility	   of	   the	   DNA.	   	   In	   eukaryotic	   cells,	   there	   exist	   chromatin-­‐remodelling	   complexes	   of	   the	   (i)	   Chromodomain-­‐Helicase-­‐DNA-­‐binding	   (CHD),	   switching	  defective	   sucrose-­‐non	   fermenting	   (SWI/SNF),	   (iii)	   imitation	   switch	   (ISWI)	   and	   (iv)	   inositol	  requiring	  80	  (INO80)	   family	  (Figure	  7).	  All	  chromatin-­‐remodelling	  enzymes	  share	  a	  conserved	  ATPase	  domain,	  but	  are	  unique	  in	  their	  flanking	  domains.	  	  The	   CHD	   family	   is	   defined	   by	   the	   presence	   of	   two	   tandem	   chromodomains,	  N-­‐terminal	   of	   the	  ATPase	  domain.	  Additional	  structural	  motifs	  are	  used	  to	  further	  divide	  the	  CHD	  family	  into	  the	  subfamilies	  CHD1,	  Mi-­‐2	  and	  CHD7	  (Flaus	  et	  al.,	  2006;	  Sims	  and	  Wade,	  2011).	  SWI/SNF	  remodellers	  are	  characterized	  by	  presence	  of	  an	  N-­‐	  terminally	  located	  HSA	  (helicase-­‐SANT)	  domain,	  which	   is	  known	  to	  recruit	  actin	  and	  actin-­‐	  related	  proteins;	  and	  a	  C-­‐terminally	  located	   bromo	   domain,	   suggested	   to	   bind	   to	   acetylated	   lysines	   on	   histone	   tails.	   SWI/SNF	  enzymes	   form	   multi-­‐subunit	   complexes	   containing	   8	   or	   more	   proteins	   and	   slide	   and	   evict	  nucleosomes	  from	  DNA,	  but	  lack	  chromatin	  assembly	  activities.	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ISWI	  family	  ATPases	  harbor	  a	  C-­‐terminal	  SANT	  domain	  adjacent	  to	  a	  SLIDE	  domain	  (SANT-­‐like	  ISWI),	  which	  together	  form	  a	  nucleosome	  recognition	  module	  that	  binds	  to	  DNA	  and	  unmodified	  H4	  tails	  (Clapier	  and	  Cairns,	  2009).	  	  In	   contrast	   to	   the	   other	   remodellers,	  members	   of	   the	   INO80	   family	   possess	   a	   dimeric	  ATPase	  domain,	   which	   functions	   as	   a	   scaffold	   for	   interaction	   with	   the	   RuvB-­‐like	   proteins,	   which	  primarily	   bind	   around	   holliday	   junctions	   to	   promote	   their	   migration	   during	   homologous	  recombination	  (West,	  1997).	  	  
	  
Figure	   7:	   Chromatin	   remodelling	   enzymes.	   Chromatin	   remodellers	   can	   be	   classified	   into	   members	   of	  Chromodomain-­‐Helicase-­‐DNA-­‐binding	   (CHD),	   switching	   defective	   sucrose-­‐non-­‐fermenting	   (SWI/SNF),	  imitation	  switch	  (ISWI)	  and	  inositol	  requiring	  80	  (INO80)	  families.	  All	  chromatin-­‐remodelling	  enzymes	  share	  the	   ATPase	   domain,	   but	   are	   unique	   in	   their	   flanking	   domains.	   Adapted	   from	   Biochemistry,	   Genetics	   and	  Molecular	  Biology	  »	  "Chromatin	  Remodelling",	  book	  edited	  by	  Danuta	  (Radzioch). 
 In	  summary,	  the	  chromatin	  environment	  and	  the	  recruitment	  of	  chromatin-­‐associated	  proteins	  determine	  the	  “on”	  versus	  “off”-­‐	  transcriptional	  state	  of	  a	  gene.  
1.5.1 Chromodomain-­‐Helicase-­‐DNA	  binding	  Proteins	  CHD	  chromatin	  remodelling	  enzymes	  contribute	  to	  the	  dynamic	  changes	  in	  chromatin	  structure	  during	   transcription,	   recombination,	   repair	   and	   replication.	   Structurally,	   CHD	   chromatin	  remodelling	  complexes	  are	  characterized	  by	  the	  presence	  of	  two	  N-­‐terminal	  chromodomains,	  a	  DNA-­‐dependant	   ATPase	   domain	   of	   the	   SNF2	   superfamily	   and,	   in	   some	   cases,	   a	   DNA-­‐binding	  domain.	  The	  ATPase	  domain	  carries	  out	  ATP	  hydrolysis,	  which	  provides	   the	  energy	  necessary	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for	   either	   the	   sliding	   of	   histone	   octamers	   (Becker	   and	   Horz,	   2002)	   or	   the	   displacement	   of	  histones	  (Durr	  et	  al.,	  2006;	  Pazin	  and	  Kadonaga,	  1997).	  Members	   of	   the	   CHD	   family	   of	   chromatin	   remodellers	   are	   subdivided	   into	   (i)	   CHD1/CHD2,	  CHD3-­‐5/Mi-­‐2	  and	  (iii)	  CHD6-­‐9	  subfamilies	  (Figure	  8).	  Subfamily	  I,	  comprising	  CHD1	  and	  CHD2,	  is	   conserved	   from	   yeast	   to	   human	   and	   regulates	   (i)	   nucleosome	   spacing	   and	   (ii)	   chromatin	  assembly.	  CHD1	  primarily	  functions	  in	  the	  maintenance	  of	  mouse	  embryonic	  stem	  cells	  (Gaspar-­‐Maia	   et	   al.,	   2009)	   and	   CHD2	   regulates	   mammalian	   development	   as	   well	   as	   DNA	   damage	  responses,	  demonstrating	  tumor	  suppressive	  functions	  (Nagarajan	  et	  al.,	  2009).	  	  
	  
Figure	   8:	   CHD	   family	   of	   chromatin	   remodelling	   enzymes.	   Characterization	   and	   classification	   of	   the	   3	  subfamilies	  of	  CHD	  proteins.	  Subfamily	  I	  comprises	  CHD1	  and	  CHD2;	  CHD3-­‐5/Mi-­‐2	  belong	  to	  subfamily	  II	  and	  subfamily	   III	   consists	   of	   CHD6,	   7,	   8	   and	   9.	   Left,	   General	   structure	   of	   CHD	   members	   according	   to	   their	  classification	   into	  subfamilies.	  Middle,	  Conservation	  of	  CHD	  members	   from	  yeast	  over	   fly	   to	  human,	  depicted	  for	   each	   family	  member.	  Right,	   Remodelling	   and	   biological	   functions	   of	   the	   different	   CHD	  proteins.	   Adapted	  from	  (Sims	  and	  Wade,	  2011).	  	  Subfamily	  II	  includes	  CHD3,	  CHD4	  and	  CHD5/Mi-­‐2,	  and	  is	  characterized	  by	  two	  N-­‐terminal	  PHD	  finger	  domains,	  initially	  identified	  as	  Cys4-­‐His-­‐Cys3	  motifs	  in	  the	  plant	  homeodomain,	  adjacent	  to	  the	   chromodomains.	   Another	   distinct	   feature	   is	   the	   significantly	   different	   chromodomain	  sequence,	  which	  allows	  interaction	  with	  histone	  tails.	  The	  members	  CHD3	  and	  CHD4	  are	  integral	  subunits	   of	   the	  Mi2-­‐NuRD	   histone	   deacetylase	   complex	   in	   flies	   and	   in	   humans,	  with	   the	   PHD	  fingers	  being	  essential	   for	   interaction	  with	  HDCA1	  and	   for	  modified	  histone	   tails	   (Zhang	  et	  al.,	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1998).	   The	   main	   functions	   of	   these	   complexes	   are	   to	   modulate	   transcription,	   to	   regulate	  chromatin	  assembly	  during	  DNA	  replication	  and	   to	   regulate	  DNA	  repair.	  Therefore,	  CHD3	  and	  CHD4	   are	   ubiquitously	   expressed.	   	   In	   contrast,	   CHD5	   is	   predominantly	   expressed	   in	   neuronal	  tissue	  (Egan	  et	  al.,	  2013),	  but	  its	  interaction	  partners	  remain	  still	  undefined.	  Interestingly,	  CHD5	  was	  reported	  to	  be	  a	  tumor	  suppressor	  in	  breast,	  colon	  and	  neuroectodermal	  cancers	  (Bagchi	  et	  al.,	   2007;	   Esteller,	   2007;	   Mokarram	   et	   al.,	   2009;	   Mulero-­‐Navarro	   and	   Esteller,	   2008),	   giving	  another	  link	  between	  the	  actions	  of	  a	  chromatin-­‐remodelling	  enzyme	  and	  cancer.	  	  	  The	  subfamily	   III	   chromatin	   remodelling	  enzymes	   consists	  of	   the	   four	  members:	  CHD6,	  CHD7,	  CHD8	  and	  CHD9.	  These	  are	  homologs	  of	  a	  single	  Drosophila	  Trithorax	  protein	  Kismet,	  which	  is	  important	   for	   the	   regulation	   of	  Hox	   genes,	   body	   segmentation	   and	   transcriptional	   elongation	  (Daubresse	   et	   al.,	   1999).	   DNA	   damage	   was	   reported	   to	   “induce”	   CHD6,	   stimulating	   its	  recruitment	  and	  interaction	  with	  other	  yet	  unidentified	  co-­‐factors	  at	  transcriptional	  start	  sites.	  CHD7	  preferentially	   binds	   to	   distal	   regulatory	   chromatin	   regions	   (Schnetz	   et	   al.,	   2010)	   and	   is	  frequently	  associated	  with	  CHARGE	  syndrome,	  a	  disease	  affecting	  multiple	  organs	  (Vissers	  et	  al.,	  2004).	   In	   contrast,	   CHD8	   was	   shown	   to	   interact	   with	   CHD7	   and	   represses	   p53	   function	   and	  induction	   of	   apoptosis	   during	   mammalian	   development	   (Nishiyama	   et	   al.,	   2009).	   Finally,	  expression	   of	   CHD9	   has	   been	   implicated	   in	   regulating	   gene	   expression	   in	   osteoblasts.	  Interestingly,	   members	   of	   all	   CHD	   subfamilies	   were	   shown	   to	   be	   deregulated	   in	   gastric	   and	  colorectal	   cancers,	   linking	   aberrant	   chromatin	   remodelling	   to	   cancer	  pathogenesis	   (Kim	  et	   al.,	  2011).	  	  
1.5.2 Identification	  of	  Chd7	  in	  a	  Microarray	  Screen	  comparing	  early	  versus	  
late-­‐stage	  Notch1-­‐driven	  T-­‐ALL	  	  A	  previous	  research	  project	  in	  the	  lab	  focused	  on	  identifying	  the	  developmental	  stage	  at	  which	  T	  cell	  progenitors	  or	  developing	  T	  cells	  can	  give	  rise	  to	  T-­‐ALL	  via	  constitutive	  over-­‐expression	  of	  the	  Notch	  1	  intracellular	  domain	  (NICD).	  Therefore,	  mouse	  models,	  in	  which	  specific	  NICD	  over-­‐expression	   from	   the	   Rosa26	   locus	   is	   induced	   at	   discrete	   stages	   of	   T	   cell	   development,	   were	  generated	  (Figure	  9;	  courtesy	  of	  Caroline	  Poisson).	  MxCre	  recombinase	  was	  used	  to	  induce	  NICD	  over-­‐expression	   in	   BM	   progenitors	   and	   two	   thymic-­‐specific	   Cre	   lines	   were	   used	   in	   order	   to	  target	  thymic	  progenitors	  at	  the	  DN2-­‐DN3a	  stage	  (LckCre)	  and	  at	  the	  DN3b-­‐DN4	  stage	  (CD4Cre)	  of	  T	  cell	  maturation	  for	  NICD	  over-­‐expression.	  This	  allowed	  identifying	  more	  precisely	  the	  stage	  of	  T	  cell	  development	  at	  which	  T-­‐ALL	  can	  be	  induced	  and	  closer	  mimicked	  the	  human	  disease,	  which	  arises	  presumably	  in	  the	  thymus.	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In	  brief,	  over-­‐expression	  of	  NICD	  in	  hematopoietic	  progenitors	  in	  the	  BM	  (RNIC+/ΔMxCre)	  resulted	  in	   a	   lethal,	   non-­‐transplantable	   polyclonal	   early-­‐stage	   T-­‐ALL.	   NICD	   over-­‐expression	   at	   early	  stages	  of	  T	  cell	  development	  (DN2	  to	  DN3a	  stage;	  LckCre)	  induced	  a	  transplantable	  T-­‐ALL	  that	  is	  also	   metastatic	   in	   non-­‐lymphoid	   tissues.	   In	   contrast,	   NICD	   over-­‐expression	   beyond	   the	   TCRβ	  selection	   checkpoint	  mediated	  by	  CD4Cre	  did	  not	   lead	   to	  T-­‐ALL	  development.	   Thus,	   the	   over-­‐expression	  of	  NICD	  in	  T	  cell	  progenitors	  gives	  rise	  to	  a	  true	  T-­‐ALL	  only	  up	  to	  the	  DN3a	  stage	  of	  T	  cell	  development,	  as	  shown	  in	  Figure	  9.	  	  
	  
Figure	  9:	  Murine	  stage-­‐specific	  RNIC	  Disease	  Models.	  The	  RNIC	  transgenic	  mouse	  was	  crossed	  to	  different	  tissue-­‐	   and	   lineage	   stage-­‐specific	   Cre	   recombinases	   in	   order	   to	   specifically	   over-­‐express	   NICD	   in	   the	   BM	  (MxCre),	  at	  the	  DN2-­‐DN3a	  (LckCre)	  or	  at	  the	  DN3b-­‐DN4	  stage	  of	  T	  cell	  development	  in	  the	  thymus.	  A,	  Schematic	  representation	  of	  the	  RNIC	  model,	  in	  which	  Cre	  recombinase	  activation	  leads	  to	  excision	  of	  the	  loxP-­‐site	  flanked	  STOP	  cassette	  preceding	  NICD	   ires	  eGFP,	  resulting	   in	  NICD	  expression	   from	  the	  Rosa26	   locus.	  B,	  Overview	  of	  disease	   outcome	   upon	   NICD	   over-­‐expression	   at	   different	   stages	   of	   T	   cell	   development:	   MxCre-­‐targeted	   BM	  progenitors	  give	  rise	  to	  an	  early	  stage	  non-­‐malignant,	  non-­‐transplantable	  disease;	  LckCre-­‐targeted	  DN2-­‐DN3a	  thymic	  progenitors	   give	   rise	   to	   aggressive,	   transplantable	   and	  metastatic	  T-­‐ALL;	  CD4Cre	   targeted	  DN3b-­‐DN4	  thymic	  progenitors	  do	  not	  give	  rise	  to	  T-­‐ALL	  upon	  NICD	  over-­‐expression.	  Courtesy	  of	  Caroline	  Poisson	  (Poisson,	  2011).	  	  	  	  Microarray	  data	  have	  been	  generated	  comparing	  the	  RNIC+/ΔMxCre	  early	  stage	  T-­‐ALL	  DP	  cells	  with	  the	  RNIC+/ΔLckCre	  late	  stage	  tumor	  cells	  in	  order	  to	  identify	  a	  gene	  expression	  signature	  for	  T-­‐ALL	  aggressiveness	   and	  metastatic	   potential	   (Poisson,	   2011).	   In	   total,	   the	   expression	  of	   190	   genes	  was	  significantly	  modulated	  with	  73	  genes	  being	  down-­‐regulated	  and	  117	  up-­‐regulated	  in	  late-­‐stage	   RNIC+/ΔLckCre	   T-­‐ALL	   versus	   RNIC+/ΔMxCre	   early	   stage	   non-­‐malignant	   T-­‐ALL.	   Pre-­‐malignant	  MxCre-­‐induced	  T-­‐ALL	   cells	   clustered	  well	   in	   their	   gene	   expression	   signature	  with	  physiologic,	  non-­‐malignant	   DP	   thymocytes,	   while	   LckCre-­‐mediated	   T-­‐ALL	   showed	   a	   distinct	   profile,	   as	  shown	   in	   the	  heat	  map,	  depicting	   the	   top	  50	  up-­‐	   and	  down-­‐regulated	  genes	   identified	   (Figure	  10).	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Figure	  10:	  Top	  50	  differentially	   regulated	   gene	   candidates	   in	   late-­‐stage	  metastatic	   versus	   early-­‐stage	  
Notch1-­‐driven	  T-­‐ALL.	  Heatmap	  depicting	  top	  gene	  candidates	  up-­‐regulated	  (green)	  and	  down-­‐regulated	  (red)	  in	   late-­‐stage	   RNIC+/ΔLckCre	   and	   early	   stage	   RNIC+/ΔMxCre	   T-­‐ALL	   tumors	   compared	   to	   physiologic	   CD4+CD8+	   DP	  thymocytes	  (Ctrl).	  Chd7	   is	   identified	  as	  the	  highest	  up-­‐regulated	  gene	   in	   late-­‐stage	  metastatic	  T-­‐ALL	  (LckCre)	  versus	  early	  stage	  pre-­‐malignant	  T-­‐ALL	  (MxCre)	  and	  is	  detected	  by	  multiple	  probe	  sets	  on	  the	  Affymertrix	  gene	  chip.	  Courtesy	  of	  Caroline	  Poisson	  (Poisson,	  2011).	  	  	  	  Chromodomain-­‐helicase-­‐DNA-­‐binding	  protein	  7,	   Chd7,	  was	   identified	   in	   the	  microarray	   as	   the	  highest	  over-­‐expressed	  gene	   in	   late	  stage	  T-­‐ALL	  with	  a	  maximal	   fold	  change	  expression	  of	  26-­‐fold	  compared	  to	  the	  early	  stage	  RNIC+/ΔMxCre	  T-­‐ALL	  cells.	  Furthermore,	  it	  was	  identified	  multiple	  times	   by	   independent	   probe	   sets	   on	   the	  GeneChip	   (Figure	  10).	   In	   addition,	  Chd7	   LOF	  had	  not	  been	  studied	  in	  the	  context	  of	  cancer	  at	  the	  time	  this	  PhD	  project	  was	  initiated.	  Therefore,	  this	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candidate	   was	   selected	   for	   in-­‐depth	   in	   vitro	   and	   in	   vivo	   validation	   for	   a	   potential	   role	   in	  hematopoiesis	  and	  T-­‐ALL	  development. 
1.5.3 Chd7	  in	  Development	  and	  Disease	  Chd7	   is	   an	   ATP-­‐dependant	   chromatin-­‐remodelling	   enzyme	   that	   is	   expressed	   mostly	   during	  embryonic	   development	   (Hurd	   et	   al.,	   2007).	   For	   dynamic	   chromatin	   regulation,	   Chd7	  preferentially	   binds	   to	   distant	   regulatory	   elements	   within	   chromatin,	   as	   demonstrated	   by	  chromatin	   immunoprecipitation	   studies	   (ChIP-­‐chip)	   in	   (i)	   human	   colorectal	   carcinoma,	   (ii)	  human	  neuroblastoma	  cells	  and	  (iii)	  mouse	  embryonic	  stem	  (ES)	  cells,	  which	  were	  either	  un-­‐	  or	  differentiated	   (Schnetz	   et	   al.,	   2009).	   Although	   Chd7	   localizes	   to	   discrete	   chromatin	   locations	  specific	  for	  each	  cell	  type,	  histone	  H3	  methylated	  at	  lysine	  4	  (H3K4me)	  is	  a	  common	  recognition	  site,	  which	  is	  similar	  to	  those	  of	  gene	  enhancer	  elements.	  This	  suggests	  that	  Chd7	  may	  function	  in	  enhancer-­‐mediated	  transcription	  of	  genes	  during	  embryonic	  development.	  	  Loss-­‐of-­‐function	  mutations	   in	   the	  Chd7	  encoding	  gene	  are	   frequently	  associated	  with	  CHARGE	  syndrome,	  a	  multi-­‐organ	  disorder	  that	  affects	  the	  eye,	  heart,	  general	  growth	  and	  development.	  CHARGE	   stands	   for	   coloboma,	   heart	   defect,	   atresia	   choanae	   (also	   known	   as	   choanal	   atresia),	  retarded	   growth	   and	   development,	   genital	   abnormality,	   and	   ear	   abnormality.	   The	   severity	   of	  malformations	  vary	  within	  patients,	  however	   infants	  diagnosed	  with	  CHARGE	  syndrome	  often	  present	  with	  life-­‐threatening	  conditions.	  	  Up	  to	  60-­‐80%	  of	  CHARGE	  patients	  carry	  mutations	  in	  
Chd7;	   these	   mutations	   were	   initially	   identified	   to	   lie	   in	   a	   2.3-­‐Mb	   spanning	   microdeletion	   on	  chromosome	  8q12,	  leading	  to	  the	  generation	  of	  pre-­‐mature	  stop	  codons,	  missense	  mutations	  or	  mutations	  at	  the	  intron-­‐exon	  boundary	  affecting	  the	  Chd7	  locus	  (Vissers	  et	  al.,	  2004).	  	  In	  addition	  to	  the	  multi-­‐organ	  defects,	  a	  small	  cohort	  of	  CHARGE	  syndrome	  patients	  also	  suffer	  from	  severe	  T-­‐cell	  deficiency,	  linking	  Chd7	  function	  to	  T-­‐cell	  development	  and	  in	  T-­‐cell	  mediated	  immunity	   (Writzl	   et	   al.,	   2007).	   These	   observations	  may	   support	   the	   potential	   role	   of	   Chd7	   in	  driving	  aggressiveness	  in	  T-­‐ALL,	  which	  arises	  from	  transformed	  immature	  T	  cell	  progenitors.	  	  To	   study	   Chd7	   in	   vivo,	   Chd7	   knock	   out	   animals	   were	   generated,	   however	   these	   mice	   are	  embryonic	   lethal	  at	  embryonic	  day	  10.5	  (E	  10.5)	  (Hurd	  et	  al.,	  2007).	   In	  contrast,	  heterozygous	  gene-­‐trapped	  reporter	  Chd7(Gt/+)	  male	  and	  female	  mice	  are	  viable	  and	  exhibit	  variable	  degrees	  of	   head-­‐bobbing	   and	   circling,	   consistent	   with	   vestibular	   dysfunction.	   Paint-­‐filling	   and	   beta-­‐galactosidase	   staining	   of	   E12.5	   and	   E14.5	   embryos	   confirmed	   Chd7	   expression	   in	   CHARGE-­‐syndrome	   affected	   organs	   such	   as	   the	   brain,	   ear,	   heart	   and	   craniofacial	   structures.	   Therefore,	  
Chd7	  (Gt/+)	  reporter	  mice	  are	  a	  valuable	  means	  to	  study	  this	  disease	  in	  vivo	  (Hurd	  et	  al.,	  2007).	  The	  same	  research	  group	  also	  generated	  Chd7	  conditional	  knock	  out	  (cKO)	  animals	  in	  order	  to	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study	  Chd7	   function	   beyond	   embryogenesis	   (Hurd	   et	   al.,	   2012).	   Conditional	  Chd7	   targeting	   in	  the	   subventricular	   zone	   neural	   stem	   cell	   niche	   and	   in	   the	   inner	   ear	   resulted	   in	   abnormal	  proliferation	  of	  the	  stem	  cells	  within	  this	  niche	  and	  malformations	  in	  the	  inner	  ear	  (Hurd	  et	  al.,	  2012).	   Further	   studies,	   inducing	   Chd7	   ablation	   in	   the	   developing	   eye,	   ear,	   nose,	   pharyngeal	  pouch,	   forebrain	   (Foxg1Cre)	   and	   gut	   (Wnt1Cre)	   demonstrated	   that	   Chd7	   is	   essential	   for	  craniofacial	  and	  tracheal	  development	  (Micucci	  et	  al.,	  2014).	  	  In	  addition,	  preliminary	  data	  generated	  by	   the	   laboratory	  of	  Leonard	  Zon	   identified	  Chd7	  as	  a	  cell	   autonomous	   regulator	   of	   chromatin	   in	   HSCs	   performing	   a	   reverse	   genetic	   screen	   to	   find	  chromatin	   factors	   required	   for	   HSC	   induction	   in	   zebrafish	   (Hsuan-­‐Ting	   Huang,	   2010).	   Their	  work	   demonstrated	   that	  Chd7-­‐deficient	  Tg(c-­‐myb:GFP)	   cells	   transplanted	   into	  Tg(Imo2:DsRed)	  blastomeres	  resulted	  in	  more	  chimeric	  embryos	  compared	  to	  controls,	  indicating	  that	  Chd7	  may	  have	  a	  role	   in	  repressing	  HSC	   formation	  during	  zebrafish	  embryogenesis.	   	  Similarly,	  Chd7	  was	  identified	  as	  a	  regulator	  of	  adult	  hematopoiesis	  in	  a	  screen	  for	  Runx1-­‐Cbfb	  interaction	  partners	  in	  the	  regulation	  of	  HSCs	  (Hsu	  J,	  2011).	  In	  murine	  adult	  hematopoiesis,	  VaviCre-­‐mediated	  Chd7	  deficiency	   does	   not	   cause	   any	   lineage	   specification	  defects	   but	  Chd7-­‐deficient	  BM	   cells	   have	   a	  competitive	   advantage	   in	   reconstituting	   T	   cell	   numbers	   compared	   to	   controls.	   Therefore,	   the	  group	  of	  Nancy	  Speck	  suggested	  that	  Chd7	  may	  play	  a	  role	  in	  the	  regulation	  of	  the	  generation	  of	  mature	  T	  cells	  under	  competitive	  conditions	  (Hsu	  J,	  2011).	  	  These	  observations	  are	  supported	  by	  a	  study	  by	  Bajpai	  et	  al.,	  which	  demonstrated	  that	  another	  stem	  cell	  type,	  namely	  human	  neural	  crest-­‐like	  stem	  cells,	  require	  Chd7	  for	  migration	  (Bajpai	  et	  al.,	  2010).	  Therefore,	  we	  speculated	  that	  Chd7	  may	  play	  a	  role	  in	  driving	  leukemic	  cell	  invasion	  into	  other	  non-­‐hematopoietic	  tissues.	  In	  addition,	  some	  studies	  have	  proposed	  Chd7	  as	  a	  cancer-­‐related	  gene.	  A	  study	  by	  Engelen	  et	  al.	  identified	  Chd7	  as	  transcriptional	  co-­‐factor	  for	  Sox2	  performing	  proteomic	  and	  genomic	  screens	  (Engelen	  et	  al.,	  2011).	  Chd7	  and	  Sox2	  were	  demonstrated	  to	  physically	  interact,	  to	  share	  similar	  genome-­‐binding	  sites	  as	  well	  as	  common	  target	  genes,	  such	  as	  the	  Notch	  target	  Jagged1,	  the	  Wnt	  target	  Gli3	  and	  Mycn.	  These	  genes	  in	  turn	  were	  reported	  mutated	  in	  diseases	  that	  affect	  multiple	  organs	  similar	  to	  CHARGE	  syndrome,	  thereby	  linking	  the	  deregulation	  of	  Jagged1,	  Gli3	  and	  Mycn	  by	   the	   Sox2-­‐Chd7	   complex	   with	   disease	   outcome.	   Furthermore,	   Jagged1-­‐expression	   was	  strongly	   down-­‐regulated	   in	   the	   inner	   ear	   of	   Chd7-­‐haploinsufficient	   embryos,	   linking	   Chd7	  function	  with	  Notch	  signalling	  (Engelen	  et	  al.,	  2011).	  	  
Chd7	   GOF	  had	  only	  been	   reported	   in	   one	  disease	   setting,	   at	   the	  beginning	  of	   this	   project.	   The	  group	  of	  PJ	  Campbell	  set	  out	  to	  identify	  novel	  driver	  mutations	  in	  human	  small-­‐cell	  lung	  cancer	  by	  performing	  massive	  parallel	  sequencing	  of	  3	  representative	  small-­‐cell	   lung	  cancer	  cell	   lines.	  Within	   the	   identified	   22,910	   somatic	   substitutions,	   Campbell	   et	   al.	   discovered	   (i)	   an	   in	   frame	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tandem	  duplication	  affecting	  exons	  3-­‐8	  of	   the	  CHD7	  encoding	  gene	  and	   	  (ii)	  PVT1-­‐CHD7	   fusion	  genes,	  indicating	  that	  CHD7	  may	  be	  frequently	  rearranged	  in	  small-­‐cell	  lung	  cancer	  (Pleasance	  et	  al.,	  2010).	  	  This	  was	  the	  first	  evidence	  Chd7	  may	  play	  a	  role	  in	  cancer	  development	  at	  the	  starting	  point	  of	  the	  project.	  Recently,	  however,	  Chd7	  GOF	  was	  reported	  in	  pancreatic	  ductal	  adenomocarcinoma	  (PDAC)	  (Colbert	  et	  al.,	  2014).	  In	  this	  study,	  Chd7	  was	  identified	  as	  DNA	  damage	  responsive	  gene,	  which,	   once	   silenced,	   conferred	   sensitization	   to	   gemcitabine	   treatment	   in	   PDAC	   cells.	   The	  authors	   therefore	  postulate	  Chd7	  as	  a	  novel	  biomarker	   to	  evaluate	  and	   further	   improve	  PDAC	  treatment.	  	  In	   summary,	   Chd7	   is	   a	   chromatin	   remodeller	   that	   acts	   in	   concert	   with	   different	   co-­‐factors	   to	  regulate	   chromatin	   structure,	   thereby	   allowing	   the	  dynamic	   regulation	  of	   genes	   important	   for	  the	  development	  of	  multiple	  organs.	  Being	  frequently	  mutated	  in	  CHARGE	  syndrome,	  Chd7	  was	  only	  recently	   identified	  having	  potential	  roles	   in	  hematopoiesis	  and	  being	  aberrantly	  activated	  in	   cancer.	   	   Therefore,	   the	   chromatin	   remodeller	   Chd7	   was	   chosen	   in	   this	   thesis	   as	   prime	  candidate	  to	  study	  its	  role	  in	  hematopoiesis	  and	  T-­‐ALL	  development.	  	  
1.6 Calcium	  Signalling	  Calcium	   signalling	   is	   involved	   in	   many	   different	   temporally	   and	   spatially	   tightly	   regulated	  processes	   within	   the	   cell.	   These	   include	   contraction,	   metabolism,	   apoptosis,	   transcription,	  proliferation	   and/or	   hypertrophic	   growth.	   Ca2+	   is	   therefore	   one	   of	   the	   most,	   if	   not	   the	   most,	  versatile	   intracellular	   signal.	   Given	   the	   many	   functions	   of	   calcium	   signalling	   calcium	   levels	  within	  the	  cell	  must	  be	  tightly	  controlled.	  Therefore,	  a	  well	  adjusted	  balance	  between	  the	  uptake	  of	  Ca2+	   into	   the	  cytoplasm	  for	  signalling	  purposes	  and	   its	   removal	   from	  the	  cytosol	  by	  buffers,	  pumps	  and	  exchangers	  after	  signalling	  needs	  to	  maintained	  (Berridge	  et	  al.,	  2003).	  The	  uptake	  of	  Ca2+	   is	   mediated	   via	   either	   voltage-­‐sensitive;	   store-­‐operated	   or	   receptor-­‐operated	   channels,	  while	   the	   plasma	   membrane	   Ca2+	   ATPase	   (PMCA)	   and	   Na+/	   Ca2+	   exchanger	   (NCX)	   are	  responsible	  for	  the	  clearance	  of	  Ca2+	   from	  the	  cytosol	  (Figure	  11).	  Within	  the	  cell,	   formation	  of	  second	   messengers	   and	   release	   of	   intracellular	   calcium	   from	   the	   sarcoplasmic/endoplasmic	  reticulum	   (SR/ER)	   make	   Ca2+	   available	   for	   downstream	   events.	   The	   ER	   is	   a	   multifunctional	  organelle	   essential	   for	   the	   synthesis,	   folding,	   and	  processing	   of	   secretory	   and	   transmembrane	  proteins.	  Members	  of	  the	  SERCA	  family	  of	  SR/ER	  Ca2+	  ATPases	  reside	  in	  the	  ER	  membrane	  and	  remove	   Ca2+	   from	   the	   cytosol	   for	   storage	   within	   the	   ER	   lumen,	   which	   has	   high	   Ca2+	   levels	  reaching	  the	  millimolar	  range.	  Thereby	  Serca	  pumps	  function	  to	  maintain	  a	  constant	  Ca2+	  supply	  available	  for	  signalling	  events	  but	  also	  maintain	  “physiological”	  levels	  of	  approximately	  100	  nM	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Ca2+	   in	   the	   cytosol.	   	  This	   is	   counteracted	  by	   the	   removal	  of	  Ca2+	   from	   the	  ER	  by	   inositol-­‐1,4,5-­‐	  trisphosphate	   receptors	   (Ins(1,4,5)P3Rs)	   and	   ryanodine	   receptors	   (RYRs),	   as	   well	   as	   Ca2+-­‐binding	  proteins,	  such	  as	  calreticulin	  and	  calsequestrin	  that	  reside	  in	  the	  ER	  lumen	  and	  thereby	  regulate	   the	   relative	   abundance	   of	   Ca2+.	   In	   mitochondria,	   Ca2+	   also	   plays	   important	   roles	   in	  regulating	  cellular	  outcomes,	  such	  as	  differentiation,	  cell	  survival	  and	  apoptosis.	  	  Mitochondrial	  Ca2+	  supply	  is	  guaranteed	  by	  the	  electrophysiological	  uptake	  through	  a	  Ca2+	  uniporter,	  whereas	  Ca2+	   removal	   from	   the	   mitochondrium	   is	   mediated	   either	   via	   a	   Na+/H+-­‐dependant	   Ca2+-­‐exchanger	  or	  via	  the	  opening	  of	  permeability	  transition	  pores	  (PTP)	  (Figure	  11)	  (Orrenius	  et	  al.,	  2003).	  	  
	  
Figure	   11:	   The	   regulation	   of	   intracellular	   Ca2+	   compartimentalization.	   Ca2+	   supply	   within	   the	   cell	   is	  regulated	  by	  several	  pumps	  and	  exchangers	   located	  in	  the	  cell	  membrane	  and	  in	   intracellular	  organelles.	  Ca2+	  uptake	   is	   mediated	   via	   voltage-­‐sensitive,	   store-­‐operated	   or	   receptor-­‐mediated	   channels	   located	   within	   the	  outer	  cell	  membrane.	   In	  contrast,	   the	  plasma	  membrane	  Ca2+	  ATPase	  (PMCA)	  and	  Na+/	  Ca2+	  exchanger	  (NCX)	  remove	   Ca2+	   from	   the	   cytosol	   by	   pumping	   it	   into	   the	   extracellular	   space.	   Within	   the	   ER,	   sarcoplasmic	  /endoplasmic	  reticulum	  (SR/ER)	  Ca2+	  ATPases	  pump	  Ca2+	  under	  hydrolysis	  of	  ATP	   into	  the	  ER	   lumen.	  This	   is	  counteracted	  by	  the	  removal	  of	  Ca2+	  by	   inositol-­‐1,4,5-­‐	  trisphosphate	  (Ins(1,4,5)P3)	  receptors	  (Ins(1,4,5)P3Rs)	  and	   ryanodine	   receptors	   (RYRs)	   in	   the	  ER	  membrane.	   In	   addition,	   Ca2+-­‐binding	  proteins,	   such	   as	   calreticulin	  and	  calsequestrin	  residing	  in	  the	  ER	  lumen	  regulate	  the	  relative	  abundance	  of	  Ca2+.	  Adapted	  from	  (Orrenius	  et	  al.,	  2003).	  
1.6.1 Calcium	  Levels,	  ER	  stress	  and	  Unfolded	  Protein	  Response	  Calcium	   homeostasis	   within	   the	   cell	   is	   guaranteed	   by	   the	   interplay	   between	   several	   ATP-­‐dependent	   calcium	  pumps;	   ion	  channels	  and	  exchangers;	   as	  well	   as	   receptor-­‐mediated	  second	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messenger	  uptake	  of	  Ca2+.	  Therefore,	   aberrant	   activation	  or	   inactivation	  of	   components	  of	   the	  calcium	  signalling	  network	  can	  have	  detrimental	  effects	  for	  the	  cell.	  	  Alterations	   in	   intracellular	   calcium	   levels	   (exceeding	   ≈	   100	   nM)	   but	   also	   inhibition	   of	   N-­‐glycosylation	   were	   demonstrated	   to	   cause	   an	   accumulation	   and	   aggregation	   of	   unfolded	  proteins	   in	   the	  ER.	   In	   response	   to	   this	   “danger”	   signal,	   chaperones	   are	   induced	   to	   resolve	   the	  presence	  of	  unfolded	  proteins;	   a	  phenomenon	   termed	  unfolded	  protein	   response	   (UPR)	  or	  ER	  stress	   (Sidrauski	   et	   al.,	   1998).	   In	  mammals,	   the	   UPR	   is	  mediated	   by	   three	  major	   and	   parallel	  signalling	   branches,	   mediated	   by	   (i)	   the	   ER-­‐resident	   transmembrane	   protein	   kinase-­‐endoribonucleases	  (RNAse)	  IRE1,	  (ii)	  the	  protein	  RNA-­‐like	  ER	  kinase	  PERK	  and	  (iii)	  a	  family	  of	  type	   II	   transmembrane	   transcription	   factors,	   with	   ATF6	   being	   its	   most	   prominent	   member	  (Figure	  12).	  	  In	  brief,	  PERK	  phosphorylates	  eukaryotic	   initiation	   factor	  (eIF2a)	   in	  order	  to	  suppress	  general	  protein	   translation	   (Ron	   and	   Walter,	   2007).	   IRE1	   activation	   leads	   to	   recruitment	   of	   several	  signaling	  molecules	  that	  can	  engage	  inflammatory	  and	  survival-­‐related	  signals,	  and	  activation	  of	  its	  RNase	  domain	  leads	  to	  the	  splicing	  and	  production	  of	  an	  active	  transcription	  factor	  called	  X	  box–binding	   protein	   1	   (XBP-­‐1)	   (Todd	   et	   al.,	   2008).	   ATF6	   translocates	   to	   the	   Golgi	   apparatus,	  where	   it	   is	   processed	   by	   two	   proteases	   to	   become	   an	   active	   transcription	   factor (Chen	   et	   al.,	  2002).	  Taken	  together,	   the	  three	  arms	  of	   the	  UPR	  act	   to	  (i)	  reduce	  general	  protein	  translation,	  (ii)	   stimulate	   protein	   degradation	   and	   (iii)	   increase	   folding	   capacity	   to	   cope	   with	   ER	   stress	  (Figure	  12).	  Therefore,	   the	  UPR	   is	  a	  key	  response	  mechanism	  activated	   in	  order	   to	  resolve	  ER	  stress.	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Figure	  12:	  Canonical	  unfolded	  protein	   response	   (UPR).	  The	   canonical	  UPR	   is	  mediated	  by	   the	   three	  UPR	  sensors	  PERK,	  IRE1a	  and	  ATF6.	  PERK	  mainly	  functions	  in	  phosphorylating	  eIF2a	  to	  attenuate	  general	  protein	  translation,	  but	  can	  also	  regulate	   the	  activity	  of	  several	   transcription	   factors	  such	  as	  ATF4,	  ATF3	  and	  nuclear	  factor	   E2–related	   factor-­‐2	   (Nrf2).	   Upon	   autophosphorylation,	   the	   RNase	   activity	   of	   IRE1a	   results	   in	   the	  production	   of	   the	   active	   spliced	   XBP-­‐	   1,	   leading	   to	   the	   expression	   and	   production	   of	   ER	   chaperones	   and	  components	   of	   the	   ER-­‐associated	   degradation	   (ERAD)	   process.	   Consequently,	   ATF6	   moves	   to	   the	   Golgi	  apparatus,	   where	   it	   is	   proteolytically	   processed	   to	   become	   an	   active	   transcription	   factor.	   Taken	   together,	  activation	  of	   the	  three	  branches	  results	   in	  expression	  of	  chaperone	  proteins	  and	  XBP-­‐1,	   thereby	  (i)	   inhibiting	  translation,	  (ii)	  facilitating	  protein	  degradation	  and	  (iii)	  producing	  of	  ER	  chaperones	  and	  other	  molecules	  that	  restore	  the	  ER	  folding	  environment.	  Adapted	  from	  (Hotamisligil,	  2010).	   	  But,	  if	  this	  stress	  cannot	  be	  resolved	  successfully	  after	  UPR	  induction,	  apoptosis	  is	  initiated	  (Ron	  and	  Walter,	  2007).	  This	  process,	  however,	  is	  poorly	  understood	  and	  there	  are	  studies	  proposing	  different	  mechanisms	  for	  apoptosis	  induction	  in	  response	  to	  ER	  stress.	  For	  instance,	  deregulated	  calcium	  levels	  within	  the	  cell	  were	  demonstrated	  to	  negatively	  impact	  on	  the	  translocation	  of	  the	  pro-­‐apoptotic	  proteins	  BAX	  and	  BAK	   from	   the	  ER	   to	   the	  mitochondria	   (Scorrano	  et	   al.,	   2003).	  Further	   evidence	   suggests	   that	   IRE-­‐mediated	   activation	   of	   Jun	   N-­‐terminal	   kinase	   (JNK)	   may	  contribute	  to	  apoptosis	  by	  phosphorylating	  and	  thereby	  inactivating	  the	  anti-­‐apoptotic	  protein	  BCL-­‐2	   (Urano	   et	   al.,	   2000).	   In	   addition,	   PERK-­‐mediated	   phosphorylation	   of	   eIF2α	   was	  demonstrated	  to	  contribute	  to	  apoptosis	  by	  inhibiting	  the	  synthesis	  of	  pro-­‐survival	  proteins	  and	  in	   induction	   of	   the	   CCAAT/-­‐enhancer-­‐binding	   protein	   homologous	   protein,	   downstream	   of	  PERK,	  may	  repress	  expression	  of	  BCL2	  (McCullough	  et	  al.,	  2001).	  This	  was	  confirmed	  in	  CHOP-­‐/-­‐	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mice,	   in	   which	   a	   negative	   feedback	   loop	   leads	   to	   eIF2α	   dephosphorylation,	   which	   in	  consequence	  favours	  recovery	  of	  protein	  synthesis.	  	  Further	  studies	  in	  mice	  suggested	  that	  ER-­‐stress	  induced	  apoptosis	   is	  mediated	  via	  caspase	  12	  (Nakagawa	  and	  Yuan,	  2000),	  whose	  cleavage	  is	  activated	  through	  tumor	  necrosis	  factor	  receptor	  signalling.	  There	  exist	  different	  chemicals	  to	  induce	  and	  study	  ER	  stress	  in	  vitro.	  The	  chemical	  thapsigargin	  (TH),	  a	   sesquiterpene	   lactone	   isolated	   from	  the	  plant	  Thapsia	  garganica,	  was	  demonstrated	   to	  inhibit	  SERCA	  pumps,	  thereby	  causing	  ER	  store	  depletion	  of	  Ca2+	  and	  consequently	  inducing	  ER	  stress	   and	   apoptosis	   (Jiang	   et	   al.,	   1994).	   In	   contrast,	   tunicamycin,	   a	   mixture	   of	   homologous	  nucleoside	   antibiotics,	   inhibits	  N-­‐linked	   glycosylation	   and	   is	   therefore	   also	   frequently	   used	   to	  induce	  ER	  stress	  and	  UPR	  (Chan	  and	  Egan,	  2005).	  	  	  	  
1.6.2 Calcium	  Signalling	  and	  ER	  Stress	  in	  Hematopoietic	  Stem	  Cells	  	  	  Hematopoietic	  stem	  cells	  have	  also	  been	  studied	  in	  the	  context	  of	  calcium	  signalling.	  The	  group	  of	  DT	  Scadden	   identified	   expression	  of	   the	  Calcium	  sensing	   receptor	   (CaR)	  on	  HSCs	  as	   crucial	  requirement	   for	   their	   proper	  migration	   from	   fetal	   liver	   into	   the	   endosteal	   BM	  niche.	   Notably,	  fetal	   liver	  CaR-­‐deficient	  HSCs	  were	  normal	   in	  numbers	  and	  were	  found	  in	  circulation	  in	  spleen	  and	   BM,	   however	   their	   capacity	   to	   constantly	   lodge	   to	   the	   endostelial	   niche	   was	   severely	  impaired.	  Therefore,	  CaR	  was	  shown	  to	  critically	  retain	  HSCs	  in	  close	  proximity	  to	  the	  endosteal	  surface	  in	  the	  BM	  niche	  (Adams	  et	  al.,	  2006).	  Consequently,	  pharmacological	  modulation	  of	  CaR	  using	  the	  agonist	  Cinacalcet	  led	  to	  increased	  primitive	  hematopoietic	  cell	  activity	  in	  vitro,	  such	  as	  enhanced	   growth	   and	  migration	   towards	   the	   chemotactic	   stimulus	   stromal	   cell	   derived	   factor	  1α.	   This	   is	   confirmative	   of	   the	   studies	   in	   CaR	   KO	   animals	   and	   gives	   the	   modulation	   of	   this	  receptor	   a	   rational	   for	   the	   treatment	   of	   HSC	   during	   stem	   cell	   therapy,	   thereby	   enhancing	  lodgement	  towards	  into	  the	  BM	  niche	  (Lam	  et	  al.,	  2011).	  	  In	  addition,	  the	  group	  of	  Means	  AR	  (Kitsos	  et	  al.,	  2005)	  studied	  the	  role	  of	  calmodulin-­‐dependant	  protein	  kinase	  IV	  (CaMKIV)	  in	  HSC	  biology	  in	  CaMKIV	  KO	  animals.	  Notably,	  KLS	  cells	  deficient	  for	  
CaMKIV	  are	  significantly	  reduced	  in	  numbers	  and	  are	  impaired	  in	  their	  reconstitutive	  capacity	  in	  serial	  transplantation	  assays.	  This	  KLS	  cell	  failure	  in	  response	  to	  CaMKIV	  deficiency	  was	  due	  to	  apoptosis	   induction	   via	   CBP	   and	   Bcl2,	   hence	   linking	   deregulated	   calcium	   levels	   with	   HSC	  homeostasis	  and	  survival.	  This	  demonstrated	  further	  evidence	  that	  calcium	  signalling	  is	  crucial	  for	  HSC	  function.	  Recently,	   the	   lab	   of	   John	  Dick	   performed	   single	   cell	   sequencing	   on	   lineage-­‐depleted	   umbilical	  cord	   blood	   populations	   and	   thereby	   identified	   a	   gene	   signature	   for	   UPR-­‐responsive	   genes	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enriched	  in	  HSC	  compared	  to	  progenitors	  (Laurenti	  et	  al.,	  2013).	  Therefore,	  Van	  Galen	  et	  al.	  set	  out	  to	  address	  the	  effect	  of	  the	  UPR	  on	  human	  HSCs	  (hHSCs)	  under	  stress	  conditions	  (van	  Galen	  et	  al.,	  2014).	  In	  this	  study,	  ER	  stress	  mediated	  via	  (i)	  inhibition	  of	  N-­‐glycosylation	  by	  tunicamycin	  and	  (ii)	  calcium	  imbalance	  provoked	  by	  deregulation	  of	  Serca	  function	  was	  studied	  in	  hHSCs	  and	  progenitor	  cells.	  Analysis	  of	  gene	  expression	  of	  candidates	  implicated	  in	  all	  three	  branches	  in	  the	  UPR	  demonstrated	  that	  hHSCs	  activated	  preferentially	  the	  PERK	  branch	  of	  UPR,	  followed	  by	  the	  induction	  of	  apoptosis.	  In	  contrast,	  progenitor	  subsets	  rather	  showed	  adaptive	  responses	  to	  UPR	  promoting	   cell	   survival	   rather	   than	   apoptosis.	   Hence	   “stressed”	   hHSCs	   rather	   committed	  apoptotis	   compared	   to	  more	   differentiated	   progenitors,	   thereby	   protecting	   the	   hematopoietic	  system	  from	  propagation	  of	  damaged	  or	  mutated	  genetic	   information.	  Reciprocal	  experiments,	  overexpressing	  the	  co-­‐chaperone	  ERDJ4	  in	  hHSCs,	  which	  functions	  downstream	  of	  PERK,	  led	  to	  an	  increase	  in	  HSC	  repopulation	  capacity	  in	  xenograft	  models.	  Thereby,	  a	  first	  link	  between	  ER	  stress/UPR	  and	  HSC	  function	  was	  established	  (van	  Galen	  et	  al.,	  2014).	  
1.6.3 Identification	  of	  Serca2	  as	  potential	  Drug	  Target	  in	  Notch1-­‐driven	  T-­‐
ALL	  	  Aberrant	  Notch1	  pathway	  activation	  is	  frequently	   linked	  to	  T-­‐ALL	  and	  therefore,	  there	  exists	  a	  strong	   need	   to	   identify	   novel	   inhibitors	   of	   Notch	   in	   order	   to	   ameliorate	   treatment	   regimens	  apart	  from	  conventional	  therapy	  such	  as	  chemo-­‐	  and	  radiotherapy	  in	  this	  hematological	  tumor.	  	  Therefore,	  a	  co-­‐culture	  based	  chemical	  compound	  screen	  was	  performed	  in	  house	  (Lehal,	  2011)	  to	   identify	  molecules	  with	   inhibitory	  potential	  against	  Notch	  (Figure	  13	  A).	   In	  this	  assay,	  HeLa	  cells,	   stably	   expressing	   either	   the	   DL4	   ligand	   or	   the	   N1	   receptor,	   were	   cultured	   in	   close	  proximity	   in	   order	   to	   induce	   Notch	   signaling.	   A	   co-­‐transfected	   luciferase	   reporter	   construct,	  harboring	  multiple	  CSL	  binding	  sites,	  was	  utilized	  as	  read	  out	  for	  Notch	  pathway	  activation,	  and	  hence	  served	  as	  means	   to	  quantify	   inhibitory	  effects	  of	   the	  screened	  compounds	  on	   the	  Notch	  pathway.	   With	   the	   use	   of	   this	   screening	   approach,	   cyclopiazonic	   acid	   (CPA),	   which	   targets	  calcium	  pumps	  of	  the	  Serca	  family,	  was	  identified	  (Lehal,	  2011).	  	  Similarly,	   in	   a	   recent	   study	   Roti	   et	   al.	   performed	   a	   (i)	   Notch1	   “loss-­‐of-­‐function”	   (LOF)	   screen	  combined	  with	  (ii)	  a	  Notch	  “gain-­‐of-­‐function”	  (GOF)	  screen	  in	  order	  to	  identify	  Notch	  inhibitory	  compounds	  on	  the	  one	  hand	  and	  proteins,	  which	  may	  regulate	  Notch,	  on	  the	  other	  hand	  (Roti	  et	  al.,	  2013)	  (Figure	  13	  B).	  Pursuing	  the	  chemical	  compound	  screen	  in	  Notch-­‐activated	  DND41	  T-­‐ALL	  cells,	   led	  to	  the	  identification	  of	  the	  compounds	  thapsigargin	  (TH)	  and	  strikingly	  also	  CPA,	  both	   targeting	   the	   calcium	  ATPases	  of	   the	  Serca	   family.	   Furthermore,	   overexpression	  of	   cDNA	  clones	   from	   an	   open	   reading	   frame	   library	  was	   performed	   in	   U2OS	   osteosarcoma	   cells	   These	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expressed	  a	  mutated	  form	  of	  the	  N1	  receptor	  hence	  displaying	  oncogenic	  activity,	  and	  were	  used	  to	   find	   potential	   Notch	   cooperating	   molecules	   in	   T-­‐ALL.	   Using	   this	   approach,	   Serca2,	   the	  biological	  target	  of	  TH	  and	  CPA,	  was	  confirmed.	  	  	  
	  
Figure	  13:	  Identification	  of	  SERCA2	  as	  a	  potential	  drug	  target	  in	  Notch-­‐1	  driven	  T-­‐ALL.	  Three	  independent	  screening	  approaches	  led	  to	  identification	  of	  the	  chemical	  compounds	  Thapsigargin	  and	  CPA,	  which	  specifically	  target	   SERCA2,	   a	   Calcium	   ATPase	   in	   the	   ER	   membrane.	   A,	   Co-­‐culture-­‐based	   chemical	   compound	   screen	  performed	  in	  house	  to	  discover	  novel	  inhibitors	  for	  DL4-­‐Notch1	  mediated	  Notch	  signaling	  in	  HeLa	  cells	  (Lehal,	  2011).	  B,	  (left),	  Nocth1	  loss	  of	  function	  screen	  in	  DND41	  T-­‐ALL	  cells	  and	  (right)	  Notch	  1	  gain	  of	  function	  screen	  in	   Notch-­‐mutated	   U2OS	   cells	   performed	   by	   Stegmaier	   et	   al.	   to	   identify	   chemical	   Notch	   inhibitors	   and	  cooperating	  partners	  of	  mutated	  Notch1	  (Roti	  et	  al.,	  2013).	  	  	  Rajwinder	  Lehal	  studied	  CPA	  treatment	  of	  leukemic	  cell	  lines	  in	  the	  context	  of	  his	  PhD	  thesis	  and	  confirmed	   that	   CPA	   blocks	   Notch	   pathway	   activation	   in	   the	   co-­‐culture	   system	   and	   down-­‐regulates	  Notch	   target	   genes	   (Lehal,	   2011).	   The	   study	  by	  Roti	  et	   al.	   addressed	   the	   function	  of	  Serca2	   for	   N1	   receptor	   maturation	   and	   proved	   TH	   treatment	   detrimental	   for	   T-­‐ALL	   cell	  engraftment	  in	  xenografts,	  thereby	  proposing	  Serca2	  as	  a	  potential	  drug	  target	  in	  Notch-­‐driven	  T-­‐ALL	  (Roti	  et	  al.,	  2013).	  	  Given	   the	   identification	   of	   CPA	   as	   a	   putative	   drug	   to	   treat	   N1-­‐driven	   T-­‐ALL,	   we	   set	   out	   to	  characterize	  the	  function	  of	   its	  biological	  target,	  Serca2,	   in	  hematopoiesis	  to	  better	  understand	  (i)	   how	  deregulation	   of	   intracellular	   calcium	   signalling	  may	   impact	   on	   hematopoietic	   lineages	  and	  (ii)	  to	  decipher	  the	  mode	  of	  action	  of	  CPA	  in	  treatment	  of	  T-­‐ALL.	  
1.6.4 Sarco-­‐Endoplasmatic	  Reticulum	  Calcium	  ATPases	  (Sercas)	  Serca	  pumps	  are	  responsible	  for	  the	  accumulation	  of	  Ca2+	  in	  the	  SR/ER	  lumen	  and	  therefore	  have	  important	   function	   in	   the	  regulation	  of	   intracellular	  calcium	   levels.	  The	  mobilisation	  of	   	   [Ca2+]i	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from	  intracellular	  organelles	  is	  highly	  specialized	  in	  cardiac	  and	  skeletal	  muscle	  cells	  and	  Serca	  ATPases	  are	  mainly	  studied	  in	  the	  context	  of	  muscle	  contraction	  and	  heart	  biology.	  In	  brief,	  Ca2+	  transport	  from	  the	  cytosol	  into	  the	  SR	  causes	  relaxation	  of	  muscle	  cells,	  while	  high	  cytosolic	  Ca2+	  levels	  in	  contrast	  lead	  to	  muscle	  excitation.	  	  	  The	  Serca	  family	  of	  Ca2+	  ATPases	  comprises	  the	  three	  members	  Serca1,	  Serca2	  and	  Serca3,	  which	  are	  evolutionary	  highly	  conserved	  but	   localized	  on	  different	   chromosomes.	  Serca	   isoforms	  are	  diverse	  in	  their	  nature	  due	  to	  alternative	  splicing	  predominantly	  affecting	  their	  COOH-­‐terminus.	  At	  present,	  7	  mammalian	  Serca	   isoforms	  have	  been	   identified,	  which	   can	  be	   subclassified	   into	  Serca1a-­‐b,	  Serca2	  a-­‐c	  and	  Serca3a-­‐c.	  	  The	  first	  subfamily	  of	  Serca	  pumps	  is	  specific	   for	  the	  SR	  in	  fast-­‐twich	  skeletal	  muscle	  and	  both	  isoforms	  Serca1a	  and	  Serca1b	  are	  regulating	  the	  uptake	  of	  Ca2+	  into	  the	  SR.	  Autosomal	  recessive	  (LOF)	   mutations	   in	   SERCA1	   are	   linked	   to	   Brody	   disease,	   a	   rare	   inherited	   muscle	   disorder	  characterized	  by	  stiffness	  and	  cramps	  due	  to	  exercise-­‐induced	  impairment	  of	  muscle	  relaxation	  (Prasad	  et	  al.,	  2004).	  Generation	  of	  Serca1	  KO	  mice	  by	  conventional	  gene	  targeting	  revealed	  that	  
Serca1	   null	   mice	   develop	   normally	   after	   birth,	   but	   die	   due	   to	   an	   aberrant	   Ca2+	   uptake	   and	  hypercontracture	   injury	   to	   the	   diaphragm	   muscles.	   Furthermore,	   it	   was	   demonstrated	   that	  neither	  Serca2	  nor	  Serca3	   compensate	   for	  Serca3	  LOF,	  which	   is	  confirmative	  of	   the	   lethality	  of	  
Serca1	  KO	  animals	  (Pan,	  2003).	  Serca2	  family	  members	  are	  important	  for	  calcium	  transport	  into	  the	  ER	  and	  similarly	  show	  differential	  expression	  depending	  on	  the	  isoform.	  Serca2,	  being	  focus	  of	  this	  thesis,	  will	  be	  discussed	  in	  the	  next	  section.	  In	  contrast	  to	  Serca1	  and	  Serca2,	  Serca3	  has	  3	  splice	  variants	   (Serca3a-­‐c),	  which	  vary	   in	   their	  C-­‐termini.	  Serca3	  members,	   initially	   thought	   to	  be	  expressed	  only	  in	  a	  limited	  number	  of	  tissues	  such	  as	  endothelial	  cells	  and	  pancreatic	  β-­‐cells	  (Prasad	  et	  al.,	  2004),	  were	  recently	  demonstrated	  expressed	  in	  cardiomayocytes.	  However,	  mice	  deficient	  for	  Serca3	  develop	  normally	  and	  do	  not	  display	  any	  gross	  developmental	  abnormalities	  other	   than	   mild	   defects	   in	   Ca2+	   uptake	   detected	   in	   vascular	   endothelial	   cells	   (Buckley	   and	  Whorton,	  1997).	  
1.6.5 Serca2	  in	  Development	  and	  Disease	  The	  Serca2a	  protein	   is	  prominently	  expressed	  in	  cardiac	  and	  slow-­‐twitch	  muscle	  and	  was	  first	  cloned	   in	   1985	   (MacLennan	   et	   al.,	   1985).	   In	   contrast,	   the	   isoform	   Serca2b	   is	   expressed	   in	   all	  tissues,	   including	  heart	   and	   smooth	  muscle,	   and	   is	   the	  main	  non-­‐cardiac	  ER	  Ca2+	  ATPase	  with	  house	  keeping	  function	  and	  differs	  from	  Serca2a	  in	  its	  C-­‐terminus	  (Figure	  14).	  Structurally,	  both	  Serca2a	  and	  b	  are	  anchored	   to	   the	  ER	  membrane	  by	   its	  10	   transmembrane	  helices,	  which	  are	  intersected	  by	  a	  β-­‐strand	  domain	  between	  loop	  2-­‐3	  and	  by	  the	  phosphorylation	  and	  nucleotide	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binding	  domains	  between	   loop	  4-­‐5.	  While	  both	  the	  N-­‐	  and	  C-­‐terminal	  segments	  of	  Serca2a	  are	  exposed	  to	  the	  cytoplasm,	  the	  C-­‐terminus	  of	  Serca2b	  enters	  into	  the	  ER	  lumen.	  In	  both	  of	  these	  isoforms,	  the	  active	  site	  for	  ATP	  hydrolysis	  is	  located	  within	  the	  phosphorylation	  and	  nucleotide	  binding	   domains	   and	   the	   transmembrane	   domain,	   containing	   Ca2+	   binding	   sites,	   builds	   the	  channel	  for	  Ca2+	  transport	  from	  the	  cytosol	  into	  the	  ER	  (Figure	  14).	  	  
	  
Figure	  14:	  Structure	  of	  Serca2a	  and	  Serca2b	  residing	  in	  the	  ER	  membrane.	  Serca2	  is	  anchored	  to	  the	  ER	  membrane	  by	   its	  10	  transmembrane	  helices,	  which	  are	   intersected	  with	  a	  β-­‐strand	  domain	  between	   loop	  2-­‐3	  and	  the	  phosphorylation	  and	  nucleotide	  binding	  domains	  between	  loop	  4-­‐5.	  The	  active	  site	  for	  ATP	  hydrolysis	  is	  formed	  in	  the	  phosphorylation	  and	  nucleotide	  binding	  domains.	  The	  transmembrane	  domain,	  containing	  Ca2+	  binding	   sites,	   builds	   the	   channel	   for	   Ca2+	   transport	   from	   the	   cytosol	   into	   the	  ER.	  Both	   the	  N-­‐	   and	  C-­‐terminal	  segments	  of	  Serca2a	  are	  exposed	  to	  the	  cytoplasm,	  while	  the	  C-­‐terminus	  of	  Serca2b	  enters	  into	  the	  ER	  lumen.	  Adapted	  from	  (Dhitavat	  et	  al.,	  2004).	  	  In	   2003,	   another	   isoform,	   Serca2c,	   was	   identified	   in	   monocytes.	   Serca2c	   is	   ubiquitously	  expressed	  and	  arises	   from	   the	   Serca2a	   isoform	  but	  displays	   a	   short	   intronic	   sequence	   located	  between	   exons	   20	   and	   21.	   Furthermore,	   structurally	   the	   Serca2c	   protein	   was	   predicted	   to	  posses	   a	   truncated	   C-­‐terminus	   containing	   a	   short	   but	   unique	   peptide	   stretch	   (Gelebart	   et	   al.,	  2003).	  However,	  to	  date,	  little	  is	  known	  about	  this	  isoform	  of	  the	  Serca2	  family.	  	  In	  general,	  upon	  hydrolysis	  of	  one	  ATP	  molecule,	  Serca2	  pumps	   two	  Ca2+	   ions	   into	   the	  SR/ER,	  thereby	  working	  against	  the	  1:7000	  calcium	  gradient,	   that	   is	  established	  from	  the	  cytosol	  over	  the	  SR/ER	  (Shannon	  and	  Bers,	  1997).	  Ample	  evidence	  suggests	  however,	  that	  in	  neutral	  pH,	  two	  H+	   ions	   are	   exported	   out	   of	   the	   SR/ER	   per	   two	   Ca2+	   ions	   transported	   into	   this	   compartment,	  speculating	  that	  Serca2	  may	  function	  as	  a	  Ca2+-­‐H+	  antiporter	  (Kuhlbrandt,	  2004;	  Niggli	  and	  Sigel,	  2008).	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  In	  order	  to	  study	  the	  function	  of	  Serca2	  in	  vivo,	  conventional	  and	  conditional	  Serca2	  KO	  animals	  have	   been	   generated.	   Serca2	   null	  mice	   die	   in	   utero	   due	   to	   cardiac	   defects	   caused	   by	   severely	  reduced	  Ca2+	  levels	  in	  the	  SR.	  	  SERCA2	  heterozygous	  mice	  (Serca2+/-­‐)	  mice	  are	  viable	  but	  display	  impaired	   cardiac	   contractility	   and	   relaxation,	   suggesting	   that	   Serca2	   function	   is	   crucial	   for	  sequestration	  of	  Ca2+	  within	  cardiac	  cells	  and	  their	  intracellular	  compartments	  (Periasamy	  et	  al.,	  1999).	   In	   contrast,	   conditional	   Serca2	   ablation	   in	   cardiomyocytes	   in	   the	   adult	   leads	   to	   only	   a	  mild	  heart	  dysfunction	  (Andersson	  et	  al.,	  2009).	  	  In	  1993,	   the	  chromosomal	   locus	  12q23-­‐24.1,	  encoding	  SERCA2,	  was	   linked	   to	  Darier´s	  disease	  for	   the	   first	   time	   (Bashir	   et	   al.,	   1993;	   Craddock	   et	   al.,	   1993).	   Darier´s	   disease	   patients	  mainly	  present	   missense	   mutations	   in	   a	   single	   copy	   of	   the	   SERCA2	   encoding	   gene	   ATP2A2,	   thereby	  attributing	   it	   a	   role	   as	   haploinsufficient	   tumor	   suppressor	   in	   this	   pathologic	   setting.	   Darier´s	  disease	   is	   an	   autosomal-­‐dominant	   skin	   disease	   in	   humans	   characterized	   by	   keratinized	  squamous	   epithelial	   cells	   (Sakuntabhai	   et	   al.,	   1999).	   However,	   since	   these	   patients	   do	   not	  display	   with	   any	   heart	   malfunction,	   the	   functional	   copy	   of	   the	   residual	   SERCA2	   allele	   can	  compensate	   for	   its	   counter	   partner.	   Interestingly,	   mice	   heterozygous	   for	   SERCA2	   (SERCA2+/-­‐)	  develop	  squamous	  cell	  carcinoma	  of	  the	  skin	  (Prasad	  et	  al.,	  2004),	  which	  is	  confirmative	  of	  the	  identification	   of	   ATP2a2	   as	   the	   Darier´s	   disease-­‐causing	   gene.	   Taken	   together,	   these	   studies	  demonstrate	  a	  gene	  dosage	  effect	  for	  SERCA2	  in	  regulating	  skin	  homeostasis.	  	  Studies	  in	  our	  laboratory	  identified	  CPA	  as	  potential	  Notch	  inhibitor,	  through	  targeting	  SERCA2	  (Lehal,	   2011).	   Lehal	   Rajwinder	   demonstrated	   that	   CPA	   significantly	   down-­‐regulates	   Notch	  pathway	  activation	  in	  the	  co-­‐culture	  based	  screening	  system	  and	  as	  a	  consequence	  Notch	  target	  gene	  expression	   (Hes1,	  Deltex,	  c-­‐myc)	   is	   similarly	   reduced	   in	  human	  T-­‐ALL	  cells.	   Furthermore,	  
Hes1	   down-­‐regulation	   was	   due	   to	   impaired	   recruitment	   of	   NICD	   to	   CSL/RBPJκ	   binding	   sites	  within	   the	  Hes1	   promoter.	  When	   treating	   human	  T-­‐ALL	   cells	   lines	  with	   CPA,	   Rajwinder	   Lehal	  demonstrated	   that	   most	   Notch-­‐driven	   leukemic	   cells	   were	   sensitive	   to	   CPA,	   resulting	   in	   a	  proliferation	  block	  upon	   treatment.	   	   Preliminary	   in	   vivo	   data	  demonstrated	   that	  CPA	  does	  not	  induce	  goblet	  cell	  metaplasia	  in	  mice,	  a	  well	  described	  N1	  and	  N2	  double	  LOF	  phenotype	  in	  the	  gut	   (Riccio	   et	   al.,	   2008).	   These	  data	   supported	   in	   vitro	   results	   and	   suggest	   that	   CPA	  primarily	  negatively	  impacts	  on	  N1	  rather	  than	  N2	  signalling.	  Similarly,	  work	  by	  Roti	  et	  al.	   linked	  over-­‐activation	  of	  SERCA2	  with	  T-­‐ALL,	   thereby	  giving	   first	  evidence,	  that	  SERCA2	  GOF	  is	  linked	  to	  cancer	  development	  (Roti	  et	  al.,	  2013).	  In	  this	  study	  the	  chemical	  compounds	  TH	  and	  CPA	  were	  identified	  as	  Notch	  inhibitory	  drugs,	  targeting	  SERCA2.	  Inhibition	  of	  SERCA	  by	  TH	  led	  to	  down-­‐regulation	  of	  Notch	  target	  genes	  like	  MYC,	  DELTEX1	  and	  
HES1,	   confirming	   that	   SERCA	  was	   a	   valid	   target	   in	   N1	   driven	   T-­‐ALL.	   Furthermore,	   Roti	   et	   al.	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demonstrated	   growth-­‐inhibitory	   effects	   of	   TH	   in	   human	   T-­‐ALL	   cells	   in	   vitro	   as	   well	   as	   in	  Xenografts,	   which	   display	   decreased	   tumor	   volume	   when	   treated	   with	   TH.	   This	   was	  demonstrated	   to	   be	   due	   to	   impaired	  Notch	   receptor	  maturation	   specifically	   in	  N1-­‐mutated	  T-­‐ALL	  cells,	  which	  displayed	  lower	  NICD	  levels	  in	  response	  to	  TH	  treatment	  and	  therefore,	  SERCA2	  was	  proposed	  to	  be	  a	  possible	  therapeutic	  target	  in	  T-­‐ALL.	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  2 Objectives	  of	  this	  work	  
2.1 Part	  I:	  Role	  of	  Chd7	  in	  the	  Hematopoietic	  system	  and	  in	  T-­‐ALL	  Aberrant	  Notch1	  pathway	  activation	  is	  reported	  in	  more	  than	  50%	  of	  T-­‐ALL	  patients.	  Treatment	  regimens	  include	  chemotherapy	  in	  concert	  with	  radiotherapy,	  however	  the	  incidence	  of	  relapse	  in	  patients	  is	  extremely	  high.	  Therefore,	  there	  exists	  a	  strong	  need	  to	  not	  only	  specifically	  inhibit	  the	  Notch	  signalling	  pathway	  but	  to	  also	  identify	  molecular	  players	  that	  cooperate	  with	  Notch	  in	  T-­‐ALL	  development.	  Microarray	  analysis	  performed	  by	  a	  former	  student	  in	  the	  lab,	  PhD	  Caroline	  Poisson,	   identified	   the	   chromatin-­‐remodelling	   enzyme	   Chromodomain	   Helicase	   DNA-­‐binding	  protein	  7,	  Chd7,	  as	  such	  a	  potential	  partner	  cooperating	  with	  Notch	  in	  T-­‐ALL	  maintenance.	  Aim	  of	  this	  work	  was	  to	  assess	  whether	  genetic	  ablation	  of	  Chd7	  would	  improve	  or	  accelerate	  disease	  outcome	  in	  murine	  and	  human	  Notch1-­‐driven	  T-­‐ALL.	  In	  addition,	  given	  the	  identification	  of	  Chd7	  in	   late-­‐stage	   T-­‐ALL,	   we	   set	   out	   to	   characterize	   the	   role	   of	   Chd7	   in	   the	   hematopoietic	   system	  under	  physiological	  and	  competitive	  conditions.	  	  	  
2.2 Part	  II:	  Role	  of	  Serca2	  in	  the	  Hematopoietic	  system	  Aberrant	  Notch	  signaling	  has	  been	  implicated	  in	  many	  different	  aspects	  of	  human	  cancer	  such	  as	  hyperproliferation,	   invasiveness	   and	   angiogenesis.	   Therefore,	   the	   Notch	   signaling	   pathway	  represents	   a	   bona	   fide	   drug	   target.	   We	   and	   Roti	   et	   al.	   have	   performed	   chemical	   compound	  screenings	  and	  identified	  Cyclopiazonic	  acid	  (CPA)	  to	  be	  a	  potent	  Notch	  inhibitor	  (Lehal,	  2011;	  Roti	   et	   al.,	   2013).	   Biological	   target	   of	   this	   compound	   is	   the	   Sarco/Endoplasmic	   Reticulum	  ATPase2	  (Serca2)	  that	  is	  involved	  in	  calcium	  homeostasis	  within	  the	  cell.	  	  Aim	  of	  this	  study	  was	  to	  characterize	  the	  function	  of	  Serca2	  in	  the	  hematopoietic	  system	  in	  order	  to	   better	   understand	   the	   mode	   of	   action	   of	   CPA	   in	   the	   treatment	   of	   T-­‐ALL.	   Therefore,	   we	  generated	  BM	  specific	  Serca2-­‐deficient	  chimeric	  mice	  that	  either	   lacked	  one	  or	  both	  functional	  alleles	  of	  Serca2	  and	  assessed	  the	  impact	  of	  Serca2	   loss	  of	  function	  (LOF)	  on	  the	  hematopoietic	  system	   under	   physiologic	   and	   competitive	   conditions.	   In	   addition	   and	   more	   relevant	   to	   the	  clinic,	  we	   studied	   the	   effect	   of	   the	  proposed	  anti-­‐cancer	  drug	  Thapsigargin,	   a	  non-­‐competitive	  Serca	  ATPase	  inhibitor	  and	  CPA	  analogue,	  on	  BM	  progenitor	  and	  HSC	  biology.	  	  
	  
	  3 Results	  –	  Part	  I:	  Role	  of	  Chd7	  in	  Hematopoiesis	  &	  T-­‐
ALL	  
3.1 Validation	  of	  Potential	  Mediators	  cooperating	  with	  Notch1	  in	  
T-­‐ALL	  	  Based	   on	   the	   microarray	   study	   performed	   by	   a	   former	   PhD	   student,	   Caroline	   Poisson	  (unpublished	  data),	  we	  set	  out	  to	  validate	  potential	  mediators	  that	  may	  co-­‐operate	  with	  Notch1	  in	  T-­‐ALL	  (Poisson,	  2011).	  The	  top	  40	  up-­‐	  and	  down-­‐regulated	  candidate	  genes	   identified	  to	  be	  differentially	   regulated	   between	   early-­‐stage	   non-­‐malignant	   RNIC+/ΔMxCre	   and	   late-­‐stage	  metastasizing	  RNIC+/ΔLckCre-­‐induced	  T-­‐ALL	  were	  validated	  by	  qRT-­‐PCR.	  Data	  achieved	  during	  this	  microarray	  validation	  can	  be	   found	   in	   the	  Appendix	  section	   I.	  The	  chromatin	  remodeller	  Chd7	  was	  selected	   for	  study	   in	   this	   thesis	  because	   it	  was	  (i)	   the	  highest	  over-­‐expressed	  gene	   in	   late	  stage	   tumors	   out	   of	   117	   gene	   candidates	   (Figure	   15	   A	   and	   B)	   and	   (ii)	   Chd7	   gain-­‐of-­‐function	  effects	  in	  cancer	  were	  until	  then	  only	  identified	  by	  one	  research	  group	  but	  not	  studied.	  	  	  
	  
Figure	  15:	  Chd7	   is	   the	  highest	  over-­‐expressed	  gene	   in	   late-­‐stage	  T-­‐ALL	  compared	   to	  pre-­‐malignant	  T-­‐
ALL.	  A,	  Pie	  chart	  of	  differentially	  expressed	  genes	  identified	  in	  late-­‐stage	  metastatic	  T-­‐ALL	  (RNIC+/ΔLckCre)	  versus	  pre-­‐malignant	  (RNIC+/ΔMxCre)	  T-­‐ALL.	  B,	  Top	  up-­‐regulated	  gene	  candidates	  in	  late-­‐stage	  T-­‐ALL	  compared	  to	  early-­‐stage	  T-­‐ALL	  (set	  to	  1).	  Chd7	  is	  the	  highest	  up-­‐regulated	  gene	  in	  RNIC+/ΔLckCre	  T-­‐ALL	  with	  a	  maximal	  expression	  change	   of	   26-­‐fold	   normalized	   to	   RNIC+/ΔMxCre	   pre-­‐malignant	   T-­‐ALL.	   	   Courtesy	   of	   Caroline	   Poisson	   (Poisson,	  2011).	  	  Since	  Chd7	  was	  highly	   expressed	   in	   late-­‐stage	  Notch1-­‐driven	  T-­‐ALL,	  we	  wanted	   to	   investigate	  the	   function	   of	   Chd7	   first	   in	   normal	   hematopoiesis	   followed	   by	   its	   putative	   function	   in	   the	  context	  of	  T-­‐ALL	  development	  and	  maintenance.	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3.2 Functional	  Characterization	  of	  Chd7	  in	  Hematopoiesis	  To	  study	  the	  role	  of	  Chd7	  during	  hematopoiesis,	  Chd7ΔMxCre	  mice	  were	  generated	  by	  crossing	  the	  
Chd7lox/lox	   cKO	   strain	   (Hurd	   et	   al.,	   2010)	   with	   the	   INF	   type	   I-­‐responsive	   MxCre	   recombinase,	  which	  efficiently	  targets	  BM	  progenitors.	  	  	  
	  
Figure	  16:	  Strategy	  for	  conditional	  in	  vivo	   inactivation	  of	  Chd7	   in	  the	  BM.	  A,	  Schematic	  representation	  of	  the	   genetically	   modified	   murine	   Chd7	   locus,	   in	   which	   the	   ATG-­‐encoding	   exon	   2	   is	   flanked	   by	   loxP	   sites.	  Activation	  of	  MxCre	  recombinase	  by	  administration	  of	  PIC	   leads	   to	   the	  generation	  of	  a	  Chd7	  null	   allele	   in	  BM	  cells.	  B,	   Deletion	  PCR	   analysis	   demonstrating	   a	   987	  bp	   lox	   band	   and	   a	   324	  bp	  deletion	   band	   amplified	   from	  genomic	  DNA	  isolated	  from	  Chd7lox/lox	  or	  Chd7ΔMxCre	  BM	  cells.	  	  	  MxCre-­‐mediated	   Chd7	   conditional	   deletion	   was	   induced	   via	   administration	   of	   Poly(I):Poly(C)	  (PIC)	   every	   second	  day	   over	   10	  days,	   resulting	   in	   excision	   of	   the	  ATG-­‐encoding	   exon	  2	   in	   the	  murine	   Chd7	   locus	   (Figure	   16	   A).	   Four	   weeks	   post	   PIC	   induction,	   deletion	   efficiency	   was	  confirmed	  by	  PCR	  analysis	  of	  DNA	  isolated	  from	  BM	  of	  Chd7ΔMxCre	  or	  Chd7lox/lox	  mice:	  Excision	  of	  the	  loxP-­‐site	  flanked	  exon	  2	  resulted	  in	  amplification	  of	  a	  324	  bp	  deletion	  (Δ)	  band	  as	  compared	  to	  a	  987	  bp	  amplicon	  from	  the	  Chd7	  floxed	  locus	  (Figure	  16	  B).	  	  	  
3.2.1 Chd7	   Deficiency	   does	   not	   affect	   Hematopoiesis	   under	   Steady	   State	  
Conditions	  It	  was	  previously	  reported	  that	  CHD7	  is	  important	  for	  stem	  cell	  biology	  (Bajpai	  et	  al.,	  2010)	  and	  it	  was	  hypothesized	  that	  Chd7	  may	  negatively	  regulate	  T	  cell	  numbers	  (Hsu	  J,	  2011).	  Therefore,	  we	  characterized	  all	  hematopoietic	  lineages	  in	  absence	  or	  presence	  of	  Chd7	  with	  a	  primary	  focus	  on	  HSCs	  and	  T	  cells.	  Conditional	  loss	  of	  Chd7	  utilizing	  the	  MxCre	  recombinase	  was	  found	  to	  have	  no	   effect	   on	   the	   HSC	   compartment.	   Figure	   17	   shows	   representative	   FACS	   plots	   of	   (A)	   the	  Lineage−c-­‐kit+Sca1+	   (KLS)	   population	   enriched	   for	   HSCs	   and	   progenitor	   cells	   that	   was	   further	  analyzed	   for	   expression	   of	   the	   markers	   CD135	   and	   CD34,	   which	   allow	   the	   classification	   into	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long-­‐term	   HSC	   (LT-­‐HSC,	   CD135-­‐CD34-­‐),	   short-­‐term	   HSC	   (ST-­‐HSC,	   CD135-­‐CD34+)	   and	   multi-­‐potent	  progenitors	  (MPP,	  CD135+,	  CD34+).	  	  	  
	  
Figure	  17:	  Chd7	  Deficiency	  does	  not	  perturb	  hematopoietic	  development.	  Chd7ΔMxCre	  and	  Chd7lox/lox	   (Ctrl)	  BM	   cells	   were	   analysed	   for	   the	   KLS	   compartment	   5	   weeks	   post	   MxCre	   induction.	   A	   upper	   panel,	  Representative	  FACS	  plots	  showing	  Ctrl	  and	  Chd7ΔMxCre	  Lineage-­‐CD117+Sca1+	  (KLS)	  cells	  and	  lower	  panel,	  Ctrl	  and	  Chd7ΔMxCre	   LT-­‐HSCs	   (KLS,	   CD135-­‐CD34-­‐),	   ST-­‐HSCs	   (KLS,	   CD135-­‐CD34+)	   and	  MPPs	   (KLS,	   CD135+CD34-­‐).	  B,	  Absolute	  cell	  numbers	  of	  total	  KLS	  and	  HSC	  subpopulations	  depicted	  in	  A.	  Error	  bars	  represent	  mean	  ±	  SD,	  n	  =	  5	  (Ctrl)	  and	  n	  =	  5	  (Chd7ΔMxCre).	  	  	  Upon	  analysis	  of	  the	  HSC	  compartment	  five	  weeks	  post	  PIC	  induction,	  no	  significant	  differences	  in	  (i)	  percentages	  (Figure	  17	  A)	  and	  (ii)	  absolute	  numbers	  (Figure	  17	  B)	  of	  total	  KLS,	  LT-­‐HSCs,	  ST-­‐HSCs	  and	  MPPs	  were	  found	  between	  Chd7-­‐competent	  and	  Chd7-­‐deficient	  cells.	  	  Furthermore,	  we	  hypothesized	   that	  Chd7	  may	  regulate	  T	  cell	  development	  given	   that	  Notch	   is	  crucial	  for	  T	  lineage	  commitment	  (Radtke	  et	  al.,	  1999)	  and	  that	  Chd7	  was	  identified	  as	  highly	  up-­‐regulated	   in	   late-­‐stage	   N1-­‐driven	   T-­‐ALL	   compared	   to	   pre-­‐malignant	   T-­‐ALL.	   Therefore,	   we	  analyzed	  the	  thymi	  of	  Chd7ΔMxCre	  and	  Chd7lox/lox	  Ctrls	  5	  weeks	  post	  MxCre	  activation	  focusing	  on	  T	  cell	  progenitors	  at	   the	  DN	  stages	  and	  immature	  and	  mature	  αβ	  and	  γδ	  T	  cells.	  However,	  Chd7-­‐deficient	  hematopoietic	  progenitors	  gave	  rise	  to	  normal	  numbers	  of	  T	  cell	  progenitors	  at	  double	  negative	  stages	  DN1	  to	  DN4	  (Figure	  18	  A)	  as	  well	  as	  immature	  CD4+CD8+	  DP	  and	  mature	  CD4+SP,	  CD8+	  SP	  effector	  T	  cells	  (Figure	  18	  B)	  and	  TCRγδ	  T	  cells	  as	  shown	  in	  Figure	  18	  C.	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Figure	   18:	   Chd7	   deficiency	   does	   not	   affect	   T	   cell	   development	   in	   the	   thymus.	   Chd7ΔMxCre	   and	   Chd7lox/lox	  (Ctrl)	  thymi	  were	  analysed	  5	  weeks	  post	  MxCre	  induction.	  A,	  left	  panel,	  Representative	  FACS	  analysis	  showing	  Ctrl	   and	  Chd7ΔMxCre	   CD4-­‐CD8-­‐Lin-­‐	   thymocytes	   stained	  with	   anti-­‐CD25	   and	   anti-­‐CD44	   antibodies	   to	   distinguish	  DN1	   (CD44+CD25-­‐),	  DN2,	   (CD44+CD25+),	  DN3	   (CD44-­‐CD25+)	   and	  DN4	   stages	   (CD44-­‐CD25-­‐)	  of	  maturation	  and	  
right	  panel	  corresponding	  absolute	  cell	  numbers.	  B,	  left	  panel,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  CD4	  and	  CD8	  in	  Chd7lox/lox	  (Ctrl)	  and	  Chd7ΔMxCre	  mice,	  and	  right	  panel	  corresponding	  absolute	  cell	  numbers.	  C,	  left	  panel,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  TCRγδ	  and	  TCRβ,	  gated	  on	  CD4-­‐CD8-­‐	  thymocytes,	  and	  right	  panel	  corresponding	  absolute	  cell	  numbers.	  Error	  bars	  represent	  mean	  ±	  SD,	  n	  =	  5	  (Ctrl)	  and	  n	  =	  5	  (Chd7ΔMxCre).	  	  In	   addition,	   given	   the	   importance	   of	   Notch	   signalling	   in	   the	   development	   of	  marginal	   zone	   B	  (MZB)	  cells	  in	  the	  spleen	  (Tanigaki	  et	  al.,	  2002),	  we	  also	  investigated	  whether	  Chd7	  plays	  a	  role	  in	  MZB	  differentiation.	  No	  significant	  differences	  in	  the	  percentage	  (Figure	  19	  A),	  nor	  in	  absolute	  cell	  numbers	  of	  MZB	  cells	  (Figure	  19	  B)	  was	  observed	  in	  Chd7-­‐competent	  or	  Chd7-­‐deficient	  cells.	  However,	   similarly,	   other	   mature	   hematopoietic	   lineages	   in	   the	   periphery	   such	   as	   B	   cells	  (B220+),	  overall	  T	  cells	  (TCRb+)	  and	  CD4+	  SP	  or	  CD8+	  SP	  T	  cells	  were	  also	  not	  affected	  by	  genetic	  ablation	  of	  Chd7	  as	  depicted	  in	  Figure	  19	  B.	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Figure	   19:	   Chd7	   deficiency	   does	   not	   affect	   mature	   lineages	   or	   marginal	   zone	   B	   cells	   in	   the	   spleen.	  
Chd7ΔMxCre	   and	  Chd7lox/lox	   (Ctrl)	   spleens	  were	  analysed	  5	  weeks	  post	  MxCre	   induction.	  A,	  Representative	  FACS	  plots	   showing	   Ctrl	   and	   Chd7ΔMxCre	   marginal	   zone	   B	   cells,	   gated	   for	   B220+IgM+CD21+CD23-­‐.	   B,	   Absolute	   cell	  numbers	  of	  total	  splenic	  cellularity,	  B	  cells	  (B220+),	  T	  cells	  (TCRb+,	  CD4+,	  CD8+)	  and	  marginal	  zone	  B	  cells	  (MZB)	  in	  the	  spleen	  of	  Ctrl	  (n	  =	  5)	  and	  Chd7ΔMxCre	  	  (n=5)	  mice.	  Error	  bars	  represent	  mean	  ±	  SD.	  
3.2.2 Chd7	  Deficiency	  does	  not	  affect	  on	  Hematopoiesis	  under	  Competitive	  
Conditions	  upon	  Serial	  Transplantation	  Genetic	   ablation	   of	   Chd7	   did	   not	   result	   in	   any	   overt	   phenotype	   in	   the	   hematopoietic	   system	  under	  physiologic	   conditions.	  However,	   previous	  data	   generated	  by	   the	   group	  of	  Nancy	  Speck	  indicated	   that	   Chd7-­‐deficient	   BM	   cells	   had	   a	   competitive	   advantage	   in	   T	   cell	   reconstitution	  compared	  to	  wild	  type	  cells,	  when	  serially	  transplanted	  into	  lethally	  irradiated	  recipients	  (Hsu	  J,	  2011).	   This	   suggested	   a	   role	   for	   Chd7	   in	   restraining	  T	   cell	   numbers	   in	   the	   adult.	   Futhermore,	  work	   by	   the	   Zon	   lab	   suggested	   that	   Chd7	   regulates	   HSC	   induction	   in	   the	   zebrafish,	   as	   Chd7-­‐deficient	   progenitor	   cells	   transplanted	   into	   blastomeres	   induced	   less	   chimeric	   embryos	  compared	  to	  Ctrls	  (Huang	  HT,	  2010).	  These	   results	   suggested	   that	   Chd7	   may	   play	   a	   role	   in	   regulating	   hematopoiesis	   under	  competitive	  conditions.	  Therefore,	  we	  set	  out	  to	  study	  whether	  loss	  of	  Chd7	  renders	  HSCs	  more	  or	  less	  sensitive	  to	  stress	  conditions.	  This	  was	  performed	  in	  the	  5-­‐FU	  in	  vivo	  challenging	  system	  and	  by	  generation	  of	  primary	  and	  secondary	  competitive	  BM	  chimeras.	  	  	  
3.2.2.1 Chd7	  Deficiency	  does	  not	  render	  Hematopoietic	  Stem	  Cells	  more	  susceptible	  to	  5-­‐
FU-­‐mediated	  Exhaustion	  Hematopoietic	  stem	  cells	  posses	  the	  capacity	  to	  self-­‐renew	  but	  also	  to	  maintain	  homeostasis	  by	  differentiation	   in	   order	   to	   replenish	   the	   entire	   pool	   of	   all	   mature	   cell	   types	   in	   the	   blood	   in	  response	   to	   injury.	   The	   chemotherapeutic	   agent	   5-­‐FU	  depletes	   all	   cycling	   cells	  within	   the	  BM,	  thereby	  stimulating	  HSC	  proliferation	  (Lerner	  and	  Harrison,	  1990).	  Therefore,	  5-­‐FU	  is	  frequently	  administered	  to	  study	  HSC	  mobilization	  in	  response	  to	  stress	  in	  vivo.	  5-­‐FU	  was	  administered	  bi-­‐weekly	   in	  Chd7-­‐competent	   and	  Chd7-­‐deficient	   chimeras	   over	   a	   period	  of	   12	  days	   and	   animals	  were	  analysed	  for	  the	  HSC	  compartment.	  	  Chd7-­‐competent	  BM	  chimeras	  (n	  =	  10)	  had	  a	  median	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survival	  of	  11	  days	  as	  compared	  to	  Ctrl	  mice	  (n	  =	  10)	  with	  a	  10	  day-­‐median	  survival	  (Figure	  20	  A)	   demonstrating	   that	   Chd7	   deficiency	   does	   not	   confer	   a	   survival	   advantage	   in	   this	   in	   vivo	  challenging	   system.	   In	   response	   to	   5-­‐FU	   treatment,	   total	   BM	   cellularity	   (Figure	   20	  B)	   and	   the	  percentage	   of	   mobilized	   donor-­‐derived	   CD45.2+Lin-­‐CD117-­‐Sca1+	   HSCs	   (Figure	   20	   C)	   in	   Chd7-­‐deficient	  (n	  =	  4)	  and	  Ctrl	  (n	  =	  5)	  mice	  were	  comparable.	  	  	  
	  
Figure	  20:	  Chd7	  deficiency	  does	  not	   render	  hematopoietic	   stem	  cells	  more	   susceptible	   to	  exhaustion.	  Three	  weeks	  post	  MxCre	  induction	  Chd7lox/lox	  (Ctrl)	  and	  Chd7ΔMxCre	  mice	  were	  treated	  with	  5-­‐FU	  twice	  per	  week	  over	   12	   days.	   A,	   Kaplan-­‐Meier	   survival	   curve	   of	   5-­‐FU	   treated	   BM	   chimeras	   with	   Chd7ΔMxCre	   (n	   =	   10)	   mice	  depicted	  in	  blue	  and	  Ctrl	  (n	  =	  10)	  mice	  depicted	  in	  black.	  Arrows	  indicate	  5-­‐FU	  injections.	  Median	  survival	  was	  calculated	  using	  Log-­‐rank	  Mantel-­‐Cox	  test.	  B,	  Absolute	  number	  of	  total	  BM	  cells	  and	  C,	  Percentage	  of	  HSCs	  (KLS;	  Lin-­‐CD117+Sca1+)	  from	  control	  and	  indicated	  cKO	  mice.	  Error	  bars	  represent	  mean	  ±	  SD.	  	  Taken	   together,	   these	   data	   indicate	   that	   Chd7	   does	   not	   render	   HSCs	   more	   susceptible	   to	  exhaustion	  upon	  5-­‐FU	  mediated	  stress.	  	  
3.2.2.2 Chd7	  Deficiency	   does	   not	   render	  Hematopoietic	   Stem	   Cells	  more	   competent	   in	  
Primary	  Competitive	  BM	  Chimeras	  
Chd7	   deficiency	   did	   not	   affect	   the	   “fitness”	   of	   HSCs	   upon	   ablation	   of	   mature	   cycling	  hematopoietic	   lineages	   and	   the	   hereby-­‐induced	   mobilization	   of	   the	   quiescent	   HSC	   pool	   to	  replenish	  the	  blood	  system	  after	  repetitive	  5-­‐FU	  administration	  in	  vivo.	  To	  assess	  another	  form	  of	  stress,	  we	  investigated	  the	  ability	  of	  Chd7-­‐deficient	  BM	  cells	  to	  reconstitute	  the	  hematopoietic	  system	  under	   competitive	   conditions.	   Therefore,	   competitive	  BM	   chimeras	  were	   generated	  by	  mixing	   CD45.1+	  WT	   C57BL6/J	   BM	   cells	   with	   either	   CD45.2+	   Chd7ΔMxCre	   or	   Chd7lox/lox	   (Ctrl)	   BM	  cells	  in	  a	  3:1	  ratio	  and	  transplanting	  into	  lethally	  irradiated	  CD45.1+	  recipients	  (Figure	  21	  A)	  and	  the	   short-­‐term	  reconstitution	  was	  assessed	  8	  weeks	  post	   transplantation.	  DNA	   from	   input	  BM	  (Figure	   21	   B,	   left	   panel)	   and	   from	   BM	   of	   analysed	   chimeras	   (Figure	   21	   B,	   right	   panel)	   was	  analysed	  for	  the	  ratio	  of	  Chd7	  WT	  and	  Chd7-­‐deleted	  or	  Chd7lox/lox	  cells	  by	  PCR.	  Three	  to	  one	  ratio	  of	  WT	  versus	  Chd7-­‐competent	   or	  Chd7-­‐deficient	   hematopoietic	   reconstitution	  was	  maintained	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short-­‐term	  post	   transplantation	   (Figure	   21	   C)	   as	   indicated	   by	   the	   percentage	   CD45.2+	   cells	   in	  PBLs	  of	  chimeric	  mice.	  	  When	   analysing	   Chd7	   competitive	   BM	   chimeras,	   we	   focussed	   on	   the	   stem	   cell	   compartment	  given	   the	   importance	  of	  Chd7	   in	  regulating	   the	   transcriptional	  program	  in	  human	  neural	  crest	  derived	   stem	   cells	   and	   thereby	   enhancing	   migratory	   properties	   in	   these	   cells	   (Bajpai	   et	   al.,	  2010).	   Overall,	   the	   total	   BM	   cellularity	   of	   Chd7-­‐competent	   and	   Chd7-­‐deficient	   mixed	   BM	  chimeras	  was	  comparable	  (Ctrl	  =	  86.12	  ±	  5.04	  *	  106	  cells;	  Chd7ΔMxCre	  =	  87.13	  ±	  6.4	  *	  106	  cells,	  21	  D).	   Similarly,	   the	   percentage	   and	   absolute	   numbers	   of	   KLS	   (Lin-­‐CD117+Sca1+)	   remained	  comparable	  between	   these	   cohorts	   (21	  E).	   	   Subfractionation	  of	   the	  KLS	  compartment	   into	  LT-­‐HSCs	  (CD135-­‐CD34-­‐),	  ST-­‐HSCs	  (CD135-­‐CD34+)	  and	  MPPs	  (CD135+,	  CD34+)	  also	  demonstrated	  no	  apparent	   effect	   of	   Chd7	   deficiency	   on	   these	   subpopulations	   of	   the	   stem	   cell	   pool	   (21	   F).	   In	  addition,	   thymi	  of	   chimeric	  mice	  were	  analysed,	  however	  Chd7	   deficiency	  did	  not	   affect	  T	   cell	  development	  in	  these	  mice	  (data	  not	  shown).	  Taken	  together,	  these	  data	  indicate	  that	  Chd7	  does	  not	  confer	  any	  advantage	  or	  disadvantage	   in	  the	  short-­‐term	  repopulation	  of	   the	  hematopoietic	  system	  of	  lethally	  irradiated	  recipients	  in	  primary	  3:1	  competitive	  BM	  chimeras.	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Figure	   21:	   Chd7	   deficiency	   does	   not	   alter	   the	   short-­‐term	   repopulation	   capacity	   of	   HSCs	   under	  
competitive	  conditions	  in	  primary	  3:1	  mixed	  BM	  chimeras.	  A,	  Schematic	  representation	  of	  the	  generation	  of	  
Chd7ΔMxCre	  and	  Chd7lox/lox	  (Ctrl)	  3:1	  mixed	  BM	  chimeras.	  B,	  left	  panel,	  Deletion	  PCR	  analysis	  of	  input	  DNA	  pooled	  from	  total	  BM	  of	  either	  Ctrl	  or	  Chd7ΔMxCre	  mixed	  with	  CD45.1+	  WT	  BM,	  and	  right	  panel,	  Deletion	  PCR	  of	  output	  DNA	  from	  recipient	  3:1	  chimeras.	  C,	  Percentage	  of	  CD45.2+	  reconstitution	  in	  PBLs	  4	  weeks	  post	  ATBM.	  D,	  Total	  BM	   cellularity	   of	   3:1	   competitive	   chimeras.	   E,	   left	   panel,	   Representative	   FACS	   plots	   of	   CD45.2+	   Ctrl	   and	  
Chd7ΔMxCre	  KLS	  cells	  with	  right	  panel,	  absolute	  cell	  numbers	  depicted.	  F,	  left	  panel,	  Representative	  FACS	  plots	  of	   Ctrl	   and	   Chd7ΔMxCre	   LT-­‐HSCs	   (KLS,	   CD135-­‐CD34-­‐),	   ST-­‐HSCs	   (KLS,	   CD135-­‐CD34+)	   and	   MPPs	   (KLS,	  CD135+CD34+),	  with	  right	  panel,	  absolute	  cell	  numbers	  depicted.	  Chd7ΔMxCre	  :	  CD45.1+	  (n	  =	  9)	  and	  Ctrl	  :	  CD45.1+	  BM	  (n	  =	  8)	  cells	  were	  analysed	  8	  weeks	  post	  MxCre	  induction.	  Error	  bars	  represent	  mean	  ±	  SD.	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3.2.2.3 Chd7	  Deficiency	  does	  not	  affect	  HSCs	  in	  Secondary	  Competitive	  BM	  Chimeras	  	  We	  demonstrated	  that	  Chd7	  deficiency	  does	  not	  affect	  short-­‐term	  HSC	  reconstitutive	  capacity	  in	  primary	  mixed	  BM	  chimeras.	  However	  certain	  genes,	  such	  as	  p21,	  only	  functionally	  regulate	  HSC	  self-­‐renewal	   and	   multilineage	   reconstitution	   potential	   upon	   multiple	   rounds	   of	   serial	  transplantation	   (Siu	   et	   al.,	   2014).	   Therefore,	  we	  wanted	   to	   investigate	  whether	  Chd7	   ablation	  may	   affect	   HSC	   function	   upon	   serial	   transplantation	   as	   inducer	   of	   hematological	   stress.	  Secondary	  mixed	  BM	  chimeras	  were	  generated	  by	  pooling	  BM	  from	  Chd7ΔMxCre	  :	  CD45.1+	  (n	  =	  3)	  and	   Chd7lox/lox	   :	   CD45.1+	   (Ctrl,	   n	   =	   3)	   primary	   chimeras,	   which	   had	   similarly	   engrafted,	   and	  performed	  serial	  transplantation	  into	  lethally	  irradiated	  recipient	  mice	  (Figure	  22	  A).	  Successful	  engraftment	  of	  donor-­‐derived	  BM	  was	  monitored	  in	  PBLs	  4	  weeks	  post	  transplantation	  and	  the	  BM	   of	   chimeric	   mice	   was	   analysed	   focusing	   on	   the	   HSC	   compartment	   10	   weeks	   after	  transplantation.	  	  	  Deletion	  PCR	  analysis	  of	  input	  BM	  demonstrated	  the	  maintenance	  of	  3:1	  ratio	  of	  WT	  and	  deleted	  
Chd7	  or	  Chd7	  lox	  band	  at	  the	  time	  of	  transplantation	  (Figure	  22	  B)	  and	  flow	  cytometric	  analysis	  of	   CD45.2+	   donor-­‐derived	   cells	   confirmed	   similar	   reconstitution	   between	   Chd7ΔMxCre	   and	   Ctrl	  chimeras	  (Figure	  22	  C).	  	  No	   significant	   differences	   in	   (i)	   total	   BM	   cellularity	   (Figure	   22	   D),	   nor	   in	   (ii)	   the	   KLS	  compartment	   (Figure	   22	   E)	   were	   detected	   in	   Chd7-­‐competent	   and	   Chd7-­‐deficient	   secondary	  competitive	  BM	  chimeras.	  However,	  Chd7ΔMxCre	  secondary	  chimeras	  contained	  significantly	  more	  LT-­‐HSCs	   (KLS	   CD135-­‐CD34-­‐)	   compared	   to	   control	   chimeras	   (Figure	   22	   F)	   with	   Chd7ΔMxCre	  chimeras	  containing	  3.36	  ±	  1.08	  *	  104	  LT-­‐HSCs	  (n	  =	  7)	  compared	  to	  0.88	  ±	  0.15	  *	  104	  LT-­‐HSCs	  in	  control	   chimeras	   (n	   =	   8).	   This	   increase	   in	   LT-­‐HSCs	   did	   however	   not	   translate	   into	   significant	  differences	   for	   ST-­‐HSCs	   or	   MPPs,	   including	   more	   mature	   lineages	   such	   as	   T	   cells	   (data	   not	  shown).	  	  Taken	   together,	   our	   work	   suggests	   that	   Chd7	   does	   not	   play	   a	   major	   role	   in	   regulating	  hematopoiesis	   under	   normal	   and	   5FU-­‐mediated	   stress	   conditions	   and	   in	   competitive	  repopulation	   assays	   and	   if	   so,	   only	   under	   strong	   competition	   against	   C57BL6/J	   WT	   cells,	  however,	  without	  significant	  benefit	  for	  the	  recipient	  host.	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Figure	  22:	  Chd7	  deficiency	  does	  affect	  the	  short-­‐term	  repopulation	  capacity	  of	  HSCs	  under	  competitive	  
conditions	  in	  secondary	  mixed	  BM	  chimeras.	  A,	  Schematic	  representation	  of	  the	  generation	  of	  Chd7ΔMxCre	  and	  
Chd7lox/lox	  (Ctrl)	  secondary	  3:1	  mixed	  BM	  chimeras.	  B,	  Deletion	  PCR	  analysis	  of	  input	  DNA	  pooled	  from	  total	  BM	  of	  either	  Ctrl	  or	  Chd7ΔMxCre	  primary	  mixed	  BM	  chimeras.	  C,	  Percentage	  of	  CD45.2+	  reconstitution	  in	  PBLs	  4	  weeks	  post	   ATBM.	  D,	   Total	   BM	   cellularity	   of	   secondary	   3:1	   chimeras.	   E,	   left	   panel,	   Representative	   FACS	   plots	   of	  CD45.2+	   Ctrl	   and	   Chd7ΔMxCre	   KLS	   cells	   with	   right	   panel,	   absolute	   cell	   numbers	   depicted.	   F,	   left	   panel,	  Representative	  FACS	  plots	  of	  CD45.2+	  Ctrl	  and	  Chd7ΔMxCre	  LT-­‐HSCs	  (KLS,	  CD135-­‐CD34-­‐),	  ST-­‐HSCs	  (KLS,	  CD135-­‐CD34+)	  and	  MPPs	  (KLS,	  CD135+CD34+)	  with	  right	  panel,	  absolute	  cell	  numbers	  depicted.	  Chd7ΔMxCre	  :	  CD45.1+	  (n	  =	  7)	  and	  Ctrl	   :	  CD45.1+	   (n	  =	  8)	  BM	  cells	  were	  analysed	  10	  weeks	  post	  MxCre	   induction.	  Error	  bars	   represent	  mean	  ±	  SD	  (*	  p	  <	  0.05).	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3.3 Chd7	  Deficiency	  does	  not	  affect	  Notch1-­‐driven	  murine	  T-­‐ALL	  Previous	  work	  demonstrated	   that	  Chd7	   is	   highly	   expressed	   in	   late-­‐stage	  Notch1-­‐driven	  T-­‐ALL	  (RNIC+/ΔLckCre	   model)	   compared	   to	   non-­‐metastasizing	   pre-­‐malignant	   precursor	   T-­‐ALL	   	   cells	  (RNIC+/ΔMxCre	  model).	   A	   study	   by	  Bajpai	   et	   al.	   demonstrated	   that	   human	   neural	   crest	   like	   stem	  cells	   require	  CHD7	   for	  normal	  migration.	   If	   this	  Chd7	   function	  would	  also	  be	  conserved	   in	   the	  context	   of	   Notch-­‐driven	   T-­‐ALL,	   then	   Chd7	   could	   promote	   leukemic	   cell	   invasion	   into	   non-­‐hematopoietic	  tissues.	  To	  test	  this	  hypothesis,	  we	  first	  assessed	  Chd7	  expression	  levels	  in	  T-­‐ALL	  cells	  generated	  in	  the	  genetic	  RNIC+/ΔMxCre	  and	  RNIC+/ΔLckCre	  mouse	  models.	  	  In	  addition,	  we	  also	   studied	   the	   role	  of	  Chd7	  by	  LOF	  experiments	   in	  murine	  Notch1-­‐driven	  T-­‐ALL.	   These	   studies	   were	   performed	   using	   two	   different	   murine	   T-­‐ALL	   models:	   (i)	   the	   RNIC	  model,	   in	   which	   Chd7	   was	   initially	   identified	   and	   in	   (ii)	   a	   retroviral	   MigR1-­‐NICD	   BM	  transduction	  model.	  MxCre	  and	  CD4Cre	  transgenic	  mice	  were	  crossed	  into	  the	  retroviral	  T-­‐ALL	  transduction	   model	   to	   inactivate	   Chd7	   in	   either	   BM	   cells	   or	   at	   DN3b-­‐DN4	   stages	   of	   T	   cell	  maturation.	   MxCre	   and	   LckCre	   transgenic	  mice	   were	   crossed	   into	   the	   genetic	   RNIC	  model	   to	  ablate	   Chd7	   function	   in	   BM	   progenitors	   or	   in	   T	   cells	   at	   the	   earlier	   DN2-­‐DN3a	   stage	   of	   T	   cell	  development.	  	  
3.3.1 Chd7	  is	  highly	  expressed	  in	  murine	  Notch-­‐driven	  T-­‐ALL	  Microarray	  analysis	  performed	  on	  RNIC+/ΔMxCre	  versus	  RNIC+/ΔLckCre	  T-­‐ALL	  tumors	  demonstrated	  that	  Chd7	  was	  the	  highest	  over-­‐expressed	  gene	  in	  late	  stage	  T-­‐ALL	  tumors	  compared	  with	  early	  stage	   tumours	   (26-­‐fold	   increased	   expression,	   Figure	   23	   A,	   courtesy	   of	   Caroline	   Poisson).	  Therefore,	  we	  selected	  this	  candidate	   for	   in-­‐depth	   in	  vitro	  and	   in	  vivo	  validation.	   In	  agreement	  with	  previous	  findings,	  Chd7	  was	  highly	  up-­‐regulated	  in	  BM	  samples	  of	  T-­‐ALL-­‐bearing	  RNICΔLckCre	  mice	  and	  in	  cell	   lines	  generated	  from	  these	  mice	  compared	  to	  primary	  early	  stage	  RNICΔMxCre	  T-­‐ALL	  (Figure	  23	  B).	  While	  primary	  RNIC+/ΔLckCre-­‐derived	  leukemic	  cells	  showed	  a	  mean	  expression	  of	   26.12	   ±	   9.54	   FC	   compared	   and	   normalized	   to	   T-­‐ALL	   cells	   derived	   from	   pre-­‐malignant	  
RNIC+/ΔMxCre	  T-­‐ALL	  x(set	   to	  1),	   cultured	  murine	  T-­‐ALL	  cell	   lines	  derived	   from	   these	  mice	  had	  a	  mean	  FC	  Chd7	  expression	   of	   13.78	  ±	   4.80	   (Figure	   23	  B),	   suggesting	   that	  Chd7	   is	   expressed	   at	  higher	  levels	  in	  vivo	  than	  in	  vitro.	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Figure	   23:	  Chd7	   is	   highly	   expressed	   in	   aggressive	  metastasizing	   late	   stage	   versus	   early	   stage	  murine	  
Notch1-­‐driven	   T-­‐ALL.	   A,	   Top	   gene	   candidates	   up-­‐regulated	   in	   late	   (RNIC+/ΔLckCre)	   versus	   early	   stage	  (RNIC+/ΔMxCre)	  murine	  Notch1-­‐driven	  T-­‐ALL	  identified	  by	  PhD	  Caroline	  Poisson.	  B,	  Chd7	  relative	  gene	  expression	  assess	  by	  qRT-­‐PCR	  in	  cDNA	  derived	  from	  independent	  primary	  RNIC+/ΔLckCre	  T-­‐ALL	  cells	  and	  RNIC+/ΔLckCre-­‐derived	  cell	  lines	  compared	  to	  primary	  RNIC+/ΔMxCre	  T-­‐ALL	  cells	  isolated	  from	  BM.	  Error	  bars	  represent	  mean	  ±	  SD,	  n	  =	  3.	  	  Taken	  together,	  we	  confirmed	  over-­‐expression	  of	  Chd7	  in	  late-­‐stage	  T-­‐ALL	  tumors	  and	  therefore	  set	  out	  to	  study	  the	  role	  of	  Chd7	  in	  T-­‐ALL	  development	  in	  vivo.	  	  
3.3.2 Chd7	  Deficiency	  does	  not	  affect	  T-­‐ALL	  Initiation	  Aberrant	  Notch	  pathway	  activation	  is	  frequently	  observed	  in	  T-­‐ALL	  (Ellisen	  et	  al.,	  1991;	  Weng	  et	  al.,	  2004)	  and	  over-­‐expression	  of	  NICD	  via	  retroviral	  infection	  of	  BM	  progenitor	  cells	  leads	  to	  T-­‐ALL	  development	  with	  100%	  penetrance	  (Pear	  et	  al.,	  1996b).	  We	  utilized	  this	  well-­‐established	  T-­‐ALL	   induction	  model	   to	   assess	  whether	   conditional	   ablation	  of	  Chd7	  may	  have	  beneficial	   or	  detrimental	  effects	  on	  hematopoietic	  cells	  driven	  towards	  leukemia.	  	  
3.3.2.1 Chd7	  Deficiency	  does	  not	  affect	  T-­‐ALL	  Initiation	  in	  the	  Retroviral	  Chd7ΔMxCre	  NICD-­‐
NGFR	  Model	  Bone	  marrow	  of	  Chd7ΔMxCre	   or	  Chd7lox/lox	   (Ctrl)	  mice	  was	   harvested	   4	  weeks	   after	   induction	   of	  MxCre	   by	   administration	   of	   PIC	   and	   enrichment	   for	   lineage	   negative	   BM	   cells	  was	   performed	  using	  MACS	   technology.	  Chd7ΔMxCre	  or	  Ctrl	  Lin-­‐	  BM	  cells	  were	  retrovirally	   infected	  with	  MigR1-­‐NICD-­‐ires-­‐NGFR	   to	   induce	   stable	   expression	  of	  NICD	   fused	   to	   an	   internal	   ribosomal	   entry	   site	  followed	  by	  the	  cDNA	  encoding	  the	  Nerve	  Growth	  Factor	  Receptor	  (NGFR).	  Upon	  in	  vitro	  culture	  for	   three	   days,	   infected	   NICD-­‐expressing	   BM	   cells	   were	   transplanted	   into	   lethally	   irradiated	  recipient	   mice	   in	   order	   to	   give	   rise	   to	   T-­‐ALL	   (Figure	   24	   A).	   Chd7-­‐deficient	   NICD-­‐NGFR	   over-­‐expressing	  chimeras	  (n	  =	  5)	  had	  a	  median	  survival	  of	  79	  days	  compared	  with	  a	  67-­‐day	  median	  survival	  in	  Ctrl	  chimeras	  (n	  =	  7),	  indicating	  that	  Chd7	  does	  not	  impact	  on	  T-­‐ALL	  induction	  in	  this	  retroviral	  model	  (Figure	  24	  B).	  In	  addition,	  PCR	  analysis	  confirmed	  efficient	  deletion	  of	  Chd7	  in	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BM	   cells	   of	   tumor-­‐bearing	   chimeras	   (Figure	   24	   C).	   Flow	   cytometric	   analysis	   of	   CD45.2+NICD-­‐NGFR+	   T-­‐ALL	   cells	   revealed	   no	   phenotypic	   difference	   in	   CD4+	   CD8+	   cell	   surface	   expression	  between	   Chd7-­‐competent	   and	   Chd7-­‐deficient	   cells	   (Figure	   24	   D).	   Chd7-­‐competent	   and	   Chd7-­‐deficient	  BM	  progenitors	  over-­‐expressing	  NICD	  had	  comparable	  relative	  and	  absolute	  numbers	  of	  abnormal	  CD4+CD8+	  DP	  and	  CD8+	  SP	  cells	   in	  (i)	   the	  BM	  (Figure	  24	  E)	  and	   	  (ii)	   in	  peripheral	  organs	  such	  as	  the	  spleen	  (Figure	  24	  G).	  Similarly,	   total	  BM	  cellularity	  (Figure	  24	  F)	  as	  well	  as	  total	  splenic	  cellularity	  (Figure	  24	  H)	  was	  comparably	   increased	   in	  Chd7-­‐competent	  and	  Chd7-­‐deficient	  chimeras	  due	  to	  CD45.2+NGFR+	  T-­‐ALL	  cell	  expansion.	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Figure	  24:	  Chd7	  deficiency	  does	  not	  alter	  T-­‐ALL	   induction	   in	   the	  murine	  MxCre-­‐mediated	  MigR1-­‐NICD	  
model.	  A,	   Schematic	   representation	  of	  Chd7ΔMxCre	  MigR1-­‐NICD-­‐NGFR	  T-­‐ALL	   induction	  model.	  B,	  Kaplan-­‐Meier	  survival	   curve	   of	   Chd7ΔMxCre	   MigR1-­‐NICD-­‐NGFR	   chimeras	   (n	   =	   5)	   depicted	   in	   blue	   and	   Ctrl	   (n	   =	   7)	   chimeras	  depicted	  in	  black.	  Median	  survival	  was	  calculated	  using	  Log-­‐rank	  Mantel-­‐Cox	  test.	  C,	  Chd7	  deletion	  PCR	  analysis	  on	  BM	  cells	  from	  T-­‐ALL	  bearing	  mice.	  Representative	  FACS	  plots	  for	  cell	  surface	  expression	  of	  CD4	  and	  CD8	  in	  
Chd7ΔMxCre	  MigR1-­‐NICD-­‐NGFR	  and	  Ctrl	  T-­‐ALL	  cells	  in	  the	  BM	  and	  spleen	  (D).	  Bar	  diagrams	  depicting	  percentage	  of	  CD45.2+NGFR+	  T-­‐ALL	  cells	   in	  BM	  (E)	  and	  spleen	  (G).	  Total	  BM	  (F)	  and	  splenic	  (H)	  cellularity	  calculated	  for	  CD45.1+	  WT	  and	  CD45.2+NGFR+	  T-­‐ALL	  cells	  in	  chimeras.	  	  	  Collectively,	  these	  data	  demonstrate	  that	  loss	  of	  Chd7	  does	  not	  detectably	  influence	  induction	  of	  T-­‐ALL	  in	  the	  retroviral	  NICD	  BM	  transduction	  model	  using	  the	  MxCre	  deleter.	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3.3.2.2 Chd7	   Deficiency	   does	   not	   affect	   T-­‐ALL	   Initiation	   in	   the	   Retroviral	   Chd7ΔCD4Cre	  
NICD-­‐NGFR	  Model	  To	   test	   whether	   ablation	   of	   Chd7	   at	   a	   somewhat	   later	   developmental	   stage,	   once	   Notch	   has	  induced	   the	   development	   of	   pre-­‐leukemic	   cells,	   may	   influence	   disease	   outcome,	   we	   used	  
Chd7ΔCD4Cre	  transgenic	  mice.	  The	  CD4	  Cre	  recombinase	  is	  activated	  in	  thymic	  progenitor	  cells	  at	  the	  DN3b-­‐DN4	  stage	  of	  differentiation	  beyond	  the	  TCRβ	  checkpoint,	  up	  to	  which	  Notch	  signalling	  is	   required	   for	   T	   lineage	   specification.	   Crossing	   Chd7	   cKO	  mice	   with	   CD4Cre	   transgenic	  mice	  generated	   Chd7ΔCD4Cre	   and	   T-­‐ALL	   was	   induced	   in	   Chd7-­‐deficient	   and	   Ctrl	   cells	   via	   retroviral	  infection	  of	  BM	  progenitors	  with	  MigR1-­‐NICD-­‐NGFR	  as	  previously	  described	  (Figure	  25	  A).	  	  	  
Chd7ΔCD4Cre-­‐MigR1-­‐NICD	  chimeric	  mice	  (n	  =	  6)	  had	  a	  median	  survival	  of	  67.5	  days	  in	  comparison	  with	  74.5	  days	  in	  Ctrl	  chimeras	  (n	  =	  8,	  Figure	  25	  B).	  In	  addition,	  PCR	  analysis	  confirmed	  efficient	  deletion	  of	  Chd7	   in	  BM	  cells	  of	  T-­‐ALL-­‐bearing	  chimeras	  (Figure	  25	  C).	  Flow	  cytometric	  analysis	  of	  CD45.2+NICD-­‐NGFR+	  T-­‐ALL	   cells	   revealed	  no	  phenotypic	  difference	  between	  CD4+	  CD8+	   cell	  surface	   expression	   on	   Chd7-­‐competent	   and	   Chd7-­‐deficient	   T-­‐ALL	   cells	   in	   the	   BM	   and	   spleen	  (Figure	  25	  D).	  Comparable	  expansion	  of	  abnormal	  CD4+CD8+	  DP	  and	  CD8+	  SP	  cells	  in	  (i)	  the	  BM	  (Figure	  25	  E)	  and	  (ii)	  in	  the	  spleen	  (Figure	  25	  G)	  was	  observed	  in	  both	  cohorts.	  Similarly,	  total	  BM	  cellularity	   (Figure	  25	  F)	  as	  well	  as	   total	  splenic	  cellularity	   (Figure	  25	  H)	  were	  comparably	  increased	   in	   Chd7-­‐competent	   and	   Chd7-­‐deficient	   chimeras	   due	   to	   CD45.2+NGFR+	   T-­‐ALL	   cell	  expansion.	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Figure	  25:	  Chd7	  deficiency	  does	  not	  alter	  T-­‐ALL	  induction	  in	  the	  murine	  CD4Cre-­‐mediated	  MigR1-­‐NICD	  
model.	  A,	  Schematic	  representation	  of	  Chd7ΔCD4Cre	  MigR1-­‐NICD-­‐NGFR	  T-­‐ALL	  induction	  model.	  B,	  Kaplan-­‐Meier	  survival	   curve	  of	  Chd7ΔCD4Cre	  MigR1-­‐NICD-­‐NGFR	  chimeras	   (n	  =	  6)	  depicted	   in	  green	  and	  Ctrl	   (n	  =	  8)	   chimeras	  depicted	  in	  black.	  Median	  survival	  was	  calculated	  using	  Log-­‐rank	  Mantel-­‐Cox	  test.	  C,	  Chd7	  deletion	  PCR	  analysis	  on	  BM	  cells	  from	  T-­‐ALL	  bearing	  mice.	  Representative	  FACS	  plots	  for	  cell	  surface	  expression	  of	  CD4	  and	  CD8	  in	  
Chd7ΔCD4Cre	  MigR1-­‐NICD-­‐NGFR	  and	  Ctrl	  T-­‐ALL	  cells	  in	  the	  BM	  and	  spleen	  (D).	  Bar	  diagrams	  depicting	  percentage	  of	  CD45.2+NGFR+	  T-­‐ALL	  cells	   in	  BM	  (E)	  and	  spleen	  (G).	  Total	  BM	  (F)	  and	  splenic	  (H)	  cellularity	  calculated	  for	  CD45.1+	  WT	  and	  CD45.2+NGFR+	  T-­‐ALL	  cells	  in	  chimeras.	  	  	  Taken	  together,	  these	  data	  suggest	  that	  Chd7	  does	  not	  influence	  T-­‐ALL	  initiation	  when	  deleted	  in	  thymic	  progenitor	  cells	  at	  the	  DN3b-­‐DN4	  stage	  of	  maturation.	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3.3.2.3 Chd7	  Deficiency	  does	  not	  affect	  T-­‐ALL	  initiation	  in	  the	  Genetic	  MxCre	  or	  LckCre-­‐
driven	  RNIC	  Chd7	  Models	  Chd7	  was	   originally	   identified	   in	   the	   genetic	   RNIC	   T-­‐ALL	  model,	  which	   differs	   from	   the	  NICD	  retrovirally	   induced	  T-­‐ALL	  model	  as	  NICD	   is	  expressed	   from	  the	  Rosa26	   locus.	  To	  exclude	   the	  possibility	   that	  we	  missed	   a	   possible	   Chd7	   function	   due	   to	   the	   experimental	   system	  used,	  we	  also	   performed	   Chd7	   LOF	   experiments	   using	   the	   genetic	   RNIC	   T-­‐ALL	   model.	   Therefore,	   we	  generated	  the	  Chd7lox/lox	  RNIC+/ΔMxCre	  (early	  stage	  T-­‐ALL)	  and	  Chd7lox/lox	  RNIC+/ΔLckCre	  (late-­‐stage	  T-­‐ALL)	  mice.	  	  	  Bone	   marrow	   chimeras	   reconstituted	   with	   RNIC+/ΔChd7ΔMxCre	   BM	   were	   generated	   to	  simultaneously	  over-­‐express	  NICD	  and	  delete	  Chd7	  within	  the	  BM	  compartment	  (Figure	  26	  A).	  PIC-­‐mediated	  MxCre	   activation	   led	   to	   T-­‐ALL	   development	   in	   both	  Chd7-­‐competent	   and	  Chd7-­‐deficient	   mice.	   However,	   no	   significant	   difference	   in	   the	   overall	   survival	   of	   T-­‐ALL-­‐bearing	  chimeras	  was	  found	  with	  RNIC+/ΔChd7ΔMxCre	  mice	  exhibiting	  a	  median	  survival	  of	  105	  days	  (n	  =	  9)	  and	  RNIC+/ΔMxCre	  mice	  a	  median	  survival	  of	  95	  days	  (n	  =	  7),	  Figure	  26	  B.	  	  	  
	  
Figure	  26:	  A,	   Schematic	  representation	  of	  RNIC+/ΔChd7ΔMxCre	  T-­‐ALL	   induction	  model.	  B,	  Kaplan-­‐Meier	  survival	  curve	   of	   RNIC+/ΔChd7ΔMxCre	   chimeras	   (n	   =	   7)	   depicted	   in	   blue	   and	   Ctrl	   (n	   =	   9)	   chimeras	   shown	   in	   black.	   C,	  Schematic	   representation	   of	   the	  RNIC+/ΔChd7ΔCD4Cre	   T-­‐ALL	   induction	  model.	  D,	   Kaplan-­‐Meier	   survival	   curve	   of	  
RNIC+/ΔChd7ΔCD4Cre	   tumor	  mice	  (n	  =	  17)	  depicted	   in	  red	  and	  Ctrl	   (n	  =	  7)	  mice	  shown	  in	  black.	  Median	  survival	  was	  calculated	  using	  Log-­‐rank	  Mantel-­‐Cox	  test.	  	  T-­‐ALL	   development	   in	   the	   RNIC+/ΔChd7ΔLckCre	   model	   was	   monitored	   in	   the	   non-­‐chimeric	  (physiological)	   setting	   (Figure	  26	  C),	   since	  activation	  of	   the	  LckCre	  deleter	   is	   restricted	   to	   the	  thymic	   compartment.	   Median	   survival	   of	   both	   cohorts	   was	   not	   significantly	   altered	   by	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conditional	  ablation	  of	  Chd7	  (Ctrl	  =	  131	  days,	  n	  =	  7	  and	  RNIC+/ΔChd7ΔLckCre	  =	  117	  days,	  n	  =	  17)	  as	  shown	  in	  Figure	  26	  D.	  In	   summary,	   we	   have	   shown	   that	   conditional	   deletion	   of	   Chd7	   in	   NICD-­‐over-­‐expressing	   BM	  progenitors,	  as	  well	  as	  in	  thymic	  progenitors	  at	  the	  DN2-­‐DN3a	  stage	  of	  differentiation,	  does	  not	  impact	   on	   T-­‐ALL	   development.	   This	   observation	   raises	   the	   question	   whether	   Chd7	   may	   be	  compensated	   by	   other	   members	   of	   the	   Chd	   family	   of	   chromatin	   remodellers	   or	   may	   be	   up-­‐regulated	   in	   late-­‐stage	   T-­‐ALL	   tumors	   as	   a	   defense	   mechanism	   in	   order	   to	   counteract	  leukemogenic	  cues	  induced	  by	  NICD.	  	  	  
3.4 Chd7	  Deficiency	  does	  not	  affect	  Notch1-­‐driven	  human	  T-­‐ALL	  Although	  our	  studies	  using	  mouse	  models	  of	  T-­‐ALL	  did	  not	  indicate	  a	  major	  contribution	  of	  Chd7	  in	   Notch-­‐driven	   T-­‐ALL	   development,	   its	   putative	   role	   in	   human	   T-­‐ALL	   remained	   to	   be	  investigated.	  	  	  
3.4.1 Chd7	  is	  expressed	  in	  human	  T-­‐ALL	  cells	  Several	  human	  T-­‐ALL	  cell	   lines	  that	  harbor	  Notch	  activating	  mutations	  such	  as	  KOPTK1,	  RPMI,	  HPB-­‐ALL,	  DND41,	  T-­‐ALL1	  and	  CUTL1	  were	  screened	  for	  the	  expression	  of	  CHD7	  mRNA	  (Figure	  27	  A)	  and	  protein	  (Figure	  27	  B).	  CHD7	  expression	  was	  detected	  in	  HPB-­‐ALL,	  DND41	  and	  CUTL1	  cell	  lines,	  with	  HPB-­‐ALL	  showing	  least	  and	  CUTL1	  showing	  highest	  expression.	  In	  contrast,	  CHD7	  was	  expressed	  at	  very	   low	  levels	   in	  KOPTK1	  and	  RPMI	  cells,	  as	  depicted	   in	  Figure	  27	  A.	  CHD7	  was	  also	  expressed	  in	  the	  Notch-­‐independent	  B	  lymphocyte-­‐derived	  cell	  line,	  Raji,	  at	  the	  mRNA	  but	  not	  at	  the	  protein	  level,	  indicating	  that	  CHD7	  expression	  can	  be	  regulated	  independently	  of	  Notch	  signaling.	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Figure	  27:	  CHD7	   is	  expressed	   in	  human	  T-­‐ALL	  cells	  at	  different	   levels.	  A,	  Quantitative	  RT-­‐PCR	   for	  CHD7	  expression	  levels	  in	  human	  T-­‐ALL	  cell	   lines	  KOPTK1,	  RPMI,	  HPB-­‐ALL,	  DND41,	  T-­‐ALL1	  and	  CUTL1.	  The	  Notch-­‐independent	   B	   cell	   line	   Raji	   served	   as	   internal	   control.	   B,	   Representative	   western	   blot	   for	   CHD7	   (300	   kD)	  expression	  in	  human	  T-­‐ALL	  cell	  lines.	  Tata-­‐box	  binding	  protein	  (TBP;	  55	  kD)	  served	  as	  internal	  loading	  control	  for	  nuclear	  proteins.	  	  
3.4.2 Chd7	  does	  not	  regulate	  Cell	  Cycle,	  Apoptotis	  or	  Proliferation	  of	  human	  
T-­‐ALL	  cells	  
Chd7	   was	   identified	   as	   highly	   up-­‐regulated	   gene	   in	   late-­‐stage	   versus	   pre-­‐malignant	   Notch	   –driven	  murine	  T-­‐ALL	   and	  we	  hence	  wanted	   to	   address	  whether	  CHD7	   deficiency	  would	   affect	  survival	   and	   growth	   of	   established	   human	   T-­‐ALL	   cell	   lines,	   which	  more	   closely	   resemble	   the	  human	  cancer	   situation.	   Since	  CHD7	  was	  most	   abundantly	   expressed	   in	  HPB-­‐ALL,	  DND41	  and	  CUTL1	  T-­‐ALL	  cells,	   these	  Notch-­‐dependent	  cell	   lines	  were	  selected	   to	  study	   the	  effect	  of	  CHD7	  LOF	  on	  human	  T-­‐ALL	  cell	  lines	  in	  vitro.	  CHD7	  KD	  was	  performed	  using	  either	  (i)	  a	  non-­‐inducible	  shRNA	   lentiviral	   vector	   in	  HPB-­‐ALL	   cells	   or	   (ii)	   a	   doxycycline-­‐inducible	  RFP+	   shRNA	   lentiviral	  vector	  in	  DND41	  and	  CUTL1	  cells	  that	  both	  specifically	  target	  CHD7	  mRNA	  for	  degradation.	  	  DND41	  cells	  showed	  most	  efficient	  CHD7	  KD	  in	  presence	  of	  doxycycline	  with	  25%	  residual	  CHD7	  levels,	  whereas	  CHD7	  mRNA	  could	  only	  be	  reduced	  to	  about	  40%	  in	  HPB-­‐ALL	  and	  50%	  in	  CUTL1	  (Figure	   28	   A).	   These	   results	  were	   confirmed	   by	   the	   reduction	   in	   CHD7	   protein	   expression	   in	  treated	  HPB-­‐ALL	  and	  CUTL1	  cell	  lines	  (Figure	  28	  B).	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Figure	  28:	  CHD7	  knock	  down	  in	  human	  T-­‐ALL	  cell	  lines	  HPB-­‐ALL,	  DND41	  and	  CUTL1.	  A,	  Quantitative	  RT-­‐PCR	   for	  CHD7	   expression	   in	   human	   T-­‐ALL	   cell	   lines	   HPB-­‐ALL,	   DND41	   and	   RPMI	   stably	   expressing	   lentiviral	  shRNA	  constructs.	  B,	  Representative	  western	  blot	  for	  CHD7	  (300	  kD)	  expression	  in	  human	  T-­‐ALL	  cell	  lines	  HPB-­‐ALL	  and	  CUTL1	  expressing	   shCtrl	   or	   shCHD7	   lentiviral	   vectors	  one	  week	  post	  puromycin	   selection.	  Tata-­‐box	  binding	  protein	  (TBP;	  55	  kD)	  served	  as	  internal	  loading	  control	  for	  nuclear	  proteins.	  	  In	  order	  to	  test	  to	  functional	  outcome	  of	  CHD7	  KD	  we	  synchronized	  the	  cells	  by	  serum	  starvation	  and	  performed	  apoptosis	  and	  cell	  cycle	  analysis	  over	  a	  time	  course	  of	  5	  to	  7	  days	  after	  release	  into	  serum-­‐containing	  medium.	  	  No	  significant	  differences	   in	   i)	   the	  percentage	   (Figure	  29	  B),	  nor	   in	   ii)	   the	  absolute	  number	  of	  apoptotic	   cells	   (Annexin-­‐V+7AAD+/-­‐	   cells)	  was	  observed	   in	  all	   three	  studied	  CHD7	  KD	  cell	   lines	  (Figure	   29	   C-­‐E)	   over	   a	   time	   course	   of	   5	   or	   7	   days	   respectively	   post	   synchronization.	   The	   cell	  cycle	  of	  DND41	  and	  CUTL1	  cells	  was	  unperturbed	  by	  CHD7	  KD	  (Figure	  29	  I,	  J).	  shRNA-­‐mediated	  KD	   of	   CHD7	   in	   HPB-­‐ALL	   cells	   caused	   a	   transient	   G1	   arrest	   at	   early	   time	   points	   post	  synchronization	  (Figure	  29	  G	  &	  H).	  However,	  similar	  to	  DND41	  and	  CUTL1	  cell	   lines,	  CHD7	  KD	  did	  not	  significantly	  impair	  the	  proliferation	  of	  HPB-­‐ALL	  cells	  over	  time	  (Figure	  29	  K-­‐M).	  	  	  
Results	  –	  Part	  I:	  Role	  of	  Chd7	  in	  Hematopoiesis	  &	  T-­‐ALL	   57	  
	  
Figure	  29:	  CHD7	  knock	  down	  does	  not	  alter	  apoptosis,	   cell	   cycle	  or	  proliferation	   in	  human	  T-­‐ALL	  cell	  
lines	   HPB-­‐ALL,	   DND41	   and	   CUTL1.	   A,	   Gating	   strategy	   to	   distinguish	   live	   from	   early	   apoptotic	   and	   late	  apoptotic	  cells.	  B,	  Representative	  FACS	  plots	  depicting	  Annexin-­‐V	  versus	  7-­‐AAD	  staining	  in	  HPB-­‐ALL	  cells	  stably	  expressing	  shCHD7	  or	  shCtrl	  (Ctrl)	  at	  2	  days	  post	  synchronisation.	  Percentage	  of	  apoptotic	  cells	  in	  HPB-­‐ALL	  (C),	  DND41	  (D)	  and	  CUTL1	  (E)	  CHD7	  knock	  down	  cells	  compared	  to	  ctrl.	  F,	  Gating	  strategy	  to	  identify	  cells	  in	  G0,	  G1	  and	  S/G2/M	  cell	  cycle	  phases	  G,	  Representative	  FACS	  plots	  depicting	  staining	  for	  Ki-­‐67	  versus	  Hoechst	  in	  HPB-­‐ALL	  cells	  stably	  expressing	  shCHD7	  or	  shCtrl.	  Quantification	  of	  cell	  cycle	  kinetics	  in	  HPB-­‐ALL	  (H),	  DND41	  (I)	  and	  CUTL1	  (J)	  CHD7	  knock	  down	  cells	  over	  5	  or	  7	  days	  respectively.	  Proliferation	  of	  HPB-­‐ALL	  (K),	  DND41	  (L)	  and	  CUTL1	   (M)	   cells,	   stably	   expressing	   shCtrl	   and	   shCHD7	   shRNAs,	   measured	   by	   Alamar	   Blue	   assay.	   Error	   bars	  represent	  mean	  ±	  SD,	  n	  =	  3.	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Overall,	  these	  data	  indicate	  that	  KD	  of	  CHD7	  does	  not	  affect	  (i)	  the	  viability,	  (ii)	  the	  cell	  cycle	  or	  (iii)	   the	   growth	   of	   human	   T-­‐ALL	   cell	   lines.	   Therefore,	   in	   conclusion,	   CHD7	   does	   not	   seem	   to	  majorly	  affect	  the	  maintenance	  of	  established	  human	  T-­‐ALL	  cells	  lines.	  	  	  	  
	  4 Discussion	  Part	  I:	  Role	  of	  Chd7	  in	  Hematopoiesis	  &	  
T-­‐ALL	  
4.1 Validation	  of	  Potential	  Mediators	  cooperating	  with	  Notch1	  in	  
T-­‐ALL	  Aberrant	  Notch	  pathway	  activation	  was	  firstly	  linked	  to	  T-­‐ALL	  in	  1987,	  when	  the	  chromosomal	  translocation	  t(7;9),	  leading	  to	  expression	  of	  NICD	  under	  the	  control	  of	  	  the	  TCRβ	  enhancer,	  was	  identified	   in	   a	   small	   subset	   of	   T-­‐ALL	   patients	   (Ellisen	   et	   al.,	   1991;	   Reynolds	   et	   al.,	   1987).	  Furthermore,	  it	  was	  experimentally	  demonstrated	  that	  NICD	  overexpression	  in	  BM	  progenitors	  induces	  T-­‐ALL	  upon	  transplantation	   into	   lethally	   irradiated	  recipient	  mice	  (Pear	  et	  al.,	  1996b).	  	  The	   land	   marking	   study	   by	   Weng	   et	   al.	   identified	   activating	   mutations	   in	   the	   HD	   and	   PEST	  domain	  of	  N1,	  thereby	  initiating	  ligand-­‐independent	  signalling	  and	  delayed	  decoy	  of	  NICD,	  when	  sequencing	   96	   primary	   human	   T-­‐ALL	   samples	   and	   T-­‐ALL	   cell	   lines.	   This	   provided	   further	  evidence	   that	   hyperactivated	   Notch	   signalling	   is	   strongly	   linked	   to	   T-­‐ALL	   and	   proposes	   the	  Notch	  pathway	  as	  therapeutic	  target	  in	  this	  malignancy	  (Weng	  et	  al.,	  2004).	  A	  previous	  research	  project	  in	  the	  lab	  aimed	  at	  identifying	  genes	  that	  would	  cooperate	  with	  N1	  in	  the	  transformation	  of	  T	  cell	  progenitors	  to	  give	  rise	  to	  aggressive	  metastatic	  T-­‐ALL.	  Therefore,	  mouse	  models	  have	  been	  generated	  to	  specifically	  over-­‐express	  NICD	  at	  different	  stages	  of	  T	  cell	  maturation	  with	   the	   outcome	   that	   targeted	   BM	   progenitors	   give	   rise	   to	   pre-­‐malignant	   T-­‐ALL,	  while	  only	  DN2-­‐DN3a	  thymocytes	  are	  fully	  responsive	  to	  oncogenic	  Notch	  and	  give	  rise	  to	  late-­‐stage	  T-­‐ALL.	  Performing	  microarray	  based	  screening,	   the	  chromatin	  remodelling	  enzyme	  Chd7	  was	   identified	   as	   highly	   up-­‐regulated	   gene	   in	   late	   stage	   metastatic	   N1-­‐driven	   T-­‐ALL	  (RNIC+/ΔLckCre)	  compared	  to	  early	  stage	  pre-­‐malignant	  T-­‐ALL	  (RNIC+/ΔLckCre).	  	  Aim	  of	  my	  thesis	  was	  the	  validation	  of	  this	  gene	  candidate	  in	  the	  context	  of	  T-­‐ALL	  development	  and	  normal	  hematopoiesis.	  When	  initiating	  the	  project,	  Chd7	  had	  not	  been	  functionally	  studied	  in	  the	  context	  of	  cancer.	  However,	  one	  study	  (Pleasance	  et	  al.,	  2010)	  identified	  a	  duplication	  in	  the	   CHD7	   locus	   and	   the	   occurrence	   of	   two	   PVT1-­‐CHD7	   fusion	   genes	   when	   screening	   human	  small-­‐cell	   lung	   cancer	   cells	   for	   mutations	   via	   next-­‐generation	   sequencing.	   This	   was	   the	   first	  study,	   linking	   aberrant	   expression	   of	   CHD7	   with	   tobacco	   exposure-­‐induced	   development	   of	  small-­‐cell	   lung	  cancer.	  Only	  recently,	  Colbert	  et	  al.	  reported	  Chd7	  overexpression	  in	  pancreatic	  cancer	   and	   therefore	   proposed	   Chd7	   as	   a	   potential	   biomarker	   (Colbert	   et	   al.,	   2014).	   We	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demonstrated	  that	  Chd7	  was	  26-­‐fold	  higher	  expressed	  in	  late-­‐stage	  versus	  pre-­‐malignant	  T-­‐ALL	  (Poisson,	  2011)	  and	  confirmed	  these	  data	  when	  screening	  independent	  primary	  murine	  T-­‐ALL	  samples	   derived	   from	   the	  RNIC+/ΔLckCre	   and	  RNIC+/ΔMxCre	  models.	   Furthermore,	  Chd7	   expression	  was	   still	   elevated	   in	  murine	   cell	   lines	  derived	   from	   the	   same	  genetic	  T-­‐ALL	   induction	  models.	  Therefore,	  during	  T-­‐ALL	  progression	  Chd7	  may	  similarly	  be	  proposed	  as	  biomarker	  to	  delineate	  stage	  and	  severity	  of	  T-­‐ALL.	  We	  did	  not	  identify	  Chd7	  up-­‐regulation	  in	  pre-­‐malignant	  RNIC+/ΔMxCre	  T-­‐ALL	   versus	   physiological	   immature	   CD4+CD8+	   DP	   T	   cells,	   suggesting	   that	   Chd7	   expression	  and/or	  function	  may	  be	  correlated	  with	  only	  later	  events	  during	  leukemogenesis.	  This	  rules	  out	  that	   Chd7	   expression	   may	   be	   applicable	   as	   biomarker	   during	   early	   stage	   T-­‐ALL.	   Colbert	   and	  colleagues	  published	  that	  Chd7	  ablation	  sensitizes	  pancreatic	  tumors	  to	  gemcitabine	  treatment	  (Colbert	  et	  al.,	  2014).	  Therefore,	  Chd7	  inactivation	  or	  silencing	  by	  inhibiting	  its	  ATPase	  function	  with	  a	  competitive	   inhibitor	  may	  have	  additive	  effects	   to	  conventional	  chemotherapy	   in	  T-­‐ALL	  patients.	  However,	   this	   is	   purely	   speculative,	   since	  we	  did	   not	   use	   chemotherapeutic	   drugs	   in	  order	  to	  perform	  and	  test	  different	  treatment	  regimens	  in	  our	  murine	  N1-­‐driven	  T-­‐ALL	  models.	  In	  addition,	  Chd7	  function	  in	  cancer	  progression	  in	  solid	  pancreatic	  ductal	  adenoma	  carcinomas	  may	  be	  strikingly	  different	  compared	  to	  downstream	  effects	  of	  Notch	  during	  leukemogenesis.	  	  
4.2 Functional	  Characterization	  of	  Chd7	  in	  Hematopoiesis	  Epigenetic	  regulators	  such	  as	  chromatin	  remodelling	  enzymes	  can	  modulate	  gene	  transcription	  beyond	  the	  information	  encoded	  in	  the	  DNA.	  They	  are	  powerful	  enzymes,	  which	  slide	  nucleomes	  along	   the	   DNA,	   thereby	   compacting	   chromatin	   into	   heterochromatin	   or	   opening	   it	   up	   into	  euchromatin,	   which	   is	   accessible	   for	   transcription	   machinery.	   CHD7	   is	   strongly	   linked	   to	  CHARGE	   syndrome	   (Vissers	   et	   al.,	   2004),	   in	   which	   loss	   of	   one	   functional	   CHD7	   allele	   affects	  multiple	   organs,	   such	   as	   the	   eye,	   the	   ear,	   the	   heart	   as	  well	   as	   the	   genital	   and	   urinary	   tract.	   A	  minority	   of	   CHARGE	   syndrome	   patients	   were	   reported	   to	   suffer	   from	   congenital	   T	   cell	  immunodeficiency	   (Chopra	   et	   al.,	   2009;	   Hoover-­‐Fong	   et	   al.,	   2009),	   suggesting	   that	   CHD7	  may	  regulate	  adaptive	  T-­‐cell	  mediated	   immune	  responses	   in	  these	  patients.	  However,	   these	  studies	  are	   only	   descriptive	   case	   reports,	   not	   delineating	   any	   functional	   impact	   of	   CHD7	   on	   T	   cell	  biology.	   Preliminary	   data	   generated	   by	   the	   Zon	   and	   Speck	   labs	   postulated	   a	   role	   for	   Chd7	  hematopoiesis.	   In	   zebrafish,	   Chd7-­‐deficient	   HSCs	   gave	   rise	   to	   more	   chimeric	   embryos	   upon	  transplantation	   into	   blastomeres	   compared	   to	   Chd7-­‐competent	   HSCs,	   suggesting	   that	   Chd7	  suppresses	   HSC	   formation	   during	   zebrafish	   embryogenesis	   (Huang	   HT,	   2010).	   In	   contrast,	  Nancy	  Speck	  demonstrated	  that	  VavCre-­‐mediated	  Chd7	   inactivation	  does	  not	   lead	  to	  any	  overt	  phenotype	  in	  the	  BM.	  However,	  under	  competitive	  conditions	  Chd7-­‐deficiency	  led	  to	  increased	  T	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cell	  numbers	  as	  studied	  in	  serial	  transplantation	  experiments	  (Hsu	  J,	  2011).	  We	  studied	  MxCre-­‐mediated	   Chd7	   ablation	   in	   BM	   progenitors,	   which	   in	   contrast	   to	   VavCre,	   is	   activated	   after	  embryogenesis.	   We	   did	   not	   observe	   any	   lineage	   specification	   defects	   in	   HSC	   or	   mature	  hematopoietic	  lineages,	  which	  supports	  the	  findings	  by	  Nancy	  Speck.	  Upon	  analysis	  of	  the	  T	  cell	  compartment,	   we	   did	   not	   observe	   abnormal	   accumulation	   of	   DN1	   thymic	   progenitors	   nor	  ectopic	  accumulation	  of	  B	  cells	  in	  the	  thymus	  as	  described	  for	  N1	  LOF	  (Radtke	  et	  al.,	  1999).	  Upon	  analysis	  of	  the	  spleen,	  Chd7ΔMxCre	  MZB	  cell	  numbers	  were	  comparable	  to	  control,	  indicating	  that	  
Chd7	  deficiency	  does	  not	  phenocopy	  N2	  LOF	  (Saito	  et	  al.,	  2003).	  Upon	  serial	  transplantation	  of	  BM	  from	  competitive	  Chd7-­‐deficient	  and	  Chd7-­‐competent	  chimeras,	  similarly	  the	  HSC	  and	  T	  cell	  compartment	   were	   not	   significantly	   affected.	   However,	   in	   secondary	   chimeras	   numbers	   of	  CD45.2+LT-­‐HSCs	  were	   slightly	   increased	   in	  Chd7ΔMxCre	   chimeras	   compared	   to	   controls	   but	   this	  did	  not	  translate	  into	  any	  competitive	  advantage	  during	  multi-­‐lineage	  reconstitution.	  	  Therefore,	  Chd7	   does	   not	   play	   a	   role	   in	   regulating	   hematopoiesis	   under	   “steady	   state”	   or	   competitive	  conditions	   studied	   in	   this	   thesis.	   However,	   we	   cannot	   rule	   out	   a	   potential	   compensatory	  mechanism	   by	   the	   other	   8	  members	   of	   the	   CHD	   family	   of	   chromatin	   remodellers,	   in	   order	   to	  counter-­‐balance	  a	  putative	  hematopoietic	  transcriptional	  program	  in	  absence	  of	  Chd7.	  	  
4.3 Chd7	  does	  not	  affect	  Notch1-­‐driven	  murine	  T-­‐ALL	  Bajpai	  et	  al.	  demonstrated	  that	  CHD7	  is	  essential	  during	  the	  formation	  of	  multipotent	  migratory	  neural	   crest	   cells	   in	  both	  humans	  and	  Xenopus	   (Bajpai	   et	   al.,	   2010).	  This	   transient	  ectodermal	  cell	  population	  is	  transcriptionally	  reprogrammed	  by	  CHD7	  in	  order	  to	  differentiate	  and	  migrate	  throughout	   the	  body	   to	   form	   the	  peripheral	  nervous	   system,	   craniofacial	   bones	  and	   cartilages	  and	   cardicac	   structures.	   During	   this	   developmental	   process,	   CHD7	   was	   demonstrated	   to	  cooperate	  with	   the	   transcription	   factors	   SOX9,	  TWIST	  and	  SLUG.	  TWIST	  and	  SLUG	  are	  known	  mediators	   of	   the	   epithelial-­‐to-­‐mesenchymal	   transition	   (EMT),	   a	   process	   often	   aberrantly	  activated	  during	  tumor	  cell	  invasion	  (De	  Craene	  and	  Berx,	  2013).	  Therefore,	  we	  speculated	  that	  Chd7	  may	  render	   leukemic	  cells	  more	  aggressive	  and	  enhance	  their	   invasion	  properties	   in	  our	  Notch1-­‐driven	   T-­‐ALL	   models.	   Consequently,	   we	   addressed	   the	   question,	   whether	   conditional	  inactivation	  of	  Chd7	   in	  murine	  models	  of	  Notch1-­‐driven	  T-­‐ALL	  may	  affect	  development	  of	   this	  disease.	  Therefore,	  we	  studied	  the	  absence	  of	  Chd7	   in	  the	  (i)	  retroviral	  T-­‐ALL	  induction	  model,	  using	  the	  BM-­‐specific	  MxCre	  and	  the	  thymus-­‐specific	  CD4Cre	  and	  in	  (ii)	  the	  genetic	  RNIC	  T-­‐ALL	  induction	   model,	   in	   which	   Chd7	   had	   been	   originally	   identified.	   Retroviral	   transformation	   of	  
Chd7-­‐deficient	   BM	   progenitors	  with	  MigR1-­‐NICD	   and	   subsequent	   transplantation	   into	   lethally	  irradiated	  recipient	  mice	  (Chd7ΔMxCre	  MigR1-­‐NICD	  induction	  model)	  did	  not	  confer	  any	  survival	  
Discussion	  Part	  I:	  Role	  of	  Chd7	  in	  Hematopoiesis	  &	  T-­‐ALL	   62	  
advantage	  or	  disadvantage	  to	  the	  recipient	  mice	  but	  demonstrated	  similar	  T-­‐ALL	  development.	  Phenotypically,	   Chd7-­‐competent	   and	   Chd7-­‐deficient	   T-­‐ALLs	   were	   comparable	   with	   the	  expansion	   of	   CD45.2+NGFR+CD4+CD8+	   DP	   cells	   within	   the	   BM	   and	   the	   spleen.	   Similarly,	   over-­‐expression	  of	  NICD	  in	  DN3b-­‐DN4	  thymocytes	  in	  the	  Chd7ΔCD4Cre	  MigR1-­‐NICD	  induction	  model	  did	  not	  ameliorate	  nor	  accelerate	  T-­‐ALL	  survival	  outcome.	  Furthermore,	  abnormal	  proliferation	  of	  immature	  NICD-­‐transformed	  T	  cells	  was	  similar	  in	  both	  cohorts,	  with	  the	  majority	  of	  cells	  being	  CD4CD8	   DP	   and	   CD8	   iSPs,	   which	   is	   a	   hallmark	   of	   experimentally	   induced	   T-­‐ALL	   via	   over-­‐expression	  of	  NICD.	  In	  addition,	  we	  wanted	  to	  exclude	  the	  possibility	  that	  we	  missed	  a	  possible	  Chd7	   function	   due	   to	   the	   experimental	   system	   used.	   Therefore,	   we	   studied	   Chd7	   conditional	  inactivation	  in	  the	  RNIC+/ΔMxCre	  (early	  stage	  T-­‐ALL)	  and	  RNIC+/ΔLckCre	  (late-­‐stage	  T-­‐ALL)	  models,	  in	  which	  Chd7	  was	  initially	  identified.	  Similarly,	  NICD	  over-­‐expression	  from	  the	  Rosa26	  locus	  upon	  deletion	   of	   Chd7	   in	   the	   BM	   (MxCre)	   or	   in	   thymic	   progentors	   (LckCre)	   did	   not	   impair	   nor	  accelerate	   T-­‐ALL	   development,	   hence	   supporting	   our	   studies	   in	   the	   retroviral	   MigR1-­‐NICD	  induction	  model.	  	  	  In	  conclusion	  and	  in	  contrast	  to	  our	  hypothesis,	  Chd7	  is	  not	  important	  for	  T-­‐ALL	  induction	  and	  does	  not	  affect	  T-­‐ALL	  cell	   invasion	   into	  the	  spleen.	  However,	  Chd7	  belongs	  to	  a	   large	   family	  of	  chromatin	  remodellers,	  which	  counts	  nine	  members.	  It	  is	  possible	  that	  in	  absence	  of	  Chd7	  other	  family	   members	   may	   compensate	   for	   its	   loss	   to	   drive	   a	   transcriptional	   leukemic	   program	  downstream	  of	  N1	  in	  T-­‐ALL.	  	  On	   the	   other	   hand,	   is	   it	   tempting	   to	   speculate	   whether	   Chd7	   may	   be	   up-­‐regulated	   in	   more	  aggressive	   T-­‐ALL	   in	   order	   to	   counteract	   the	   transforming	   potential	   of	   NICD.	   In	   that	   scenario	  however,	   the	   absence	   of	   Chd7	   should	   have	   conferred	   a	   survival	   disadvantage	   compared	   to	  control	  chimeras	  and	  T-­‐ALL	  cells	  should	  have	  expanded	  more	  rapidly.	  Reciprocal	  experiments,	  over-­‐expressing	  Chd7	  cDNA	  in	  immature	  BM	  progenitors,	  may	  shed	  more	  light	  into	  the	  function	  of	   Chd7	   during	  malignant	   transformation	   and	   T-­‐ALL	   progression.	   This	   approach	  was	   initially	  pursued	  but	  was	  experimentally	  challenging	  since	  the	  murine	  Chd7	  coding	  sequence	  spans	  8.9	  kb,	  resulting	  in	  expression	  of	  a	  300	  kD	  protein.	  Upon	  successful	  cloning,	  we	  were	  unfortunately	  not	  able	  to	  transiently	  or	  lentivirally	  express	  Chd7	  cDNA	  in	  T-­‐ALL	  suspension	  or	  adherent	  cells	  (data	   not	   shown).	   As	   an	   experimental	   alternative,	   the	   generation	   of	   Chd7	   knock	   in	   animals	  would	  have	  allowed	  to	  study	  the	  role	  of	  Chd7	  over-­‐activation	  in	  pre-­‐malignant	  T-­‐ALL	  by	  crossing	  these	  mice	  with	  the	  RNIC+/ΔMxCre	  model.	  	  Unfortunately,	  Chd7	  GOF	  studies	  in	  the	  context	  of	  T-­‐ALL	  were	  experimentally	  challenging	  and	  not	  possible	  in	  the	  given	  time	  frame.	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4.4 Chd7	  does	  not	  affect	  Notch1-­‐driven	  human	  T-­‐ALL	  CHD7	  over-­‐expression	  was	  reported	  in	  solid	  tumors	  like	  PDAC	  and	  NSCLC	  in	  humans	  (Colbert	  et	  al.,	  2014).	  Since	  Chd7	  was	  identified	  as	  highly	  over-­‐expressed	  candidate	  gene	  in	  late-­‐stage	  versus	  pre-­‐malignant	  murine	  T-­‐ALL,	  we	  set	  out	  to	  characterize	  CHD7	  expression	  human	  N1-­‐driven	  T-­‐ALL	   cell	   lines.	   HPB-­‐ALL,	   DND41	   and	   CUTL1	   expressed	   high	   CHD7	   mRNA	   and	   protein	   levels.	  Therefore,	  these	  cell	  lines	  were	  chosen	  for	  CHD7	  KD	  studies	  in	  vitro.	  Sufficient	  shRNA-­‐mediated	  KD	  of	  CHD7	  was	  achieved	  in	  all	  three	  cell	  lines.	  Overall,	  CHD7	  KD	  T-­‐ALL	  cells	  were	  not	  apoptotic,	  nor	  displayed	  a	   significantly	  deregulated	   cell	   cycle	   to	   translate	   into	  proliferative	   advantage	  or	  disadvantage	   as	   compared	   to	   CHD7	   competent	   cells.	   However	   CHD7	   KD	   levels	   were	   ranged	  between	  50-­‐80%	  depending	  on	  the	  cell	   line	  studied.	  Residual	  CHD7	   levels	  may	  account	  for	  the	  unaffected	  growth	  and	  survival	  of	  human	  CHD7	  KD	  T-­‐ALL	  cell	   lines.	   In	   conclusion,	  CHD7	  does	  not	  impact	  on	  survival	  of	  established	  human	  T-­‐ALL	  cell	  lines	  under	  the	  experimental	  conditions	  studied	   herein.	   These	   results	   are	   confirmative	   of	   the	   results	   achieved	   when	   studying	   Chd7	  function	  in	  murine	  NICD-­‐driven	  T-­‐ALL	  models.	  	  	  	   	  
Discussion	  Part	  I:	  Role	  of	  Chd7	  in	  Hematopoiesis	  &	  T-­‐ALL	   64	  
	  
	   	  
	  5 Results	  –	  Part	  II:	  Role	  of	  Serca2	  in	  Hematopoiesis	  
Serca2	  was	   identified	  to	  be	  a	  suitable	  drug	  target	   in	  Notch1-­‐driven	  T-­‐ALL	  by	  two	  independent	  screening	   approaches:	   i)	   Roti	   et	   al.	   initiated	   a	   chemical	   compound	   screen	   and	   identified	  thapsigargin	  and	  CPA	  as	  potential	  drugs	  to	  inhibit	  Notch	  via	  targeting	  of	  Serca2	  and	  this	  target	  was	   further	   confirmed	   when	   over-­‐expressing	   cDNA	   clones	   from	   an	   ORF	   library	   to	   identify	  proteins	  that	  may	  regulate	  a	  truncated	  and	  leukemic	  N1	  receptor	  (Roti	  et	  al.,	  2013);	  ii)	  Previous	  work	  in	  our	  lab	  by	  Rajwinder	  Lehal	  led	  to	  the	  identification	  of	  CPA	  as	  a	  Notch	  inhibitor	  in	  a	  co-­‐culture-­‐based	   chemical	   compound	   screen	   (Lehal,	   2011).	   Rajwinder	   Lehal	   showed,	   that	   CPA	  blocks	  Notch	  pathway	  activation	  in	  a	  concentration-­‐dependant	  manner	  (Figure	  30	  A),	  resulting	  in	  the	  down-­‐regulation	  of	  the	  Notch	  target	  genes	  Hes1,	  cmyc	  and	  Deltex1	  (Dtx1)	  (Figure	  30	  B).	  
	  
Figure	  30:	  CPA	   treatment	  blocks	  Notch	  pathway	  activation	  and	  down-­‐regulates	  Notch	   target	  genes.	  A,	  Co-­‐cultured	   Dll4-­‐	   and	   N1-­‐expressing	   HeLa	   cells	   were	   treated	   with	   increasing	   concentrations	   of	   CPA,	   which	  blocks	   Notch	   pathway	   activation	   in	   a	   dose-­‐dependant	   manner.	  B,	   Quantitative	   RT-­‐PCR	   on	   cDNA	   from	   CPA-­‐treated	   human	   RPMI	   8402	   T-­‐ALL	   cells	   for	   Notch	   target	   genes	   Hes1,	   cMYC	   and	   Deltex1	   (Dtx1).	   Courtesy	   of	  Rajwinder	  Lehal.	  	  	  Furthermore,	  Roti	  et	  al.	  showed	  that	  Serca2	  regulates	  the	  maturation	  of	  the	  Notch	  receptor	  and	  that	   inhibition	  of	  Serca	  ATPases	   in	  T-­‐ALL	  xenografts	  significantly	  ameliorates	  disease	  outcome	  (Roti	  et	  al.,	  2013).	  Although	  this	  work	  shows	  that	  Serca2	  is	  indeed	  regulating	  N1,	  the	  work	  did	  not	   address,	   whether	   Serca2	   function	   is	   specific	   for	   Notch,	   or	   may	   have	   additional	   function	  within	   the	   hematopoietic	   system.	   This	   is	   of	   importance	   since	   Serca2	   has	   been	   suggested	   as	   a	  potential	   novel	   drug	   target	   to	   fight	   Notch-­‐driven	   T-­‐ALL.	   Therefore,	   we	   set	   out	   to	   study	   the	  impact	   of	   Serca2	   ablation	   on	   the	   hematopoietic	   system,	   mainly	   to	   address	   whether	   i)	   Serca2	  deficiency	  may	   recapitulate	   the	   Notch	   LOF	   effects	   on	   T	   and	  MZB	   cell	   development	   and	   ii)	   to	  assess	  whether	  a	  Serca2	  inhibitor	  may	  be	  an	  applicable	  therapeutic	  approach	  for	  the	  treatment	  of	  T-­‐ALL,	  as	  previously	  suggested.	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5.1 Expression	   of	   Serca	   Family	   Members	   in	   the	   Hematopoietic	  
System	  	  The	  Serca	  family	  of	  calcium	  ATP-­‐ases	  comprises	  three	  members	  that	  are	  expressed	  in	  a	  tissue-­‐specific	   fashion:	   Serca1	   is	   expressed	   predominantly	   in	   skeletal	   muscle,	   all	   three	   isoforms	   of	  Serca2	   (a-­‐c)	   are	   widely	   expressed	   in	   smooth	   muscle	   and	   nonmuscle	   tissues	   and	   Serca3	   is	  expressed	  in	  most	  tissues	  (Prasad	  et	  al.,	  2004).	  	  	  Therefore,	  we	  first	  set	  out	  to	  analyse	  the	  gene	  expression	  pattern	  of	  the	  Serca	  family	  members	  Serca1,	   Serca2	   (isoforms	   a	   and	   b)	   and	   Serca3	   among	  different	   hematopoietic	   lineages	   (Figure	  31).	   Stem	   and	   progenitor	   subsets	   such	   as	   KLS	   cells,	  MPP2s	   (KLSCD150+CD48+),	  MPP3-­‐MPP4s	  (KLSCD150-­‐CD48+)	  and	  overall	  CD117+Sca1-­‐	  progenitors,	   further	  subfractionated	   into	  common	  myeloid	   progenitors	   (CMPs;	   Lin-­‐CD117+Sca1-­‐CD34+D16/32int),	   granulocyte	   macrophage	  progenitors	   (GMPs;	   Lin-­‐CD117+Sca1-­‐CD34+CD16/32hi)	   and	   myeloid	   erythroid	   progenitors	  (MEPs;	   Lin-­‐CD117+Sca1-­‐CD34-­‐CD16/32lo)	  were	   sorted	   from	   total	  BM	  of	   8	  weeks	   old	  C57BL6/J	  WT	  mice.	  	  	  
	  
Figure	   31:	   Serca	   family	  member	   expression	   in	  WT	   hematopoietic	   stem	   and	   progenitor	   cells.	  Relative	  gene	  expression	  of	  Serca1	   (A),	  Serca2	   (B)	  and	  Serca3	   (C)	   in	  sorted	  BL6/J	  WT	  KLS	  cells,	  MPP2s,	  MPP3-­‐MPP4s,	  CD117+Sca1-­‐	  progenitors,	   common	  myeloid	  progenitors	   (CMPs;	  Lin-­‐CD117+Sca1-­‐CD34+D16/32int),	   granulocyte	  macrophage	  progenitors	   (GMPs;	  Lin-­‐CD117+Sca1-­‐CD34+CD16/32hi)	  and	  myeloid	  erythroid	  progenitors	   (MEPs;	  Lin-­‐CD117+Sca1-­‐CD34-­‐CD16/32lo)	   normalized	   to	   expression	   of	   HPRT	   (set	   to	   1).	   Experiment	   performed	   in	   at	  least	  biological	  duplicates.	  Error	  bars	  represent	  mean	  ±	  SD.	  	  Quantitative	  RT-­‐PCR	  analysis	  demonstrated	   that	  Serca2	   and	  Serca3	   are	  expressed	   in	  KLS	  cells.	  However,	   Serca2	   was	   expressed	   at	   higher	   levels	   in	   progenitors	   than	   Serca3	   (Figure	   31	   B,	   C).	  
Serca1	  expression	  was	  not	  detectable	  in	  any	  of	  the	  hematopoietic	  subsets	  (Figure	  31	  A).	  These	  results	  are	  confirmative	  of	  the	  published	  expression	  data	  for	  members	  of	  the	  Serca	  family.	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5.2 Consequences	   of	   Serca2	   Haploinsufficiency	   in	   the	  
Hematopoietic	  System	  
Serca2	   haploinsufficiency	   is	   strongly	   linked	   to	   Darier’	   s	   Disease	   in	   humans,	   in	   which	   LOF	  mutations	   affecting	   one	   Serca2	   allele	   result	   in	   keratinized	   epithelial	   cells,	   leading	   to	   the	  formation	  of	  crusty	  patches	  on	  the	  skin	  (Sakuntabhai	  et	  al.,	  1999).	  	  Therefore,	   we	   wondered	   whether	   conditional	   ablation	   of	   one	   Serca2	   allele	   may	   affect	  hematopoiesis.	  We	   studied	  Serca2	   haploinsufficiency	  under	  homeostatic	   conditions	   and	  under	  hematological	   stress,	   induced	   by	   5-­‐FU	   treatment	   and	   competitive	   as	   well	   as	   serial	  transplantation	  assays	  (data	  shown	  in	  Appendix	  section	  7.6).	  However,	  conditional	  inactivation	  of	   one	   Serca2	   allele	   in	   the	   BM	   did	   not	   cause	   any	   defects	   in	   hematopoietic	   differentiation	   or	  hematopoietic	  maintenance	  under	  these	  physiologic	  and	  competitive	  conditions.	  	  
5.3 Consequences	  of	  Serca2	  LOF	  in	  the	  Hematopoietic	  System	  Since	  Serca2	  was	  proposed	  to	  be	  a	  therapeutic	  target	  in	  Notch-­‐driven	  T-­‐ALL	  (Roti	  et	  al.,	  2013),	  we	  set	  out	  to	  study	  the	  physiological	  role	  of	  Serca2	  in	  the	  hematopoietic	  system	  via	  conditional	  deletion	  in	  BM	  cells	  using	  the	  MxCre	  recombinase.	  In	  Serca2	  cKO	  mice,	  the	  translational	  start	  site	  containing	   exon	  2	   as	  well	   as	   exon	  3	   are	   flanked	   by	   loxP	   sites,	   resulting	   in	   a	  Serca2	   null	   allele	  upon	  Cre	  recombinase	  activation	  following	  administration	  of	  PIC	  (Figure	  32	  A).	  	  
	  
Figure	  32:	  Strategy	  for	  in	  vivo	  conditional	  inactivation	  of	  Serca2	  in	  the	  BM.	  A,	  Schematic	  representation	  of	  the	  genetically	  modified	  murine	  Serca2	  locus,	  in	  which	  the	  ATG-­‐encoding	  exon	  2	  and	  exon	  3	  are	  flanked	  by	  loxP	  sites.	   Activation	   of	   the	   efficient	   BM-­‐deleter	   strain	  MxCre	   recombinase	   by	   administration	   of	   PIC	   leads	   to	   the	  generation	  of	  a	  Serca2	  null	  allele	  in	  BM	  cells.	  B,	  Deletion	  PCR	  analysis	  demonstrating	  a	  381	  bp	  lox	  band,	  a	  324	  bp	  deletion	  band	  and	  a	  282	  bp	  WT	  band	  amplified	  from	  genomic	  DNA	  isolated	  from	  Serca2lox/lox	  or	  Serca2ΔMxCre	  BM	  cells	  from	  chimeras.	  	  Efficient	  (>	  90%)	  conditional	  Serca2	  deletion	  was	  confirmed	  by	  PCR	  analysis	  on	  DNA	  from	  BM	  cells	  of	  Serca2-­‐deficient	  chimeras:	  MxCre-­‐mediated	  excision	  of	  exon	  2	  and	  3	  out	  of	   the	  murine	  Serca2	  locus	  led	  to	  amplification	  of	  a	  324	  bp	  deletion	  band	  (Δ),	  whereas	  the	  genetically	  modified	  
Serca2lox/lox	   locus	   would	   yield	   in	   a	   381	   bp	   band	   (lox)	   and	  WT	  murine	   Serca2	   locus	   (residual	  CD45.1+	  WT	  cells	  from	  recipient)	  a	  smaller	  282	  bp	  amplicon	  (Figure	  32	  B).	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5.3.1 Genetic	  Ablation	  of	  Serca2	  impairs	  Hematopoiesis	  We	  questioned	  whether	  ablation	  of	  both	  functional	  Serca2	  alleles	  may	  impact	  on	  hematopoiesis	  and	   therefore	   generated	  Serca2ΔMxCre	   and	  Serca2lox/lox	   (Ctrl)	   chimeras	  by	   transplanting	  CD45.2+	  
Serca2lox/lox	  MxCre	  or	  Ctrl	  BM	  into	  lethally	  irradiated	  CD45.1+	  hosts.	  Analysis	  of	  CD45.2+	  cells	  in	  the	   peripheral	   blood	   of	   non-­‐competitive	   chimeric	   mice	   indicated	   that	   reconstitution	   of	  
Serca2ΔMxCre	   chimeras	   was	   significantly	   impaired	   compared	   to	   Ctrl	   chimeras.	   	   PBL	   analysis	   of	  chimeric	  mice	  (Figure	  33	  A)	  over	  a	  time	  course	  of	  8	  weeks	  post	  PIC	  administration	  indicated	  a	  progressive	   loss	   of	   donor-­‐derived	   CD45.2+	   cells	   in	   Serca2-­‐deficient	   chimeras	   compared	   to	  
Serca2-­‐competent	   chimeras	   (Figure	   33	   B).	   For	   example,	   5	   weeks	   post	   MxCre	   activation	   only	  70.05	  ±	  3.35%	  CD45.2+	  cells	  were	  present	  in	  PBLs	  of	  Serca2-­‐deficient	  chimeras	  (n	  =	  4)	  compared	  to	   98.50	   ±	   0.18%	   in	   Serca2-­‐competent	   chimeras	   (n	   =	   5).	   Reduction	   in	   CD45.2+	   cells	   (35.30	   ±	  1.45%,	   n	   =	   3)	   in	   the	   PBLs	   of	   Serca2-­‐deficient	   chimeras	  was	  most	   prominent	   at	   8	  weeks	   post	  MxCre	  activation	  compared	  to	  Serca2-­‐competent	  chimeras	  (98.53	  ±	  0.49%,	  n	  =	  4).	  	  
	  
Figure	  33:	  Serca2-­‐deficient	  CD45.2+	  peripheral	  blood	  cells	  get	  outcompeted	  from	  residual	  host-­‐derived	  
CD45.1+	  C57BL6/J	  WT	  cells	  over	  time.	  Peripheral	  blood	  analysis	  of	  Serca2ΔMxCre	  versus	  Serca2lox/lox	  (Ctrl)	  was	  performed	   to	  assess	   reconstitution	  efficiency	  over	  a	   time	  course	  of	  8	  weeks.	  A,	   Schematic	  depicting	  congenic	  markers	  CD45.1+	  derived	  from	  residual	  host	  cells	  and	  CD45.2+	  donor-­‐derived	  cells.	  B,	  PBL	  analysis	  for	  CD45.2+	  reconstitution	  over	  8	  weeks.	  Error	  bars	  represent	  mean	  ±	  SD	  (****	  p	  <	  0.0001).	  	  These	  data	  indicate	  that	  homozygous	  loss	  of	  Serca2	  negatively	  affects	  reconstitutive	  capacity	  of	  BM	  cells	  in	  lethally	  irradiated	  recipients.	  These	  results	  raised	  the	  question	  whether	  Serca2	  may	  play	  a	  role	  in	  regulating	  rather	  mature	  hematopoietic	  lineages	  or	  the	  HSC	  compartment.	  	  To	   address	   this	   question,	   the	   BM	   compartment	   of	   Serca2-­‐competent	   and	   Serca2-­‐deficient	  chimeras	   was	   analysed	   at	   1,	   4	   and	   8	   weeks	   post	   PIC	   administration.	   Analysis	   of	   mature	  hematopoietic	   lineages	   in	   the	   BM	  demonstrated	   that	   the	   absolute	   numbers	   of	   B,	  myeloid	   and	  erythroid	   cells	   were	   significantly	   reduced	   in	   Serca2-­‐deficient	   chimeras,	   compared	   with	   Ctrl	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chimeras,	   at	   all	   time	   points	   analysed	   (Figure	   34	   A-­‐C).	   This	   likely	   contributed	   to	   the	   overall	  significant	  reduction	  in	  total	  BM	  cellularity.	  	  	  
	  
Figure	  34:	   Serca2	  deficiency	  negatively	  affects	  hematopoietic	  development	   in	   the	  BM.	  Bone	  marrow	  of	  
Serca2ΔMxCre	  and	  Serca2lox/lox	  (Ctrl)	  chimeras	  was	  analysed	  at	  1,	  4	  and	  8	  weeks	  post	  MxCre	  induction.	  A,	  Absolute	  cell	  numbers	  for	  total	  BM	  cellularity,	  B220+	  B	  cells,	  CD11b+Gr1+	  myeloid	  cells	  and	  Ter119+CD71+	  erythroid	  cells	  analysed	  at	  1	  week	  (A),	  4	  weeks	  (B)	  and	  8	  weeks	  post	  MxCre	  induction	  (C).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001,	  ****	  p	  <	  0.0001).	  	  In	  the	  thymus,	  CD45.2+	  donor	  cells	  were	  out-­‐competed	  by	  residual	  CD45.1+	  host-­‐derived	  cells	  in	  
Serca2-­‐deficient	  chimera	  	  (Figure	  35	  A).	   	  Overall,	  total	  thymic	  cellularity	  progressively	  reduced	  from	  19.20	  ±	  8.84	  *	  106	  cells	  at	  1	  week	  (n	  =	  6,	  Figure	  35	  C)	  to	  0.16	  ±	  0.14	  *	  106	  cells	  at	  3	  weeks	  (n	  =	  3,	  Figure	  35	  D)	  post	  Serca2	  conditional	  deletion	  compared	  to	  128.30	  ±	  14.83	  *	  106	  (n	  =	  4)	  or	  76.36	   ±	   16.20	   *	   106	   (n	   =	   3)	   cells,	   at	   the	   equivalent	   time	   points	   in	   Ctrl	   chimeras.	   Phenotypic	  analysis	   of	   CD4	   and	   CD8	   cell	   surface	   expression	   (Figure	   35	   B)	   demonstrated	   progressive	  reduction	  in	  the	  percentage	  of	  immature	  CD4+CD8+	  DP	  thymocytes	  and	  a	  corresponding	  increase	  in	  mature	  CD4+	  and	  CD8+	  SP	  cells,	  compared	  to	  Ctrl	  chimeras.	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Figure	  35:	   Serca2	  deficiency	  negatively	  affects	  T	   cell	  numbers	   in	   the	   thymus.	  Thymi	  of	  Serca2ΔMxCre	   and	  
Serca2lox/lox	   (Ctrl)	   chimeric	  mice	  were	  analysed	  1	  and	  3	  weeks	  post	  MxCre	   induction.	  A,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  congenic	  markers	  CD45.1	  and	  CD45.2	  in	  Ctrl	  and	  Serca2ΔMxCre	  chimeric	  mice.	  B,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  CD45.2+CD4	  and	  CD45.2+CD8	  in	  Ctrl	  and	  
Serca2ΔMxCre	   chimeric	   mice.	   Corresponding	   absolute	   cell	   numbers	   for	   total	   thymic	   cellularity,	   mature	  CD45.2+CD4+CD8+,	  CD45.2+CD4+	  and	  CD45.2+CD8+	  T	  cells	  are	  shown	  for	  time	  points	  1	  week	  (C)	  and	  3	  weeks	  (D).	  
E,	  Representative	  FACS	  plots	   showing	  cell	   surface	  expression	  of	  TCRγδ	  and	  TCRβ,	  gated	  on	  CD45.2+CD4-­‐CD8-­‐	  thymocytes	   and	   corresponding	   absolute	   cell	   numbers	  depicted	   in	  F.	   Absolute	   cell	   numbers	   are	  derived	   from	  Ctrl	  (n	  =	  5)	  and	  Serca2ΔMxCre	  (n	  =	  5)	  mice.	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  
Serca2	   conditional	   inactivation	   also	   negatively	   affected	   the	   percentage	   (Figure	   35	   E)	   and	  absolute	  numbers	  (Figure	  35	  F)	  of	  TCRγδ	  T	  cells	  compared	  to	  Ctrl	  chimeras.	  In	   addition,	   thymic	   progenitors	   progressing	   through	   the	   DN	   stages	   of	   T	   cell	  maturation	  were	  analysed.	  The	  (i)	  percentages	  (Figure	  36	  A)	  and	  (ii)	  absolute	  numbers	  (Figure	  36	  B)	  of	  immature	  thymic	  progenitors	  (DN1-­‐DN4)	  were	  also	  significantly	  reduced	  in	  Serca2-­‐deficient	  chimeras	  (n	  =	  5)	  compared	  to	  Ctrl	  chimeras	  (n	  =	  5).	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Figure	  36:	  Serca2	  deficiency	  negatively	  affects	  T	  cell	  progenitors	  in	  the	  thymus.	  Thymi	  of	  Serca2ΔMxCre	  and	  
Serca2lox/lox	  (Ctrl)	  chimeric	  mice	  were	  analysed	  1	  week	  post	  MxCre	  induction.	  A,	  Representative	  FACS	  analysis	  showing	   Ctrl	   and	   Serca2ΔMxCre	   CD4-­‐CD8-­‐Lin-­‐	   thymocytes	   stained	   with	   anti-­‐CD25	   and	   anti-­‐CD44	   antibodies	   to	  distinguish	   DN1	   (CD44+CD25-­‐),	   DN2	   (CD44+CD25+),	   DN3	   (CD44-­‐CD25+)	   and	   DN4	   stages	   (CD44-­‐CD25-­‐)	   of	  maturation.	  Corresponding	  absolute	  cell	  numbers	  (n	  =	  5+5)	  are	  shown	  in	  B.	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  Upon	   analysis	   of	   the	   spleen	   at	   1	   w	   (Figure	   37	   A)	   and	   4	   weeks	   (Figure	   37	   B)	   post	   MxCre	  activation,	  we	  observed	  that	  total	  splenic	  cellularity	  and	  absolute	  numbers	  of	  mature	  peripheral	  T	  and	  B	  cells	  were	  likewise	  strongly	  reduced	  in	  Serca2-­‐deficient	  compared	  to	  Serca2-­‐competent	  chimeras.	  	  
	  
	  
Figure	  37:	  Serca2	  deficiency	  negatively	  affects	  splenic	  cellularity	  and	  mature	  peripheral	  T	  and	  B	  cells.	  Spleens	  of	  Serca2ΔMxCre	  and	  Serca2lox/lox	  (Ctrl)	  chimeric	  mice	  were	  analysed	  1	  and	  4	  weeks	  post	  MxCre	  induction.	  Total	   splenic	   cellularity	   and	   absolute	   cell	   numbers	  of	  TCRb+,	   CD4+	   and	  CD8+	  T	   cells	   and	   IgM+B220+	  B	   cells	   in	  
Serca2ΔMxCre	  (n	  =	  4)	  and	  Ctrl	  (n	  =	  4)	  chimeras	  at	  1	  week	  (A)	  and	  4	  weeks	  (B)	  post	  MxCre	  induction.	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  In	   order	   to	   address	   the	   hypothesis	  whether	   conditional	   inactivation	   of	   Serca2	   in	   the	   BM	  may	  phenocopy	  N2	  LOF,	  we	  analysed	  the	  spleens	  of	  1	  week	  deleted	  Serca2ΔMxCre	  and	  Ctrl	  chimeras	  for	  MZB	  cells.	   Interestingly,	  percentages	  of	  Serca2-­‐deficient	  MZBs	   (B220+IgM+CD21hiCD23int)	  were	  significantly	   increased	   at	   the	   expense	   of	   the	   follicular	   B	   cell	   population	  (B220+IgM+CD21intCD23hi)	   (Figure	   38	   A).	   This	   relative	   increase	   did,	   however,	   not	   reflect	   in	  absolute	  numbers	  as	  the	  overall	  splenic	  cellularity	  was	  reduced,	  affecting	  all	  other	  mature	  B	  cell	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numbers.	  In	  contrast,	  the	  relative	  enrichment	  of	  MZBs	  was	  levelled	  out	  in	  absolute	  cell	  numbers	  due	  to	  the	  reduction	  in	  splenic	  cellularity	  in	  absence	  of	  Serca2	  (Figure	  38	  B).	  	  	  
	  
Figure	  38:	  Serca2	  deficiency	  leads	  to	  a	  relative	  enrichment	  of	  MZB	  cells,	  while	  negatively	  affecting	  other	  
mature	  B	  cell	  populations.	  Spleens	  of	  Serca2ΔMxCre	  and	  Serca2lox/lox	  (Ctrl)	  chimeric	  mice	  were	  analysed	  1	  post	  MxCre	  induction.	  A,	  Representative	  FACS	  analysis	  of	  spleen	  cells	  stained	  with	  anti-­‐CD21	  and	  anti-­‐CD23	  gated	  on	  CD45.2+B220+IgM+	   population	   (B)	   Total	   splenic	   cellularity	   and	   absolute	   cell	   numbers	   of	   B220+,	   MZB	   and	  Follicular	  B	  cells	   in	  Serca2ΔMxCre	   (n	  =	  4)	  and	  Ctrl	   (n	  =	  4)	  chimeras	  at	  1	  week	  post	  MxCre	   induction.	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  Collectively,	   these	   data	   suggest	   that	   conditional	   Serca2	   ablation	   globally	   affects	   mature	  hematopoietic	  lineages	  within	  the	  BM;	  T	  cell	  development	  in	  the	  thymus;	  and	  peripheral	  mature	  T	  and	  B	  cells	  in	  the	  spleen.	  	  Relative	  enrichment	  of	  MZB	  cells	  upon	  Serca2	  inactivation	  suggests	  that	  Serca2	  may	  regulate	  not	  only	  N1	  but	  also	  N2.	  Serca2,	  pumps	  Ca2+	  from	  the	  cytosol	  into	  the	  ER	  and	  its	  function	  is	  therefore	  crucial	  for	  calcium	  homeostasis	   within	   the	   cell	   (Berridge	   et	   al.,	   2003).	   Therefore,	   we	   set	   out	   to	   characterize	   the	  effect	   of	   Serca2	   LOF	   on	   calcium	   levels	   within	   peripheral	   mature	   T	   and	   B	   cells	   by	   measuring	  calcium	   flux	   with	   the	   ratiometric	   Ca2+	   indicator	   Indo1	   (Figure	   39).	   In	   brief,	   calcium	   baseline	  levels	  were	  measured	  over	  time	  and	  calcium	  flux	  was	   induced	  by	  addition	  of	   ionomycin,	  a	  cell	  membrane	   permeabilizing	   agent.	   Baseline	   calcium	   levels	  were	   defined	   as	   INDO-­‐1	   ratio	   before	  adding	   ionomycin,	  while	   intracellular	   Ca2+	   store	   release	  was	  measured	   as	   increase	   in	   INDO-­‐1	  ratio	  upon	  ionomycin	  stimulation.	  	  Analysis	   of	   calcium	   flux	   by	   peripheral	   T	   (Figure	   39	   A)	   and	   B	   cells	   (Figure	   39	   B)	   in	   chimeras	  demonstrated	  that	  (i)	  baseline	  levels	  of	  intracellular	  Ca2+	  were	  significantly	  elevated	  in	  Serca2-­‐deficient	  mice	  compared	  to	  Ctrl	  chimeras	  (Figure	  39	  C)	  and	  (ii)	  intracellular	  ER	  calcium	  stores	  of	  
Serca2-­‐deficient	   cells	   released	   significantly	   less	   Ca2+	   (Figure	   39	  D).	   These	   results	   demonstrate	  that	  calcium	  flux	  is	  deregulated	  in	  Serca2-­‐deficient	  hematopoietic	  cells,	  giving	  a	  functional	  proof	  of	  concept	  for	  the	  cKO	  animals	  studied.	  This	  is	  in	  agreement	  with	  previously	  published	  work,	  in	  which	  thapsigargin-­‐treated	  cells	  show	  similar	  calcium	  flux	  kinetics	  (Takemura	  et	  al.,	  1989).	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Figure	  39:	  Calcium	  kinetics	  are	  deregulated	  in	  Serca2-­‐deficient	  mature	  splenic	  T	  and	  B	  cells.	  T	  and	  B	  cells	  of	   Serca2ΔMxCre	   and	   Serca2lox/lox	   (Ctrl)	   spleens	  were	   isolated	   8	  weeeks	   post	  MxCre	   induction	   and	   loaded	  with	  INDO-­‐1.	   Calcium	  kinetics	  were	  measured	  over	   time	  and	   ionomycin	  was	   added	   to	   induce	   flux.	  Representative	  calcium	  flux	  responses	  in	  Serca2ΔMxCre	  and	  Ctrl	  CD4+	  T	  cells	  (A)	  and	  IgM+B220+	  B	  cells	  (B)	  shown	  as	  ratio	  Indo-­‐violet	  versus	  Indo-­‐blue	  (INDO1	  ratio).	  Quantification	  of	  Indo1	  baseline	  levels	  (C)	  and	  Ca2+	  release	  (D)	  depicted	  for	   Serca2ΔMxCre	   (n	   =	   3)	   and	   Ctrl	   (n	   =	   3)	   mice.	   Error	   bars	   represent	   mean	   ±	   SD	   (*	   p	   <	   0.05;	   **	   p	   <	   0.01).	  Experiment	  performed	  in	  collaboration	  with	  Danny	  Labes	  at	  the	  UNIL	  flow	  facility.	  	  Taken	  together,	  we	  demonstrated	  that	  ablation	  of	  both	  alleles	  of	  Serca2	  in	  the	  BM	  led	  to	  a	  severe	  reduction	  of	   total	  BM	  (Figure	  34),	   total	   thymic	  (Figure	  35)	  and	  total	  splenic	  cellularity	  (Figure	  37),	  indicating	  that	  Serca2	  is	  likely	  important	  for	  the	  survival	  of	  the	  herein	  studied	  cell	  types	  in	  these	  compartments.	  This	  raised	  the	  question	  whether	  Serca2	  ablation	  may	  negatively	  affect	  cell	  survival	  via	  induction	  of	  apoptosis.	  	  
5.3.2 Genetic	  Ablation	  of	  both	  Serca2	  alleles	   leads	   to	  Apoptosis	  of	  Mature	  
Lineages	  due	  to	  ER	  stress	  and	  activation	  of	  UPR	  We	   demonstrated	   that	   Serca2	   ablation	   in	   the	   hematopoietic	   system	   using	   MxCre	   leads	   to	   a	  severe	   reduction	   in	   total	   BM	   cellularity	   (Figure	   34).	   Analysis	   of	   apoptosis	   (Figure	   40	   A)	   in	  lineage-­‐committed	  BM	   cells	   (CD45.2+Lin+)	   revealed	   that	  Serca2-­‐deficient	   cells	   are	   significantly	  more	   apoptotic	   than	   Serca2-­‐competent	   cells	   (46.96	   ±	   3.75%	   in	   Serca2ΔMxCre	   versus	   16.84	   ±	  1.49%	  in	  Ctrl	  chimeras,	  Figure	  40	  B,	  C).	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Figure	  40:	  Serca2-­‐deficient	  mature	  BM	  cells	  activate	  apoptosis.	  Serca2-­‐deficient	  lineage	  positive	  cells	  were	  analysed	   for	   apoptosis	   one	   week	   post	   MxCre	   induction.	   A,	   Gating	   strategy	   to	   distinguish	   live	   from	   early	  apoptotic	  and	  apoptotic	  cells.	  B,	  Representative	  FACS	  plots	  depicting	  apoptosis	  staining	   for	  Annexin-­‐V	  versus	  DAPI,	   gated	   on	   the	   overall	   CD45.2+	   Lin+	   population	   of	   Serca2lox/lox	   (Ctrl)	   versus	   Serca2ΔMxCre	   animals.	   C,	  Quantification	   of	   the	   percentage	   of	   apoptotic	   cells	   in	   CD45.2+	   Lin+	   BM	   cells	   in	  Serca2ΔMxCre	   versus	  Serca2lox/lox	  mice	  (n	  =	  5	  +	  5).	  Error	  bars	  represent	  mean	  ±	  SD	  (***	  p	  <	  0.001).	  	  Imbalance	   of	   calcium	   levels	   within	   the	   cell	   can	   lead	   to	   the	   induction	   of	   the	   unfolded	   protein	  response	   (UPR),	   promoting	   apoptosis	   if	   chaperone	   proteins	   cannot	   counteract	   the	   protein	  misfolding	   in	   the	   ER.	   	   We	   hypothesized	   that	   Serca2	   deficiency	   may	   induce	   UPR	   and	   thereby	  activate	  apoptosis	  in	  Lin+	  cells.	  Unfolded	  protein	  response	  genes	  Ern2/Ire1,	  encoding	  one	  of	  the	  three	  upstream	  UPR	  sensors,	  and	  Hspa5/Grp78,	  encoding	  the	  chaperone	  Hspa5	  of	  the	  heat	  shock	  family,	  were	   found	   to	   be	   up-­‐regulated	   in	  Serca2-­‐deficient	   compared	   to	  Serca2-­‐competent	   Lin+	  BM	   cells	   (Figure	  41	  A).	   In	   agreement	  with	  our	  hypothesis,	   pro-­‐apoptotic	   genes	   including	  Bad,	  
Bax	  and	  Bim	  were	  also	  up-­‐regulated	  with	  a	  concomitant	  down-­‐regulation	  of	   the	  anti-­‐apoptotic	  gene,	  Bcl2l1,	   in	  Lin+	  Serca2-­‐deficient	  BM	  cells	  (Figure	  41	  B).	   	  However,	  anti-­‐apoptotic	  Bcl2	  was	  also	  up-­‐regulated	  upon	  conditional	  Serca2	  inactivation	  in	  the	  BM.	  	  
	  
Figure	  41:	  Unfolded	  Protein	  Response	  Genes	  are	  deregulated	  and	  pro-­‐apoptotic	  genes	  up-­‐regulated	  in	  
Serca2-­‐deficient	   lineage	  positive	  BM	  cells.	  Quantitative	  RT-­‐PCR	  gene	  expression	  analysis	  of	  UPR	  candidate	  genes	   	  (A)	  and	  apoptosis-­‐related	  genes	  (B)	   in	  sorted	  Serca2ΔMxCre	  versus	  Serca2lox/lox	  (Ctrl)	   lineage	  positive	  BM	  cells.	  Error	  bars	  represent	  mean	  ±	  SD,	  n	  =	  3	  (Serca2ΔMxCre)	  and	  n	  =	  3	  (Ctrl).	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In	  summary,	  we	  demonstrated	  that	  the	  calcium	  ATPse	  Serca2	  is	  crucial	  for	  maintaining	  calcium	  levels	  within	  hematopoietic	  cells.	  This	  imbalance	  in	  calcium	  flux	  likely	  contributes	  to	  ER	  stress	  and	  activation	  of	  the	  UPR	  in	  hematopoietic	  cells,	  leading	  to	  the	  induction	  of	  apoptosis.	  	  	  
5.3.3 Genetic	  Ablation	  of	  Serca2	  negatively	  affects	  the	  HSC	  compartment	  	  
Serca2	   conditional	   ablation	   in	   the	   BM	   led	   to	   a	   severe	   reduction	   in	   BM,	   thymic	   and	   splenic	  cellularity.	   This	   was	   likely	   due	   to	   ER	   stress	   and	   induction	   of	   UPR,	   resulting	   in	   subsequent	  activation	   of	   the	   apoptosis	   cascade	   in	   mature	   hematopoietic	   lineages.	   We	   then	   wondered,	  whether	  loss	  of	  both	  alleles	  of	  Serca2	  may	  equally	  affect	  cells	  within	  the	  HSC	  compartment.	  Upon	  analysis	  of	  the	  BM	  over	  a	  time	  course	  of	  1,	  4	  and	  8	  weeks	  post	  MxCre	  induction,	  CD45.2+	  donor-­‐derived	   BM	   cells	   were	   rapidly	   outcompeted	   by	   residual	   CD45.1+	   host	   cells	   with	   a	   maximal	  decrease	  in	  CD45.2+	  reconstitution	  observed	  at	  8	  weeks	  post	  induction,	  as	  shown	  by	  phenotypic	  flow	  cytometric	  analysis	  (Figure	  42	  A).	  	  These	  data	  support	  the	  progressive	  loss	  of	  CD45.2+	  cells	  in	   PBLs	   of	   Serca2-­‐deficient	   mice	   compared	   to	   Ctrl	   (Figure	   33).	   When	   analysing	   the	   HSC	  compartment,	  relative	  numbers	  of	  Serca2ΔMxCre	  KLS	  cells	  were	  significantly	  enriched	  at	  1,	  4	  and	  at	   8	   weeks	   post	   induction	   compared	   to	   control	   (Figure	   42	   B).	   Subfractionation	   into	   HSCs	  (KLSCD150-­‐CD48+),	   MPP2	   (KLSCD150+CD48+)	   and	   MPP3-­‐MPP4	   (KLSCD150-­‐CD48+)	   cells	  demonstrated	   an	   accumulation	   of	   MPP2s	   and	   MPP3-­‐MPP4s	   in	   percentages	   (Figures	   42	   C),	  accounting	  for	  the	  overall	  enrichment	  of	  the	  KLS	  compartment	  in	  Serca2-­‐deficient	  chimeras.	  In	  contrast,	   relative	  HSC	  numbers	   (Figure	   42	   C)	  were	   strongly	   reduced	   in	   these	  mice	   at	   all	   time	  points	  of	  analysis.	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Figure	  42:	  Serca2	  deficiency	  leads	  to	  an	  enrichment	  of	  KLS	  cells	  with	  concomitant	  loss	  of	  LT-­‐HSCs.	  Bone	  marrow	  of	  Serca2ΔMxCre	  and	  Serca2lox/lox	  (Ctrl)	  chimeras	  was	  analysed	  at	  1,	  4	  and	  8	  weeks	  post	  MxCre	  induction.	  
A,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  congenic	  markers	  CD45.1	  and	  CD45.2	   in	  Ctrl	  and	  Serca2ΔMxCre	  chimeric	  mice.	  B,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  CD117	  and	  Sca1	  gated	   on	   CD45.2+Lin-­‐	   cells	   and	   C,	   CD150	   and	   CD48	   cell	   surface	   expression	   to	   identify	   HSCs	   (CD150+CD48-­‐),	  MPP2	  (CD150+CD48+)	  and	  MPP3-­‐MPP4	  cells	  (CD150-­‐CD48+),	  gated	  on	  CD45.2+Lin-­‐KLS,	   in	  Ctrl	  and	  Serca2ΔMxCre	  chimeric	  mice.	  	  	  Upon	  Serca2	  inactivation	  in	  the	  BM,	  donor-­‐derived	  CD45.2+	  were	  continuously	  outcompeted	  by	  residual	   CD45.1+	   WT	   cells	   from	   the	   recipient.	   This	   effect	   was	   evident	   at	   all	   time	   points	   of	  analysis,	   as	   the	   percentage	   of	   CD45.2+	   cells	  was	   significantly	   reduced	   in	  Serca2ΔMxCre	   chimeras	  compared	  to	  controls	  at	  1w	  (Figure	  43	  D,	  left),	  4w	  (Figure	  43	  E,	  left)	  and	  8w	  (Figure	  43	  F,	  left)	  post	  MxCre	  induction.	  When	   analysing	   the	   HSC	   compartment,	   absolute	   numbers	   of	   Serca2ΔMxCre	   KLS	   cells	   were	  significantly	  enriched	  at	  1	  week	  (108.20	  ±	  33.41	  *	  106	  versus	  Ctrl	  =	  9.86	  ±	  0.36	  *	  106,	  Figure	  43	  D),	  4	  weeks	  (10.60	  ±	  1.55	  *	  106	  versus	  Ctrl	  =	  3.08	  ±	  0.31	  *	  106,	  Figure	  43	  E)	  and	  at	  8	  weeks	  post	  induction	  (13.81	  ±	  5.31	  *	  106	  versus	  Ctrl	  =	  2.09	  ±	  0.49	  *	  106,	  Figure	  43	  F)	  compared	  to	  controls.	  This	  was	  due	  to	  an	  accumulation	  of	  MPP2	  and	  MPP3-­‐MPP4	  cells	  at	  all	  given	  time	  points	  with	  a	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concomitant	   reduction	   in	  HSC	  numbers	   as	   shown	   for	   all	   analysed	   time	  points	   (Figure	   43	  D-­‐F,	  right).	  	  	  
	  
Figure	  43:	  Serca2	  deficiency	  leads	  to	  an	  enrichment	  of	  KLS	  cells	  with	  concomitant	  loss	  of	  LT-­‐HSCs.	  Left,	  Percentage	  of	  CD45.2+	  cells	  in	  the	  BM	  of	  Serca2ΔMxCre	  and	  Ctrl	  chimeras	  analysed	  1	  w	  (D),	  4w	  (E)	  and	  8w	  (F)	  post	  MxCre	  induction.	  Right,	  Corresponding	  absolute	  cell	  numbers	  for	  HSCs,	  MPP2	  and	  MPP3-­‐MPP4	  cells	  are	  shown	  for	  1	  week	  (D),	  4	  week	  (E)	  and	  8	  week	  (F)	  time	  points	  depicted	  Figure	  42.	  Absolute	  cell	  numbers	  are	  derived	  from	  Ctrl	  (n	  =	  5)	  and	  Serca2ΔMxCre	  (n	  =	  5)	  mice.	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  In	   summary,	   Serca2	   deficiency	   severely	   perturbs	   hematopoietic	   homeostasis	   in	   the	   BM	   by	  enriching	   the	   KLS	   pool	   with	   abnormal	   high	   numbers	   of	   MPP2	   and	   MPP3-­‐MPP4	   cells	   and	  concomitant	  reduction	  of	  HSCs.	  	  
5.3.4 Enrichment	   of	   KLS	   in	   Serca2	   cKO	   Animals	   1	   week	   post	   MxCre	  
Induction	  is	  not	  due	  to	  Interferon	  α-­‐induced	  Mobilization	  of	  HSCs	  Interferon-­‐α	  (INF-­‐α)	  was	  previously	  shown	  to	  be	  a	  potent	  inducer	  of	  HSC	  mobilization	  (Essers	  et	  al.,	   2009).	   Therefore,	   we	   investigated	   whether	   PIC	   administration	   may	   explain	   the	   observed	  enrichment	  of	  KLS	  cells	   in	  Serca2-­‐deficient	  chimeras.	  We	  set	  out	   to	  compare	   the	  effects	  of	  PIC	  administration	   on	   HSCs	   in	   interferon-­‐responsive	   MxCre	   mice	   and	   interferon-­‐irresponsive	  
INFαR_KO	   animals	   16	   h	   after	   induction	   and	   1	   week	   post	   induction	   when	   Serca2	   deficient	  chimeras	  had	  been	  analysed.	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INFαR_KO	  and	  ΔMxCre	  chimeric	  mice	  were	  generated	  by	  transplanting	  total	  BM	  from	  INFαR_KO	  (n	  =	  3)	  or	  MxCre	  (n	  =	  3)	  donors	  into	  lethally	  irradiated	  CD45.1+	  recipient	  mice.	  Upon	  successful	  engraftment	   of	   donor	   cells	   after	   4	  weeks,	   5	   injections	   of	   PIC	  were	   administered	   every	   second	  day	  and	   the	  HSC	  compartment	  was	  analysed	   (i)	  16	  h	   (Figure	  44	  A)	  and	   	   (ii)	  1	  week	   following	  final	  PIC	   injection	  (Figure	  44	  B).	  The	  percentages	  (Figure	  44	  A)	  and	  absolute	  numbers	  (Figure	  44	  C)	  of	  KLS	  cells,	  MPP2	  and	  MPP3-­‐MPP4	  cells	  were	  significantly	  increased	  in	  ΔMxCre	  chimeras	  in	   comparison	   with	   INFαR_KO	   chimeras	   16	   h	   post	   PIC	   administration.	   Phenotypic	  characterization	   of	   the	   KLS	   compartment	   demonstrated	   significantly	   lower	   (i)	   percentages	  (Figure	  44	  A)	  and	  (ii)	  absolute	  numbers	  (Figure	  44	  C)	  of	  ΔMxCre	  HSCs	  compared	  to	  INFαR_KO	  (n	  =	   5	   +	   5),	   while	   MPP2	   and	   MPP3	   -­‐	   MPP4	   cells	   were	   significantly	   enriched	   accounting	   for	   the	  overall	   enrichment	   of	   the	   KLS	   compartment	   16	   h	   post	   PIC	   administration	   (Figure	   44	   C).	   We	  demonstrated	  a	  similar	  deregulation	  of	  HSC	  and	  MPPs	  numbers	  in	  the	  KLS	  compartment,	  when	  analysing	  Serca2ΔMxCre	  chimeras	  at	  1	  week	  post	  PIC	  administration.	  
	  
Figure	   44:	   Sixteen	   hours	   post	   PIC	   treatment	   hematopoietic	   stem	   cells	   are	  mobilized	   but	   are	   back	   to	  
homeostatic	  state	  after	  1	  week	  in	  interferon-­‐sensitive	  ΔMxCre	  competitive	  BM	  chimeras	  as	  compared	  to	  
INFαR_KO	  controls.	  INFαR_KO	  and	  ΔMxCre-­‐derived	  BM	  cells	  were	  analysed	  for	  the	  KLS	  compartment	  16	  h	  and	  1	  week	  PIC	  administration.	  Representative	  FACS	  plots	  depicting	  staining	  for	  CD117	  versus	  Sca1	  to	  identify	  the	  overall	   CD45.2+	   Lin-­‐CD117+Sca1+	   (KLS)	   population,	   upper	   panel,	   further	   subfractionated	   into	   HSCs	   (KLS,	  CD150+CD48-­‐),	  MPP2,	   (KLS,	  CD150+CD48+)	  and	  MPP3-­‐MPP4	  cells	   (KLS,	  CD150-­‐CD48+),	   lower	  panel,	   for	  16	  h	  time	  point	  (A)	  and	  1	  week	  time	  point	  (B).	  C	  and	  D,	  Absolute	  cell	  numbers	  of	  donor-­‐derived	  CD45.2+	  KLS	  cells,	  HSCs,	  MPP2	  and	  MPP3-­‐MPP4	  cells	  in	  INFαR_KO	  versus	  ΔMxCre	  competitive	  BM	  chimeras	  (n	  =	  5+5)	  analysed	  16	  h	  or	  1	  week	  post	  last	  PIC	  administration.	  Error	  bars	  represent	  mean	  ±	  SD	  (±	  SD,	  *	  p	  <	  0.05;	  **	  p	  <	  0.011).	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In	   contrast,	   analysis	   of	   the	   KLS	   compartment	   1	   week	   post	   PIC	   administration	   demonstrated	  comparable	   (i)	   percentages	   (Figure	  45	  B)	   and	   (ii)	   absolute	  numbers	   of	  KLS	   cells,	  HSCs,	  MPP2	  and	  MPP3	   -­‐	  MPP4	   cells	   (Figure	  45	  D)	   in	  ΔMxCre	   and	   INFαR_KO	   chimeras.	   These	  data	   indicate	  that	  HSC	  mobilization	  is	  rapidly	  induced	  in	  response	  to	  INFα	  treatment	  (16	  h)	  but	  is	  a	  transient	  effect	  since	  1	  week	  post	  PIC	  administration	  the	  KLS	  compartment	  is	  back	  to	  normal	  numbers	  as	  under	  physiologic	  conditions.	  This	  is	  to	  some	  extent	  comparable	  to	  previously	  published	  work,	  in	  which	  dormant	  LT-­‐HSCs	   (KLS	  CD150-­‐CD48+)	  were	  demonstrated	   to	  highly	  proliferate	  upon	  INFα	   stimulation	   in	   vivo	   (Essers	   et	   al.,	   2009).	   Therefore,	   we	   speculated	   that	   Serca2-­‐deficient	  HSCs	  may	   have	   an	   intrinsic	   defect	   in	   coping	   with	   INFα-­‐induced	   stress	   and	   this	   until	   up	   to	   8	  weeks	  post	  PIC	  administration.	  	  In	   addition,	  we	   studied	   the	   cell	   cycle	   kinetics	   of	  ΔMxCre	   and	   INFαR_KO	   KLS,	   HSCs,	  MPP2	   and	  MPP3	  –	  MPP4	  cells	  at	  (i)	  16	  h	  (Figure	  45	  A)	  and	  (ii)	  1	  week	  post	  PIC	  administration	  (Figure	  45	  A).	  After	  16	  h	  post	  final	  PIC	  injection,	  the	  HSC	  compartment	  in	  INF-­‐responsive	  ΔMxCre	  chimeras	  was	   significantly	   deregulated	   with	   more	   KLS	   cells	   residing	   in	   G0	   phase	   compared	   to	   INF-­‐irresponsive	  INFαR_KO	  chimeras	  (Figure	  45	  B).	  	  ΔMxCre	  HSCs	  showed	  an	  enrichment	  of	  G1	  phase	  of	  the	  cell	  cycle	  with	  a	  concomitant	  reduction	  in	  the	  percentage	  of	  cells	  in	  S/G2/M	  phase,	  while	  cell	   cycle	   kinetics	   were	   similar	   in	   MPP2s	   at	   16	   h	   post	   PIC	   administration	   (Figure	   45	   B).	   In	  addition,	  significantly	  more	  MPP3	  –	  MPP4	  cells	  were	  in	  G1	  phase	  in	  ΔMxCre	  chimeras	  compared	  to	   INFαR_KO	   chimeras	   (Figure	   45	   B).	   A	   significant	   accumulation	   of	   KLS	   cells	   in	   G0	   phase	  was	  observed	  in	  INF-­‐responsive	  ΔMxCre	  chimeras	  compared	  to	  INFαR_KO	  chimeras	  (42.16	  ±	  3.35%	  versus	  31.46	  ±	  1.42%,	  n	  =	  5	  +5).	  Similarly,	  MPP3	  –	  MPP4	  cells	  were	  significantly	  enriched	  in	  G0	  (40.04	  ±	  3.37	  %	  versus	  26.68	  ±	  2.13%)	  in	  ΔMxCre	  chimeras	  compared	  to	  INFαR_KO	  chimeras.	  In	  addition,	  a	  significant	   increase	  of	  HSCs	  (58.88	  ±	  6.01%	  versus	  39.98	  ±	  2.66%)	  in	  G1	  phase	  was	  observed	   in	   ΔMxCre	   chimeras	   compared	   to	   INFαR_KO	   chimeras.	   However,	   the	   cell	   cycle	  distribution	  of	  MPP2	  cells	  appeared	  to	  be	  unaffected.	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Figure	  45:	  Sixteen	  hours	  post	  PIC	  treatment	  cell	  cycle	  kinetics	  are	  perturbed	  in	  ΔMxCre	  competitive	  BM	  
chimeras	   as	   compared	   to	   INFαR_KO	   controls.	   INFαR_KO	   and	  ΔMxCre-­‐derived	   HSCs	  were	   analysed	   for	   cell	  cycle	  kinetics	  16	  h	  post	  PIC	  administration.	  A,	  Representative	  FACS	  plots	  depicting	  cell	  cycle	  staining	  for	  Ki-­‐67	  versus	   Hoechst,	   gated	   on	   the	   overall	   CD45.2+	   KLS	   population,	   further	   subfractionated	   into	   HSCs	   (KLS,	  CD150+CD48-­‐),	   MPP2,	   (KLS,	   CD150+CD48+)	   and	   MPP3-­‐MPP4	   cells	   (KLS,	   CD150-­‐CD48+)	   in	   INFαR_KO	   versus	  
ΔMxCre	  competitive	  BM	   chimeras.	  C,	   Percentage	  of	   cells	   in	   cell	   cycle	  phases	  G0,	  G1	   and	   S/G2/M	   for	  KLS	   cells,	  HSCs	  (KLS,	  CD150+CD48-­‐),	  MPP2,	  (KLS,	  CD150+CD48+)	  and	  MPP3-­‐MPP4	  cells	  (KLS,	  CD150-­‐CD48+)	  in	  INFαR_KO	  versus	  ΔMxCre	  competitive	  BM	  chimeras	  (n	  =	  5	  +	  5).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.011).	  	  Taken	  together,	  these	  data	  demonstrate	  that	  the	  cell	  cycle	  of	  ΔMxCre	  HSCs	  in	  response	  to	  PIC	  is	  significantly	   affected	   as	   early	   as	   16	   h	   post	   induction,	   corresponding	   with	   the	   observed	  enrichment	  of	  the	  KLS	  population	  (Figure	  44	  A).	  	  	  In	   this	   study,	   the	   KLS	   compartment	   of	   Serca2-­‐deficient	   chimeras	   was	   analysed	   over	   a	   time	  course	  with	   time	  point	  1	  week	  being	   the	  earliest	   time	  point	  of	  analysis.	  Therefore,	  we	  studied	  INF-­‐responsive	   (ΔMxCre)	   and	   INF-­‐irresponsive	   (INFαR_KO)	   HSCs	   at	   1	   w	   post	   final	   PIC	  administration	  and	  analysed	   their	   cell	   cycle	  profile	   (Figure	  46	  A).	  ΔMxCre	   and	   INFαR_KO	  HSCs	  represented	  with	  comparable	  and	  physiologic	  numbers	  1	  week	  post	  PIC	  administration,	  which	  is	  in	   contrast	   to	   the	  deregulation	   of	  HSC	  numbers	   in	  Serca2-­‐deficient	   chimeras	   observed	   for	   the	  same	   time	   point.	   At	   1	   week	   post	   PIC	   administration,	   the	   rare	   and	   quiescent	   HSCs	  (KLSCD150+CD48-­‐)	   in	  both	  ΔMxCre	  and	   INFαR_KO	   cohorts	  primarily	  resided	   in	   the	  G0	  phase	  of	  the	   cell	   cycle.	   It	   was	   shown	   previously,	   that	   approximately	   70%	   of	   LT-­‐HSCs	   (KLSCD150-­‐
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CD48+CD34-­‐)	   reside	   in	   G0	   phase	   (Trumpp	   et	   al.,	   2010;	  Wilson	   et	   al.,	   2008);	   therefore	  we	   can	  experimentally	  reproduce	  these	  data.	  Overall,	  the	  cell	  cycle	  phase	  distribution	  of	  KLS	  cells,	  HSCs,	  MPP2	   and	   MPP3-­‐MPP4	   cells	   was	   not	   significantly	   perturbed	   when	   comparing	   ΔMxCre	   with	  
INFαR_KO	  chimeras	  at	  1	  week	  post	  last	  PIC	  injection	  (Figure	  46	  B).	  	  
	  
Figure	   46:	   One	   week	   post	   PIC	   treatment	   cell	   cycle	   kinetics	   are	   no	   longer	   perturbed	   in	   ΔMxCre	  
competitive	  BM	   chimeras	   as	   compared	   to	   INFαR_KO	   controls.	   INFαR_KO	   and	  ΔMxCre-­‐derived	  HSCs	  were	  analysed	   for	   cell	   cycle	   kinetics	   one	   week	   post	   PIC	   administration.	   A,	   Representative	   FACS	   contour	   plots	  depicting	   cell	   cycle	   staining	   for	   Ki-­‐67	   versus	   Hoechst,	   gated	   on	   the	   overall	   CD45.2+	   KLS	   population,	   further	  subfractionated	  into	  HSCs	  (KLS,	  CD150+CD48-­‐),	  MPP2	  (KLS,	  CD150+CD48+)	  and	  MPP2-­‐MPP4	  cells	  (KLS,	  CD150-­‐CD48+)	  in	  INFαR_KO	  versus	  ΔMxCre	  competitive	  BM	  chimeras.	  C,	  Percentage	  of	  cells	  in	  cell	  cycle	  phases	  G0,	  G1	  and	  S/G2/M	  for	  KLS	  cells,	  LT-­‐HSCs	  (KLS,	  CD150+CD48-­‐),	  ST-­‐HSCs,	  (KLS,	  CD150+CD48+)	  and	  MPPs	  (KLS,	  CD150-­‐CD48+)	  in	  INFαR_KO	  versus	  ΔMxCre	  competitive	  BM	  chimeras	  (n	  =	  5	  +	  4).	  Error	  bars	  represent	  mean	  ±	  SD.	  	  	  In	   summary,	   we	   demonstrated	   that	   16	   h	   post	   PIC	   administration,	   INF-­‐responsive	   ΔMxCre	  chimeras	   show	   similar	   enrichment	   in	   the	   KLS	   compartment	   with	   simultaneous	   loss	   of	   HSCs	  compared	  to	  Serca2-­‐deficient	  chimeras.	  This	  was	   likely	  due	  to	   INF-­‐induced	  mobilization	  of	   the	  quiescent	  HSC	   pool,	   stimulating	   altered	   cell	   cycle	   kinetics	   in	   these	   cells	   at	   16	   h	   post	   final	   PIC	  injection.	  While	  this	  effect	  was	  only	  transient	  in	  ΔMxCre	  chimeras	  treated	  with	  PIC	  for	  16	  h	  and	  HSCs	  were	  back	   to	  homeostatic	   state	  at	  1	  week	  post	   treatment,	  Serca2-­‐deficent	  KLS	   remained	  enriched	   for	   up	   to	   8	   weeks	   post	   MxCre	   induction	   (Figure	   43).	   	   This	   raised	   the	   hypothesis	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whether	  Serca2-­‐deficient	  KLS	  may	  harbor	  other	   functional	  defects	   in	  addition	   to	   the	  observed	  impaired	  long-­‐term	  reconstitutive	  capacity.	  	  	  
5.3.5 Serca2-­‐deficient	  KLS	  form	  less	  and	  smaller	  CFUs	  Hematopoietic	   stem	   cells	   have	   the	   potential	   to	   self-­‐renew	  and	   to	   differentiate	   into	   progenitor	  cells	   and	   all	   mature	   lineages	   of	   the	   blood	   system.	   The	   colony	   forming	   unit	   (CFU)	   assay	   is	   a	  methylcellulose-­‐based	  assay	  to	  study	  the	  differentiation	  potential	  of	  HSCs	  in	  vitro	  and	  was	  used	  herein	   to	   study	   the	   impact	   of	   Serca2	   ablation	   on	  HSC	   function.	   Serca2ΔMxCre	   and	   Ctrl	   KLS	   cells	  were	   sorted	   and	   cultured	   in	   methylcellulose	   containing	   HSC-­‐specific	   supplementary	   growth	  factors	  for	  1	  week.	  Serca2-­‐deficient	  KLS	  differentiated	  into	  GEMM,	  monocyte,	  granulocyte	  (CFU-­‐G)	   and	   granulocyte-­‐macrophage	   (CFU-­‐GM)	   colonies	   in	   vitro	   (Figure	   47	   A).	   However,	   the	  numbers	   and	   size	   of	   these	   colonies	   generated	   from	   Serca2-­‐deficient	   KLS	   were	   significantly	  reduced	  compared	  to	  those	  from	  Serca2-­‐competent	  KLS	  (Figure	  47	  B).	  	  	  
	  
Figure	   47:	   Serca2-­‐deficient	   KLS	   form	   less	   and	   smaller	   CFUs	   in	   vitro.	   Sorted	   Serca2lox/lox	   (Ctrl)	   and	  
Serca2ΔMxCre	   CD45.2+	   KLS	   cells	   were	   plated	   in	   methylcellulose	   and	   CFUs	   were	   counted	   following	   1	   week	   of	  culture.	   A,	   Representative	   pictures	   of	   Ctrl	   and	   Serca2ΔMxCre	   GEMM,	   monocyte,	   granulocyte	   (CFU-­‐G)	   and	  granulocyte-­‐macrophage	   (CFU-­‐GM)	   colonies	   formed	   in	   vitro.	  B,	   Absolute	   Numbers	   of	   GEMM,	  megakaryocyte	  erythrocyte	  (MK/E)	  and	  granulocyte	  (G),	  macrophage	  (M)	  and	  mixed	  granulocyte	  -­‐	  macrophage	  	  colonies.	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001),	  n	  =	  8	  (Ctrl)	  and	  n	  =	  6	  (Serca2ΔMxCre).	  	  	  These	  results	  demonstrate	  that	  Serca2	  deficiency	  negatively	  impacts	  on	  HSC	  function,	  as	  the	   in	  
vitro	  differentiation	  potential	  of	  Serca2ΔMxCre	  KLS	  cells	  was	  significantly	  reduced	  compared	  with	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Serca2-­‐competent	   cells,	   as	   demonstrated	   in	   the	   CFU	   in	   vitro	   assay.	   We	   hence	   addressed	   the	  question	  whether	  Serca2	  deficiency	  may	  affect	  the	  overall	  survival	  of	  HSCs.	  	  
5.3.6 Serca2-­‐deficient	   KLS	   cells	   are	   not	   driven	   into	   Apoptosis	   but	   have	   a	  
Cell	  Cycle	  Defect	  We	  demonstrated	  that	  Serca2-­‐deficient	  lineage	  committed	  cells	  in	  the	  BM	  were	  apoptotic,	  likely	  contributing	   to	   the	   strong	   reduction	   in	   total	   BM	   cellularity	   observed	   in	   Serca2ΔMxCre	   chimeras	  compared	   to	   Ctrl	   chimeras	   (Figures	   34,	   39).	   Given	   the	   persistent	   enrichment	   of	   KLS	   cells	   in	  
Serca2-­‐deficient	   chimeras	   up	   to	   8	  weeks	   following	  MxCre	   induction	  with	   concomitant	   loss	   of	  reconstitutive	  potential,	  we	  hypothesized	  that	  HSCs	  may	  have	  a	  cell	  intrinsic	  defect	  in	  absence	  of	  Serca2.	  Therefore,	   apoptosis	   analysis	   was	   performed	   on	   1	   week	   deleted	   Serca2	   and	   Ctrl	   chimeras	  (Figure	  48).	  Serca2-­‐deficient	  and	  Serca2-­‐competent	   chimeras	  had	  comparably	   low	  numbers	  of	  apoptotic	   (Annexin-­‐V+DAPI+/-­‐)	   cells	   in	   the	   KLS	   compartment.	   However,	   apoptotic	   cells	   were	  slightly	   but	   not	   significantly	   increased	   in	   the	   KLS	   population	   in	   Serca2-­‐deficient	   chimeras	  compared	  to	  Ctrl	  (data	  not	  shown).	  This	  was	  mainly	  due	  to	  more	  apoptotic	  HSCs	  (Figure	  48	  B),	  while	  MPP2	  cells	  were	  significantly	   less	  apoptotic	  and	  MPP3-­‐4	  cells	  remained	  unaffected	  upon	  MxCre-­‐mediated	  Serca2	  ablation	  (Figure	  48	  C).	  Therefore,	  we	  ruled	  out	  that	  Serca2	  deficiency	  as	  early	  as	  1	  week	  post	  MxCre	  induction	  triggers	  massive	  apoptosis	  in	  the	  HSC	  compartment	  of	  the	  studied	  chimeras.	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Figure	  48:	  Serca2-­‐deficient	  HSCs	  are	   slightly	  more	  apoptotic,	  while	  MPP	  subsets	   less	  apoptotic	  or	  are	  
not	   affected.	   Serca2-­‐deficient	   HSCs	   were	   analysed	   for	   apoptosis	   one	   week	   post	   MxCre	   induction.	   A,	  Representative	   FACS	   plots	   depicting	   anti-­‐CD150	   and	   anti-­‐CD48	   staining,	   gated	   on	   the	   overall	   CD45.2+	   KLS	  population	  of	  Serca2lox/lox	   (Ctrl)	   versus	  Serca2ΔMxCre	   animals.	  B,	   Representative	  FACS	  plots	  depicting	   apoptosis	  staining	   for	   Annexin-­‐V	   versus	   DAPI,	   gated	   on	   the	   overall	   CD45.2+	   HSC	   population	   (KLS,	   CD150+CD48-­‐)	   of	  
Serca2lox/lox	   (Ctrl)	  versus	  Serca2ΔMxCre	  animals.	  C,	  Quantification	  of	   the	  percentage	  of	  apoptotic	  cells	   in	  CD45.2+	  HSCs,	  containing	  MPP1	  cells	  (KLS,	  CD150+CD48-­‐),	  MPP2	  (KLS,	  CD150+CD48+)	  and	  MPP3-­‐4	  (KLS,	  CD150-­‐CD48+)	  populations	  in	  Serca2ΔMxCre	  versus	  Serca2lox/lox	  mice	  (n	  =	  5+5).	  Error	  bars	  represent	  mean	  ±	  SD.	  	  These	   observations	   nevertheless	   raised	   the	   question	   whether	   KLS	   cells	   and	   the	   rare	   HSC	  subpopulations	  may	  still	  resist	  apoptotic	  cues	  up	  to	  8	  weeks	  post	  MxCre	  induction,	  while	  mature	  lineages	   rapidly	   underwent	   apoptosis	   upon	   Serca2	   inactivation.	   Therefore,	   apoptosis	   analysis	  was	   performed	   on	   8	   week-­‐long	   deleted	   Serca2	   chimeras	   using	   AMNIS	   imaging	   technology	  	  ((McGrath	   et	   al.,	   2008);	   Figure	   49).	   Strikingly,	   donor-­‐derived	   CD45.2+	   KLS	   cells	   did	   not	   show	  significant	  differences	   in	  percentages	  of	   (i)	   live	  cells	   (Annexin-­‐V-­‐DAPI-­‐,	  Figure	  49	  A),	   	   (ii)	  early	  apoptotic	   (Annexin-­‐V+)	   cells	   (Figure	   49	   B)	   or	   (iii)	   dead	   cells	   (Annexin-­‐V+DAPI+,	   Figure	   49	   C),	  while	  the	  percentage	  of	  KLS	  cells	  was	  still	  significantly	  enriched	  (Figure	  49	  D)	  when	  comparing	  
Serca2-­‐deficient	  with	  Serca2-­‐competent	  chimeras.	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Figure	  49:	  Serca2-­‐deficient	  hematopoietic	   stem	  cells	  are	  not	  apoptotic	  8	  weeks	  post	  MxCre	   induction.	  
Serca2ΔMxCre	  and	  Serca2lox/lox	  (Ctrl)	  KLS	  cells	  were	  analysed	  for	  apoptosis	  using	  AMNIS	  flow	  cytometry-­‐imaging	  technology.	  Representative	  images	  of	  live	  (A),	  Annexin-­‐V+	  (B)	  and	  dead	  (C)	  Ctrl	  and	  Serca2ΔMxCre	  single	  KLS	  cells,	  gated	  on	  CD45.2+,	  Lin-­‐CD117+Sca1+	  and	  DAPI	  versus	  Annexin-­‐V.	  D,	  Percentage	  of	  KLS	  cells	  and	  quantification	  of	  apoptosis	   data	   depicted	   in	   (A)-­‐(C.)	   E,	   Percentage	   of	   CD45.2+Lin+	   cells	   and	   apoptotis	   results.	   N	   =	   3	  mice	   per	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experimental	   group.	   Error	   bars	   represent	   mean	   ±	   SD	   (*	   p	   <	   0.05;	   **	   p	   <	   0.01,	   ***	   p	   <	   0.001).	   Experiment	  performed	  in	  collaboration	  with	  Dr.	  Stefanie	  Siegert	  at	  the	  UNIL	  flow	  facility.	  	  In	   contrast,	   analysis	   of	   lineage	   committed	   (Lin+)	   BM	   cells	   confirmed	   the	   previously	  demonstrated	   reduction	   in	   the	   total	   cell	   numbers	   and	   the	   increased	   proportions	   of	   apoptotic	  cells	   (Figure	   46	   B).	   Subsequently	  we	   set	   out	   to	   analyse	   the	   cell	   cycle	   of	   KLS	   cells,	   containing	  HSCs,	  MPP2	  and	  MPP3-­‐MPP4	  subpopulations.	  	  Serca2-­‐deficient	  total	  KLS	  cells,	  remaining	  HSCs	  and	  MPP3-­‐MPP4	  cells	  showed	  a	  deregulated	  cell	  cycle	  with	  the	  majority	  of	  cells	  residing	  in	  G0	  phase	  of	  the	  cell	  cycle	  compared	  to	  Ctrl,	  as	  depicted	  in	  (i)	  percentages	  (Figure	  50	  A)	  and	  (ii)	  in	  quantified	  percentages	  of	  n	  =	  5	  +	  5	  chimeras	  (Figure	  50	  B).	  	  	  	  	  	  	  	  
	  
Figure	   50:	   Serca2-­‐deficient	   hematopoietic	   stem	   cells	   are	   driven	   into	   cell	   cycle	   arrest.	   Serca2-­‐deficient	  HSCs	   were	   analysed	   for	   cell	   cycle	   kinetics	   1	   week	   post	   MxCre	   induction	   via	   PIC	   administration.	   A,	  Representative	   FACS	   plots	   depicting	   cell	   cycle	   staining	   for	   Ki-­‐67	   versus	   Hoechst,	   gated	   on	   the	   overall	  CD45.2+KLS	  population,	  further	  subfractionated	  into	  HSCs	  (KLS,	  CD150+CD48-­‐),	  MPP2	  (KLS,	  CD150+CD48+)	  and	  MPP3-­‐MPP4	   cells	   (KLS,	   CD150-­‐CD48+)	   of	   Ctrl	   versus	   Serca2ΔMxCre	   animals.	  C,	   Percentage	   of	   cells	   in	   cell	   cycle	  phases	   G0,	   G1	   and	   S/G2/M	   for	   donor-­‐derived	   CD45.2+	   KLS	   cells,	   HSCs	   (KLS,	   CD150+CD48-­‐),	   MPP2	   (KLS,	  CD150+CD48+)	  and	  MPP3-­‐MPP4	  cells	  (KLS,	  CD150-­‐CD48+)	  in	  Serca2-­‐deficient	  versus	  Ctrl	  (n	  =	  5	  +	  5).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01).	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This	   analysis,	   however,	   only	   captured	   the	   cell	   cycle	   profile	   of	   Serca2-­‐deficient	   versus	   Serca2-­‐competent	  HSCs	   at	   the	  discrete	   time	  point	   of	   1	  week	  post	  MxCre	   induction.	   To	   further	   assess	  whether	  Serca2-­‐deficient	  KLS	  cells	  harbor	  cell	   cycle	  defects,	   the	  proliferation	  capacity	  of	   these	  cells	   was	   measured	   in	   vitro.	   In	   contrast	   to	   Hoechst-­‐Ki-­‐67	   staining,	   Carboxyfluorescein	  succinimidyl	  ester	  (CFSE)	  cell	  division	  tracking	  allows	  quantifying	  the	  number	  of	  cell	  divisions	  made	  by	  a	  given	  cell	  type	  over	  time.	  CFSE	  is	  a	  fluorescent	  dye	  that	  labels	  the	  totality	  of	  a	  given	  cell	   population	   but	   washes	   out	   with	   every	   division	   the	   cell	   undergoes,	   thereby	   constantly	  decreasing	  in	  fluorescence	  intensity	  (Weston	  and	  Parish,	  1990).	  	  In	  brief,	  Serca2ΔMxCre	  or	  Ctrl	  Lin-­‐	  BM	  cells	  were	  labelled	  with	  CFSE	  and	  analysed	  by	  flow	  cytometry	  daily	  over	  5	  days	  (Figure	  51	  A).	  Total	  BM	  cells,	  containing	  a	  mix	  of	  about	  20-­‐30%	  Lin-­‐	  enriched	  progenitor	  cells	  and	  mature	  Lin+	   cells,	   demonstrated	   slower	   cycling	   kinetics	   in	   (i)	   percentages	   (Figure	   51	   B)	   and	   in	   (ii)	  percentages	  quantified	  (Figure	  51	  C;	  Serca2ΔMxCre	  (n	  =	  4)	  and	  Ctrl	  (n	  =	  4))	   in	  absence	  of	  Serca2	  compared	  to	  Ctrl.	  This	  effect	  was	  more	  evident	  when	  analysing	  the	  KLS	  compartment	  (Figure	  51	  D),	   in	   which	   significantly	   less	   KLS	   cells	   underwent	   one	   additional	   division	   at	   day	   3	   (68.07	   ±	  5.81%	  versus	  89.98	  ±	  0.22%,	  n	  =	  4	  +	  4)	  and	  at	  day	  4	  (33.05	  ±	  9.93%	  versus	  90.40	  ±	  0.55%,	  n	  =	  4	  +	  4)	  when	  comparing	  Serca2-­‐deficient	  with	  Serca2-­‐competent	  cells.	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Figure	   51:	   Serca2-­‐deficient	   KLS	   cells	   show	   slower	   cell	   cycle	   kinetics	   in	   CFSE	   cell	   division	   assay.	   A,	  Experimental	   set	   up	   for	   CFSE	   cell	   division	   tracking	   of	   Serca2lox/lox	   (Ctrl)	   versus	   Serca2ΔMxCre	   derived	   lineage	  negative	  BM	   cells.	   Representative	   FACS	  histograms	  depicting	   cell	   divisions	   of	   Ctrl	   versus	  Serca2ΔMxCre	   lineage	  negative	  BM	  (B)	  and	  KLS	  (D)	  cells	  measured	  daily	  over	  5	  days.	  Quantification	  of	  cell	  divisions	  in	  total	   lineage	  negative	  cells	  (C)	  and	  KLS	  cells	  (E)	  of	  Ctrls	  and	  Serca2ΔMxCre	  mice	  (n	  =	  4	  +	  4).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  In	  summary,	  these	  data	  demonstrate	  that	  Serca2-­‐deficient	  KLS	  cells	  have	  a	  deregulated	  cell	  cycle	  with	   cells	   predominantly	   enriched	   G0	   phase,	  which	   is	   likewise	   reflected	   in	   the	   slower	   cycling	  behavior	   of	   KLS	   cells	   as	   shown	   in	   the	   CFSE	   cell	   division	   tracking	   assay.	  We	   have	   shown	   that	  
Serca2-­‐deficient	  lineage	  committed	  BM	  cells	  undergo	  apoptosis	  most	  likely	  due	  to	  ER	  stress	  and	  induction	  of	  UPR,	   in	   line	  with	   the	  up-­‐regulation	  of	  pro-­‐apoptotic	  genes	  (Figure	  41).	  Therefore,	  we	   wanted	   to	   validate	   whether	   Serca2-­‐deficient	   KLS	   may	   be	   resistant	   to	   UPR-­‐mediated	  induction	  of	  apoptosis.	  	  Expression	  of	  target	  genes	  of	  the	  UPR	  were	  mildly	  affected	  in	  Serca2ΔMxCre	  KLS	  compared	  to	  Ctrl	  (Figure	   52	   A),	   while	   expression	   of	   the	   anti-­‐apoptotic	   genes	   Bcl-­‐2	   and	   Bcl2l1	   remained	  unchanged,	  whereas	  pro-­‐apoptotic	  genes	  Bax	  and	  Bim	  were	  down-­‐	  or	  up-­‐regulated,	  respectively	  in	  Serca2-­‐deficient	  KLS	   cells	   (Figure	  52	  B).	  Overall,	   expression	   changes	   for	   candidate	  genes	  of	  UPR	   and	   apoptosis	   were	   not	   dramatically	   altered	   in	   Serca2-­‐deficient	   KLS	   cells	   compared	   to	  those	  in	  Serca2-­‐competent	  KLS	  cells.	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Figure	   52:	   Unfolded	   Protein	   Response	   Genes	   and	   apoptotis-­‐related	   genes	   are	   slightly	   deregulated	   in	  
Serca2-­‐deficient	   KLS	   cells.	   Quantitative	   RT-­‐PCR	   gene	   expression	   data	   for	   UPR	   candidate	   genes	   (A)	   and	  apoptosis-­‐related	  genes	  (B)	  of	  sorted	  Serca2ΔMxCre	  versus	  Serca2lox/lox	  (Ctrl)	  KLS	  cells.	  Error	  bars	  represent	  mean	  ±	  SD.	  N=	  minimum	  of	  3+3.	  	  In	   addition,	   we	   analysed	   UPR	   and	   apoptosis-­‐related	   gene	   expression	   comparing	   mature	  hematopoietic	   lineages	  to	  those	   in	  KLS	  cells	  (set	  to	  1)	  sorted	  from	  Serca2ΔMxCre	  chimeras.	  Upon	  
Serca2	  conditional	  inactivation,	  Lin+	  cells	  up-­‐regulated	  UPR-­‐associated	  genes	  (Figure	  53	  A)	  with	  simultaneous	  up-­‐regulation	  of	  pro-­‐apoptotic	  Bad,	  Bax	  and	  Bim	  (Figure	  53	  B).	  This	  demonstrates	  that	  in	  our	  chimeric	  mice,	  Serca2	  deficiency	  primarily	  affects	  mature	  cells	  compared	  to	  the	  KLS	  pool,	  that	  contains	  HSC	  and	  MPP	  subpopulations.	  	  	  
	  
Figure	   53:	   Unfolded	   Protein	   Response	   Genes	   and	   pro-­‐apoptotic	   genes	   are	   highly	   enriched	   in	  mature	  
lineages	   compared	   to	   Serca2-­‐deficient	   KLS	   cells.	   Quantitative	   RT-­‐PCR	   gene	   expression	   data	   for	   UPR	  candidate	  genes	  (A)	  and	  apoptosis-­‐related	  genes	  (B)	  in	  sorted	  Serca2ΔMxCre	  Lin+	  BM	  compared	  to	  Serca2ΔMxCre	  KLS	  cells	  (set	  to	  1).	  Error	  bars	  represent	  mean	  ±	  SD.	  N=	  minimum	  of	  3+3.	  	  	  Taken	   together,	   we	   have	   demonstrated	   that	   Serca2-­‐deficient	   KLS	   are	   likely	   resistant	   to	   ER	  stress,	  which	  in	  contrast	  had	  a	  drastic	  effect	  on	  mature	  lineages	  by	  inducing	  apoptosis.	  This	  is	  to	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some	  extent	  consistent	  to	  the	  previously	  published	  work	  by	  the	  group	  of	  John	  Dick	  (van	  Galen	  et	  al.,	   2014),	   which	   postulates	   that	   human	   HPSCs	   (Lin-­‐CD117+CD59+CD34+CD38-­‐)	   are	   more	  sensitive	  to	  ER	  stress	  than	  progenitor	  cells	  (Lin-­‐CD117+CD59+CD34+CD38+),	   thereby	  protecting	  the	  integrity	  of	  the	  hematopoietic	  system.	  	  
5.4 Thapsigargin	  treatment	  mimics	  Serca2	  LOF	  in	  vitro	  	  The	  chemical	  compound	  thapsigargin	  (TH)	  is	  known	  to	  cause	  calcium	  imbalance	  in	  the	  cells	  by	  specifically	  blocking	   the	  ATPase	   function	  of	  Serca	  pumps	  (Thastrup	  et	  al.,	  1990).	  The	  group	  of	  Kimberly	   Stegmaier	   identified	   TH	   as	   potential	   Notch1	   inhibitor	   in	   human	   T-­‐ALL	   cells	   and	  therefore	  TH	  represents	  a	  drug	   candidate	   for	   the	   treatment	  of	  T-­‐ALL	   (Roti	   et	   al.,	   2013).	  TH,	   a	  non-­‐competitve	  ATP-­‐ase	  inhibitor	  specifically	  blocking	  the	  action	  of	  calcium	  pumps	  of	  the	  Serca	  family,	  was	   shown	   to	   induce	  ER	  stress	  primarily	   in	  human	  HSCs	  compared	   to	  progenitor	   cells	  (van	  Galen	  et	  al.,	  2014).	  Therefore,	  we	  set	  out	  to	  study	  the	  effect	  of	  TH	  treatment	  on	  BM	  cells	  and	  investigated	  whether	   inhibition	   of	   Serca2	   in	  BM	   cells	   in	   vitro	  may	   recapitulate	   the	   phenotype	  observed	   in	   Serca2-­‐deficient	   animals.	   Therefore,	   BM	   cells	   from	   C57BL6/J	   WT	   animals	   were	  isolated,	  enriched	  for	  lineage	  negative	  cells	  and	  treated	  with	  200	  nM	  TH	  for	  1,	  6,	  24	  and	  40	  h	  or	  DMSO	  (Ctrl)	  (Figure	  54	  A).	  Prolonged	  TH	  treatment	  significantly	  affected	  the	  proliferation	  of	  the	  total	   population	   of	   MACS	   enriched	   Lin-­‐	   BM	   cells	   in	   culture.	   Absolute	   cell	   numbers	   were	  dramatically	  reduced	  upon	  24	  h	   treatment	  (0.52	  ±	  0.24	  *	  106	  cells,	  n	  =	  3)	  compared	  to	  DMSO-­‐treated	  controls	  (3.14	  ±	  0.22	  *	  106	  cells,	  n	  =	  3)	  and	  cell	  numbers	  remained	  equally	  low	  at	  40	  h	  post	  treatment	  (Figure	  54	  B).	  	  	  	  
	  
Figure	   54:	   Prolonged	   thapsigargin	   treatment	   inhibits	   proliferation	   of	   total	   MACS	   enriched	   lineage	  
negative	  BM	  population	  cells	  in	  vitro.	  A,	  WT	  C57BL6/J	  BM	  cells	  were	  enriched	  for	  lineage	  negative	  cells	  and	  the	  total	  population	  was	  cultured	  in	  presence	  of	  200	  nM	  thapsigargin	  (TH)	  or	  DMSO	  (Ctrl)	  over	  a	  time	  course	  of	  1,	  6,	  24	  and	  40	  h.	  B,	  Absolute	  cell	  numbers	  in	  presence	  of	  TH	  compared	  to	  Ctrl	  over	  0,	  1,	  6,	  24	  and	  40	  h	  (n	  =	  3	  +	  3).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	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5.4.1 Thapsigargin	   induces	   Apoptosis	   of	   Total	   MACS	   enriched	   Lineage	  
negative	  Cells	  in	  vitro	  Given	  the	  significant	  reduction	  in	  absolute	  cell	  numbers	  of	  TH-­‐treated	  cells	  compared	  to	  control,	  we	   speculated	   that	   TH	   may	   induce	   apoptosis	   as	   shown	   for	   mature	   BM	   lineages	   in	   Serca2-­‐deficient	  chimeric	  mice.	  	  Analysis	   of	   MACS	   enriched	   Lin-­‐	   total	   BM	   cells	   cultured	   in	   the	   presence	   of	   200	   nM	   TH	  demonstrated	  that	  with	  increasing	  treatment	  duration,	  TH	  is	  a	  strong	  apoptosis-­‐inducing	  agent	  in	  these	  cells	  (Figure	  55	  A	  upper	  panel).	  At	  24	  h	  post	  treatment,	  51.57	  ±	  3.75%	  of	  cells	  (n	  =	  3)	  were	   apoptotic	   compared	   to	   13.37	   ±	   2.88%	   in	   DMSO-­‐treated	   controls	   (n	   =	   3).	   The	   cytotoxic	  effect	   of	   TH	   was	   even	   more	   striking	   after	   40	   h,	   when	   71.67	   ±	   4.14%	   of	   Lin+	   BM	   cells	   were	  apoptotic	   compared	   to	  14.10	  ±	  3.77%	   in	  control	   cultures.	   In	   contrast,	  when	  gating	  on	   the	  Lin-­‐	  cell	   fraction	   in	   the	   same	   culture	   conditions,	   we	   did	   not	   observe	   apoptotic	   cells	   (Figure	   55	   A	  lower	  panel),	  which	  was	  consistent	  until	  up	  to	  40	  h	  post	  TH	  treatment	  (Figure	  55C).	  
	  
Figure	  55:	  Prolonged	  thapsigargin	  treatment	  induces	  apoptosis	  in	  Lin+	  but	  not	  Lin-­‐	  MACS	  enriched	  BM	  
cells	  in	  vitro.	  Total	  MACS	  enriched	  lineage	  negative	  BM	  cells	  were	  treated	  with	  200	  nM	  thapsigargin	  (TH)	  for	  1,	  6,	   24	  or	  40	  h.	  A,	   Representative	  FACS	  plots	  depicting	   apoptosis	   staining	   for	  Annexin-­‐V	  versus	  DAPI	  over	   the	  timecoure	  of	  thapsigargin	  treatment	  for	  Lin+	  (upper	  panel)	  and	  Lin-­‐	  fraction	  (lower	  panel).	  Quantification	  of	  apoptotic	  cells	   in	  presence	  of	  thapsigargin	  compared	  to	  DMSO	  treatment	  (n	  =	  3)	  for	  Lin+	  fraction	  (B)	  and	  Lin-­‐	  cells	  (C).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001).	  	  	  	  	  These	  data	  indicate	  that	  in	  vitro	  inhibition	  of	  Serca	  ATPases	  in	  C57BL6/J	  WT	  cells	  via	  treatment	  with	  TH	  recapitulates	  the	  induction	  of	  apoptosis	  we	  observed	  in	  mature	  lineages	  of	  Serca2	  cKO	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animals.	   This	   observation	   raised	   the	   question	   whether	   the	   KLS	   compartment	   may	   also	   be	  affected	  in	  response	  to	  TH	  treatment.	  	  	  
5.4.2 Thapsigargin	  induces	  an	  enrichment	  of	  the	  KLS	  population	  in	  vitro	  We	  then	  investigated	  whether	  TH-­‐mediated	  blockage	  of	  Serca	  pumps	  in	  WT	  MACS	  enriched	  Lin-­‐	  BM	   cells	   may	   affect	   the	   HSC	   compartment	   over	   time.	   Phenotypic	   analysis	   for	   cell	   surface	  expression	   of	   CD117	   and	   Sca1	   on	   Lin-­‐	   BM	   cells	   revealed	   an	   enrichment	   of	   KLS	   cells	   in	   (i)	  percentages	  (Figure	  56	  A,	  B)	  and	  (ii)	  absolute	  cell	  numbers	  (Figure	  56	  C)	  following	  TH	  treatment	  for	  6,	  24	  and	  40	  h.	  	  	  
	  
Figure	  56:	  Prolonged	  thapsigargin	  treatment	  induces	  an	  enrichment	  of	  the	  KLS	  population	  in	  vitro.	  Total	  population	  of	  MACS	  enriched	  lineage	  negative	  BM	  cells	  were	  treated	  with	  200	  nM	  thapsigargin	  (TH)	  or	  DMSO	  (Ctrl)	  for	  1,	  6,	  24	  and	  40	  h.	  A,	  Representative	  FACS	  plots	  depicting	  cell	  surface	  staining	  for	  CD117	  versus	  Sca1,	  gated	  on	  lineage	  negative	  cells,	  over	  the	  time	  course	  of	  TH	  treatment.	  Percentage	  (B)	  and	  absolute	  cell	  numbers	  (C)	  of	  KLS	  cells	  in	  presence	  of	  TH	  compared	  to	  DMSO	  (n	  =	  3	  +	  3).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001,	  ****	  p	  <	  0.0001).	  	  	  	  	  The	  percentage	  of	  KLS	  cells	  progressively	  increased	  over	  time	  in	  presence	  of	  TH,	  with	  a	  maximal	  enrichment	  of	  35.80	  ±	  2.05%	  KLS	  cells	  in	  TH-­‐treated	  cultures	  versus	  6.10	  ±	  0.10%	  KLS	  cells	  in	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DMSO-­‐treated	  cultures	  (Figure	  56	  A).	  In	  contrast,	  the	  absolute	  number	  of	  KLS	  cells	  peaked	  at	  6	  h	  with	   12.97	   ±	   0.84	   *	   104	   compared	   to	   3.82	   ±	   0.31*	   104	   for	   Ctrl	   (Figure	   56	   C).	   Prolonged	   TH	  treatment	  for	  24	  h	  still	  led	  to	  increased	  absolute	  cell	  numbers	  (TH	  =	  4.97	  ±	  0.81	  *	  104	  versus	  Ctrl	  =	  2.13	  ±	  0.37	  *	  104),	  40	  h	  treatment	  in	  contrast	  did	  no	  longer	  reflect	  in	  more	  KLS	  cells	  compared	  to	  Ctrl,	  which	  is	  likely	  due	  to	  the	  (i)	  overall	  strong	  reduction	  in	  proliferation	  (Figure	  56)	  and	  (ii)	  induction	   of	   apoptosis	   (Figure	   56)	   in	   the	   total	   population	   of	   MACS	   enriched	   Lin-­‐	   BM	   cells	   in	  response	  to	  TH.	  Overall,	  these	  data	  indicate	  that	  KLS	  cells	  were	  persistently	  enriched	  in	  presence	  of	   TH,	   indicating	   that	   chemical	   inhibition	   of	   Serca	   pumps	   in	   vitro	   recapitulates	   the	   KLS	  enrichment	  phenotype	  observed	  in	  Serca2ΔMxCre	  chimeras	  in	  vivo.	  	  
5.4.3 Thapsigargin	  does	  not	   induce	  Apoptosis	   in	  KLS	  cells	  but	  deregulates	  
their	  Cell	  Cycle	  in	  vitro	  Upon	   analysis	   of	   TH	   treated	   Lin-­‐	   BM	   cells	   we	   observed	   an	   enrichment	   of	   KLS	   cells	   with	  simultaneous	   and	   progressive	   apoptosis	   of	   lineage-­‐committed	   cells	  with	   increasing	   treatment	  duration.	   	   We	   hypothesized	   that	   TH	   treatment,	   similarly	   to	   Serca2	   deficiency	   in	   vivo,	   may	  regulate	  the	  survival	  of	  KLS	  cells.	  Apoptosis	  analysis	  of	  the	  KLS	  compartment	  after	  1,	  6,	  24	  and	  40	  h	  of	  treatment	  demonstrated	  similarly	  low	  levels	  of	  apoptotic	  cells	  in	  presence	  or	  absence	  of	  TH	  (data	  not	  shown).	  These	   in	  vitro	   results	  were	  confirmative	  of	   the	  absence	  of	  apoptotic	  KLS	  cells	   in	   Serca2-­‐deficient	   chimeras	   described	   earlier	   (Figures	   48,	   49)	   and	   raised	   the	   question	  whether	  TH-­‐treated	  KLS	  may	  have	  a	  cell	  cycle	  defect.	  	  One	  hour	  TH	  treatment	  did	  not	  affect	  cycling	  behavior	  of	  KLS	  cells	   in	  comparison	  with	  DMSO-­‐treated	   Ctrls	   (Figure	   57	   A,	   B),	   while	   6	   h	   treatment	   induced	   an	   enrichment	   of	   KLS	   cells	   in	   G1	  phase	   at	   the	   expense	   of	   S/G2/M	   phase	   cells	   (Figure	   57	   A,	   B).	   Prolonged	   treatment	   with	   TH,	  however	   led	   to	   a	   block	   of	   KLS	   cells	   in	   G0	   phase	   of	   the	   cell	   cycle,	   in	   which	   predominantly	  quiescent	  HSCs	  reside	  under	  physiologic	  conditions.	  This	  effect	  was	  most	  evident	  with	  87.47	  ±	  4.18%	   TH-­‐treated	   KLS	   cells	   in	   G0	   phase	   compared	   to	   27.33	   ±	   6.57%	   Ctrl-­‐treated	   KLS	   cells	  (Figure	  57	  B)	  at	  40	  h	  post	  treatment.	  	  
Results	  –	  Part	  II:	  Role	  of	  Serca2	  in	  Hematopoiesis	   94	  
	  
Figure	   57:	   Prolonged	   thapsigargin	   treatment	   induces	   cell	   cycle	   arrest	   in	   KLS	   cells	   in	   vitro.	   Lineage	  negative	  BM	  cells	  were	  treated	  with	  thapsigargin	  (TH)	  or	  DMSO	  (Ctrl)	  for	  1,	  6,	  24	  and	  40	  h.	  A,	  Representative	  FACS	   contour	   plots	   depicting	   cell	   cycle	   staining	   for	   Ki-­‐67	   versus	   Hoechst,	   gated	   on	   KLS	   cells,	   over	   the	   time	  course	  of	  thapsigargin	  treatment.	  B,	  Percentage	  of	  cells	  in	  cell	  cycle	  phases	  G0,	  G1	  and	  S/G2/M	  in	  presence	  of	  thapsigargin	  compared	  to	  DMSO	  treatment	  (n	  =	  3+3).	  Error	  bars	  represent	  mean	  ±	  SD	  (*	  p	  <	  0.05;	  **	  p	  <	  0.01,	  ***	  p	  <	  0.001,	  ****	  p	  <	  0.0001).	  	  In	   summary,	   we	   have	   demonstrated	   that	   inhibition	   of	   Serca	   calcium	   pumps	   using	   the	   non-­‐competitive	   ATPase	   inhibitor	   TH	   in	   vitro	   effectively	   mimics	   Serca2	   LOF	   in	   the	   BM	   in	   vivo.	  Prolonged	  TH	  treatment	  of	  BM	  cells	  induces	  apoptosis	  in	  the	  majority	  of	  mature	  hematopoietic	  cells	  (Lin+),	  while	  rare	  HSCs	  (KLS)	  are	  resistant	  to	  apoptosis	  and	  rather	  accumulate	  in	  G0	  phase	  of	   the	   cell	   cycle	   in	   presence	   of	   TH.	   These	   data	   are	   somewhat	   confirmative	   to	   previously	  published	  data,	  which	  claims	  that	  HSCs	  are	  very	  sensitive	  to	  ER	  stress.	  More	  importantly,	  these	  data	  question	  the	  use	  of	  TH	  for	  the	  treatment	  of	  T-­‐ALL.	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Aberrant	   Notch	   pathway	   activation	   is	   frequently	   linked	   to	   T-­‐ALL	   and	   therefore	   the	   Notch	  signalling	   pathway	   represents	   a	   bona	   fide	   drug	   target.	   Therefore,	   Rajwinder	   Lehal	   and	  Stegmaier	  et	  al.	  set	  out	  to	  identify	  novel	  inhibitors	  of	  the	  Notch	  pathway	  by	  performing	  chemical	  compound	   screens	   (Lehal,	   2011;	   Roti	   et	   al.,	   2013).	   Co-­‐culture	   based	   chemical	   compound	  screening	   in	  HeLa	  cells,	   stably	  expressing	  N1	  and	  Dll4	   ligand,	   identified	  CPA	  as	  potent	  drug	   to	  down-­‐regulate	  Notch	  pathway	  activation	  and	  downstream	  target	  genes	  such	  as	  Hes1,	  cmyc	  and	  
Deltex1	  (Lehal,	  2011).	  Similarly,	  when	  screening	  for	  chemical	  inhibitors	  in	  Notch-­‐driven	  DND41	  T-­‐ALL	   cells,	   Stegmaier	   et	   al.	   identified	   CPA	   and	   TH,	   both	   compounds	   inhibiting	   pumps	   of	   the	  Serca	   family	   of	   calcium	   ATPases.	   A	   complementary	   cDNA	   library	   screen	   was	   conducted	   in	  parallel	  in	  order	  to	  identify	  factors	  that	  would	  potentiate	  oncogenic	  Notch.	  This	  approach	  led	  to	  the	  identification	  of	  Serca2,	  thereby	  confirming	  previous	  results	  (Roti	  et	  al.,	  2013).	  Although	  this	  work	   shows	   that	   Serca2	   is	   indeed	   regulating	   N1,	   the	   work	   did	   not	   address,	   whether	   Serca2	  function	  is	  specific	  for	  Notch,	  or	  may	  have	  additional	  function	  within	  the	  hematopoietic	  system.	  This	   is	  of	   importance	  since	  Serca2	  has	  been	  suggested	  as	  a	  potential	  novel	  drug	  target	   to	   fight	  Notch-­‐driven	   T-­‐ALL.	   Therefore,	   we	   set	   out	   to	   study	   the	   impact	   of	   Serca2	   ablation	   on	   the	  hematopoietic	   system,	   mainly	   to	   address	   whether	   i)	   Serca2	   deficiency	   may	   recapitulate	   the	  Notch	  LOF	  effects	  on	  T	  and	  MZB	  cell	  development	  and	   ii)	   to	  assess	  whether	  a	  Serca2	   inhibitor	  may	  be	  an	  applicable	  therapeutic	  target	  for	  T-­‐ALL,	  as	  previously	  suggested.	  
6.1 Functional	  Characterization	  of	  loss	  of	  one	  Serca2	  allele	  in	  the	  
Hematopoietic	  system	  Missense	  mutations	  in	  the	  SERCA2	  encoding	  gene	  ATP2A2	  are	  strongly	  linked	  to	  Darier´s	  disease	  in	  humans	  (Sakuntabhai	  et	  al.,	  1999).	  As	  a	  result,	  one	  SERCA2	  allele	   is	   functionally	   inactivated	  leading	   to	   genodermatosis,	   characterized	   by	   an	   abnormal	   hyperkeratotic	   epidermis,	   nail	  abnormalities	   and	   mucous	   membrane	   defects.	   Interestingly,	   mice	   heterozygous	   for	   Serca2	  (Serca2+/-­‐)	   develop	   squamous	   cell	   carcinoma	   of	   the	   skin	   (Prasad	   et	   al.,	   2004),	   which	   is	  confirmative	   of	   the	   identification	   of	   ATP2a2	   as	   the	   Darier´s	   disease-­‐causing	   gene.	   Taken	  together,	   these	   studies	   demonstrate	   a	   gene	   dosage	   effect	   for	   SERCA2	   in	   regulating	   skin	  homeostasis.	   Therefore,	   we	   addressed	   the	   question	   whether	   Serca2	   haploinsufficiency	   may	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impact	  on	  the	  hematopoietic	  system	  and	  studied	  conditional	  ablation	  of	  one	  Serca2	  allele	  under	  physiological	  and	  competitive	  conditions	  (Appendix	  Section	  7.6).	  We	  did,	  however,	  not	  observe	  any	   lineage	   specification	   deficits	   in	   these	   chimeric	   mice	   under	   steady	   state	   conditions.	  Furthermore,	   Serca2	   haploinsufficiency	   did	   not	   render	   HSCs	   less	   susceptible	   to	   5-­‐FU-­‐induced	  mobilization	   and	   subsequent	   exhaustion	   upon	   prolonged	   treatment,	   thereby	   ablating	   mature	  hematopietic	   lineages	  and	  forcing	  HSCs	  to	  self-­‐renew	  and	  differentiate.	  We	  also	  studied	  Serca2	  haploinsufficiency	   in	  competitive	  BM	  chimeras	  and	  under	  serial	   transplantation	  stress,	  but	  did	  not	  observe	  any	  overt	  changes	  in	  short-­‐term	  multi-­‐lineage	  reconstitution	  capacity	  in	  absence	  of	  one	   functional	  Serca2	  allele.	   In	  addition,	  T	  cell	  development	  was	  unperturbed	  when	  studied	   in	  these	   chimeras	  under	  physiological	   and	   competitive	   conditions.	  N1	   conditional	   ablation	   in	   the	  BM	  is	  crucial	  for	  T	  lineage	  versus	  B	  lineage	  commitment,	  however	  ectopic	  B	  cell	  development	  in	  the	  thymus	  only	  occurs	  when	  conditionally	  targeting	  both	  N1	  alleles	  for	  inactivation	  (Radtke	  et	  al.,	   1999).	   Recent	   studies	   by	   Stegmaier	   et	   al.	   proposed	   that	   Serca2	   regulates	   N1	   maturation	  leading	  to	   increased	  NICD	  protein	  available	   for	  signalling.	  Consequently,	  chemical	   inhibition	  of	  Serca2	   with	   TH,	   resulted	   in	   the	   accumulation	   of	   misfolded	   Notch	   receptors	   within	   the	   ER,	  thereby	  reducing	  Notch	  receptor	  numbers	  available	  for	  trafficking	  to	  the	  cell	  membrane	  (Roti	  et	  al.,	   2013).	   For	   our	  work,	   this	  may	   suggest,	   that	   Serca2	   haploinsufficiency	   does	   not	   efficiently	  induce	  misfolding	  of	  Notch	  receptors,	  whereby	  the	  trafficking	  and	  occurrence	  of	  Notch	  receptors	  to	  and	  at	  the	  cell	  membrane	  remains	  unperturbed.	  Therefore,	  Serca2	  haploinsufficiency	  cannot	  mimic	  N1	   LOF	   in	   the	   thymus	   and	   T	   cell	   development	   remains	   unaffected.	   To	   experimentally	  prove	   this	   hypothesis,	   target	   genes	   of	   the	   UPR	   could	   be	   measured	   in	   BM	   cells	   derived	   from	  
Serca2-­‐haploinsufficient	  and	  Ctrl	  chimeras.	  	  	  In	   conclusion,	   one	   functional	   Serca2	   allele	   can	   compensate	   haploinsufficiency	   during	  hematopoiesis,	  suggesting	  that	  gene	  dosage	  does	  not	  majorly	  impact	  in	  this	  self-­‐renewing	  organ,	  which	  is	  in	  contrast	  to	  Serca2	  function	  in	  the	  skin.	  	  
6.2 Functional	  Characterization	  of	  SERCA2	  loss	  of	  function	  in	  the	  
Hematopoietic	  System	  
Serca2	  conditional	  inactivation	  was	  studied	  in	  chimeras	  in	  order	  to	  limit	  Serca2	  deletion	  to	  BM	  cells.	   Upon	   transplantation,	   residual	   recipient-­‐derived	   WT	   CD45.1+	   cells	   outnumbered	  
Serca2ΔMxCre	   CD45.2+	   cells	   over	   time,	   leading	   to	   a	   significant	   reduction	   in	   overall	  multi-­‐lineage	  reconstitution	   in	  Serca2-­‐deficient	   chimeras.	   This	   effect	  was	   cell	   intrinsic	   as	  Serca2	   conditional	  ablation	   was	   studied	   solely	   in	   BM	   chimeras,	   in	   which	   BM	   niche	   cells	   are	   not	   targeted	   for	  deletion.	  Upon	  analysis	  of	  the	  BM,	  we	  observed	  a	  strong	  reduction	  in	  total	  BM	  cellularity,	  which	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was	   characterized	   by	   reduced	   numbers	   of	   mature	   lineages	   of	   myeloid	   origin	   (CD11b+Gr1+),	  erythroid	   origin	   (Ter119+CD71+)	   and	   also	   affecting	   B	   (B220+IgM+)	   cell	   numbers.	   Further	  analysis	  demonstrated	  that	  these	  cells	  underwent	  apoptosis	  in	  response	  to	  Serca2	  inactivation.	  These	   data	   indicate	   that	   conditional	   Serca2	   ablation	   in	   the	   BM	   globally	   affects	   the	   survival	   of	  mature	   hematopoietic	   lineages.	   	   Since	   N1	   signaling	   is	   crucial	   for	   T	   lineage	   versus	   B	   lineage	  commitment	   in	   the	   thymus	   (Radtke	  et	  al.,	  1999)	  and	  Serca2	  was	  demonstrated	   to	  regulate	  N1	  maturation	  (Roti	  et	  al.,	  2013),	  we	  analysed	  thymi	  of	  Serca2ΔMxCre	  and	  control	  chimeras.	  Similarly	  to	   the	  BM,	   total	   thymic	   cellularity	  was	   severely	   reduced	  upon	   conditional	  Serca2	   inactivation.	  Upon	   analysis	   of	   T	   cell	   maturation	   stages,	   we	   observed	   reduced	   numbers	   of	   cells	   passing	  through	  all	  DN1	   to	  DN4	  stages	  of	  differentiation,	  which	   is	  majorly	  due	   to	   reduced	  Serca2ΔMxCre	  ETP	  numbers	  migrating	  from	  the	  BM	  into	  the	  thymus.	  Upon	  closer	  analysis	  CD4-­‐CD8-­‐Lin-­‐	  thymic	  progenitors,	  we	  did	  observe	  an	  enrichment	  of	  CD44hiCD117-­‐	  cells,	  similar	  to	  the	  phenotype	  for	  
N1	  LOF	  previously	  published	  (Radtke	  et	  al.,	  1999).	  These	  cells,	  however,	  were	  not	  committed	  to	  the	  B	  cell	  lineage	  as	  assessed	  by	  the	  markers	  B220	  and	  IgM.	  Beyond	  TCRβ	  selection,	  Serca2ΔMxCre	  chimeras	  had	  significantly	  less	  immature	  CD4+CD8+DP	  cells	  compared	  to	  controls,	  which	  may	  be	  explained	  by	  their	  higher	  sensitivity	  to	  apoptotic	  cues	  than	  CD4+SP	  or	  CD8+SP	  cells,	  which	  have	  passed	  negative	  and	  positive	  selection.	  	  In	   addition,	   we	   studied	   mature	   peripheral	   lineages	   in	   the	   spleen	   of	   Serca2ΔMxCre	   and	   control	  chimeras.	   Similarly	   to	   the	   BM	   and	   the	   thymus,	   absolute	   cell	   numbers	   were	   reduced	   in	   the	  spleens	  of	  Serca2-­‐deleted	  chimeras,	  affecting	  all	  studied	  cell	  types	  of	  mature	  B	  and	  T	  cells.	  	  While	  N1	   is	   crucial	   for	  T	  cell	  differentiation,	  N2	  regulates	  MZB	  cell	  development	   in	   the	  spleen	  (Saito	   et	   al.,	   2003).	   Therefore,	  we	   studied	  MZB	   cells	   in	  Serca2-­‐deficient	   chimeras,	  which	  were	  significantly	   enriched	   in	   relative	   numbers;	   however	   this	   effect	   was	   not	   reflected	   in	   absolute	  numbers	   due	   to	   the	   reduced	   overall	   cell	   number	   of	   splenocytes.	   This	   suggests	   that	   either	   (i)	  follicular	  zone	  B	  cells	  are	  more	  sensitive	  to	  Serca2	  ablation	  and	  therefore	  MZBs	  accumulate	  or	  (ii)	   Serca2	   may	   regulate	   N2	   and	   as	   a	   consequence	   of	   Serca2	   inactivation	   N2	   signalling	   is	  deregulated	   during	   MZB	   development.	   In	   contrast,	   Serca2	   was	   identified	   to	   be	   important	   for	  maturation	   and	   cleavage	   of	   N1,	   thereby	   modulating	   Notch	   1	   signalling	   strength	   (Roti	   et	   al.,	  2013).	   This	   work	   however,	   solely	   focussed	   on	   N1	   and	   therefore,	   our	   in	   vivo	   studies	   are	  complementary,	   demonstrating	   that	   Serca2	   inhibition	   may	   also	   impact	   on	   N2	   signalling.	  However,	   in	   vitro	   studies	   performed	   by	   Rajwinder	   Lehal,	   demonstrated,	   that	   CPA,	   targeting	  Serca	   ATPases,	   primarily	   down-­‐regulates	   N1-­‐Dll4	   mediated	   Notch	   signalling,	   while	   N2-­‐Dll1-­‐induced	  signalling	  was	  not	  blocked	  in	  response	  to	  CPA	  in	  the	  co-­‐culture	  system	  (Lehal,	  2011).	  It	  is	   possible	   that	   global	   Serca	   inhibition	   by	   CPA	   treatment	  may	   account	   for	   these	   in	   vitro	   data.	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Therefore,	  further	  in	  vitro	  and	  in	  vivo	  studies	  are	  needed	  to	  delineate	  the	  potential	  role	  of	  Serca2	  in	  regulating	  N2	  signalling.	  	  	  In	  addition,	  we	  have	  studied	  functional	  consequences	  of	  Serca2	  inactivation.	  Upon	  calcium	  flux	  measurements,	  Serca2ΔMxCre	   peripheral	  T	   and	  B	   cells	   have	   a	  higher	   calcium	  baseline	  but	   lower	  intracellular	   Ca2+	   levels.	   These	   results	   indicate	   that	   Serca2-­‐deficient	   hematopoietic	   cells	   have	  indeed	  a	  deregulated	  calcium	  load	  characterized	  by	  Ca2+	  store	  depletion	  and	  thereby	  increasing	  cytosolic	   free	   Ca2+.	   	   These	   data	   are	   confirmative	   of	   previously	   published	   work,	   in	   which	   TH-­‐treatment	   induces	   Ca2+	   store	   depletion	   in	   neuronal	   cells,	   thereby	   interfering	   with	   protein	  synthesis	   (Paschen	   et	   al.,	   1996).	   	   In	   addition,	   it	   was	   shown	   previously	   that	   Notch	   receptors	  require	  Ca2+	  for	  proper	  protein	  folding	  in	  the	  ER	  (Aster	  et	  al.,	  1999)	  and	  that	  calcium	  imbalance	  within	  the	  cell	  can	  lead	  to	  protein	  misfolding	  and	  induction	  of	  the	  UPR	  (Ron	  and	  Walter,	  2007).	  During	  UPR,	   three	   different	   signalling	   branches	   are	   activated	  with	   the	   sole	   aim	   to	   resolve	   ER	  stress	   or,	   if	   unable	   to	   achieve	   this	   goal,	   induce	   apoptosis.	   Given	   the	   global	   effect	   of	   Serca2	  conditional	  inactivation	  in	  reducing	  the	  cellularity	  of	  the	  BM,	  thymus	  and	  spleen	  and	  induction	  of	   apoptosis,	   we	   characterized	   expression	   of	   UPR-­‐target	   and	   apoptosis-­‐associated	   genes	   in	  lineage	   committed	   BM	   cells.	   Serca2-­‐deficient	   cells	   showed	   up-­‐regulation	   of	   the	   UPR	   effectors	  
ATF4,	   IRE1	   and	  Grp78	   with	   a	   concomitant	   up-­‐regulation	   of	   pro-­‐apoptotic	   genes	  Bad,	  Bax	   and	  
Bim.	   Therefore,	   we	   postulate	   that	   mature	   hematopoietic	   lineages	   cannot	   sufficiently	   resolve	  
Serca2-­‐ablation	  mediated	  ER	  stress	  and	  consequently	  undergo	  apoptosis	  supposedly	  via	  Bax	  and	  Bad.	  However,	  there	  are	  several	  means	  to	  study	  UPR	  activation	  in	  mammalian	  cells.	  In	  this	  work,	  we	  were	  limited	  in	  material	  sorted	  from	  the	  HSC	  compartment	  of	  chimeric	  mice,	  and	  therefore	  performed	  qRT-­‐PCR	   for	  UPR	   genes.	  Western	  Blot	   analysis	   for	   cleaved	   caspase-­‐3,	   caspase-­‐9	   or	  caspase-­‐12	   may	   shed	   light	   on	   downstream	   effects	   of	   Serca2-­‐deficiency	   induced	   apoptosis	   in	  these	  mice.	  In	  addition,	  flow	  cytometric	  analysis	  for	  expression	  of	  pro-­‐	  (Bad,	  Bax,	  Bim)	  and	  anti-­‐apoptotic	  (Bcl2,	  Bcl2l)	  proteins	  on	  peripheral	  T	  and	  B	  cell	  subsets	  would	  demonstrate	  a	  means	  to	  confirm	  our	  qRT-­‐PCR	  data.	  	  	  Given	  the	  dramatic	  effect	  of	  Serca2	  inactivation	  on	  mature	  hematopoietic	  lineages,	  we	  addressed	  the	  hypothesis	  whether	  HSCs	  would	  be	  equally	  affected.	  Upon	  analysis	  of	  the	  KLS	  compartment	  over	  a	  time	  course	  of	  1	  w,	  4	  w	  and	  8	  w	  post	  MxCre	  induction,	  relative	  and	  absolute	  numbers	  of	  KLS	   cells	   were	   significantly	   enriched.	   This	   was	   due	   to	   an	   accumulation	   of	   both	  MPP	   subsets,	  MPP2	  (KLS,	  CD150+CD48+)	  and	  MPP3-­‐MPP4	  (KLS,	  CD150-­‐CD48+),	  while	   the	  KLS,	  CD150-­‐CD48+	  fraction,	  enriched	  for	  LT-­‐HSCs,	  was	  reduced.	  	  In	  this	  thesis,	  Serca2	  was	  deleted	  in	  BM	  progenitors	  using	  MxCre	  recombinase,	  which	  is	  induced	  by	  INFα	  and	  INFβ.	  INFα	  is	  a	  potent	  inducer	  of	  HSC	  mobilization,	  thereby	  regulating	  the	  cell	  cycle	  of	   these	   cells	   in	   order	   to	   induce	   proliferation	   (Essers	   et	   al.,	   2009).	   Therefore,	   we	   conducted	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complementary	   studies	   in	   INF-­‐responsive	  MxCre	   and	   INF-­‐irresponsive	   INFαR_KO	   chimeras	   in	  order	   to	   delineate	   the	   effect	   of	   INF-­‐induced	   stress	   in	   Serca2-­‐deficient	   chimeras.	   We	  demonstrated	  that	  ΔMxCre	   (i)	  KLS	  cells	  are	  enriched	  due	  to	  (ii)	  accumulated	  MMP	  subsets	  but	  (iii)	  reduced	  HSC	  numbers	  16h	  post	  last	  PIC	  administration.	  This	  effect	  was	  only	  transient	  as	  1	  w	  post	   last	   PIC	   injection	   HSCs	   and	   MPPs	   were	   back	   to	   homeostatic	   numbers.	   In	   contrast,	   PIC	  administration	  did	  not	  affect	  INFαR_KO	  HSCs	  confirming	  previously	  published	  data	  (Essers	  et	  al.,	  2009).	  Therefore,	  we	  propose	  that	  Serca2-­‐deficient	  KLS	  and	  HSC	  subpopulations,	  analysed	  at	  1	  w	   post	   PIC	   administration,	   may	   have	   a	   cell	   intrinsic	   defect	   and	   cannot	   sufficiently	   cope	   with	  INFα-­‐induced	   mobilization.	   This	   may	   explain	   the	   observation	   that	   Serca2ΔMxCre	   KLS	   cells	   are	  enriched	  until	  up	  to	  8	  w	  post	  PIC	  administration.	  	  In	   order	   to	   delineate	   the	   mechanisms	   by	   which	   HSC	   numbers	   are	   deregulated	   in	   absence	   of	  
Serca2,	  we	   set	  out	   to	  perform	   functional	   in	   vivo	   and	   in	   vitro	   studies.	  Cell	   cycle	  analysis	   at	  1	  w	  post	  Serca2	  ablation	  revealed	  that	  the	  majority	  of	  HSCs	  and	  MPP	  cells	  resided	  in	  G0	  phase	  of	  the	  cell	  cycle,	  suggesting	  that	  these	  populations	  stop	  proliferating	  in	  response	  to	  Serca2	  inactivation.	  These	   data	  were	   confirmed	   by	   CFSE	   cell	   division	   tracking,	   as	   Serca2ΔMxCre	   KLS	   cells	   displayed	  slower	  cycling	  kinetics	  compared	  to	  controls.	  	  This	  also	  translated	  into	  impaired	  “fitness”	  during	  the	  CFU	  differentiation	  assay	  in	  vitro,	  in	  which	  
Serca2ΔMxCre	  KLS	  cells	  gave	  rise	  to	  significantly	  lower	  and	  smaller	  colonies	  compared	  to	  control.	  Whether	  Serca2ΔMxCre	  KLS	  were	   still	   able	   to	   form	  colonies	   in	   vitro	  may	  be	  due	   to	   sort	   impurity	  and	  the	  potential	  outgrowth	  of	  CD45.1+	  WT	  in	  the	  sorted	  cell	  population.	  In	  a	  future	  experiment,	  this	  potential	  contamination	  of	  host-­‐derived	  WT	  cells,	  while	  sorting	  Serca2ΔMxCre	  KLS	  cells,	  needs	  to	  be	  monitored	  by	  deletion	  PCR	  on	  DNA	  from	  input	  KLS	  cells	  and	  DNA	  derived	  from	  Serca2ΔMxCre	  colonies.	  	  	  Therefore,	   we	   conclude	   that	   Serca2	   conditional	   ablation	   in	   the	   BM	   does	   not	   majorly	   induce	  apoptosis	   in	   the	  KLS	   compartment;	   however	   apoptosis	   analysis	   of	   the	   subfractions	  within	   the	  KLS	  pool	  demonstrated	  that	  HSCs	  (KLS,	  CD150+CD48-­‐)	  were	  more	  apoptotic	  compared	  to	  more	  differentiated	   MPP2s	   (KLS,	   CD150+CD48+)	   or	   MPP3-­‐MPP4s	   (KLS,	   CD150-­‐CD48+),	   which	   is	  confirmative	   of	   previously	   published	   work	   by	   John	   Dicks	   group.	   In	   addition,	   Serca2	   ablation	  resulted	  in	  a	  deregulation	  of	  the	  cell	  cycle	  and	  fitness	  of	  KLS	  cells.	  This	  raised	  the	  hypothesis	  if	  KLS	  cells	  may	  cope	  differently	  with	  ER	  stress	  induced	  by	  Serca2	  ablation	  than	  MPPs	  or	  mature	  lineages.	  Human	  HSCs	  have	  previously	  been	  studied	  in	  the	  context	  of	  ER	  stress	  (van	  Galen	  et	  al.,	  2014).	   In	   this	   study,	   TH-­‐	   or	   tunicamycin-­‐treated	   human	  HSC	   and	   progenitor	   cells	   (HSPC;	   Lin-­‐CD34+CD38-­‐CD59+CD117+)	  have	  been	  assessed	  for	  UPR	  activation	  upon	  ER	  stress	  compared	  to	  hematopoietic	   progenitors	   (Lin-­‐CD34+CD38+CD59+CD117+).	   Interestingly,	   hHPSCs	   activate	   the	  PERK	  branch	  of	   the	  UPR	  and	  are	  prone	   to	  ER-­‐stress-­‐induced	  apoptosis,	  while	  progenitors	   can	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cope	  with	   this	   stress	   and	   are	   resistant	   to	   apoptosis.	   Therefore,	   John	  Dick	   et	   al.	   postulate	   that	  hHSCs	   protect	   themselves	   and	   their	   progeny	   from	   potential	   stress–induced	   accumulation	   of	  mutations	   by	   choosing	   apoptosis	   over	   propagation.	   Our	   apoptosis	   analysis	   on	   overall	   KLS,	  further	  subfractionated	  into	  HSCs,	  MPP2	  and	  MPP3-­‐MPP4	  cells	  are	  confimative	  of	  this	  study,	  as	  
Serca2-­‐deficient	  HSCs	  were	  more	  apoptotic	  compared	  to	  control,	  while	  MPPs	  were	  resistant	  to	  apoptotic	  cues.	  	  We	   set	   out	   to	   study	   ER	   stress	   in	   our	   chimeras	   and	   discovered	   that	   Serca2ΔMxCre	   KLS	   did	   not	  majorly	  up-­‐regulate	  genes	  of	  the	  UPR	  or	  pro-­‐apoptotic	  genes	  in	  response	  to	  Serca2	  ablation.	  This	  is	   in	  contrast	  to	  the	  work	  by	  John	  Dicks	  laboratory	  and	  may	  be	  due	  to	  the	  fact	  that	  we	  studied	  the	  mixed	   pool	   of	   KLS	   cells	   compared	   to	   lineage	   committed	  mature	   (Lin+)	   cells.	   The	   hHPSCs	  studied	  were	  compared	  to	  progenitors,	  which	  correspond	  to	  the	  KLSCD150-­‐CD48+	  pool	  of	  HSCs	  and	  MPP1	  cells	  compared	  to	  MPP2	  cells	  (KLS,	  CD150+CD48+)	  in	  the	  mouse.	  We	  did,	  however,	  not	  include	   the	  markers	   CD150,	   CD48,	   CD34	   to	   enrich	   for	   the	   rare	   and	   pure	   LT-­‐HSCs	   and	   cannot	  state,	   at	   the	   molecular	   level,	   whether	   true	   HSCs	   are	   less	   resistant	   to	   Serca2ΔMxCre-­‐induced	   ER	  stress	  compared	  to	  MPPs	  in	  general.	  Experimentally,	  it	  will	  be	  challenging	  to	  purify	  the	  HSC	  and	  MPP	  subpopulations	  for	  downstream	  qRT-­‐PCR	  analysis,	  as	  the	  HSC	  containing	  KLSCD150-­‐CD48+	  fraction	   is	   severely	   reduced	   in	   absence	   of	   Serca2.	   Therefore,	   we	   cannot	   truly	   compare	   our	  experimental	  system	  with	  the	  one	  studied	  by	  Van	  Galen	  et	  al.	  and	  it	  is	  difficult	  to	  draw	  concrete	  conclusions.	   In	   order	   to	   so,	   Serca2ΔMxCre	   HSCs	   and	   different	  MPP	   subsets	   within	   the	   KLS	   pool	  need	  to	  be	  sorted	  and	  analysed	  for	  UPR	  target	  gene	  expression	  using	  single	  cell	  PCR	  technology.	  Nevertheless,	  our	  work	  demonstrates	  that	  HSCs	  are	  more	  prone	  to	  ER-­‐stress	  induced	  apoptosis,	  while	  MPPs	   are	  more	   resistant;	   but	   the	   overall	   KLS	   cells	   preferentially	   reside	   in	   a	   somewhat	  “frozen”	  state,	  in	  which	  they	  exist	  the	  cell	  cycle.	  	  In	   summary,	   Serca2	   conditional	   ablation	   severely	   affects	   hematopoiesis	   by	   driving	   mature	  lineages	   into	  apoptosis	   through	  activation	  of	   the	  UPR,	  while	  KLS	  cells	  are	  not	  overly	  apoptotic	  but	   show	   a	   deregulated	   cell	   cycle	   and	   impaired	   “fitness”.	   Therefore,	   we	   question	   targeting	  Serca2	  as	  potential	  treatment	  of	  T-­‐ALL	  in	  patients	  as	  Serca2	  inhibition	  will	  cause	  dramatic	  side	  effects	  on	  normal	  hematopoietic	  cells	  and	  will	  not	  specifically	   target	  T-­‐ALL	  cells,	  as	  previously	  postulated	  (Roti	  et	  al.,	  2013).	  	  
6.3 Thapsigargin	  treatment	  mimics	  Serca2	  LOF	  in	  vitro	  The	   chemical	   compounds	   CPA	   and	   TH,	   targeting	   Serca	   ATPases,	   were	   identified	   as	   putative	  Notch	  inhibitors	  by	  Rajwinder	  Lehal	  and	  Roti	  et	  al.	  (Lehal,	  2011;	  Roti	  et	  al.,	  2013).	  TH	  treatment	  of	  Notch-­‐driven	  T-­‐ALL	   cell	   lines	   negatively	   affected	   their	   proliferation,	   induced	   apoptosis	   and	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led	  to	  a	  deregulation	  of	  the	  cell	  cycle	  in	  vitro,	  while	  TH	  in	  vivo	  marginally	  but	  significantly	  slowed	  down	  T-­‐ALL	  in	  Xenograft	  models.	  Therefore,	  TH	  treatment	  was	  postulated	  as	  novel	  therapeutic	  approach	   to	   dampen	   oncogenic	  Notch1	   in	   T-­‐ALL	   through	  modulation	   of	   Ca2+	   levels	   by	   Serca2	  inhibition	   (Roti	   et	   al.,	   2013).	  However,	   this	  work	  did	  not	   address	   potential	   function	   of	   Serca2	  regulating	  hematopoiesis.	  We	  therefore	  investigated	  the	  effect	  of	  conditional	  Serca2	  inactivation	  in	  the	  BM	  and	  demonstrated	  that	  (i)	  mature	  hematopoietic	  lineages	  are	  apoptotic	  in	  response	  to	  Serca2	   LOF,	   while	   (ii)	   KLS	   cells	   accumulate	   and	   (iii)	   LT-­‐HSCs	   and	   the	   most	   HSC-­‐like	   MMP1	  subset	   are	   severely	   reduced,	   leading	   to	   a	   concomitant	   increase	   in	   other	   further	   differentiated	  MPP	  cells.	  	  Being	   clinically	  more	   relevant,	  we	   set	   out	   to	   study	   the	   effect	   of	   TH	   on	   BM	  progenitor	   cells	   in	  
vitro.	  Upon	  enrichment	  of	  Lin-­‐	   cells	   from	  BM	  of	  WT	  animals	  and	   treatment	  over	  a	   time	  course	  over	  1,	  6,	  24	  and	  40	  h,	  we	  observed	  a	  strong	  reduction	  in	  proliferation	  of	  the	  overall	  mixed	  cell	  population	  (Lin-­‐	  and	  Lin+	  fractions)	  in	  response	  to	  TH.	  	  Calcium	   imbalance	   in	   the	   cell	   and	   chemical	   blockage	   of	   Serca	   pumps	   was	   shown	   to	   induce	  accumulation	   of	   unfolded	   proteins	   in	   the	   ER,	   consequently	   leading	   to	   induction	   of	  chaperone/stress	   proteins	   in	   an	   effort	   to	   increase	   the	   impaired	   folding	   capacity.	   In	   case	   of	  “unresolved”	   ER	   stress	   the	   cell	   however	   decides	   to	   undergo	   apoptosis	   (Kim	   et	   al.,	   2008).	  Therefore,	  we	  hypothesized	  TH-­‐mediated	  Serca	   inhibition	  may	   induce	   apoptosis	   in	   these	   cells	  and	  assessed	   their	  viability	  at	   the	   indicated	   time	  points	  of	   treatment.	  Lineage	   committed	   cells	  were	   highly	   apoptotic	   with	   increasing	   treatment	   duration,	   while	   KLS	   cells	   were	   viable	   at	   all	  assessed	  time	  points.	  This	  suggests,	  that	  similar	  to	  the	  results	  achieved	  in	  Serca2ΔMxCre	  chimeras,	  mature	   lineages	   are	  more	   sensitive	   to	   calcium	   imbalance-­‐induced	   ER	   stress	   and	   induction	   of	  apoptosis.	   Interestingly,	   upon	   TH-­‐treatment,	   KLS	   cells	   were	   significantly	   enriched	   in	   vitro.	   As	  early	   as	   6	   h	   post	   treatment,	   KLS	   cells	   accumulated	   and	  were	  maximal	   enriched	   at	   40	   h	   post	  treatment.	  We	  reasoned	  that	   this	  may	  be	  due	   to	  enhanced	  proliferation	  of	  KLS	  cells.	  Upon	  cell	  cycle	  analysis,	  however,	  TH-­‐treatment	  caused	  a	  predominant	  block	  of	  KLS	  cells	  in	  G0	  phase	  of	  the	  cell	  cycle.	  Within	  the	  KLS	  pool,	   there	  are	  quiescent	  HSCs	  (>70%	  in	  G0	  phase)	  and	  the	  different	  MPP	  subsets	  (<10%	  in	  G0	  phase)	  (Wilson	  et	  al.,	  2008).	  It	  would	  be	  interesting	  to	  include	  the	  cell	  surface	  markers	  CD34,	  CD48	  and	  CD150	  in	  our	  analysis	  in	  order	  to	  characterize	  whether	  Serca	  inhibition	   predominantly	   enriches	   for	   the	   rare	   dormant	   HSC	   (KLSCD34-­‐CD150-­‐CD48+)	   or	  whether	  HSCs	  and	  MPPs	  are	  equally	  affected	  upon	  TH	  treatment	  in	  vitro.	  	  	  These	  data	  indicate	  that	  Serca	  inhibition	  in	  vitro,	  renders	  lineage	  committed	  cells	  more	  sensitive	  to	   TH-­‐induced	   ER	   stress	   and	   induction	   of	   apoptosis	   than	   KLS	   cells.	   This	   may	   be	   an	   adaptive	  response	  of	  KLS	  cells	  to	  cope	  with	  this	   intrinsic	  stress	  signals,	   in	  order	  to	  protect	  their	  genetic	  information	  from	  mutations,	  which	  would	  consequently	  be	  passed	  on	  to	  their	  progeny.	  However,	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long-­‐term	   reconstitutive	   potential	   of	  MPPs	   is	   limited	   and	   if	   HSCs	  within	   the	   KLS	   pool	   rapidly	  undergo	   apoptosis	   upon	   TH	   treatment,	   then	   MPPs	   cannot	   account	   for	   multilineage	  differentiation	   over	   unlimited	   time.	   These	   results	   demonstrate	   that	   low	   doses	   of	   TH	   in	   the	  nanomolar	  range	  (200	  nM)	  significantly	  affect	   total	  MACS	  enriched	  Lin-­‐	  BM	  cells	   in	  vitro	  by	  (i)	  inducing	  apoptosis	  in	  the	  overall	  population,	  while	  (ii)	  inducing	  an	  enrichment	  of	  KLS	  cells,	  that	  (iii)	  primarily	  reside	  in	  G0	  phase	  of	  the	  cell	  cycle,	  when	  treated	  for	  6	  h	  or	  longer.	  	  These	  observations	  closely	  mimic	  Serca2	  conditional	  inactivation	  in	  the	  BM	  as	  described	  during	  this	  work.	  However,	  TH	  is	  a	  non-­‐competitive	  ATPase	  inhibitor	  blocking	  the	  function	  of	  all	  Serca	  family	   members.	   In	   order	   to	   confirm	   Serca2	   specificity	   in	   these	   in	   vitro	   studies,	   it	   would	   be	  worth	  targeting	  WT	  BM	  progenitors	  for	  CRISPR-­‐	  mediated	  Serca2	  KD.	  	  	  However,	   comparison	   of	   genetic	   Serca2	   LOF	   studies	   in	  Serca2ΔMxCre	   chimeras	  with	   TH	   studies	  performed	  in	  vitro	  strongly	  suggests	  that	  the	  effect	  is	  Serca2-­‐specific.	  In	  addition,	  it	  is	  tempting	  to	  hypothesize	  whether	  other	  ER	  stress-­‐inducing	  agents	  may	  induce	  similar	  downstream	  effects	  in	  BM	  progenitors	  as	  TH.	  	  In	   conclusion,	   we	   demonstrate	   that	   TH	   treatment	   induces	   apoptosis	   in	   the	   overall	   MACS	  enriched	   Lin-­‐	   population,	   while	   leading	   to	   a	   deregulated	   cell	   cycle	   of	   KLS	   cells.	   Therefore,	  treatment	   of	   N1-­‐induced	   T-­‐ALL	   with	   TH	   may	   result	   in	   severe	   side	   effects	   and	   needs	   to	   be	  carefully	   monitored	   and	   controlled.	   Taken	   together,	   we	   question	   the	   applicability	   of	   Serca2	  inhibition	  as	  treatment	  regimen	  to	  fight	  Notch1-­‐activated	  T-­‐ALL.	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  7 Material	  and	  Methods	  
7.1 Mouse	  Work	  	  
7.1.1 Experimental	  Mice	  Multiple	  genetically	  modified	  mouse	  strains	  were	  used	   in	   this	  work.	  RosaNotchIC	   (RNIC)	  mice	  were	  generated	  by	  L.C.	  Murtaugh	   	  and	  kindly	  provided	  by	  Prof.	  D.	  Melton,	  Harvard	  University,	  MA.	  These	  mice	  harbor	  the	  intracellular	  domain	  of	  the	  mouse	  Notch1	  receptor	  lacking	  the	  PEST	  domain	  (NICD	  aa	  1749-­‐2293),	  which	  is	  preceeded	  by	  a	  stop	  cassette	  flanked	  by	  loxP	  sites.	  This	  allows	  the	  over-­‐expression	  of	  NICD	  from	  the	  Rosa26	  locus	  upon	  activation	  of	  Cre	  recombinase.	  NICD	   is	   fused	   to	   an	   internal	   ribosomal	   entry	   site	   (IRES)	   and	   the	   enhanced	   green	   fluorescent	  protein	  (eGFP).	  Therefore,	  detection	  of	  eGFP	  expressing	  cells	  can	  be	  used	  as	  an	  indirect	  means	  of	  monitoring	   NICD	   expression.	   In	   this	   work,	   RNIC	   mice	   were	   crossed	   onto	   the	   Chd7lox/lox	  background	  in	  combination	  with	  either	  the	  Mx1Cre	  (Kuhn	  et	  al.,	  1995)	  or	  the	  LckCre	  (Orban	  et	  al.,	   1992)	   deleter	   strain.	   Experimental	   animals	   were	   heterozygous	   for	   the	   RNIC	   locus	   and	  homozygous	  for	  the	  Chd7	  locus.	  	  Chd7lox/lox	   mice	   (Hurd	   et	   al.,	   2010)	   were	   kindly	   provided	   by	   Prof.	   D.M.	   Martin,	   University	   of	  Michigan,	  MI.	  In	  these	  mice,	  the	  ATG-­‐containing	  exon	  2	  of	  Chd7	  is	  flanked	  by	  loxP	  sites,	  allowing	  the	  excision	  of	  the	  translation	  initiation	  site	  upon	  Cre	  recombinase	  activation,	  which	  results	  in	  a	  
Chd7	  null	  allele.	  In	  this	  study	  Chd7loxlox	  mice	  were	  intercrossed	  with	  the	  Mx1Cre	  as	  well	  as	  with	  the	  CD4Cre	   transgenic	   	  mice	   to	  obtain	  Chd7loxlox	  ±	  Mx1Cre	  or	  Chd7loxlox	  ±	  CD4Cre	  experimental	  mice.	  	  Serca2lox/lox	  mice	  (Andersson	  et	  al.,	  2009)	  were	  kindly	  provided	  by	  Prof.	  Christensen,	  University	  of	  Oslo,	  Norway.	  In	  these	  mice,	  the	  ATG-­‐containing	  exon	  2	  and	  exon	  3	  of	  Serca2	  are	  flanked	  by	  loxP	   sites,	   hence	   resulting	   in	   a	  Serca2	  null	   allele	  upon	  Cre	   recombinase	  activation.	   Serca2lox/lox	  mice	  were	  bred	  onto	  the	  MxCre	  background	  in	  order	  to	  generate	  Serca2lox/+	  ±	  MxCre	  as	  well	  as	  Serca2lox/lox	  ±	  MxCre	  experimental	  mice.	  	  	  Animal	   husbandry	   and	   experimental	   procedures	   were	   conducted	   according	   to	   Swiss	   national	  guidelines	  under	  the	  licence	  1099.5.	  Animals	  were	  kept	  in	  individual	  cages	  at	  23	  ±	  1°C	  with	  a	  12	  h	  light/dark	  cycle	  in	  the	  EPFL	  animal	  facility.	  Food	  and	  water	  were	  supplied	  ad	  libitum.	  	  For	  genotyping	  of	  transgenic	  animals	  a	  standard	  PCR	  program	  of	  denaturation	  for	  5	  min	  at	  95°,	  *	  cycles	   of:	   	   95°C	   for	   30	   s,	   annealing	   at	   #	   °C	   for	   30	   s,	   extension	   at	   72°C	   for	   30	   s,	   and	   a	   final	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extension	   at	   72°C	   for	   5	   min	   was	   followed.	   Gene	   specific	   primers	   and	   PCR	   conditions	   for	   the	  above	  mentioned	  transgenic	  animals	  are	  depicted	  in	  Table	  Appendices	  1.	  	  	  Efficient	   Cre	   recombinase	   activation	   and	  hence	   generation	   of	   either	  Chd7	   or	  Serca2	  null	   allele	  was	   confirmed	   by	   deletion	   PCR,	   for	   which	   primer	   sequences	   and	   conditions	   are	   depicted	   in	  Table	  Appendices	  2.	  	  
7.1.2 Poly(I)-­‐poly(C):	  Preparation	  and	  Administration	  The	  double-­‐stranded	  RNA	  analogue	  polyinosinic:polycytidylic	   acid	   (Poly(I)-­‐poly(C);	   Invivogen,	  Toulouse,	  France)	  was	  administered	  in	  vivo	  in	  order	  to	  activate	  the	  interferon-­‐inducible	  Mx1Cre	  recombinase.	  Therefore,	  Poly(I)-­‐poly(C)	  was	  dissolved	  in	  physiologal	  water	  at	  a	  concentration	  of	  2	  mg/ml	  for	  10	  min	  at	  65°C	  followed	  by	  cooling	  down	  to	  RT	  to	  enable	  annealing	  single	  stranded	  RNA	  molecules.	  Poly(I)-­‐poly(C)	  stock	  was	  further	  diluted	  in	  sterile	  PBS	  to	  a	  final	  concentration	  of	   0.2	   mg/ml.	   Five	   Poly(I)-­‐poly(C)	   injections	   of	   2	   μg/g	   body	   weight	   were	   administered	  intraperitoneally	  (i.p.)	  at	  2-­‐day	  intervals.	  	  
7.1.3 5-­‐FU:	  Preparation	  and	  Administration	  The	  pyrimidine	  analogue	  5-­‐fluorouracil	  (5-­‐FU,	  Invitrogen,	  CA,	  USA)	  was	  administered	  in	  order	  to	  deplete	  all	  cycling	  cells	  within	  the	  BM,	  stimulating	  HSC	  proliferation.	  A	  5-­‐FU	  stock	  concentration	  of	   15	   mg/ml	   was	   prepared	   in	   sterile	   PBS	   for	   10	   min	   at	   65°C.	   150	   mg/kg	   body	   weight	   was	  administered	  i.p.	  3	  days	  prior	  to	  HSC	  isolation.	  
7.1.4 Generation	  of	  Single	  Cell	  Suspensions	  from	  Isolated	  Organs	  Experimental	  mice	  were	  sacrificed	  under	  carbon	  dioxide	  conditions.	  Single	  BM	  cell	  suspensions	  were	   prepared	   from	   2	   femurs	   and	   2	   tibiae	   per	  mouse	   by	   crushing	   bones	   in	   ice-­‐cold	   staining	  medium	  (SM;	  HBSS	  containing	  2%	  fetal	  calf	  serum	  (FCS),	  12.5	  mM	  HEPES	  and	  2mM	  EDTA)	  using	  a	   pestle	   and	   mortar.	   Cell	   suspensions	   from	   other	   organs	   such	   as	   spleen,	   thymus	   and	   lymph	  nodes	  	  were	  prepared	  by	  disaggregating	  the	  appropriate	  tissues	  using	  a	  nylon	  mesh	  in	  cold	  SM.	  Filtration	   through	  a	  70	  μm	   filter	   removed	  debris	   as	  well	   as	  non-­‐dissociated	   fat	  or	   conjunctive	  tissue.	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7.1.5 Generation	  of	  Bone	  Marrow	  Chimeras	  
7.1.5.1 Preparation	  of	  T	  cell	  Depleted	  Bone	  Marrow	  Cells	  for	  Transplantation	  (ATBM)	  Femurs	  and	  tibiae	  of	  3	  donor	  mice	  were	  pooled	  per	  experimental	  group	  and	  BM	  cell	  suspensions	  were	  prepared	  in	  SM	  as	  previously	  described.	  Cells	  were	  counted	  and	  pelleted	  by	  centrifugation	  at	   1700	   rpm	   for	   10	   min	   at	   4°C.	   Cells	   were	   then	   resuspended	   at	   a	   concentration	   of	   1	   *	   106	  cells/ml	  and	  incubated	  with	  anti-­‐Thy	  1.2	  mAb	  (clone	  AT83;	  rat	  IgG)	  at	  a	  1:20	  dilution	  for	  30	  min	  on	   ice.	   Rabbit	   complement	   was	   added	   at	   a	   1:40	   dilution	   and	   cells	   were	   incubated	   for	   an	  additional	   60	   min	   at	   37°C.	   One	   hundred	   μl	   DNAse	   (0.01%	   w/v)	   was	   added	   per	   10	   ml	   cell	  suspension	  and	  cells	  were	  mixed	  gently	  every	  10	  min	  in	  order	  to	  prevent	  clumping.	  Cells	  were	  then	   filtered	   through	   a	   70	  μm	   filter	   and	  washed	   three	   times	  with	   excessive	   volumes	  of	   SM	   to	  remove	   residual	   traces	   of	   antibody	   and	   complement.	   T-­‐cell	   depleted	   BM	   was	   counted	   and	  resuspended	   in	   sterile	   PBS	   at	   a	   concentration	   of	   5-­‐10	   *	   106	   cells/100	   μl	   and	   subsequently	  injected	   retro-­‐orbitally.	   Input	   BM	   was	   assessed	   for	   contribution	   of	   HSCs	   by	   flow	   cytometric	  analysis	  and	  genomic	  DNA	  from	  BM	  samples	  was	  prepared	  to	  monitor	  for	  unspecific	  activation	  of	  Mx1Cre.	  	  	  	  
7.1.5.2 Treatment	  of	  Recipient	  Mice	  prior	  to	  ATBM	  Two	   days	   prior	   to	   ATBM,	   recipient	   C57BL6/J_CD45.1	   mice	   were	   each	   injected	   with	   100	   μg	  purified	   anti-­‐NK1.1	   	  mAb	   (clone	  PK1.36)	   to	  deplete	   radio-­‐resistant	  host-­‐derived	  NK	   cells.	  One	  day	  prior	  to	  ATBM,	  mice	  were	  lethally	  irradiated	  using	  a	  split	  dose	  of	  2	  x	  450	  Gy.	  	  
7.1.5.3 Treatment	  of	  Chimeric	  Mice	  post	  ATBM	  Upon	   ATBM,	   reconstituted	   mice	   were	   kept	   on	   drinking	   water	   containing	   antibiotics	   (3	   ml	  Baytril/250	  ml)	  and	  painkiller	  (Dafalgan	  500	  mg/250	  ml).	  Donor	  reconstitution	  was	  monitored	  by	   flow	   cytometric	   analysis	   of	   peripheral	   blood	   lymphocytes	   (PBL)	   4	   weeks	   post	  transplantation.	  	  
7.1.6 Isolation	  of	  Peripheral	  Blood	  Lymphocytes	  (PBL)	  Fifty	   μl	   total	   blood	   was	   collected	   from	   the	   retro-­‐orbital	   vein	   of	   anesthetised	   mice	   using	  haematocrit	   capillaries.	   Blood	   samples	  were	   incubated	   in	   3	  ml	   erythrocyte	   lysis	   buffer	   for	   10	  min	   at	   RT	   to	   lyse	   erythrocytes.	   Samples	  were	   then	   centrifuged	   and	  washed	   twice	   in	   cold	   SM	  prior	  to	  cell	  surface	  staining.	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7.1.7 White	  Blood	  Cell	  Count	  White	   blood	   cell	   counts	  were	   determined	   from	   cell	   suspensions	   diluted	   1:30	   in	   SM	   using	   the	  automated	  ViCell	  Cell	  Counter	  (Beckman	  Coulter).	  	  
7.2 Flow	  Cytometry	  Analysis	  	  
7.2.1 Cell	  Surface	  Staining	  	  For	  flow	  cytometric	  analysis,	  cells	  were	  stained	  with	  specific	  antibodies	  prepared	  in	  Fc	  blocking	  staining	  buffer	  containing	  the	  clone	  2.4G2.	  Following	  incubation	  on	  ice,	  cells	  were	  washed	  in	  SM	  and	   resuspended	   in	   100-­‐500	   μl	   SM	   (depending	   on	   cell	   concentration)	   for	   further	   analysis.	  Fluorophore-­‐conjugated	  monoclonal	  antibodies	  were	  purchased	   from	  eBiosciences	  (San	  Diego,	  CA)	   and	   are	   listed	   in	   Table	   3	   (Appendix).	   Biotin-­‐conjugated	   antibodies	   were	   purified	   from	  hybridoma	  supernatants	  and	  produced	  in	  house	  following	  standard	  laboratory	  techniques.	  	  	  
7.2.2 Cell	  Sorting	  Fluorescence	   activated	   cell	   sorting	   (FACS)	   was	   performed	   on	   either	   a	   FACS	   Aria	   II	   (BD	  Biosciences)	   at	   the	   EPFL	   or	   UNIL	   Flow	   Cytometry	   Core	   Facility	   or	   on	   a	   MoFlo	   AstriosEQ	  (Beckman	   Coulter	   Life	   Sciences)	   at	   the	   CHUV	   site	   of	   the	   UNIL	   Core	   Facility.	   Cell	   sorting	   was	  performed	   under	   sterile	   conditions	   at	   4°C	   and	   cells	   were	   collected	   in	   pure	   FCS	   for	   further	  analysis.	  	  
7.2.3 Automated	  Cell	  Sorting	  using	  Magnetic	  Beads	  (AutoMACS)	  AutoMACS	   technology	  was	  used	   in	  order	   to	  enrich	   for	   lineage	  negative	  cells	  using	   the	  Lineage	  Cell	  Depletion	  Kit	  (Miltenyi	  Biotec,	  Germany).	  Volumes	  are	  indicated	  for	  1	  *	  107	  cells.	  In	  brief,	  BM	  cells	   were	   resuspended	   in	   20	   μl	   SM	   followed	   by	   addition	   of	   5	   μl	   biotin-­‐conjugated	   antibody	  following	   incubation	   for	   20	  min	   at	   4°C.	   Fifteen	   μl	   SM	   and	   10	   μl	   anti-­‐biotin	   Microbeads	   were	  added	   to	   each	   sample	   for	   a	   further	   30	  min	   incubation.	   	   Following	  washing	   in	   SM,	   cells	   were	  filtered	   through	   a	   30	   μm	   nylon	   mesh	   and	   pelleted	   at	   1700	   rpm	   for	   10	   min.	   Cells	   were	   then	  resuspended	  in	  1-­‐2	  ml	  SM	  for	  magnetic	  bead	  separation	  on	  an	  AutoMacs	  Pro	  Seperator	  (Miltenyi	  Biotec,	  Germany).	  Enrichment	  of	  lineage	  negative	  cells	  was	  assessed	  by	  flow	  cytometric	  analysis	  of	  labelled	  cells	  pre-­‐	  and	  post-­‐AutoMACS.	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7.2.4 Cell	  Cycle	  Analysis	  (Ki67	  vs.	  Hoechst)	  Cell	   cycle	   status	   was	   assessed	   by	   intracellular	   staining	   of	   the	   nuclear	   cell	   proliferation-­‐associated	   antigen,	   Ki67,	   and	   the	   DNA-­‐intercalating	   agent,	   Hoechst.	   Ki67	   was	   detected	   using	  FITC	  mouse	  anti-­‐human	  Ki-­‐67	  set	  (BD	  PharmingenTM).	  Volumes	  are	   indicated	  per	  5	  *	  105	  cells.	  Following	  cell	  surface	  staining,	  cells	  were	  washed	  in	  SM	  and	  then	  permeabilized	  and	  fixed	  in	  100	  μl	   Cytofix/Cytoperm	   solution	   for	   30	   min	   on	   ice.	   Cells	   were	   then	   washed	   in	   2	   ml	   Permwash	  solution	  and	  pelleted	  at	  1700	  rpm	  for	  5	  min.	  FITC	  mouse	  anti-­‐human	  Ki-­‐67	  antibody	  was	  diluted	  1:10	  in	  Permwash	  solution	  and	  intracellular	  staining	  was	  performed	  in	  100	  μl	  per	  sample	  at	  4°C	  overnight.	  The	  following	  day,	  cells	  were	  stained	  in	  100	  μl	  Permwash	  containing	  1:250	  dilution	  of	  Hoechst	   33342	   for	   10	   min	   at	   4°C.	   Cells	   were	   washed	   once	   in	   1	   ml	   Permwash,	   pelleted	   by	  centrifugation	  and	  then	  resuspended	  in	  SM	  for	  flow	  cytometric	  analysis.	  	  
7.2.5 CFSE	  Cell	  Division	  Assay	  	  The	   CFSE	   cell	   division	   assay	   enables	   monitoring	   of	   individual	   cell	   divisions	   over	   time.	   Bone	  marrow	  cells	  enriched	  for	  lineage	  negative	  cells	  were	  labelled	  with	  1	  μM	  CFSE	  (Ebioscience)	  in	  PBS	   for	   10	  min	   at	   37°C.	   CFSE	   signal	  was	   quenched	   twice	   by	   addition	   of	   45	  ml	  RPMI	  medium	  containing	  10%	  FCS	  followed	  by	  centrifugation	  at	  1700	  rpm	  for	  10	  min	  at	  4°C.	  Cells	  were	  then	  maintained	   in	  HSC	  culture	  medium	  (see	  7.3.1)	   in	  5%	  CO2	  at	  37°C	  and	  flow	  cytometric	  analysis	  was	  performed	  each	  day	  over	  a	  period	  of	  5	  days.	  	  
7.2.6 Apoptosis	  Analysis	  (Annexin	  V	  vs.	  7-­‐AAD	  or	  DAPI)	  Apoptosis	  analysis	  was	  performed	  by	   staining	   cells	  with	  Annexin	  V–Cy5,	   followed	  by	   the	  DNA	  intercalating	  fluorescent	  dyes	  7-­‐aminoactinomycin	  D	  (7-­‐AAD)	  or	  4',6-­‐diamidino-­‐2-­‐phenylindole	  (DAPI).	   Cells	   were	   washed	   twice	   in	   PBS	   and	   incubated	   with	   anti-­‐Annexin	   V-­‐Cy5	   antibody	  (Biolegend)	  diluted	  1:100	  and	  7-­‐AAD	  diluted	  1:20	  in	  Annexin	  V	  binding	  buffer	  for	  15	  min	  on	  ice.	  Annexin	  V	  binding	  buffer	  was	  added	  to	  a	  final	  volume	  of	  500	  μl	  shortly	  before	  acquisition	  on	  the	  flow	  cytometer.	  7-­‐AAD	  was	  replaced	  by	  DAPI	  at	  a	  dilution	  of	  1:50	  in	  staining	  combinations	  that	  exceeded	  9	  colours.	  	  	  
7.2.7 Calcium	  Flux	  Assay	  Indo1-­‐AM	  is	  a	  cell	  permeable	  ratiometric	  Ca2+	  indicator	  used	  to	  monitor	  changes	  in	  intracellular	  calcium	   levels.	   Following	   cell	   surface	   staining,	   cells	   were	   incubated	   with	   1	   μM	   Indo1-­‐AM	  (Molecular	  Probes,	  Invitrogen)	  in	  cell	  loading	  medium	  (CLM;	  HBSS,	  2mM	  MgCl2,	  2mM	  CaCl2)	  for	  30	  min	  at	  37°C	  in	  the	  dark.	  Following	  washing	  in	  SM,	  cells	  were	  resuspended	  in	  CLM	  and	  kept	  on	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ice.	  Cell	  suspensions	  were	  incubated	  at	  37°C	  shortly	  before	  and	  during	  flow	  cytometric	  analysis	  and	  the	  ratio	  of	  Indo-­‐violet	  against	  Indo-­‐blue	  was	  acquired	  at	  a	  70°	  angle	  over	  time.	  After	  30-­‐60	  s	  of	  acquisition	  10	  μl	  ionomycin	  (1	  mg/ml)	  was	  added	  per	  500	  μl	  cells	  to	  induce	  calcium	  flux.	  2	  mM	  EGTA	  was	  added	  to	  the	  cells	  5	  min	  before	  acquisition	  to	  bind	  all	  free	  extracellular	  calcium	  present	  in	  the	  CLM	  allowing	  to	  measure	  intracellular	  calcium	  levels.	  The	  addition	  of	  2	  mM	  EGTA	  with	   the	   cell	   permeable	   form	   EGTA-­‐AM	   (Molecular	   Probes,	   Invitrogen)	   served	   as	   negative	  control	  to	  bind	  both	  extra-­‐	  as	  well	  as	  intracellular	  free	  Ca2+.	  	  
7.3 Cell	  Culture/In	  vitro	  Experiments	  
7.3.1 Culture	  of	  Lineage	  Negative	  Bone	  Marrow	  Cells	  Lineage	   depleted	   cells	  were	   cultured	   at	   1-­‐2	   *	   106	   cells	   per	  well	   of	   a	   24	  well	   plate	   in	   Iscove´s	  medium	  supplemented	  with	  20%	  FCS,	  25	  mM	  Hepes,	  β-­‐mercaptoethanol	  (ME),	  2	  mM	  glutamine,	  1	  mM	  non-­‐essential	  amino	  acids,	  1	  mM	  sodium	  pyruvate,	  100	  ng/ml	  Flt3	  ligand,	  10	  ng/ml	  IL1,	  6	  ng/ml	  IL3	  and	  100	  ng/ml	  stem	  cell	  factor	  hereafter,	  referred	  to	  as	  HSC	  culture	  medium.	  	  
7.3.2 Retroviral	  Infection	  of	  Bone	  Marrow	  Cells	  In	   this	   work,	   lineage	   depleted	   BM	   cells	   were	   infected	   with	   the	   MigR1-­‐NICD-­‐IRES-­‐NGFR	  expression	  vector,	  which	  allows	  expression	  of	  NICD	  fused	  to	  IRES	  followed	  by	  the	  Nerve	  Growth	  Factor	  Receptor	   (NGFR)	  encoding	   cDNA.	  Therefore,	   detection	  of	  NGFR	  expressing	   cells	   can	  be	  used	   as	   an	   indirect	   means	   of	   monitoring	   NICD	   expression.	   In	   brief,	   1-­‐2	   *	   105	   BM	   cells	   were	  transferred	   into	   a	   5	   ml	   round-­‐bottom	   tube;	   viral	   particles	   were	   added	   to	   achieve	   a	   final	  multiplicity	  of	  infection	  (MOI)	  of	  10	  and	  infection	  was	  performed	  during	  spin	  oculation	  at	  1700	  rpm	  at	  42°C	  for	  45	  min.	  Cells	  were	  then	  resuspended	  in	  HSC	  culture	  medium	  and	  maintained	  at	  5%	  CO2	  at	  37°C	  for	  48	  h	  prior	  to	  transplantation.	  	  
7.3.3 Thapsigargin	  Treatment	  	  The	  ATPase	  inhibitor	  Thapsigargin	  (Enzo	  Lifesciences)	  was	  dissolved	  at	  a	  stock	  concentration	  of	  1	  mM	  in	  DMSO	  and	  stored	  in	  aliquots	  at	  −20°C.	  Lineage	  depleted	  BM	  cells	  were	  treated	  with	  a	  final	   concentration	   of	   200	   nM	   or	   1	   μM	   Thapsigargin	   for	   1,	   6,	   24	   and	   40	   h.	   DMSO	   treatment	  served	  as	  internal	  control.	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7.3.4 Colony	  Forming	  Unit	  (CFU)	  Assay	  	  The	   colony	   forming	   unit	   (CFU)	   assay	   enables	   measurement	   of	   HSC	   differentiation	   potential	  under	  in	  vitro	  conditions.	  	  In	  brief,	  500-­‐700	  sorted	  KLS	  cells	  were	  resuspended	  in	  100	  μl	  Iscove´s	  Modified	  Dulbecco´s	  Medium	  supplemented	  with	  20%	  FCS	  and	  Gentamycin.	  1	  ml	  of	  MethoCult	  GF	   M3434	   methylcellulose	   based	   medium,	   supplemented	   with	   cytokines	   and	   erythropoietin	  (Stemcell	   Technologies)	   was	   added	   and	   the	   sample	   vigorously	   mixed.	   Cells,	   suspended	   in	  methylcellulose,	  were	   seeded	   into	  a	  6-­‐well	  dish	  using	  a	  16	  gauge-­‐blunt	  ended	  needle.	   Six-­‐well	  dishes	   were	   then	   placed	   in	   10	   cm	   dishes,	   which	   contained	   one	   open	   6-­‐well	   dish	   with	   sterile	  water.	   Following	   incubation	   at	   5%	  CO2	   at	   37°C	   for	   one	  week,	   colonies	  were	   scored	  under	   the	  microscope	  using	  a	  60	  mm	  gridded	  scoring	  dish	  (Stemcell	  Technologies).	  	  
7.3.5 Culture	  of	  murine	  and	  human	  T-­‐ALL	  cells	  Murine	  T-­‐ALL	  cell	  lines	  established	  from	  primary	  Notch1-­‐induced	  tumors	  were	  cultured	  in	  RPMI	  containing	  10%	  FCS,	  12.5	  mM	  HEPES,	  Gentamycin	  (1/1000	  dilution)	  and	  2	  mM	  ME.	  Human	  T-­‐ALL	  cell	  lines	  were	  cultured	  in	  the	  same	  medium	  in	  absence	  of	  ME.	  
7.3.6 Lentiviral	  Infection	  of	  T-­‐ALL	  cell	  lines	  Murine	   and	   human	   T-­‐ALL	   cell	   lines	   were	   infected	   with	   viral	   particles	   encoding	   either	   non-­‐inducible	  pLKO.1	  small	  hairpin	  RNA	  (shRNA)	  or	  inducible	  pTripz	  shRNA	  targeting	  CHD7	  mRNA	  for	  degradation.	  The	  clones	  pLKO.1_shCHD7	  (RHS3979-­‐958410)	  and	  Tripz_shCHD7	  (RHS4696-­‐99634943)	   were	   purchased	   from	   Open	   Biosystems.	   Control	   vectors	   pLKO.1_shCrtl	   (Sigma,	  SHC002)	   and	   pTripz_shCtrl	   (RHS4743)	   encoding	   scrambled	   hairpin	   sequences	   were	   used	   as	  internal	  controls	  for	  off-­‐target	  effects	  of	  lentiviral	  insertion	  into	  the	  genome.	  Lentiviral	  infection	  of	  cells	  was	  performed	  by	  spin	  oculation	  as	  previously	  described	  (see	  7.3.2).	  Infected	  cells	  were	  selected	  and	  maintained	  in	  vitro	  in	  the	  presence	  of	  2	  μg/ml	  puromycin	  (pLKO.1	  expressing	  cells)	  or	  0.5	  μg/ml	  puromycin	  (pTripz	  expressing	  cells)	  for	  at	   least	  1	  week	  prior	  to	  experimentation.	  pTripz_shRNA	   vector	   expression	  was	   induced	   by	   addition	   of	   1	  mg/ml	  Doxycyclin	   resulting	   in	  concomitant	  expression	  of	  red	  fluorescent	  protein	  (RFP).	  
7.4 Molecular	  Biology	  Techniques	  	  
7.4.1 DNA	  Preparation	  from	  Cells	  and	  Tissues	  Five	  to	  10	  *	  106	  cells	  were	  resuspended	  in	  200	  μl	  extraction	  buffer	  DNA	  A	  (10	  mM	  Tris-­‐HCl,	  10	  mM	   EDTA,	   10	   mM	   NaCl,	   pH	   7.5)	   and	   200	   μl	   DNA	   B	   (DNA	   A	   containing	   2%	   SDS).	   Two	   μl	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proteinase	  K	  (15	  mg/ml	  in	  Tris-­‐HCl,	  pH	  7.6)	  was	  added	  and	  samples	  were	  incubated	  at	  500	  rpm	  overnight	   at	   56°C.	   The	   following	   day,	   100	   μl	   8	   M	   potassium	   acetate	   (KOAc)	   and	   500	   μl	  chloroform	  were	  added	  sequentially	  and	  samples	  were	  then	  vortexed	  for	  2	  min	  at	  RT.	  Following	  phase	  separation	  via	  centrifugation	  at	  13000	  rpm	  for	  10	  min	  at	  RT,	  the	  upper	  phase,	  containing	  DNA,	  was	   transferred	   into	   a	   fresh	   tube	  and	  precipitated	   in	  800	  μl	  100%	  ethanol	   (EtOH).	  DNA	  pellets	  were	  then	  washed	  in	  800	  μl	  75%	  EtOH	  and	  resuspended	  in	  50-­‐100	  μl	  TE	  buffer	  (10	  mM	  Tris,	  1	  mM	  EDTA,	  pH	  8.0)	  for	  20	  min	  at	  37°C.	  	  
7.4.2 RNA	  Isolation	  from	  Cells	  and	  Tissues	  Five	  to	  10	  *	  106	  cells	  were	  washed	  in	  1	  x	  PBS,	  pelleted	  by	  centrifugation	  at	  1700	  rpm	  at	  4°C	  and	  resuspended	   in	  50	  μl	  1	  x	  PBS	  before	  careful	  addition	  of	  1	  ml	  PeqGOLD	  TriFast	  (PeqLab,	  VWR)	  per	  sample.	  Samples	  were	  kept	  at	  RT	  for	  5	  min	  to	  allow	  dissociation	  of	  nucleotide	  complexes	  and	  then	   stored	   at	   -­‐80°C	   until	   further	   processing.	   Two	   hundred	   μl	   chloroform	  was	   added	   to	   each	  sample	   and	   then	  mixed	   by	   inversion.	   Following	   phase	   separation	   via	   centrifugation	   at	   13000	  rpm	  for	  15	  min	  at	  4°C,	  the	  upper	  phase	  containing	  RNA	  was	  transferred	  into	  a	  fresh	  tube.	  Each	  RNA	   sample	   was	   precipitated	   with	   1	   ml	   ice-­‐cold	   100%	   isopropanol	   and	   1	   μl	   of	   glycerol	   (1	  mg/ml,	  Invitrogen)	  overnight	  at	  -­‐20°C.	  RNA	  samples	  were	  centrifuged	  at	  13000	  rpm	  for	  15	  min	  at	  4°C	  and	  washed	  twice	  in	  ice-­‐cold	  80%	  EtOH.	  RNA	  pellets	  were	  then	  air-­‐dried	  for	  10	  min	  at	  RT	  and	  dissolved	  in	  10-­‐20	  μl	  RNAse-­‐free	  water	  for	  10	  min	  at	  55°C.	  	  
7.4.3 Reverse	  Transcription	  During	   reverse	   transcription	   the	   RNA-­‐dependent	   DNA	   polymerase,	   Reverse	   Transcriptase	  transcribes	  single-­‐stranded	  RNA	  into	  complementary	  double-­‐stranded	  DNA	  called	  cDNA.	  In	  this	  work,	   cDNA	  was	   generated	   using	   the	   SuperScript	   II	   reverse	   transcriptase	   (Life	   Technologies)	  and	   random	   hexamer	   primers	   to	   guarantee	   reverse	   transcription	   from	   randomized	   starting	  points	   in	   the	  RNA	  molecule.	   In	  brief,	  a	  maximum	  of	  2	  μg	   total	  RNA	  was	   transcribed	  per	  single	  reaction.	  RNA	  was	  heated	   to	  65°C	   for	  5	  min	   in	  presence	  of	  10	  mM	  dNTPs	  and	  250	  ng	  random	  primers.	  Following	  cooling	  at	  4°C,	  2	  μl	  of	  0.1	  mM	  DTT,	  4	  μl	  of	  5	  x	  First-­‐Strand	  buffer	  and	  1	  μl	  RNAse-­‐free	   H2O	   were	   added	   per	   reaction	   mix	   and	   incubated	   for	   2	   min	   at	   25°C.	   One	   μl	   of	  SuperScript	   II	   reverse	   transcriptase	   was	   added	   per	   reaction	   and	   reverse	   transcription	   was	  performed	  for	  10	  min	  at	  25°C	  followed	  by	  incubation	  for	  50	  min	  at	  42°C	  and	  then	  for	  15	  min	  at	  70°C.	  	  cDNA	  was	  stored	  at	  -­‐20°C	  until	  further	  analysis.	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7.4.4 Quantitative	  Real	  Time	  RT-­‐PCR	  	  During	  quantitative	  Real-­‐Time	  PCR	  (qRT-­‐PCR),	  fluorescent	  reporter	  molecules	  are	  incorporated	  into	  newly	  generated	  DNA	  strands.	  This	  allows	  monitoring	  of	  the	  amplification	  of	  PCR	  products	  during	  each	  cycle	   in	  real	   time.	  Power	  SYBR	  Green	  Master	  mix	  (Life	  Technologies)	  was	  used	   to	  amplify	  5-­‐10	  ng	  total	  cDNA	  in	  a	  reaction	  mix	  of	  10	  μl.	  Initial	  denaturation	  was	  performed	  for	  10	  min	   at	   95°C	   followed	   by	   40	   cycles	   of	   each	   15	   s	   denaturation	   at	   95°C	   and	   a	   1	   min	  annealing/extension	   step	   at	   60°C.	  Melting	   curve	   analysis	  was	   included	   in	   the	   qRT-­‐PCR	   run	   in	  order	  to	  monitor	  for	  specific	  amplification	  of	  the	  gene	  of	  interest.	  Relative	  expression	  of	  the	  gene	  of	   interest	  was	   normalized	   against	   the	   expression	   of	   the	   housekeeping	   gene	   HPRT.	   The	   ΔΔCt	  method	  was	  used	  to	  compare	  relative	  gene	  expression	  levels	  between	  two	  different	  groups,	  e.g.	  WT	   versus	   cKO.	   Primer	   sequences	   for	   the	   housekeeping	   gene	   hypoxanthine-­‐guanine	  phosphoribosyltransferase	  (HPRT)	  are	  the	  following:	  Fwd:	  5´-­‐	  GTT	  GGA	  TAC	  AGG	  CCA	  GAC	  TTT	  GTT	  G-­‐3´and	  Rev:	  5´-­‐	  GAT	  TCA	  ACT	  TGC	  GCT	  CAT	  CTT	  AGG	  C-­‐3´.	  Gene-­‐specific	  qRT-­‐PCR	  primers	  used	  in	  this	  work	  are	  shown	  in	  Tables	  4-­‐9	  in	  Appendices.	  
7.5 Protein	  Methods	  
7.5.1 Preparation	  of	  Whole	  Cell	  Extracts	  Following	  washing	  in	  cold	  1	  x	  PBS,	  cells	  were	  supplemented	  with	  100	  μl	  RIPA	  buffer	  (150	  mM	  NaCl,	  0.1%	  SDS,	  0.5%	  sodium	  deoxycholate,	  1%	  NP40,	  50	  mM	  Tris,	  pH	  8)	  containing	  protease	  inhibitors	   (Roche)	   and	   incubated	   on	   ice	   for	   30	  min.	   Samples	  were	   then	   centrifuged	   at	   13000	  rpm	  for	  30	  min	  at	  4°C	  and	  supernatant	  containing	  extracted	  protein	  was	  transferred	  into	  a	  fresh	  tube	  on	  ice.	  	  Protein	  extracts	  were	  stored	  at	  -­‐80°C	  until	  further	  analysis.	  	  
7.5.2 Preparation	  of	  Nuclear	  Extracts	  Preparation	   of	   nuclear	   protein	   extracts	  was	   performed	   according	   to	   the	   protocol	   provided	   by	  PhD	   Amandine	   Hurbin	   (INSERM	   U823,	   France).	   In	   brief,	   cell	   pellet	   were	   resuspended	   in	  hypotonic	  extraction	  buffer	  (10	  mM	  Tris-­‐HCl,	  pH	  7.5,	  10	  mM	  KCl,	  1.5	  mM	  MgCl2,	  0.2	  mM	  DTT)	  supplemented	   with	   protease	   inhibitors	   and	   incubated	   for	   30	   min	   on	   ice.	   Following	  centrifugation	  at	  2000	  rpm	  for	  5	  min	  at	  4°C,	  the	  supernatant	  was	  carefully	  discarded	  and	  each	  cell	   pellet	  was	   resuspended	   in	   hypotonic	   extraction	   buffer	   containing	   1%	  NP40	   and	   protease	  inhibitors.	  Following	  incubation	  for	  10	  min	  on	  ice,	  cells	  were	  centrifuged	  at	  3000	  rpm	  for	  15	  min	  at	  4°C	  and	  washed	  once	  in	  ice-­‐cold	  1	  x	  PBS.	  Nuclear	  proteins	  were	  extracted	  in	  RIPA	  buffer	  by	  sonication	  at	  200	  W	  followed	  by	  centrifugation	  at	  13000	  rpm	  for	  15	  min	  at	  4°C.	  Protein	  extracts	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were	   stored	   at	   -­‐80°C	   until	   further	   analysis.	   Protein	   concentration	   was	   measured	   using	   the	  Bradford	  Assay	  on	  an	  Ultraspec	  3000	  spectrophotometer	  (GE	  Healthcare)	  
7.5.3 SDS-­‐Polyacrylamide	  Gel	  Electrophoresis	  &	  Western	  Blot	  Analysis	  Protein	  samples	  were	  resuspended	   in	  5	  x	  SDS	   loading	  buffer	  (0.25%	  Bromophenol	  blue,	  0.5	  M	  DTT,	  50%	  glycerol,	  10%	  SDS,	  0.25	  M	  Tris-­‐HCl)	  and	  incubated	  for	  5	  min	  at	  95°C	  for	  denaturation.	  Samples	  were	  then	  loaded	  on	  a	  SDS	  gel	  comprised	  of	  an	  upper	  5%	  stacking	  gel	  and	  a	  lower	  6%	  separation	   gel	   (Table	   10	   in	   Appendix)	   and	   gel	   electrophoresis	  was	   performed	   in	   Tris	   glycine	  buffer	  (25	  mM	  Tris	  base,	  190	  mM	  glycine,	  0.1%	  SDS)	  for	  1	  h	  at	  200	  V	  at	  4°C.	  	  Seperated	  proteins	  were	   transferred	  onto	   the	  methanol-­‐activated	  PVDF	  membrane	   in	   transfer	  buffer	   containing	   48	   mM	   Tris,	   39	   mM	   glycine,	   0.04%	   SDS	   and	   20%	   fresh	   methanol	   at	   25	   V	  overnight	  at	  4°C.	  Membranes	  were	  blocked	  in	  5%	  non-­‐fat	  milk	  solution	  prepared	  in	  TBS	  buffer	  containing	   2%	   Tween-­‐20	   (TBS-­‐T)	   for	   1	   h	   at	   RT.	   Membranes	   were	   incubated	   with	   primary	  antibodies	   (1:2000	  dilution)	   at	   4°C	   overnight	   and	  with	   corresponding	  horseradish	  peroxidase	  (HRP)-­‐conjugated	  secondary	  antibodies	  (1:5000	  dilution)	  for	  1	  h	  at	  RT.	  Antibody	  incubation	  was	  separated	  by	  3	  washes	  in	  TBS-­‐T	  for	  10	  min.	  Murine	   Chd7	   protein	   was	   detected	   using	   the	   rabbit	   polyclonal	   anti-­‐Chd7	   antibody	   (ab31824,	  Abcam),	   which	   binds	   to	   residues	   2950	   within	   the	   C-­‐terminus	   of	   the	   protein.	   Human	   CHD7	  protein	  was	  detected	  using	   the	   rabbit	  polyclonal	  anti-­‐CHD7	  antibody	   from	  Bethyl	   laboratories	  (A301-­‐223A).	  Tata-­‐box	  binding	  protein	  (TBP;	  ab51841,	  Abcam)	  was	  used	  as	  loading	  control	  for	  nuclear	   extracts.	   Immunoblots	   were	   exposed	   using	   ECL	   western	   blotting	   substrate	   (Thermo	  Scientific)	  and	  X	  ray	  films	  (Kodak).	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Microarray	  Validation	  RNIC+/ΔLckCre	  late-­‐stage	  versus	  RNIC+/ΔMxCre	  early-­‐




Figure	  Appendix	  1:	  Top	  Up-­‐regulated	  Gene	  Candidates	  Validated.	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Microarray	  Validation	  RNIC+/ΔLckCre	  late-­‐stage	  versus	  RNIC+/ΔMxCre	  early-­‐
stage	  T-­‐ALL	  –	  Down-­‐regulated	  Candidate	  Genes	  	  
	  
Figure	  Appendix	  5:	  Top	  Down-­‐regulated	  Gene	  Candidates	  Validated.	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7.6 Functional	  Characterization	  of	  Loss	  of	  one	  Serca2	  Allele	  in	  the	  
Hematopoietic	  System	  Since	  Serca2	  was	  proposed	  to	  be	  a	  therapeutic	  target	  in	  Notch-­‐driven	  T-­‐ALL	  (Roti	  et	  al.,	  2013),	  we	  set	  out	  to	  study	  the	  physiological	  role	  of	  Serca2	  in	  the	  hematopoietic	  system	  via	  conditional	  deletion	   in	   the	  MxCre	   background.	   In	   Serca2	   cKO	  mice,	   the	   translational	   start	   site	   containing	  exon	   2	   as	   well	   as	   exon	   3	   are	   flanked	   by	   loxP	   sites,	   resulting	   in	   a	   Serca2	   null	   allele	   upon	   Cre	  recombinase	  activation	  following	  administration	  of	  PIC	  (Figure	  58	  A).	  	  	  
	  
Figure	  58:	  Strategy	  for	  in	  vivo	  conditional	  inactivation	  of	  Serca2	  in	  the	  BM.	  A,	  Schematic	  representation	  of	  the	  genetically	  modified	  murine	  Serca2	  locus,	  in	  which	  the	  ATG-­‐encoding	  exon	  2	  and	  exon	  3	  are	  flanked	  by	  loxP	  sites.	   Activation	   of	   the	   efficient	   BM-­‐deleter	   strain	  MxCre	   recombinase	   by	   administration	   of	   PIC	   leads	   to	   the	  generation	  of	  a	  Serca2	  null	  allele	  in	  BM	  cells.	  B,	  Deletion	  PCR	  analysis	  demonstrating	  a	  381	  bp	  lox	  band,	  a	  324	  bp	  deletion	  band	  and	  a	  282	  bp	  WT	  band	  amplified	  from	  genomic	  DNA	  isolated	  from	  Serca2lox/+	  or	  Serca2+/ΔMxCre	  BM	  cells.	  	  Efficient	  (>	  90%)	  conditional	  Serca2	  deletion	  was	  confirmed	  by	  PCR	  analysis:	  MxCre-­‐mediated	  excision	  of	  exon	  2	  and	  3	  out	  of	  the	  murine	  Serca2	  locus	  led	  to	  amplification	  of	  a	  324	  bp	  deletion	  band	  (Δ),	  whereas	  the	  genetically	  modified	  Serca2lox/lox	  locus	  would	  yield	  in	  a	  381	  bp	  band	  (lox)	  and	  WT	  murine	  Serca2	  locus	  a	  smaller	  282	  bp	  amplicon	  (Figure	  58	  B).	  	  	  
7.6.1 Serca2	   Haploinsufficiency	   does	   not	   affect	   Hematopoiesis	   under	  
Steady	  State	  Conditions	  First,	  we	  investigated	  whether	  loss	  of	  a	  single	  allele	  of	  Serca2	  may	  affect	  hematopoiesis	  given	  its	  gene	  dosage	  effect	  in	  other	  diseases	  such	  as	  Darier`s	  disease	  (Ji	  et	  al.,	  2000;	  Muller	  et	  al.,	  2006).	  
Serca2+/ΔMxCre	   mice	   were	   generated	   by	   crossing	   the	   Serca2lox/lox	   cKO	   strain	   (Andersson	   et	   al.,	  2009)	   with	   the	  MxCre	   Tg	  mice	   to	   study	   the	   effect	   of	   conditional	   loss	   of	   one	   Serca2	   allele	   on	  hematopoiesis.	  Experiments	  were	  performed	  in	  BM	  chimeras	  in	  order	  to	  specifically	  limit	  Serca2	  deletion	  to	  BM	  cells	  as	  MxCre	  is	  active	  within	  all	  INFα-­‐	  and	  INF-­‐β-­‐responsive	  cell	  types	  such	  as	  in	  the	  skin,	  liver	  and	  kidney,	  as	  well	  as	  the	  BM.	  
Appendices	   126	  
Upon	  analysis	  of	  the	  HSC	  compartment,	  no	  significant	  differences	  in	  (i)	  percentages	  (Figure	  59	  A)	  and	  absolute	  numbers	  of	  KLS,	  ST-­‐HSC	  and	  LT-­‐HSCs	  were	   found	  between	  Serca2-­‐competent	  and	  Serca2-­‐haploinsufficient	  cells	  (Figure	  59	  B).	  	  
	  
Figure	  59:	  Serca2	  haploinsufficiency	  does	  not	  perturb	  hematopoietic	  development.	  KLS	  compartment	  of	  
Serca2+/ΔMxCre	  and	  Serca2lox/+	  (Ctrl)	  BM	  cells	  was	  analysed	  5	  weeks	  post	  MxCre	  induction.	  A,	  Representative	  FACS	  plots	   depicting	   staining	   of	   donor-­‐derived	   CD45.2+Lin-­‐CD117+Sca1+	   (KLS)	   population,	  upper	   panel.	   This	   was	  further	   subfractionated	   into	   HSCs	   (KLS,	   CD150+CD48-­‐),	  MPP2s,	   (KLS,	   CD150+CD48+)	   and	  MPP3-­‐MPP4s	   (KLS,	  CD150-­‐CD48+),	   lower	  panel,	   in	  Ctrl	   and	  Serca2+/ΔMxCre	  BM	  chimeras.	  B,	  Absolute	  cell	  numbers	  of	  CD45.2+	  KLS	  cells,	  LT-­‐HSCs,	  ST-­‐HSCs	  and	  MPPs	  in	  Serca2+/ΔMxCre	  and	  Ctrl	  BM	  chimeras	  (n=	  5	  +	  5).	  Error	  bars	  represent	  mean	  ±	  SD.	  	  Furthermore,	   Serca2+/ΔMxCre	   hematopoietic	   progenitors	   gave	   rise	   to	   normal	   numbers	   of	   T	   cell	  progenitors	   in	  double	  negative	  stages	  DN1-­‐DN4	  (Figure	  60	  A)	  as	  wells	  as	   immature	  CD4+CD8+	  DP,	  CD4+	  and	  CD8+	  SP	  cells	  (Figure	  60	  B)	  and	  TCRγδ	  T	  cells	  (Figure	  60	  C),	  indicating	  that	  Serca2	  haploinsufficiency	   does	   not	   recapitulate	   the	   N1	   LOF	   function	   phenotype	   in	   T	   lineage	  commitment.	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Figure	   60:	   Serca2	   haploinsufficiency	   does	   not	   affect	   T	   cell	   development	   in	   the	   thymus.	   Thymi	   of	  
Serca2+/ΔMxCre	   and	   Serca2lox/+	   (Ctrl)	   chimeric	   mice	   were	   analysed	   5	   weeks	   post	   MxCre	   induction.	   A,	  Representative	   FACS	   analysis	   of	   Ctrl	   and	  Serca2+/ΔMxCre	   CD4-­‐CD8-­‐Lin-­‐	   thymocytes	   stained	  with	   anti-­‐CD25	   and	  anti-­‐CD44	   to	   distinguish	   DN1	   (CD44+CD25-­‐),	   DN2,	   (CD44+CD25+),	   DN3	   (CD44-­‐CD25+)	   and	  DN4	   (CD44-­‐CD25-­‐)	  stages	  of	  maturation	  and	  left	  panel	  corresponding	  absolute	  cell	  numbers,	  right	  panel.	  B,	  Representative	  FACS	  analysis	  showing	  cell	  surface	  expression	  of	  CD4	  and	  CD8	  in	  thymi	  of	  Ctrl	  and	  Serca2+/ΔMxCre	  chimeric	  mice	  and	  
left	  panel	  corresponding	  absolute	  cell	  numbers,	  right	  panel.	  C,	  Representative	  FACS	  plots	  showing	  cell	  surface	  expression	  of	  TCRγδ	  and	  TCRβ,	  on	  CD4-­‐CD8-­‐	  thymocytes,	  left	  panel	  and	  corresponding	  absolute	  cell	  numbers,	  
right	  panel.	  Error	  bars	  represent	  mean	  ±	  SD,	  n	  =	  5	  (Ctrl)	  and	  n	  =	  5	  (Serca2+/ΔMxCre).	  	  Percentages	  (Figure	  61	  A)	  and	  absolute	  numbers	  (Figure	  61	  B)	  of	  mature	  peripheral	  B220+IgM+	  B	  cells	  were	  also	  unaffected	  by	  Serca2	  deficiency	  in	  these	  chimeras	  (n	  =	  5	  +	  5).	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Figure	  61:	  Serca2	  haploinsufficiency	  does	  not	  affect	  B	  or	  T	  cell	  numbers	  in	  the	  periphery.	  Serca2+/ΔMxCre	  and	   Serca2lox/+	   (Ctrl)	   spleens	   from	   chimeric	   mice	   were	   analysed	   5	   weeks	   post	   MxCre	   induction.	   A,	  Representative	  FACS	  plots	  of	  Ctrl	  and	  Serca2+/ΔMxCre	  mature	  B220+IgM+	  B	  cells.	  B,	  Absolute	  cell	  numbers	  of	  total	  splenic	  cellularity,	  mature	  T	  cells	  (TCRb+,	  CD4+,	  CD8+)	  and	  mature	  B	  cells	  (B220+IgM+)	  in	  the	  spleens	  of	  Ctrl	  (n	  =	  5)	  and	  Serca2+/ΔMxCre	  (n=5)	  mice.	  Error	  bars	  represent	  mean	  ±	  SD.	  	  	  In	   summary,	   Serca2	   haploinsufficiency	   does	   not	   impact	   on	   the	   hematopoietic	   system	   under	  steady	  state	  conditions.	  	  
7.6.2 Serca2	  Haploinsufficiency	  does	  not	  affect	  Hematopoiesis	  under	  Stress	  	  
7.6.2.1 Serca2	   Haploinsufficiency	   does	   not	   render	   Hematopoietic	   Stem	   Cells	   more	  
susceptible	  to	  5-­‐FU-­‐mediated	  Exhaustion	  	  Hematopoietic	  stem	  cells	  posses	  the	  capacity	  to	  self-­‐renew	  but	  also	  to	  maintain	  homeostasis	  via	  differentiation	  in	  order	  to	  replenish	  the	  pool	  of	  mature	  hematopoietic	  cell	  types	  in	  response	  to	  injury.	  The	  chemotherapeutic	  agent	  5-­‐FU	  depletes	  all	  cycling	  cells,	  including	  hematopoietic	  cells,	  thereby	  stimulating	  HSC	  proliferation	  (Lerner	  and	  Harrison,	  1990).	  Therefore,	  5-­‐FU	  is	  frequently	  administered	  to	  study	  HSC	  mobilization	  in	  response	  to	  stress	  in	  vivo.	  5-­‐FU	  was	  administered	  bi-­‐weekly	   in	   Serca2-­‐haploinsufficient	   and	   Serca2-­‐competent	   chimeras	   over	   a	   period	   of	   14	   days.	  	  
Serca2-­‐haploinsufficient	  BM	  chimeras	  (n	  =	  7)	  had	  a	  median	  survival	  of	  12.5	  days	  as	  compared	  to	  13	  days	  in	  Ctrl	  chimeras	  (n	  =	  6)	  (Figure	  62	  A).	  This	  demonstrates	  that	  Serca2	  haploinsufficiency	  does	  not	  confer	  any	  survival	  advantage	  to	  HSCs	  following	  5-­‐FU	  challenge.	   	   In	  response	  to	  5-­‐FU	  treatment,	   total	   BM	   cellularity	   (Figure	   62	   B)	   and	   the	   percentage	   of	   mobilized	   donor-­‐derived	  CD45.2+Lin-­‐CD117-­‐Sca1+	  HSCs	  (Figure	  62	  C)	  in	  Serca2-­‐haploinsufficient	  (n	  =	  3)	  and	  Ctrl	  (n	  =	  3)	  chimeras	  were	  comparable.	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Figure	   62:	   Serca2	   haploinsufficiency	   does	   not	   render	   hematopoietic	   stem	   cells	   more	   susceptible	   to	  
exhaustion.	  Four	  weeks	  post	  MxCre	  induction	  Serca2lox/+	  (Ctrl)	  and	  Serca2+/ΔMxCre	  mice	  were	  treated	  with	  5-­‐FU	  twice	  per	  week	  over	  14	  days.	  A,	  Kaplan-­‐Meier	  survival	  curve	  of	  5-­‐FU	  treated	  BM	  chimeras	  with	  Serca2+/ΔMxCre	  (n	  =	   7)	  mice	   depicted	   in	   blue	   and	   Ctrl	   (n	   =	   6)	  mice	   depicted	   in	   black.	   Arrows	   indicate	   5-­‐FU	   injections.	  Median	  survival	  was	  calculated	  using	  Log-­‐rank	  Mantel-­‐Cox	  test.	  B,	  Absolute	  number	  of	  total	  BM	  cells	  and	  C,	  Percentage	  of	  HSCs	  (KLS;	  Lin-­‐CD117+Sca1+)	  from	  control	  and	  indicated	  cKO	  mice.	  Error	  bars	  represent	  mean	  ±	  SD.	  	  	  Taken	   together,	   these	  data	   indicate	   that	  Serca2	   haploinsufficiency	  does	  not	   render	  HSCs	  more	  susceptible	  to	  exhaustion	  upon	  5-­‐FU	  mediated	  stress.	  
7.6.2.2 Serca2	   Haploinsufficiency	   does	   not	   render	   Hematopoietic	   Stem	   Cells	   less	  
competent	  in	  Secondary	  Bone	  Marrow	  Chimeras	  	  We	   demonstrated	   that	   Serca2-­‐haploinsufficient	   HSCs	   retain	   their	   full	   reconstitutive	   potential	  and	  that	  mature	  lineages	  are	  also	  unaffected	  by	  haploinsufficiency	  of	  Serca2	  under	  steady	  state	  conditions	  (Figures	  59-­‐61).	  However,	  these	  conditions	  and	  the	  5-­‐FU	  challenging	  system	  do	  not	  address	  whether	   long-­‐term	  reconstitution	  of	   the	  hematopoietic	  system	  may	  be	  affected	  by	   the	  loss	  of	  one	  Serca2	   allele.	  To	  address	   this	  question,	   secondary	  BM	  chimeras	  were	  generated	  by	  serially	  transplanting	  BM	  pooled	  from	  similarly	  reconstituted	  Serca2+/ΔMxCre	  (n	  =	  3)	  and	  Ctrl	  (n	  =	  3)	   chimeras	   into	   lethally	   irradiated	   CD45.1+	   recipient	   mice	   (Figure	   63	   A).	   Reconstitution	   by	  donor-­‐derived	   CD45.2+	   HSCs	   was	   comparable	   between	   Serca2-­‐competent	   and	   Serca2-­‐haploinsufficient	   secondary	   chimeras	   (Figure	  63	  B).	   (i)	   total	  BM	  cellularity	   (Figure	  63	  C),	   	   (ii)	  percentages	  and	  (iii)	  absolute	  cell	  numbers	  of	  KLS	  (Figure	  63	  D,	  E)	  and	  HSCs,	  MPP2	  and	  MPP3-­‐MPP4	  cells	  (Figure	  63	  F,	  G)	  were	  also	  not	  significantly	  altered	  by	  Serca2	  haploinsufficiency.	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Figure	   63:	   Serca2	   haploinsufficiency	   does	   not	   alter	   the	   long-­‐term	   repopulation	   capacity	   of	   HSCs	   in	  
secondary	  BM	  chimeras.	  A,	  Schematic	  representation	  of	  the	  generation	  of	  Serca2+/ΔMxCre	  and	  Serca2lox/+	  (Ctrl)	  secondary	   BM	   chimeras.	   B,	   Relative	   percentage	   of	   CD45.2+	   cells	   in	   PBLs	   4	   weeks	   post	   ATBM.	   C,	   Total	   BM	  cellularity	   in	   secondary	   chimeras.	   D,	   Representative	   FACS	   plots	   of	   Ctrl	   and	   Serca2+/ΔMxCre	   KLS	   cells	   with	  corresponding	   absolute	   cell	   numbers	   depicted	   (E).	   F,	   Representative	   FACS	   counter	   plots	   of	   Ctrl	   and	  
Serca2+/ΔMxCre	  HSCs	  (CD150+CD48-­‐),	  MPP2	  (CD150+CD48+)	  and	  MPP3-­‐MPP4	  cells	  (CD150-­‐CD48+)	  with	  absolute	  cell	  numbers	  depicted	  in	  G.	  Serca2+/ΔMxCre	  (n	  =	  5)	  and	  Ctrl	  (n	  =	  5)	  BM	  cells	  were	  analysed	  10	  weeks	  post	  MxCre	  induction.	  Error	  bars	  represent	  mean	  ±	  SD.	  	  	  In	   addition,	   we	   addressed	   whether	   Serca2	   haploinsufficiency	   under	   conditions	   of	   stress	   may	  mimic	  Notch1	  LOF	   in	   the	   thymus.	  Overall,	   (i)	   total	   thymic	  cellularity	  (Figure	  64	  B)	  and	  (ii)	   the	  absolute	  numbers	  of	  immature	  DN	  and	  DP	  thymocytes	  (Figure	  64	  A,	  B),	  mature	  CD4+	  and	  CD8+	  SPs	  (Figure	  64	  C)	  and	   intra-­‐thymic	  B	  cells	  were	  comparable	  between	  the	  serially	   transplanted	  cohorts	  (n	  =	  5	  +	  5).	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Figure	  64:	   Serca2	  haploinsufficiency	  does	  not	   affect	   peripheral	  T	   or	  B	   cell	   numbers	   in	   secondary	  BM	  
chimeras.	  Secondary	  BM	  chimeras	  were	  analysed	  10	  weeks	  post	  MxCre	  induction.	  A,	  Absolute	  cell	  numbers	  for	  DN1,	   DN2,	   DN3	   and	   DN4	   thymic	   progenitor	   cells.	   B,	   Total	   thymic	   cellularity	   and	   absolute	   cell	   numbers	   of	  immature	   CD4+CD8+	   DP,	   CD4+	   and	   CD8+	   SP	   T	   cells.	  C,	   Total	   splenic	   cellularity	   and	   absolute	   cell	   numbers	   of	  mature	  CD4+	  and	  CD8+	  T	  cells	  and	   IgM+B220+	  B	  cells.	  Error	  bars	   represent	  mean	  ±	  SD,	  n	  =	  5	   (Ctrl)	  and	  n	  =	  5	  (Serca2+/ΔMxCre).	  	  Overall,	  Serca2	   haploinsufficiency	  did	  not	   impact	   on	  hematopoiesis	   under	   stress	   conditions	   in	  the	  serial	  transplantation	  setting.	  	  	  
7.6.2.3 Serca2	  Haploinsufficiency	  does	  not	  impact	  on	  HSC	  function	  in	  3:1	  competitive	  BM	  
Chimeras	  	  	  In	  order	   to	  assess	   the	   long-­‐term	  repopulation	  capacity	  of	   Serca2-­‐haploinsufficient	  HSCs	  under	  stress	   conditions,	   competitive	   mixed	   BM	   chimeras	   were	   generated	   by	   mixing	   either	   CD45.2+	  
Serca2+/ΔMxCre	  or	  Serca2lox/+	  (Ctrl)	  with	  CD45.1+	  WT	  C57BL6/J	  BM	  cells	  in	  a	  3:1	  ratio,	  followed	  by	  transplantation	  into	  lethally	  irradiated	  CD45.1+	  recipients	  (Figure	  65	  A).	  The	  3:1	  ratio	  of	  Serca2-­‐competent	  or	  Serca2-­‐haploinsufficient	  versus	  WT	  hematopoietic	  reconstitution	  was	  maintained	  long-­‐term	  post	  transplantation	  (Figure	  65	  B)	  as	  indicated	  by	  the	  persistence	  of	  CD45.2+	  cells	  in	  PBL	  of	  chimeric	  mice.	  	  When	   analysing	   Serca2+/ΔMxCre	   competitive	   BM	   chimeras,	   we	   first	   focussed	   on	   the	   HSC	  compartment.	  Overall,	  the	  total	  BM	  cellularity	  of	  Serca2-­‐competent	  and	  Serca2-­‐haploinsufficient	  mixed	  BM	  chimeras	  was	  comparable	  (Ctrl	  =	  152.3	  ±	  8.70	  *	  106	  cells;	  Chd7ΔMxCre	  =	  162.9	  ±	  5.13	  *	  106	   cells,	   65	   C).	   Similarly,	   the	   percentages	   and	   absolute	   numbers	   of	   KLS	   (Lin-­‐CD117+Sca1+)	  remained	  comparable	  between	  these	  cohorts	  (65	  D).	  	  Subfractionation	  of	  the	  KLS	  compartment	  into	   HSCs	   (CD150+CD48-­‐),	   MPP2	   (CD150+CD48+)	   and	   MPP3-­‐MPP4	   cells	   (CD150-­‐CD48+)	   also	  demonstrated	   no	   apparent	   effect	   of	   Serca2	   haploinsufficiency	   on	   these	   subpopulations	   of	   the	  stem	  cell	  pool	  (65	  E).	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Figure	  65:	  Serca2	  haploinsufficiency	  does	  not	  alter	  the	  long-­‐term	  repopulation	  capacity	  of	  HSCs	  in	  3:1	  
competitive	  BM	  chimeras.	  A,	  Schematic	  representation	  of	  the	  generation	  of	  Serca2+/ΔMxCre	  and	  Serca2lox/+	  (Ctrl)	  3:1	  competitive	  BM	  chimeras.	  B,	  Percentage	  CD45.2+	   reconstitution	   in	  PBLs	  4	  weeks	  post	  ATBM.	  C,	  Total	  BM	  cellularity	  of	  3:1	  mixed	  BM	  chimeras.	  D,	  Absolute	  cell	  numbers	  of	  Ctrl	  and	  Serca2+/ΔMxCre	  CD45.2+	  KLS	  cells.	  E,	  Absolute	   numbers	   of	   Ctrl	   and	   Serca2+/ΔMxCre	   HSCs	   (KLSCD150+CD48-­‐),	   MPP2	   (KLSCD150+CD48+)	   and	   MPP3-­‐MPP4	   (KLSCD150-­‐CD48+)	   cells.	   Serca2+/ΔMxCre	   (n	  =	  5)	   and	  Ctrl	   (n	  =	  5)	  BM	  cells	  were	   analysed	  10	  weeks	  post	  MxCre	  induction.	  Error	  bars	  represent	  mean	  ±	  SD.	  
	  In	   addition,	   we	   addressed	   whether	   Serca2	   haploinsufficiency	   under	   conditions	   of	   stress	   may	  mimic	  Notch1	  LOF	  in	  the	  thymus.	  Overall,	  (i)	  total	  thymic	  cellularity	  (Figure	  66	  B)	  and	  	  (ii)	  the	  absolute	  numbers	  of	  immature	  DN	  and	  DP	  thymocytes	  (Figure	  66	  A,	  B),	  mature	  CD4+	  and	  CD8+	  SPs	  (Figure	  66	  C)	  and	   intra-­‐thymic	  B	  cells	  were	  comparable	  between	  the	  serially	   transplanted	  cohorts	  (n	  =	  5	  +	  5).	  	  	  
	  
Figure	   66:	   Serca2	  haploinsufficiency	  does	  not	   affect	   peripheral	   T	   or	  B	   cell	   numbers	   in	   3:1	  mixed	  BM	  
chimeras.	  Competitive	  BM	  chimeras	  were	  analysed	  10	  weeks	  post	  MxCre	  induction.	  A,	  Absolute	  cell	  numbers	  for	   DN1,	   DN2,	   DN3	   and	  DN4	   thymocytes.	  B,	   Total	   thymic	   cellularity	   and	   absolute	   cell	   numbers	   of	   immature	  CD4+CD8+	  DP,	  mature	  CD4+	  and	  CD8+	  SP	  T	  cells.	  C,	  Total	  splenic	  cellularity	  and	  absolute	  cell	  numbers	  of	  mature	  CD4+	  and	  CD8+	  T	  cells	  and	  IgM+B220+	  B	  cells.	  Error	  bars	  represent	  mean	  ±	  SD,	  n	  =	  5	  (Ctrl	  :	  CD45.1+)	  and	  n	  =	  5	  (Serca2+/ΔMxCre	  :	  CD45.1+).	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In	   summary,	   these	   data	   indicate	   that	   Serca2	   haploinsufficiency	   does	   not	   affect	   the	   long-­‐term	  repopulation	  of	  HSCs	  in	  3:1	  competitive	  BM	  chimeras.	  Therefore,	  we	  can	  rule	  out	  a	  gene	  dosage	  effect	  of	  Serca2	   in	   the	  regulation	  of	  hematopoiesis	  under	  steady	  state	  and	  under	  conditions	  of	  stress.	  Overall,	   these	  results	  collectively	   indicate	  that	  Serca2	  haploinsufficiency	   in	  the	  BM	  does	  not	  lead	  to	  any	  overt	  phenotype,	  not	  under	  physiological,	  nor	  under	  stress	  conditions.	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Tables	  of	  Primer	  Sequences,	  Antibodies	  &	  PCR	  conditions	  
	  
Table	  Appendix	  1:	  Genotyping	  Primers	  And	  PCR	  Conditions	  For	  Experimental	  Animals.	  
Gene/ 
Transgene 




Fwd: CTA GAG CCT GTT TTG CAC GTT C 
Rev: GTT CGC AAG AAC CTG ATG GAC A 
17.5 mM MgCl2; 
#60°C; *30 cycles Tg+: 339 bp 
RosaNICD 
Fwd: AAA GTC GCT CTG AGT TGT TAT  
Rev-Neo: GCG AAG AGT TTG TCC TCA ACC  
Rev: GGA GCG GGA GAA ATG GAT ATG  
17.5 mM MgCl2; 
#60°C; *35 cycles; 
DMSO 1/10 
WT: 600 bp 
Tg+: 200 bp 
Chd7 
P458: ATT TTT CTG AAT GCA TCT TCA CCT 
P459: AGGCAAAGCCTTTCCTT CA 
17.5 mM MgCl2; 
#56°C; *35 cycles WT: 568 bp Lox: 306 bp 
Serca2 
OL86 Fwd: TCT TCA TAA CAC ACG CCA ATT T  
OL87 Rev: CCC TTT GCT GCC AAT TAA CTA   
TT  
17.5 mM MgCl2; 
#56°C; *35 cycles Lox: 381 bp WT: 282 bp 
	  
	  
Table	  Appendix	  2:	  Deletion	  PCR	  Primers	  And	  PCR	  Conditions	  For	  Experimental	  Animals.	  
Gene/ 
Transgene 
Primer sequences [5´-3´] PCR conditions Expected PCR 
product 
Chd7 
P152: CAG CAG CCA TCT TTC CAG CAG TTG 
P434: GTT CCC ACT TCC TGT TGC TCA CC 
P435: GCC CAG AGC CAT GAG TGA GTG AAA T  
15 mM MgCl2; 
#58°C; *38 cycles WT: 1249 bp Lox: 987 bp 
Δ: 324 bp 
Serca2 
OL86 Fwd: TCT TCA TAA CAC ACG CCA ATT T  
OL88 Fwd: ACC TCT AGG GGT CTC GAA TCA  
OL87 Rev: CCC TTT GCT GCC AAT TAA CTA TT  
17.5 mM MgCl2; 
#56°C; *35 cycles Lox: 381 bp Δ: 324 bp 
WT: 282 bp 
	  
Table	  Appendix	  3:	  Monoclonal	  Antibodies	  Used	  For	  Flow	  Cytometric	  Analysis.	  
Antibody Clone Conjugate 
AnnexinV  Cy5 
B220 RA3-6B2 FITC, PECy7, PE-TexasRED, Alexa700 
CD4 GK1.5 FITC, PE, PECy7, Alexa700 
CD8 α-subunit; YTS 168.4 or 53-6.7 FITC, PECy5, Alexa700, Alexa647  
CD11b/Mac1 M1/70 FITC, PECy5, Alexa700 
CD16/32 93 PE, PECy7 
CD21 eBio8D9 FITC 
CD23 B3B4 PE 
CD25/IL2Rα PC61.5 PacificBlue, APCeF780 
CD34 RAM34 FITC, eF660/APC 
CD44/Pgp1 IM7 PE 
CD45.1/Ly5.1 A20 APCeF780 
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CD45.2/Ly5.2 A104 PE, PacificBlue, BrilliantViolet650 
CD48 HM48-1 PacificiBlue, Biotin 
CD71 R17217 PE 
CD117/c-kit 2B8 APC, PECy7 
CD135/Flt3 A2F10 PE 
CD150 TC15-12F12.2 PECy5 
Gr1/Ly6G RB6-8C5 PECy7, Alexa647 
IgM II/41 APC 
Sca1/Ly6A/E D7 PE, PacificBlue, PECy7 
Ki67  FITC, PE 
TCRβ H57-597 APCeF780 
TCRγδ eBioGL3 PE 
Ter119/Ly6  APCeF780 
	  
Table	  Appendix	  4:	  qRT-­‐PCR	  Primer	  Sequences	  Used	  For	  Microarray	  Validation.	  
Gene 
name 
Forward primer [5´-3`] Reverse primer [5´-3´] Amplicon 
length 
Robo1 
CCA CGG CCA CTC TCA CCC CT 
 





TGG CTT ACT GGA AAT CGT TGG CGT 
 





CGC GCC ATG CTG ATG GGT GT 
 





CCC CCA GCT AGT TGT CAT CCT GC 
 






CCT GCA GAG ACC TCA AAA GTA GGT G 
 





TGC TCC CCC AGT CAG ACA GGT TC 
 







CTG CAC AGG TAC CGG CTG AAG CT 
 
TTT CCT GGG CCT TCT GCG TTT CC 
 




CCC AGG GCA AGC GAA AGG TGA C 
 
AGG TGG CGA TTC AAC GCG CA 
 




ACC CAG CAG GTG ACT GGC CTT 
 
CAG CTG GGG TGC CTT TTT CTC 
CA 
 




ACA GCT CAC GGG TGG GTT CG 
 
AAC TCC TCC GCT GGG GGT CC 
 




GGA CAG AAC CAG GCG TCC AGG A 
 
GAA TTC AGA TGC CTG CAA GGA 
CAG G 
 
81  bp 
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Slc30a4 
CGC CTA GAG GTT TTG TCG GCC A 
 
TGC AAC TCC AAC AGC TGC AGT 
GA 
 




CCT GGA CTT GAT GTT CCA CAG GGA G 
 
TGG CAC AAG CCA CAG TAG CAC G 
 




ACC ACA GGC CTT GTG GAC ATG 
 
AGC TGT AGC CCC AGA CCA GGG 
 




ACG TGT GCA CCA ACA GTG CCA A 
 
GAG GCT CCA CTG AGG TGA CGG 
TT 
 




AAC CCC ATG TGG CCA GAG CGT 
 
ATC GCA ACG GTG CCA TTG TGG 
 




GTG TTT ATG GGC CTT GGG AGT 
 





TGC CAG AGT TCA GTG GTG G 
 





GGA TAC ACA CAG CAA ACG TGA 
 





ATC AGT TCC GGC AAG ACA CAG 
 





CTT TTC ATG AGC CAC AAA CG 
 
TCT TCT TCA AAA GCT TTG GTC AC 
 




GGG ACT TCA TCC AGA CAC AAC TGC A 
 
TGG GCA GGA AGA TGG TGG ACC 
A 
 




GCC GCC GAC CAG TGG GTT TT 
 
ATA CCG CGT GCA CGA TGG CC 
 




GAA CAC GGG CCT GTG ACC TGT 
 
GTT CTG CGG GGC ATG GTC GA 
 




CCT CAA GCC TCT CCT GGA CCT AAC A 
 
TGG GTT TCT CAT GAA GAA CAG 
CAC C 
 





AAT CAA GGA GGG TCT GCG AAG CTC 
 






GAA AAC CGG CCA GCT CTT CCA CA 
 
TTC ACA GCA CTG GCG GAA TCT 
GC 
 




TTC AGC CCC AGT GGT AAT GTG AAG C 
 
ATT CCA GGT CAG CAG CCA TTC 
GTC 
 




AGA CTG CCG GGT TCT GGA AAG CTT 
 
CCG CTT TGC ATC AGG CAC GT 
 
127  bp 
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Lgi1  
 
ACA CCA TCG CTG CAG CTC TTG TTA 
 
TCA AAG ACT TGA GTC CCC GGA 
AAG T 
 




ACC ATC AGG CAT CGC TGG CAC 
 
GTG CCG CAT CGA GGA CCA GG 
 




CCA CGG GGT TCC CAT TCC CC 
 
CAC TTC CGG CCC CCA AAG GC 
 




ACC AAG GGA CTC ATC GCA CGG A 
 
CGC TGC AGG GCC ACG TTG TA 
 




CCA CAA GAC GGT CGG CCA GG 
 
TCC TTC TTC CCC TTA GCA CCT 
CTG C 
 





ACC GTG TCC CAC GCG GAT GA 
 
GAC AGT GGC CAC GGG GAA AGG 
 




ATG CTA CTC TGG GAG GTC CAG CC 
 
TAT GCC GCA GAC GTG GGA CCA 
 
132  bp 
 
Bcl2l1  
GAA CGG CGG CTG GGA CAC TTT 
 
CCC GTC AGG AAC CAG CGG TTG 
 




TTG TGC GAT GTG CAC CCG CA 
 
TTG GGG GTT TTG GGG CTT GGC 
 




AGG TGC ACG CCG GCC TGT ATA 
 
TGG GGT CAT CAA ATG ATC GCC 
CAT G 
 




TGG GCA CCA CAC CAA GAA CTC CTA 
 
AAA AGG CAA GTG GCT GGG ACA 
CA 
 




TTT CCG AAG ACA CTC GGC GGC 
 
TGG GAC TCG GGG GAT CAA CAT 
GTC 
 




AGA GGC GAC CAC TTT GGG AGG AG 
 
CGC ACA CTC ACG CTG ACT CCG 
 
178  bp 
 
Tdrkh  
CGA GCC CGG GTT CTT GGA ACC 
 
CCA CTC TTC ACC TGT GGG GGC A 
 




GGA CAC ATT CTG GCT CAC GCT TCC 
 
TCA GGC ATC TCG GGG CTG TCA 
TA 
 




CGA CGG AGG GGT CTC GTG GT 
 
GCC AGT TCA CAA CCT GCA TCA 
CCT 
 




ACA GCC GGG TCT CAG AGT GCA 
 
CAG GAT TGA CGA CGC GGC CC 
 




CGA AAG CAT CCG GGG CTG CTA AG 
 
CCT TCG CCT TGG CAG GGC TTT T 
 
180  bp 
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Ssbp2  
 
GTG CAG CTC CAG AGA GAC GGG A 
 







GAC CTT GTG GAC AAC TTC CCT CCC A 
 
TCG CTG AAC TGT GGC TGC CTT C 
 




GCT GAC CCC GAT GAG GTT GCC 
 
ACA CGT AGC GCT TGC CCG AAG 
 




AGC CAT TGG ATT TTG AGC AGT GGG T 
 
GCG TAG CCA TCT CGT GCC ACA A 
 




GGC CAA TTC TGG ACC ACC AAG GC 
 
GCA GTA GTC GAT GGC GCC AGG 
 
120  bp 
 
Abcg3  
TGT CAC CCC TTT CTG CCA TCA GCT 
 
TGT CAC CCC TTT CTG CCA TCA 
GCT 
 




ACA GCC AAG AGG GGC TCG ACA 
 
TGA TCA GAC CCG CCT TCC CGA 
 




CCA CCG CAG GAG TTC ACC GTG 
 
AAA ACG GTG GTG GTT TCG GCA 
CA 
 




TGA CGT TTG GCC CAC GAG GC 
 
CAG CCG GCA GTC TGA GAG CG 
 




AGT GCG CGC TCT TGG GTG TC 
 
AGG AGG CTG CAG AGA CCG GG 
 




AAA CGG CGC AGA GAC CGC AT 
 
CGG GCA TCA AAG AAC CCT GTG 
CC 
 




GCT TGG CTG CCT TCT GGG CA 
 
CCC CAA CAT GCC AGC ACC CAT 
 




CAG GAG TGC TTA AGG CCG CCA G 
 
AGG CCT TTC ACC ACC TGT ACC 
AGG 
 




ATG CAG AGC AGT GAG CTG CCT TTT 
 
TTT GCT TCC TGC GGT CGT TGG G 
 




ACA ACC CAG ACA GCT CCC AGG G 
 
CTG GCA GCA GAG CTG GGA TTC 
ATA 
 




TCT CCT GTG GCT GCA CAG TGG G 
 
CCG AGG AAG AAA ACT GGC TGG 
GT 
 




TAA CGA TCC AAG GGT GGT TCA TCC C 
 
CCG TCG TCG CCT TGG TCA ATG A 
 




CGG GGT GTG GAT TCT TGC AGA CA 
 
ACA AAG TAC AGA CCC AGC AAG 
CAG C 
 
180  bp 
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Cobll1  
 
CAC AGA GGG GCA AGG GCC GTA T 
 
CTC CTG GTT TGG GCC CAG TGT 
CT 
 




GAC GTG TCC ACC GAG CGT GA 
 
CGG TGC AGT GCA GGA CCT TCC 
 




TGG AAA TAA ATG CCT TGC AGT GGG A 
 
TGC ATT GTC ACA GTT TAG CCT 
GTC A 
 




TCG GCG TGT CGG AGA AAA CGG 
 
GCG GCG CTT CTC CCG AGA TC 
 




TTG CTA CGT CCA TGG GCC AAG G 
 
GCT GCT CGA AGG TCA TGA CAG 
CC 
 




TCT GAG GTC TGC CTG CAC CAG TT 
 








GCT TCG GCA TCT ATG AGG TTC CAG A 
 
CAT ACT CTC CCG GGG GCA GCT T 
 




GCA GAG CCA GGA GAA ACT AAC ACC A 
 
TCT CGG TTC TCT TGT GGC TGC 
CT 
 




TAA AGA CGC CAT CTC GGG CGT TG 
 
TCT TTG TAT GCG GCC ACC AGC 
TG 
 





CAC CGT CCG CTG CTG CCT AT 
 
GCG GTA GAC GGT GGC GTC TT 
 




GTG ATC CGG ATG TGG GCA GAC G 
 
GCT GCT TGT ACA GGG AGG TTC 
CAC 
 




CTG TGG CTA CAG ACC CCA CAG TGA 
 
ACT CCG CAG AGT GAA CAG CCA 
CT 
 




TCT GGG ATC CTC TCC AGC CAA GC 
 








TCG GAC TCT GAA AAC CAG CTT 
 
CGC TGG CTC CTG TAC AAT CA 
 




CCT GCA AGC ATG TTT TCC ACA 
 
CTT GGG TTC TGG TCA GCC TT 
 
165  bp 
 
Pi4k2b  
CAT CAG GAA CAC AGA CAG GGG 
 
ATG CTA GCC CAT TAT CAA TTG 
CAG 
 
149  bp 
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Table	  Appendix	  5:	  qRT-­‐PCR	  Primer	  Sequences	  Used	  For	  Expression	  Of	  Chd	  Family	  Members.	  
Gene 
name	   Forward primer [5´-3`]	   Reverse primer [5´-3´]	   Amplicon length	  
Chd1 	   GGA TCC GAA GAA GAC TCG TCC 	   CCC GTC GCA GCT GCT TTT A 	   171 bp 	  
Chd2 	   CAC TAT CCT TTC CAG CGC CT 	   CGT GTG GAG AGC AGG AAA CA 	   113 bp 	  
Chd3 	   CGG GCT CGT GTG CTT TTC A 	   TTC AGC TTC TTG GCA CGG AC 	   127 bp 	  
Chd4 
 
CTT CGC TGA GGT GGA GTG TT 
 






ATG TGG GCG CCT GAC TTT TA 
 






GGT TCT GAA CAC GGT ACA ACC T 
 
TCT TCC TGG CCA CTG CTA CA 
 
130/222/2




AGT TAG CAG CTC AGC AGG TG 
 
GGC AGA AGC AGC ATG ATT GG 
 
151  bp 
 
Ctnnd1  
CAC ATT TGA GCT CTC TCC TTC CT 
 
AGT AGG TCC CCT CAC TTC ACA 
 




CCC AGC AGG ACC AAA CTC TTA 
 
AAC TGC CAG GTA AGT CTG CG 
 




CGA AAC ACC AGC TGC GAT AC 
 
ATA CTT TGG GGC TCC CAT GC 
 




TGC CCT CTA CTC CTT CGA CT 
 
GCT TGA CCT CTT GGT TCC GA 
 





GCC GCA GCC TGT GTC CGT AG 
 
GGT CAC TGC CTC CTG GGC CT 
 




GAT CCT TCT TCA AGC CCT GGG 
 





AAG AGC TGA CGT GTG CAG AA 
 
GTT GTA CCG CAA CCT ACG GA 
 




CAG CGT GGA AGA TCA TTC AAC TT 
 
ATC ACA TGG GCA GTG GGA AG 
 




CTT CTG TTT GCC TAC AAG GAT GTG 
 
TCT GGG TTT GGA GAA TCC GC 
 




GAG AAT CGA GGA GAG CCA CAG 
 
CAA GAC TTC GAC ACT GAC CTG 
 
88/112  bp 
 
Trav15-1  
GTG GAA ATT TCC AGG AGT ATG TTC 
ATG 
 
GCC AGG TAT AGT CAG AGT GCC 
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Chd6 
 
CTC CCC GCA TGG AAA GAT GA 
 






CTT TTC ATG AGC CAC AAA CG 
 






CAC CTA CCC AGG GTG AAT CG 
 






GAG AAG GCA CGC CTC ACA G 
 
TCA TTA CCC GGT CCT TTG GC 
 
177 
 bp 	  
Table	  Appendix	  6:	  qRT-­‐PCR	  Primer	  Sequences	  Used	  For	  Expression	  Of	  Serca	  Family	  Members.	  Gene	  name	   Forward	  primer	  [5´-­‐3´]	   Reverse	  primer	  [5´-­‐3´]	   Amplicon	  length	  
Serca1 	   AGC TAC CAT CAG CTG ACT CAT TT 	   CCG CAG TAG GGA CTG GTT C 	   177 bp 	  
Serca2ab 	   ACC TTT GCC GCT CAT TTT CC 	   CGG GTT GTT CCA GGT AGT T 	   134 bp 	  
Serca3 
 
TGA AAT GTG CAA CGC CCT CA 
 





Table	  Appendix	  7:	  qRT-­‐PCR	  Primer	  Sequences	  Used	  For	  Apoptosis-­‐Related	  Genes.	  
Gene 
name 




GAA CGG CGG CTG GGA CAC TTT 
 






GCC TTC TTT GAG TTC GGT GG 
 







AAA CTG GTG CTC AAG GCC C 
 






GCC AGG CCT TCA ACC ACT AT 
 






AAA TGG GAA CCC CAA AGC AG 
 





Table	  Appendix	  8:	  qRT-­‐PCR	  Primer	  Sequences	  Used	  For	  Unfolded	  Protein	  Response-­‐Related	  Genes.	  
Gene 
name 




GAA GAC TGG GAG TCG ACG TT 
 






ATT TCC TTG TCC TCC GCT GG 
 






CGG CAA GGA GGA TGC CTT T 
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Hsp90b1  
 
TCA AAT CGA ACA CGG CTT GC 
 








CGC CGA TGG GAT AGT GAT GA 
 





Total Xbp1  
 
AAG AAC ACG CTT GGG AAT GG 
 








GAG TCC GCA GCA GGT G 
 






GAC CAC CTA TTC CTG CGT CG 
 







GAG ATT GCA GAA GCG TAT GAA 
ACA C 
 







ACC TGA GGA GAG AGT GTT CCA 
 






Table	  Appendix	  9:	  qRT-­‐PCR	  Primer	  Sequences	  Used	  For	  Cell	  Cycle-­‐Related	  Genes.	  
Gene 
name	   Forward primer [5´-3´]	   Reverse primer [5´-3´]	   Amplicon length	  
Ccnd1 	   TGC AAA TGG AAC TGC TTC TGG 	   ATG AAC TTC ACA TCT GTG GCA 	   175 bp 	  
Ccnd3 	   ATG GCA GTT GCG GGA GT 	   TTT TTG ACC AAA GCC TGC CG 	   138 bp 	  
p16 
 
AAA GCG AAC TCG AGG AGA GC 
 






TTG CAC TCT GGT GTC TGA GC 
 






CAA ACT CTG AGG ACC GGC AT 
 






AGG ACG AGA ATC AAG AGC AGC 
 






ACC ATA TAA TGG ATG CTC CCC C 
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Table	  Appendix	  10:	  Solutions	  for	  Preparing	  Stacking	  and	  Separation	  gel	  for	  SDS-­‐PAGE.	  
Solution components Volumes per 5% 
stacking gel 
Volumes per 6% 
separation gel 
H2O 1.4ml 5.3ml 
30% acrylamide mix 330μl 2.0ml 
1M Tris-HCl (pH 6.8) 250μl - 
1.5M Tris-HCl (pH 8.8) - 2.5ml 
10% SDS 20μl 100μl 
10% APS 20μl 100μl 
TEMED 2μl 8μl 	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2003	   Abitur	  (University	  entrance	  qualification)	  
	   Archigymnasium,	  Soest,	  Germany	  	  
	  
Research	  Experience	  
PhD	  project	   	   The	  chromatin	  remodeler	  Chd7	  &	  the	  calcium	  ATPase	  Serca2	  –	  adding	  new	  facets	  to	  
Notch	  in	  Hematopoiesis	  and	  T-­‐ALL	  	  
	   	   	   Notch1	   has	   been	   shown	   to	   be	   a	   key	   driver	   in	   pediatric	   T-­‐ALL.	   The	   chromatin-­‐
remodelling	   enzyme	  Chd7	  was	   identified	   as	   potential	   regulator	   of	   T-­‐ALL,	   in	   concert	  
with	   Notch1,	   as	   it	   was	   highly	   over-­‐expressed	   comparing	   aggressive	   versus	   pre-­‐
malignant	   T-­‐ALL.	   In	   a	   chemical	   compound	   screen,	   the	   Notch	   inhibiting	   compounds	  
CPA	  and	  thapsigargin,	  targeting	  the	  calcium	  ATPase	  Serca2,	  were	  identified.	  The	  aim	  




In	  vivo	   	   Murine	   bone	   marrow	   transplantation	   (tail-­‐vein/retro-­‐orbital	   injections);	   intra	  
peritoneal	  injections,	  acquisition	  of	  peripheral	  blood	  samples	  (tail	  vein	  bleedings)	  	  
	   	   	   Flow	  cytometric	  analysis	  of	  hematopoietic	  cells	  (up	  to	  12	  colors)	  
	   	   	   Breeding	  and	  characterization	  of	  transgenic	  mouse	  strains	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Histological	  tissue	  analysis	  (OCT	  /	  paraffin	  embedded)	   	   	  
In	  vitro	   	   Culturing	   and	   transfection	   /	   transduction	   of	   primary	   cells	   and	   cell	   lines	   Molecular	  
cloning	  of	  expression	  vectors	  and	  lentiviruses	  	  
	   	   	   Retro-­‐	   and	   lentivirus	   production	   and	   titration	   PCR	   and	   qPCR	   on	   cDNA	   Western	  
Blotting	  
	  
Doctoral	  Courses	  and	  Teaching	  
Bioinformatics	   Bioinformatics	   analysis	   of	   differential	   gene	   expression,	   2011,	   Apr	   04-­‐08,	   Swiss	  
Institute	  of	  Bioinformatics,	  Lausanne	  	  
Animal	  Work	   Course	  in	  laboratory	  animal	  science	  (RESAL1),	  2010,	  June	  18-­‐27,	  EPFL	  
Teaching	   	   Biotechnology	  Laboratory	   II,	  summer	  2011,	  Prof.	   Florian	  Wurm	  /	  Dr.	  David	  Hacker,	  
laboratory	  of	  cellular	  biotechnology	  
	   	   	   Supervision	  of	  Bachelor	  students,	  spring	  2010	  and	  spring	  2012	  
Doctoral	  Courses	   Notch	   in	   vascular	   development	   and	   pathology,	   2012,	   Sept	   19-­‐20,	   Faculté	   de	  
Médicine,	  Paris,	  France	  	  
	   	   	   Workshop	  on	  stem	  cell	  biology,	  2011,	  Feb	  03-­‐04,	  EPFL,	  Lausanne	  	  
	   	   	   Notch	  and	  hematopoiesis,	  2010,	  Oct	  24-­‐26,	  Edinburgh	  University,	  UK	  Model	  systems	  
in	  heart	  development,	  2010,	  Jun	  28-­‐30,	  CNIC,	  Madrid,	  Spain	  	  
	   	   	   NF-­‐kB,	  inflammation	  and	  cancer	  2010,	  Feb-­‐May,	  UNIL	  	  
	  
Conferences	  with	  Poster	  Presentation	  
2013,	  Feb	  08	   9th	  Annual	  SSCN	  Meeting,	  Inselspital,	  Bern,	  Switzerland	  (poster)	  	  
2011,	  Oct	  02-­‐06	  	   The	  Notch	  Meeting	  V	  Athens,	  Athens,	  Greece	  (poster)	   	   	  
2011,	  Sept	  07-­‐10	   ISREC	  Symposium	  on	  cancer,	  EPFL	  (poster)	  
2011,	  July	  1	   1st	  Life	  Science	  Symposium	  by	  Doctoral	  Students,	  EPFL	  (poster)	  
2011,	  Feb	  04	   7th	  Annual	  SSCN	  Meeting,	  EPFL	  (poster)	   	  
	  
Internships	  /	  Studies	  abroad	  
2008,	  April-­‐May	   Drug	  treatment	  of	  non-­‐small	  cell	   lung	  cancer,	  group	  of	  Dr.	  J.-­‐L.	  Coll,	   Institute	  Albert	  
Bonniot,	  Grenoble,	  France	  
2008,	  Jan-­‐June	   Exchange	  semester	  at	  the	  Université	  Joseph	  Fourier,	  Grenoble,	  France	  
2007,	  July-­‐Sept	   Serotonin	   signaling	   and	   depression,	   group	   of	   Dr.	  M.	   Panicker,	  National	   Centre	   for	  
Biological	  Sciences,	  Bangalore,	  India	   	  
2006,	  June-­‐July	   Voluntary	  work,	  Healesville	  Sanctuary,	  Victoria,	  Australia	   	  
2006,	  Jan-­‐Feb	   DNA	  sequencing	  techniques	  &	  finger	  printing,	  Institute	  of	  Forensic	  Medecine,	  Essen,	  
Germany	  
2005,	  Oct-­‐Dec	   Biofermentation	  techniques,	  Pharma-­‐Zentrale	  GmbH,	  Herdecke,	  Germany	  
	  
Grants	  
2010-­‐2013	  	   	   Fellow	   of	   the	   NotchIT	   7th	   Framework	   Initial	   Training	   Programme	   /	   Marie	   Curie	  
Actions	  
2008	  Jan-­‐June	   Erasmus	   Mobility	   Grant	   in	   collaboration	   with	   Université	   Joseph	   Fourier,	   Grenoble,	  
France	  
2007	  July-­‐Sept	   German	   Academic	   Exchange	   Service	   Travel	   Grant	   to	   visit	   the	   National	   Centre	   of	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Götze	  S,	  Coersmeyer	  M,	  Müller	  O,	  Sievers	  S	  (2014).	  Histone	  deacetylase	  inhibtors	  induce	  attenuation	  of	  
Wnt	  signaling	  and	  TCFL2	  depletion	  in	  colorectal	  carcinoma	  cells.	  	  Int	  J	  Oncol.	  Oct;45(4):1715-­‐23.	  	  
	  
Languages	  
German	   	   Mother	  tongue	   	  
English	   	   Fluent	  written	  and	  spoken	  
French	  	   	   Fluent	  written	  and	  spoken	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